Compounds modulating c-fms and/or c-kit activity and uses therefor

专利摘要:

公开号:AU2007323644A1
申请号:U2007323644
申请日:2007-11-20
公开日:2008-05-29
发明作者:Dean R. Artis；Ryan Bremer；Prabha N. Ibrahim；Marika Nespi；Guoxian Wu；Chao Zhang；Jiazhong Zhang；Hongyao Zhu
申请人:Plexxikon Inc；
IPC主号:A61K31-437

专利说明:
WO 2008/064255 PCT/US2007/085289 COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR RELATED PATENT APPLICATIONS 10001] This application claims priority to U.S. Provisional App. No. 60/860,749, entitled "Compounds Modulating c-Fms and c-Kit Activity and Uses Therefor", filed November 22, 2006, and is related to U.S. Patent App. No. 11/435,381, entitled "Compounds Modulating c-Kit and c-Fms Activity and Uses Therefor", filed May 16, 2006, which claims the benefit of U.S. Provisional App. No. 60/682,063, entitled "Compounds Modulating c-Kit Activity and Uses Therefor", filed May 17, 2005, U.S. Provisional App. No. 60/682,051, entitled "Compounds Modulating c-Fms Activity and Uses Therefor", filed May 17, 2005, U.S. Provisional App. No. 60/682,042, entitled "Compounds Modulating c-Kit and c-Fms Activity and Uses Therefor", filed May 17, 2005, U.S. Provisional App. No. 60/692,750, entitled "Compounds Modulating c-Kit and c-Fms Activity and Uses Therefor", filed June 22, 2005, and U.S. Provisional App. No. 60/692,960, entitled "Compounds and Methods for Kinase Modulation, and Indications Therefor", filed June 22, 2005, all of which are incorporated herein by reference in their entireties and for all purposes. FIELD OF THE INVENTION [0002] This invention relates to ligands for c-fis and c-kit, and to methods for use thereof. The information provided is intended solely to assist the understanding of the reader. None of the information provided nor references cited is admitted to be prior art to the present invention, Each of the references cited is incorporated herein in its entirety and for any purpose. BACKGROUND OF THE INVENTION [00031 C-fins and c-kit are both type III transmembrane receptor protein tyrosine kinases (RPTKs) that regulate key signal transduction cascades that control cellular growth and proliferation. Both receptors have similar structural features comprising five extracellular immunoglobulin (IG) domains, a single transmembrane domain, and a split cytoplasmic kinase domain separated by a kinase insert segment.
WO 2008/064255 PCT/US2007/085289 c-Fms 100041 C-fms is a member of the family of genes originally isolated from the Susan McDonough strain of feline sarcoma viruses. The cellular proto-oncogene FMS (c-fis, cellular feline McDonough sarcoma) codes for the receptor for the macrophage colony-stimulating factor (M CSF). C-fms is crucial for the growth and differentiation of the monocyte-macrophage lineage, and upon binding of M-CSF to the extracellular domain of c-fims, the receptor dimerizes and trans autophosphorylates cytoplasmic tyrosine residues. [0005] M-CSF, first described by Robinson and co-workers (Blood. 1969, 33:396-9), is a cytokine that controls the production, differentiation, and function of macrophages. M-CSF stimulates differentiation of progenitor cells to mature monocytes, and prolongs the survival of monocytes. Furthermore, M-CSF enhances cytotoxicity, superoxide production, phagocytosis, chemotaxis, and secondary cytokine production of additional factors in monocytes and macrophages. Examples of such additional factors include granulocyte colony stimulating factor (G-CSF), interleukin-6 (IL-6), and interleukin-8 (IL-8). M-CSF stimulates hematopoiesis, promotes differentiation and proliferation of osteoclast progenitor cells, and has profound effects on lipid metabolism. Furthermore, M-CSF is important in pregnancy. Physiologically, large amounts of M-CSF are produced in the placenta, and M-CSF is believed to play an essential role in trophoblast differentiation (Motoyoshi, Int J Hematol. 1998, 67:109-22). The elevated serum levels of M-CSF in early pregnancy may participate in the immunologic mechanisms responsible for the maintenance of the pregnancy (Flanagan & Lader, Curr Opin Hematol. 1998, 5:181-5). 100061 Related to c-fis and c-kit are two platelet-derived growth factor receptors, alpha (i.e., pdgfra) and beta (pdgfrb) (PDGF). The gene coding for pdgfra is located on chromosome 4ql1 q 12 in the same region of chromosome 4 as the oncogene coding for c-kit. The genes coding for pdgfra and c-fms appear to have evolved from a common ancestral gene by gene duplication, inasmuch as these two genes are tandemly linked on chromosome 5. They are oriented head-to tail with the 5-prime exon of the c-fims gene located only 500 bp from the last 3-prime exon of the gene coding for pdgfra. Most gastrointestinal stromal tumors (GIST) have activating mutations in c-kit, and most patients with GISTs respond well to Gleevec, which inhibits c-kit. Heinrich et al. (Science 2003, 299:708-10) have shown that approximately 35% of GISTs lacking c-kit mutations have intragenic activation mutations in the gene encoding pdgfra, and that tumors expressing c-kit or pdgfra are indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression. Thus, c-kit and pdgfra mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs. 2 WO 2008/064255 PCT/US2007/085289 10007] Similarly, the observation that production of M-CSF, the major macrophage growth factor, is increased in tissues during inflammation points out a role for c-fms in diseases, such as for example inflammatory diseases. More particularly, because elevated levels of M-CSF are found in the disease state, modulation of the activity of c-fins can ameliorate disease associated with increased levels of M-CSF. c-Kit 10008] The Stem Cell Factor (SCF) receptor c-kit plays an important role in the development of melanocytes and mast, germ and hematopoietic cells. Stem Cell Factor (SCF) is a protein encoded by the SI locus, and has also been called "kit ligand" (KL) and mast cell growth factor (MGF), based on the biological properties used to identify it (reviewed in Tsujimura, Pathol Int 1996, 46:933-938; Loveland, et al., J. Endocrinol 1997, 153:337-344; Vliagoftis, et al., Clin Immunol 1997, 100:435-440; Broudy, Blood 1997, 90:1345-1364; Pignon, Hermatol Cell Ther 1997, 39:114-116; and Lyman, et al., Blood 1998, 91:1101-1134.). Herein the abbreviation SCF refers to the physiological ligand for c-kit. 100091 SCF is synthesized as a transmembrane protein with a molecular weight of 220 or 248 Dalton, depending on alternative splicing of the mRNA to encode exon 6. The larger protein can be proteolytically cleaved to form a soluble, glycosylated protein which noncovalently dimerizes. Both the soluble and membrane-bound forms of SCF can bind to and activate c-kit. For example, in the skin, SCF is predominantly expressed by fibroblasts, keratinocytes, and endothelial cells, which modulate the activity of melanocytes and mast cells expressing c-kit. In bone, marrow stromal cells express SCF and regulate hematopoiesis of c-kit expressing stem cells. In the gastrointestinal tract, intestinal epithelial cells express SCF and affect the interstitial cells of Cajal and intraepithelial lymphocytes. In the testis, sertoli cells and granulosa cells express SCF which regulates spermatogenesis by interaction with c-kit on germ cells. SUMMARY OF THE INVENTION [0010] The present invention relates to compounds active on c-fms, c-kit, or both c-fims and c kit. In accordance with one aspect of the present invention, it has been discovered that in the treatment of diseases amenable to treatment by an effective amount of a modulator of either c-fms alone or c-kit alone, the efficacy of treatment can be enhanced if said compounds are dual inhibitors of both c-fms and c-kit. In another aspect of the present invention, compounds active on c-fms, c-kit, or both c-fms and c-kit are also active on one or more of TrkA, TrkB and HGK. In particular, the invention provides compounds of Formula II, and all sub-generic formulae thereof 3 WO 2008/064255 PCT/US2007/085289 (e.g. Formula Ila, Ilb, Ile, Ilg and Ilp), Formula III, or additional compounds as described in the synthetic examples, as well as methods of using such compounds as described below. Thus, the invention provides methods of using compounds that can be used therapeutically and/or prophylactically involving modulation of c-fins, c-kit, or both c-fins and c-kit, or involving one or more of TrkA, TrkB and HGK in addition to c-fins, c-kit, or both c-fins and c-kit. 100111 The compounds of Formula II have the following structure: A2_ D B N N H Formula 11 all salts, prodrugs, tautomers, and isomers thereof, wherein: Q12 N M4 D has a structure selected from the group consisting of Q 14 13 Q72 N -Q N-N N 'M ~Q41
M
10 -Q6 1 Q24 Q4, and Q152 S 1-Q144 in which indicates the attachment point of D to A 2 of Formula II;
A
2 is -CH 2 - or -C(O)-; B is selected from the group consisting of hydrogen, -CN, -OR 4 , -SR 4 , -NHR 41 , -NR 4 1
R
4 1 ,
-NR
39
C(O)R
41 , -NR 39
S(O)
2
R
4 1 , -C(O)NR 9
R
4 1 , -C(O)R 4 ', -S(O) 2 NR'R', -S(O) 2
R
41 , halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl, and 4 WO 2008/064255 PCT/US2007/085289 heteroaryl as B, or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH2, -CN, -NO 2 , -S(0) 2
NH
2 , -C(O)NH 2 , -OR 4 , -SR 42 , -NHR 2 , -NR 42
R
42 , -NR 3 9C(O)R 42 , -NR"S(O) 2
R
42 , -S(0) 2
R
42 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino;
M
4 is -NR"CH 2 -, -NR 39 CH(R44)-, -NR 9
CH
2
CH
2 -, or -NR 9 C(O)-;
M
5 .Mio, and Mis are selected from the group consisting of a bond, -NR"-, -S-, -0-, -NR" 9
CH
2 -,
-NR"
9
CH
2
CH
2 -, -NR 39 CH(R40)-, -SCH 2 -, -OCH 2 -, -C(O)NR 39 -, -S(O) 2
NR
9 -, -CH 2
NR"
9 -,
-CH(R
4 0 )NR"-, -NR 39 C(O)-, and -NR 9
S(O)
2 -; Ms is selected from the group consisting of a bond, -CH 2 -, -CH 2 C(O)-, -S(O) 2 -, -S(0) 2
CH
2 -,
-S(O)
2
CH(CH
3 )-, -S(O) 2
CH
2
CH
2 -, -S(O) 2
NR
9 -, -S(O) 2
NR"CH
2 -, -S(O) 2
NR
39
CH(CH
3 )-,
-S(O)
2
NR
9
CH
2
CH
2 -, -C(O)-, -C(O)CH 2 -, -C(O)CH(CH 3 )-, -C(O)CH 2
CH
2 -, -C(O)NR 39 -,
-C(O)NR
9
CH
2 -, -C(O)NR 9
CH(CH
3 )-, and -C(O)NR 39
CH
2 CH-; Q' is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of -OR 4t , -SR 4 ', -S(0)R 4 ', -S(O) 2
R
4 ',
-NHR
41 , -NR 4
'R
4 ', -NR 3
"C(O)R
4 1 , -NR"S(O) 2
R
41 , halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as a substituent of Q'or as a substituent of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NiH 2 , -CN, -NO 2 , -S(O) 2
NH
2 , -C(O)NH 2 , -OR 42 , -SR 42 , -NHR 4 2 ,
-NR
4 2
R
42 , -NR"C(O)R 42 , -NR 3 9
S(O)
2
R
42 , -S(O) 2
R
42 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; Q", Q 41 , Q 6 1 , and Q 1 4 1 are lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein lower alkyl is optionally substituted with one or more fluoro, lower alkoxy, or fluoro substituted lower alkoxy, and wherein cyclaolkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of -OR 4 ', -SR 4 ', -S(0)R 41 , -S(O) 2
R
4 ', -NHR 41 , -NR 4
'R
4 1 , -NR"C(O)R 4 ',
-NR
39
S(O)
2
R
41 , halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as a substituent of Q", Q 4 1 , Q 6 1 , or Q' 41 , or as a substituent of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of 5 WO 2008/064255 PCT/US2007/085289 -OH, -NH 2 , -CN, -NO 2 , -S(O) 2
NH
2 , -C(O)NH 2 , -OR 42 , -SR 42 , -NHR 4 2 , -NR 42
R
4 2 ,
-NR"C(O)R
4 2 , -NR 39
S(O)
2
R
4 2 , -S(O) 2
R
4 2 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; Qi 2 is fluoro, chloro or -CF 3 ; Q"3 and Q1 4 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl; Q2, Q4, Q1 2 , and Q 5 4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl, -NR 44
R
4 , -OR4, and -SR", provided, however, that at least one of Q 2 2 and Q 2 4 and at least one of Q 52 and Q 54 is hydrogen, fluoro, chloro, lower alkyl or fluoro substituted lower alkyl; Q" and Q' 5 2 are hydrogen, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, -NR"R", -OR4, or -SR";
Q
7 2 is hydrogen, lower alkyl or fluoro substituted lower alkyl;
R.
3 at each occurrence is independently hydrogen or lower alkyl;
R
4 0 is lower alkyl or fluoro substituted lower alkyl; R' at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R' or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH 2 , -CN, -NO 2 , -S(O) 2
NH
2 , -C(O)NH 2 ,
-OR
42 , -SR 42 , -NHR, -NR 42
R
4 2 , -NR"C(O)R 2 , -NR 3
'
9
S(O)
2
R
42 , -S(O) 2
R
4 1, halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; R4 at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono alkylamino, di-alkylamino, and cycloalkylamino, and wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy and fluoro substituted lower alkoxy; and each R4 is independently hydrogen, lower alkyl or fluoro substituted lower alkyl; 6 WO 2008/064255 PCT/US2007/085289 provided, however, that the compound is not S H 0 N C 0 N N N
CF
3 N N N N H H H NN - N N~-c /N-0 H H - -N NN N N N NN -IN k H H NNN FruaIa 10012 sans ponegs tauoment, an iomoun thofruaI a tutr acrigt h olwn su-gneicsttueelce Fo r m h ru ossigo aoeloe lyfur usiue 'N.N o; X NN NNN HH Foml ora, all12 sats podngs embomers, an somersn thofrua1 a tutr acrigt h olwn lower alkyl, -NHrm, -NR 4
'R
4 1 , and -OR 4 '; 7 WO 2008/064255 PCT/US2007/085289
Q
5 is hydrogen, -CN, -OR 4 ', fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4
'R
41 , and -OR 4 '; and
A
2 , M 4 , Q ", Q ", Q' 4 and R 4 ' are as defined for Formula II; provided, however, that the compound is not H H - H C - N 0 Nk- N Ccl ci CF C' N N N N N N H H or H 100131 In one embodiment of compounds of Formula Ila, A 2 is -CH 2 - and M 4 is -NHCH 2 -. In one embodiment A 2 is -C(O)- and M 4 is -NHCH 2 -. In one embodiment A 2 is -C(O)- and M 4 is -NHC(O)-. In one embodiment A 2 is -CH 2 - and M 4 is -NHC(O)-. [0014] In one embodiment of compounds of Formula Ila, A 2 is -C 2 -, M 4 is -NHCH 2 -, Q' is
-OR
4 ', -CN, C,., alkyl, fluoro substituted C,.
3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 1 , -NR4'R 4 ', -OR 4 ' and
-S(O)
2
R
4 '; and Q 3 and Q' 4 are hydrogen. 100151 In one embodiment of compounds of Formula Ila, A 2 is -C(O)-, M 4 is -NHCH-, Q 5 is
-OR
4 ', -CN, C,.
3 alkyl, fluoro substituted C1.
3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 1 , -NR 4
'R
4 , -OR 4 ' and
-S(O)
2
R
4 1; and Q 3 and Q 4 are hydrogen. 100161 In one embodiment of compounds of Formula Ila, A 2 is -C(O)-, M 4 is -NHC(O)-, Q' is -OR'", -CN, C1- 3 alkyl, fluoro substituted C, 3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4
'R
4 ', -OR 4 ' and
-S(O)
2
R
4 1 ; and Q 3 and Q' 4 are hydrogen. 100171 In one embodiment of compounds of Formula Ila, A 2 is -CH 2 -, M 4 is -NHC(O)-, Q' is -OR'", -CN, C, 3 alkyl, fluoro substituted C1.
3 alkyl, fluoro, chloro, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4
'R
4 ", -OR 4 ' and
-S(O)
2
R
4 '; and Q 3 and Q1 4 are hydrogen. 8 WO 2008/064255 PCT/US2007/085289 [0018] In one embodiment, further to any of the embodiments of Formula Ila above, R 4 ' is R 42 as defined for Formula II. [00191 In one embodiment, further to any of the embodiments of Formula Ila above, Q" is phenyl or pyridinyl, wherein phenyl or pyridinyl are substituted with I or 2 substituents selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy and trifluoromethoxy; A 2 is -CH 2 -; M 4 is -NHCH 2 -; and Q 5 is -CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. In one embodiment, further to any of the embodiments of Formula Ila above, Q'" is phenyl mono substituted with chloro, preferably at the 4-position; A 2 is -CH 2 -; M 4 is -NHCH 2 -; and Q 5 is -CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. In one embodiment, further to any of the embodiments of Formula Ila, Q"' is pyridin-3-yl monosubstituted with methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy, preferably at the 6-position; A 2 is -CH 2 -; M 4 is -NHCH 2 -; Q 5 is -CN, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy, trifluoromethoxy, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. [00201 In one embodiment of compounds of Formula Ila, A 2 is -CH 2 -; M 4 is -NHCH 2 -; Q 1 ' is phenyl or pyridinyl, wherein phenyl or pyridinyl are substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy and trifluoromethoxy; Q' is hydrogen, fluoro, chloro, methyl, methoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, -CN, or 1-methyl-IH-pyrazole-4-yl; Q" is fluoro or chloro; and Q1 3 and Q 4 are hydrogen. In one embodiment, A 2 is -CH 2 -; M 4 is -NHCH 2 -; Q" is phenyl mono substituted with chloro, preferably at the 4-position; Q 5 is hydrogen, chloro, methyl, methoxy, or -CN; Q' 2 is fluoro or chloro; and Q 3 and Q" are hydrogen. In one embodiment, A, is
-CH
2 -; M 4 is -NHCH 2 -; Q'" is pyridin-3-yl monosubstituted with methyl, methoxy, trifluoromethyl, difluoromethoxy or trifluoromethoxy, preferably at the 6-position; Q 5 is hydrogen, chloro, methyl, methoxy, -CN, or I-methyl-lI-H-pyrazole-4-yl; Q' 2 is fluoro or chloro; and Q' 3 and Q1 4 are hydrogen. [00211 In one embodiment of compounds of Formula Ila, the compound is selected from the group consisting of: 9 WO 2008/064255 PCT/US2007/085289 (4-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-bJpyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl] amine (P-0132), (4-Chloro-benzyl)-[6-chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0161), [6-Chloro-5-(l H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0174), [6-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0176), {6-Chloro-5-[5-( I-methyl-i H-pyrazol-4-yl)-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-yl} (6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-0179), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0186), [6-Fluoro-5-(5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0187), [6-Fluoro-5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0188), 3-{2-Chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}- IH pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0232), [6-Chloro-5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0233), [6-Chloro-5-(5-methyl-I H-pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridin-2-yI]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0234), [6-Fluoro-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl) amine (P-0378), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yI]-(6-methoxy-pyridin-3 ylmethyl)-amine (P-0379), (5-Fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0414), 3- {2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-I H-pyrrolo[2,3 bJpyridine-5-carbonitrile (P-0415), 3-[6-(4-Chloro-benzylamino)-2-fluoro-pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0432), and all salts, prodrugs, tautomers, and isomers thereof. [0022] In one embodiment, a compound of Formula 11 has a structure according to the following sub-generic structure, Formula I1b, 10 WO 2008/064255 PCT/US2007/085289
Q
22 M5
A
3 N
Q
15 N Q Q24 H Formula I1b, all salts, prodrugs, tautomers, and isomers thereof, wherein:
A
3 is -CH 2 - or -C(O)-; Q" is hydrogen, -CN, -OR 41 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR4'R 41 , and -OR 4 1 ; and
M
5 , Q"1, Q 2 2 , Q 2 4 , and R 41 , are as defined for Formula II. 10023] In one embodiment of compounds of Formula Ilb, M 5 is -NR CH 2 -, -NR"CH(R 40 )-,
-NR"CH
2
CH
2 -, or -NR"C(O)-; A 3 is -CH 2 - or -C(O)-, preferably -CH 2 -; Q" is cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4
'R
4 1 , -OR 41 and -S(O) 2
R
4 '; Q' 5 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ',
-NR
4
'R
4 ', -OR 4 ' and -S(O) 2
R
4 1 ; and Q 2 2 and Q 2 4 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably hydrogen, fluoro, chloro, or -CF 3 , more preferably both Q 2 and Q 2 4 are hydrogen; wherein R 4 ' is as defined for Formula II. 100241 In one embodiment, further to any of the embodiments of Formula lIb above, R 4 ' is R 4 2 as defined for Formula II. [00251 In one embodiment of compounds of Formula Ilb, M is -NHCH 2
CH
2 -, -NHCH 2 -N(CH 3
)CH
2 -, or -NHCH(CH 3 )-, preferably -NHCH 2 -; A 3 is -CH 2 -; Q" is cycloalkyl, heterocycloalkyl, phenyl or heteroaryl, wherein phenyl or heteroaryl are optionally substituted with I or 2 substituents selected from the group consisting of halogen, lower alkyl, fluoro 11 WO 2008/064255 PCT/US2007/085289 substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, di-alkylamino, and heterocycloalkyl; Q" is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, and fluoro substituted lower alkoxy; and Q 2 2 and Q1 4 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably hydrogen, fluoro, chloro, or -CF 3 , more preferably both Q 2 2 and Q 2 4 are hydrogen. 100261 In one embodiment of compounds of Formula Ilb, M 5 is -NHCH 2 -; A 3 is -CH-; Q" is phenyl substituted with I or 2 substituents selected from the group consisting of fluoro, chloro, methyl, fluoro substituted methyl, methoxy, and fluoro substituted methoxy; Q" is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, preferably hydrogen or chloro; and Q 2 2 and Q 2 4 are hydrogen. 10027] In one embodiment of compounds of Formula Ilb, the compound is selected from the group consisting of: (4-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0260), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,6-difluoro-benzyl)-amine (P-0261), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0262), (2-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylj-amine (P-0263), [5-(5-Chloro- lH-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-benzyl)-amine (P-0264), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,4-difluoro-benzyl)-amine (P-0265), [5-(5-Chloro-1H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl) amine (P-0266), [5-(5-Chloro-1H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyrimidin-2-ylj-(2,5-difluoro-benzyl)-amine (P-0267), [5-(5-Chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trifluoromethyl-benzyl) amine (P-0268), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-5-trifluoromethyl 12 WO 2008/064255 PCT/US2007/085289 benzyl)-amine (P-0289), (2-Fluoro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin- 2 -yl] amine (P-0291), (2,5-Difluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI]-amine (P-0292), (2-Chloro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0293), (3-Fluoro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0294), (3,5-Difluoro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0295), (2-Fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0300), (2-Chloro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0301), [5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl)-amine (P-0302), [5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethoxy-benzyl)-amine (P-0303), (5-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-ainine (P-0304), (2,4-Dichloro-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin- 2 -yl]-amine (P-0305), (2,4-Difluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0306), (4-Chloro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yi]-amine (P-0307), [5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmthyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl)-amine (P-0308), (2-Fluoro-3-trifluoromethyl-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0309), (2,5-Dichloro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0310), (3-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-031 1), (2-Difluoromethoxy-benzyl)-[5 -(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin- 2 -yI]-amine (P-0312), (2,3-Dichloro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0313), (4-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0314), (5-Fluoro-2-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyrimidin- 2 -yl] amine (P-0315), (2-Chloro-4-fluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0316), 13 WO 2008/064255 PCT/US2007/085289 (5-Chloro-2-methyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0317), (5-Fluoro-2-methyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0318), (2-Fluoro-4-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI] amine (P-0319), (4-Fluoro-2-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0320), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]-(2-difluoromethoxy-benzyl) amine (P-0390), [5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluoro-2-trifluoromethyl benzyl)-amine (P-0391), (3-Chloro-2-fluoro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y] amine (P-0392), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-3-trifluoromethyl benzyl)-amine (P-0393), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-4-trifluoromethyl benzyl)-amine (P-0394), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,3-difluoro-benzyl)-amine (P-0395), (2-Chloro-4-fluoro-benzyl)-[5-(5-chloro- H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0396), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethoxy-benzyl) amine (P-0402), (2-Chloro-5-fluoro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0407), (2-Chloro-5-fluoro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y] amine (P-0408), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin4-ylmethyl-amine (P-0416), [5-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-pyrrolidin-1 -yl-ethyl) amine (P-0417), Benzyl-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0418), Benzyl-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI]-methyl-amine (P-0419), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethoxy-benzyl) 14 WO 2008/064255 PCT/US2007/085289 amine (P-0420), (3-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI]-amine (P-0421), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-3-ylmethyl-amine (P-0422), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-fluoro-benzyl)-amine (P-0423), (3-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-methyl amine (P-0424), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3,5-difluoro-benzyl)-amine (P-0425), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[1 -(2-fluoro-phenyl)-ethyl] amine (P-0426), [1-(4-Chloro-phenyl)-ethyl]-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0427), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[(S)-1-(4-fluoro-phenyl) ethyl]-amine (P-0428), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0429), (2-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-methyl amine (P-0430), [5-(5-Chloro- H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-methyl-benzyl)-amine (P-0431), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl)-(2-methoxy-benzyl)-amine (P-0433), [5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-morpholin-4-yl-ethyl) amine (P-0434), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-cyclohexylmethyl-amine (P-0435), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-2-ylmethyl-amine (P-0436), [2-(4-Chloro-phenyl)-ethyl]-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yi] amine (P-0437), [5-(5-Chloro-1 H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-difluoromethoxy-benzyl) amine (P-0438), [5-(5-Chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyrimidin-2-yl]-(4-methoxy-benzyl)-amine 15 WO 2008/064255 PCT/US2007/085289 (P-0439), [5-(5-Chloro-1H-pyrrolo[2,3-b pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-methyl-benzyl)-amine (P-0440), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylinethyl)-pyrimidin-2-yl]-(2-methoxy-ethyl)-amine (P-0441), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluoro-benzyl)-amine (P-0442), (3-Chloro-4-fluoro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0443), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl-(2-ethoxy-bnzyl)-amine (P-0444), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-morpholin-4-yl-benzyl) amine (P-0445), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-difluoromethoxy-benzyl) amine (P-0446), (4-Chloro-3-fluoro-benzyl)-[5-(5-chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin- 2 -yl] amine (P-0447), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[I -(3-fluoro-phenyl)-ethyl] amine (P-0448), [5-(5-Chloro-1IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-dimethylamino-benzyl) amine (P-0449), and all salts, prodrugs, tautomers, and isomers thereof. 100281 In one embodiment, a compound of Formula H has a structure according to the following sub-generic structure, Formula Ile,
Q
52
Q
45
NM
8 aQ41 Q54 H Formula Ile, all salts, prodrugs, tautomers, and isomers thereof, wherein:
A
6 is -CH 2 - or -C(0)-; Mg. is -CH 2 -, -CH 2 C(O)-, -C(O)NR 9 CH-, -C(O)NR"CH(R 40 )-, or -C(O)NR 9
CH
2
CH
2 -; 16 WO 2008/064255 PCT/US2007/085289
Q
4 5 is hydrogen, -CN, -OR 41 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 41 ,
-NR
41
R
4 ', and -OR 41 ; and
Q
4 1 , Q 5 2 , Q 5 4 , R 39 , R4, and R 4 are as defined for Formula 11; -N N N N provided, however, that the compound is not H -N N H N N N N N N N ,or H [00291 In one embodiment of compounds of Formula Ile, Ms. is -C(O)NR"CH 2 -,
-C(O)NR"CH(CH
3 )-, or -C(O)NR(CH 2
)
2 -; A 6 is -CH 2 - or -C(O)-, preferably -CH 2 -; Q 4 ' is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ',
-NR
4
'R
41 , -OR 4 ' and -S(O) 2
R
4 ; Q4 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 41 , -NR 4
'R
41 , -OR 4 ' and -S(O) 2
R
4 '; and Q 5 ' and Q54 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably Qs 2 and Q 5 4 are independently hydrogen, fluoro, chloro, methyl, or -CF 3 ; wherein R 4 ' is as defined in Formula II. [00301 In one embodiment, further to any of the embodiments of Formula Ile above, R 4 ' is R 4 ' as defined for Formula II. 10031] In one embodiment of compounds of Formula Ile, Ms. is -C(O)NHCH 2 -,
-C(O)NHCH(CH
3 )- or -C(O)NH(CH 2
)
2 -; A 6 is -CH 2 - or -C(O)-, preferably -CH 2 -; Q 4 1 is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with I or 2 substituents selected from the group consisting of fluoro, chloro, methyl, fluoro substituted methyl, methoxy, and fluoro substituted methoxy; Q 4 5 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, preferably hydrogen or chloro; and Q1 2 and 17 WO 2008/064255 PCT/US2007/085289 Q4 are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably Q" and Q 5 4 are methyl. [00321 In one embodiment of compounds of Formula Ie, the compound is selected from the group consisting of: 3-(1-Benzyl-3,5-dimethyl-1H-pyrazol-4-ylmethyl)-I H-pyrrolo[2,3-b]pyridine (P-0133), 2-[3,5-Dimethyl-4-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazol-1-yl]-1-phenyl-ethanone (P-0134), 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1 -carboxylic acid 4-methoxy benzylamide (P-0135), 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 2-chloro benzylamide (P-0136), 3,5-Dimethyl-4-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1 -carboxylic acid 2-fluoro benzylamide (P-0137), 3-[3,5-Dimethyl-1-(5-trifluoromethyl-furan-2-ylmethyl)-1H-pyrazol-4-ylmethyl]-1 H-pyrrolo[2,3 b]pyridine (P-0138), 3-[3,5-Dimethyl-1-(5-methyl-isoxazol-3-ylmethyl)-1H-pyrazol-4-ylmethyl]-1H-pyrrolo[2,3 b]pyridine (P-0139), 3,5-Dimethyl-4-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- 1 -carboxylic acid 4-chloro benzylamide (P-0140), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid [2-(4-methoxy phenyl)-ethyl]-amide (P-0141), 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l -carboxylic acid 3-methoxy benzylamide (P-0142), 3-{3,5-Dimethyl-1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-1H-pyrazol-4 ylmethyl} -1 H-pyrrolo[2,3-b]pyridine (P-0143), 3-[3,5-Dimethyl-1-(4-methyl-2-phenyl-thiazol-5-ylmethyl)-H-pyrazol-4-ylmethyl]-1H pyrrolo[2,3-b]pyridine (P-0144), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid 2-methoxy benzylamide (P-0145), 3,5-Dimethyl-4-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I-carboxylic acid [2-(2,4 dichloro-phenyl)-ethyl]-amide (P-0146), 3,5-Dimethyl-4-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid [2-(4-fluoro phenyl)-ethyl]-amide (P-0147), 3,5-Dimethyl-4-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid [2-(2-fluoro phenyl)-ethyl]-amide (P-0148), 18 WO 2008/064255 PCT/US2007/085289 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I-carboxylic acid ((S)-1-phenyl ethyl)-amide (P-0149), 3,5-Dimethyl-4-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid 3-fluoro benzylamide (P-0150), 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 4-fluoro benzylamide (P-0151), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I-carboxylic acid 4-methyl benzylamide (P-0152), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid 2-methyl benzylamide (P-0153), 4-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole- I -carboxylic acid [2-(4 fluoro-phenyl)-ethyl]-amide (P-0157), 4-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-1-carboxylic acid 4 fluoro-benzylamide (P-0158), 4-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-I -carboxylic acid 4 chloro-benzylamide (P-0159), 4-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-I-carboxylic acid [(S) 1-(4-fluoro-phenyl)-ethyl]-amide (P-0160) , and all salts, prodrugs, tautomers, and isomers thereof. [0033] In one embodiment, a compound of Formula H has a structure according to the following sub-generic structure, Formula I1g, Q72 N-N
Q
65
A
8
M
10
-Q
61
Q
7 4 H Formula I1g, all salts, prodrugs, tautomers, and isomers thereof, wherein:
A
8 is -CH 2 -, Or -C(O)-;
Q
6 5 is hydrogen, -CN, -OR 41 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the 19 WO 2008/064255 PCT/US2007/085289 group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 1 ,
-NR
4
'R
41 , and -OR"; and M1 0 , Q 6 ', Q11, Q 7 4 , and R 4 ' are as defined for Formula II. 100341 In one embodiment of compounds of Formula hg, Mio is -NR 39
CH
2 - or -NR39-(CH,)r; As is -CH 2 - or -C(O)-, preferably -CH 2 -; Q 6 ' is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 1 , -NR 41
R
41 , -OR 4 1 and -S(O)2R 4 '; Q 6 5 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ,
-NR
4
'R
4 ', -OR 4 ' and -S(O) 2
R
41 ; and Q1 4 is hydrogen, fluoro, chloro, lower alkyl or fluoro substituted lower alkyl, wherein R 4 ' is as defined for Formula II. 100351 In one embodiment, further to any of the embodiments of Formula Ug above, R 4 is R 4 2 as defined for Formula 1. 100361 In one embodiment of compounds of Formula Hg, M1 0 is -NHCH 2 -; A 8 is -CH 2 -; Q 6 ' is phenyl optionally substituted with 1 or 2 substituents selected from the group consisting of fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy or trifluoromethoxy; Q 6 5 is hydrogen, fluoro, -CN, or 1-methyl-pyrazol-4-yl; Q" is lower alkyl or fluoro substituted lower alkyl; and Q1 4 is hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl. In one embodiment, Mio is -NHCH 2 -; A 8 is -CH 2 -; Q 6 ' is 4-fluoro-phenyl; Q 6 5 is hydrogen, chloro, -CN, or 1-methyl pyrazol-4-yl; Q" is methyl or ethyl; and Q 7 4 is hydrogen or chloro. 100371 In one embodiment, the compound of Formula Hg is selected from the group consisting of: [1 -Ethyl-5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]-(4-fluoro-benzyl)-amine (P-0165), (4-Fluoro-benzyl)-[1 -methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]-amine (P-0169), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1 -methyl-1H-pyrazol-3-yl)-(4-fluoro-benzyl) amine (P-0170), (4-Fluoro-benzyl)-( -methyl-5-[5-(] -methyl-1H-pyrazol-4-yl)-1lH-pyrrolo[2,3-bjpyridin-3 ylmethyl]-IH-pyrazol-3-yl)-amine (P-0180), (5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-[2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazol-3-yl] 20 WO 2008/064255 PCT/US2007/085289 methanone (P-0184), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)- -ethyl-I H-pyrazol-3-yl]-(4-fluoro-benzyl) amine (P-0185), 3-[5-(4-Fluoro-benzylamino)-2-methyl-2H-pyrazol-3-ylmethyl]- H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0191), (3-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-methyl-iH-pyrazol-3-yl] amine (P-0410), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-methyl-IH-pyrazol-3-ylj-(2,5-difluoro benzyl)-amine (P-041 1), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-methyl-iH-pyrazol-3-yl]-(2-fluoro-benzyl) amine (P-0413), and all salts, prodrugs, tautomers, and isomers thereof. 10038] In one embodiment, a compound of Formula II has a structure according to the following sub-generic structure, Formula i1p,
Q
152 Q145 A16 S
M
18
-Q
1 4 ' N N H Formula lIp, all salts, prodrugs, tautomers, and isomers thereof, wherein:
A
16 is -CH 2 - or -C(O)-;
Q
1 4 5 is hydrogen, -CN, -OR 4 1 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ',
-NR
41
R
41 , and -OR 4 ; Q' is hydrogen, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy; and MIS, Q1 4 ', and R 41 , are as defined for Formula II; 21 WO 2008/064255 PCT/US2007/085289 ~~OCl provided, however, that the compound is not H or CI N~ N N H [00391 In one embodiment of compounds of Formula Ip, Mis is -NR"CH 2 - or -NR"-(CH2)2 A1 6 is -Cr1 2 - or -C(O)-, preferably -CH 2 -; Q'' is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 41 , -NR 41
R
41 , -OR 4 ' and -S(O) 2
R
4 '; Q'1 4 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 1 ,
-NR
4
'R
41 , -OR 4 ' and -S(O) 2
R
4 '; and Q' 52 is hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl; wherein R 4 ' is as defined for Formula II. [0040] In one embodiment of compounds of Formula I1p, Mis is -NH-CH 2 - or -NH-(CH 2
)
2 -, preferably -NH-CH 2 -; A1 6 is -CH 2 - or -C(O)-, preferably -CH 2 -; Q'' is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with I or 2 substituents selected from the group consisting of fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, and heterocycloalkyl; Q' 45 is hydrogen, -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, preferably hydrogen, -CN, or chloro; and Q' 5 2 is hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl, preferably hydrogen or chloro, more preferably chloro. 100411 In one embodiment, the compound of Formula Th is selected from the group consisting of [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine (P-0156), [4-Ethyl-5-(1IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine (P-0162), (4-Fluoro-benzyl)-[4-methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine (P-0163), (4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl-amine (P-0164), 22 WO 2008/064255 PCT/US2007/085289 [4-Chloro-5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-2-ylmethyl-amine (P-0167), [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-pyridin-4-ylmethyl-amine (P-0168), [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(6-methyl-pyridin-2-ylmethyl) amine (P-0171), [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(1,5-dimethyl-1 H-pyrazol-3 ylmethyl)-amine (P-0172), [4-Chloro-5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0173), [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylJ-(2,5-dimethyl- 2 H-pyrazol-3 ylmethyl)-amine(P-0175), [2-(4-Fluoro-benzylamino)-thiazol-5-yl]-(IH-pyrrolo[2,3-b]pyridin-3-yl)-methanone (P-0177), {2-[(4-Chloro-benzyl)-methyl-amino]-thiazol-5-yl}-(1H-pyrrolo[2,3-b]pyridin-3-yl)-methanone (P-0178), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-thiazol-2-ylmethyl amine (P-0189), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methoxy-pyridin-3 ylmethyl)-amine (P-0190), Benzyl-[4-chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine (P-0192), [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-methoxy-benzyl) amine (P-0193), (4-Chloro-benzyl)-[4-chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI] amine (P-0194), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl) amine (P-0195), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y1]-(2,4-dimethyl-thiazol-5 ylmethyl)-amine (P-0196), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(2-ethyl-5-methyl-3H imidazol-4-ylmethyl)-amine (P-0197), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(2-ethyl-2H-pyrazol-3 ylmethyl)-amine (P-0198), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ymethyl)-thiazol-2-yl]-(6-methoxy-pyridin-2 ylmethyl)-amine (P-0199), [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmthyl)-thiazol-2-yI]-(3-fluoro-pyridin-4 ylmethyl)-amine (P-0200), 23 WO 2008/064255 PCT/US2007/085289 [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-mcthyl-thiazol-4 ylmethyl)-amine (P-0201), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-methyl-thiazol-5 ylmethyl)-amine (P-0202), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-chloro-pyridin-2 ylmethyl)-amine (P-0203), [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,4-dimethyl-thiazol-5 ylmethyl)-amine (P-0204), [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-5-methyl-3H-imidazol 4-ylmethyl)-amine (P-0205), [4-Chloro-5( H-pyrrolo[2,3-bpyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2-ylmethyl) amine (P-0206), [4-Chloro-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-methoxy-pyridin-3-ylmethyl) amine (P-0207), [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4,5-dimethyl-thiophen-2 ylmethyl)-amine (P-0208), [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yi]-(2,5-dimethyl-thiophen-3 ylmethyl)-amine (P-0209), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-3 ylmethyl)-amine (P-0231), [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl amine (P-0236), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin- 4 -ylmethyl amine (P-0237), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-chloro-pyridin-4 ylmethyl)-amine (P-0238), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-( -ethyl-I H-pyrazol-4 ylmethyl)-amine (P-0239), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2 ylmethyl)-amine (P-0240), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-methoxy-pyridin- 3 ylmethyl)-amine (P-0241), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmCthyl)-thiazol-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0242), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(2-chloro-6-fluoro benzyl)-amine (P-0243), 24 WO 2008/064255 PCT/US2007/085289 [4-Chloro-5-(5-chloro-1 proo23b~yii--lehy)tizl2y]-hnty-mn (P-0244), [4-Chloro-5-(5 -chloro-1 proo23bprdn--lehl-hao--l](,-iloobny) amine (P-0245), [4-Chloro-5-(5-chloro-1 proo23bprdn--lehl-hao--y](-loobny) amine (P-0246), [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-bI~pyridin-3 -ylmethy1)-thiazo1-2-yI-(2-methoxy-pyridifl-3 ylmethyl)-amine (P-0247), (2.Chloro-benzyl)-14-chloro-5 -(5 -chi oro- I H-pyrrolo [2,3-blpyridin-3-ylmethyl)-thiazol-2-yl] amine (P-0248), (4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin3-ylmethy)-thiazoI-2-y1]-(2-mthylbelzyl) amine (P-0249), [4-Chloro-5-(5-chloro- I H-yrl[,-lyii--lehl-hao--l-2clr--loo benzyl)-amine (P-0250), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethy)-thiazoI-2-y1]-(3-flUOro-pyridifl- 2 ylmethyl)-amine (P-0251), [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyI)-thiazo1-2-yl]-(6-morpholifl 4 -yi pyridin-2-ylmethyl)-amine (P-0252), [4-Chloro-5-(5-chloro- I H-pyrrololl2,3-b]pyridin-3 -ylmethyl)-thiazol-2-yl]-(3,5-dichloro-pyridifl- 4 ylmethyl)-amine (P-0253), [4-Chloro-5 -(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethy)-thiazol-2-y]-(2-trifluorornethyI benzyl)-amine (P-0254), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-mlethylIpyridifl 2 ylmethyl)-amine (P-0255), [5-(5-Chloro- 1 roo23bpyii--lehl-tizl2y](-lur-ezl-mn (P-0290) , and all salts, prodrugs, tautomners, and isomers thereof. 25 WO 2008/064255 PCT/US2007/085289 [00421 The compounds of Formula III have the following structure: .. H N N
L
4
-R
8 3 RR8 7 N
R
82 N N H Formula III, all salts, prodrugs, tautomers, and isomers thereof, wherein: L4 is -CH 2 -, -CH 2
CH
2 -, -CH(R 40 )-, -C(O)- or -C(O)NH-;
R
8 1 is selected from the group consisting of hydrogen, -OR 4 ', -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4
'R
41 , -OR 4 ' and -S(O) 2
R
41 ;
R
82 is selected from the group consisting of hydrogen, C , 3 alkyl, fluoro substituted C 2
-
3 alkyl, OH, C1.
3 alkoxy, and fluoro substituted C1.
3 alkoxy; R96 R95 R94
R
8 is heterocycloalkyl, heteroaryl, or R 92 , in which indicates the attachment point of R1 3 to L 4 of Formula III, wherein heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHR 4 ', -NR 4
'R
4 ',
-OR
4 ' and -S(0) 2
R
4 ';
R
92 , R 93 , R 4 , R 95 , and R 9 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHS(O) 2 R',
-NHC(O)R
4 ', -NHR 4 ', -NR 4
'R
4 ', -OR 4 ' and -S(O) 2
R
4 1 ; and
R
4 " and R 4 ' are as defined for Formula II; 26 WO 2008/064255 PCT/US2007/085289 H - NJ/F SNj N, N N N N N N N HN HH N NN N NN H HH H H CFi H N N N, H N HNN N NN N N NN H H H Hr N i k HO H-o N HN N _ - N. NNN N H N- N HI HH N N N N N N HH H g-r~lH I.CF 3 H <INN- N- N NN NN HH H YN27 WO 2008/064255 PCT/US2007/085289 (o:c .
O CF3 ~ I F NN N NN H H H C1 CF3 H CF3 N NNIN H H or H 100431 In one embodiment of compounds of Formula III, L 4 is -CH 2 -, -CH 2
CH
2 -, -CII(CH3)- or -C(O)-; R' is hydrogen, fluoro, chloro, -CN, lower alkyl, fluoro substituted lower alkyl, lower R9s R95 R94 alkoxy, or fluoro substituted lower alkoxy; R8 2 is hydrogen; R 83 is R 92
R
93 , wherein R2,
R
9 , R", R 9 , and R 9 ' are independently hydrogen, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, provided, however, that when R 94 is fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, at least one of R 92 , R", R 95 , and R 9 ' is fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy. 100441 In one embodiment of compounds of Formula III, L 4 is -CH 2 -, -CH 2
CH
2 -, -CI(CHI)- or -C(O)-; R 8 ' is hydrogen, fluoro, chloro, -CN, methyl, or methoxy, preferably hydrogen, chloro, Res
R
9 5
R
9 4 -CN, or methyl; R8 2 is hydrogen; R 8 3 is R92 R93 , wherein R1 2 , R 93 , R1 4 , R", and R9' are independently hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy, preferably hydrogen, chloro, methyl, trifluoromethyl, methoxy, ethoxy, or trifluoromethoxy, provided, however, that when R 94 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy, at least one of R 9 , R", R", and R 96 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy. 28 WO 2008/064255 PCT/US2007/085289 10045] In one embodiment of compounds of Formula I1, L 4 is -CH-; R 8 ' is fluoro, chloro, -CN, R96 R95 R94 methyl, or methoxy, preferably chloro, -CN, or methyl; R 82 is hydrogen; R" is R 92
R
9 3 wherein R 94 is hydrogen and R", R 9 ', R 9 , and R1 6 are independently hydrogen, fluoro, chloro, methyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy or trifluoromethoxy. [0046] In one embodiment of compounds of Formula III, L 4 is -CH 2 -, -CH 2
CH
2 -, -C(O)-, or
-CH(CH
3 )-, preferably -CH 2 - or -C(O)-; R 81 is hydrogen or flouro; R 8 2 is hydrogen; R 8 1 is
R
96 R95 R94
R
92 R93 , wherein R 92 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, methyl, or trifluoromethyl, and R", R 94 , R 9 ', and R 96 are independently hydrogen, fluoro, chloro, methyl, trifluoromethyl, methoxy, difluoromethoxy or trifluoromethoxy, preferably hydrogen or fluoro. In one embodiment, L 4 is -CH 2 -, -C(O)-, or -CH(CH3)-; R" is hydrogen; R1 2 is hydrogen; R 92 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, methyl, or trifluoromethyl; and R 9 ', R 94 , R 9 , and R1 6 are hydrogen. In one embodiment, L 4 is -CH 2 -, -C(O)-, or -CH(CH 3 )-; R 8 ' is hydrogen; R 82 is hydrogen; R 92 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, methyl, or trifluoromethyl; R1 4 , R", and R 96 are hydrogen; and R 93 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, trifluoromethyl or methoxy, more preferably fluoro. In one embodiment,
L
4 is -CH 2 -, -C(O)-, or -CH(CH 3 )-; R 8 1 is hydrogen; R 82 is hydrogen; R 9 2 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, methyl, or trifluoromethyl; R 93 , R 95 , and R9 6 are hydrogen; and R 94 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, methyl or trifluoromethyl, more preferably fluoro. In one embodiment, L 4 is -CH 2
CH
2 - or -C(O)-; Ro' is hydrogen; R 82 is hydrogen; R 9 2 , R 95 , and R1 6 are hydrogen; R 93 is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably hydrogen, fluoro, chloro, methyl, trifluoromethyl, methoxy, or trifluoromethoxy, more preferably fluoro, chloro, trifluoromethyl or methoxy; and R 94 is hydrogen, fluoro, or chloro; provided, however, that when L 4 is -C(O)- and R 94 is fluoro or chloro, R 93 is not hydrogen. In one 29 WO 2008/064255 PCT/US2007/085289 embodiment, L 4 is -CH 2
CH
2 -; R 8 1 is hydrogen; R 82 is hydrogen; R 92 , R 94 , R 9 ', and R 96 are hydrogen; and R 93 is hydrogen, fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably hydrogen or fluoro. In one embodiment, L 4 is -C(O)-; R 8 is hydrogen; R 8 is hydrogen; R 92 , R 9 ', and R" are hydrogen; R 93 is fluoro, chloro, methyl, ethyl, trifluoromethyl, methoxy, ethoxy, difluoromethoxy, or trifluoromethoxy, preferably fluoro, chloro, trifluoromethyl or methoxy; and R 94 is hydrogen, fluoro, or chloro. [0047] In one embodiment of compounds of Formula III, R 83 is pyrrolidine, morpholine, pyridine, pyrimidine, pyrazine, pyrazole, isoxazole, imidazol, or benzimidazole, wherein R 83 is optionally substituted with one or more substituents independently selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHR 4 ',
-NR
4
'R
4 ', -OR 4 ' and -S(O) 2
R
4 , preferably wherein R is optionally substituted with I or 2 substituents independently selected from fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, or cycloalkylamino, more preferably fluoro, chloro, methyl, trifluoromethyl, methoxy or morpholine. [0048] In one embodiment of compounds of Formula III, L 4 is -CH 2 -, -CH 2
CH
2 -, -CH(CH 3 )- or -C(O)-, preferably -CH 2 -, -CH 2
CH
2 -, or -C(O)-; R 8 is hydrogen, fluoro, chloro, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, or fluoro substituted lower alkoxy, preferably hydrogen, chloro, methyl or -CN; R" is hydrogen; and R 83 is pyrrolidine, morpholine, pyridine, pyrimidine, pyrazine, pyrazole, isoxazole, imidazole, or benzimidazole, wherein R" is optionally substituted with I or 2 substituents independently selected from fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, lower alkoxy, fluoro substituted lower alkoxy, or cycloalkylamino, preferably fluoro, chloro, methyl, trifluoromethyl, methoxy or morpholine. [00491 In one embodiment of compounds of Formula III, the compound is selected from the group consisting of: Pyridin-3-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0094), (5-Methyl-isoxazol-3-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0095), (2-Pyrrolidin-1-yl-ethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0096), [1-(4-Methanesulfonyl-phenyl)-ethyl]-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0097), (2-Morpholin-4-yl-ethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0099), 3,4-Dichloro-N-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0100), 2-Chloro-4-fluoro-N-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-01 01), 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid [5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 30 WO 2008/064255 PCT/US2007/085289 yl]-amide (P-0102), Thiophene-2-carboxylic acid [5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide (P-0103), 2-Methoxy-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonicotinamide (P-0104), N-[5-(l H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonicotinamide (P-0105), Pyrazine-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide (P-0106), Pyridine-2-carboxylic acid [5-( 1l-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide (P-0107), 6-Methyl-N-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-nicotinamide (P-0108), 4-Fluoro-3-methyl-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-benzamide (P-0109), 5-Methyl-pyrazine-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amide (P-0110), 3-Chloro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0111), 4-Fluoro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethyl-benzamide (P-0 112), N-[5-(1 H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethoxy-benzamide (P-0113), N-[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethyl-benzamide (P-0114), 3-Chloro-4-fluoro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0115), 3,4-Difluoro-N-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0116), 2-Chloro-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0117), 5-Fluoro-2-methyl-N-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0 118), 2-Fluoro-N-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-01 19), 3-Methoxy-N-[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0120), 3-Fluoro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0121), 3-Methyl-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0122), 2-Chloro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonicotinamide (P-0123), ((R)-1-Phenyl-ethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0125), (3-Morpholin-4-yl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0 126), [ I-(2-Fluoro-phenyl)-ethyl]-[5 -(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0127), [2-(3-Fluoro-phenyl)-ethyl]-[5-(I H-pyrrolo [2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine 31 WO 2008/064255 PCT/US2007/085289 (P-0128), (3-Chloro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0129), (I-Methyl-I H-imidazol-4-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylI] amine (P-0130), (1,5-Dimethyl-1H-pyrazol-3-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0131), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0181), [5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl) amine (P-0182), (3-Chloro-pyridin-4-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0183), (2-Chloro-6-fluoro-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0210), Phenethyl-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-02 11), (2,4-Difluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-amine (P-0212), (2-Fluoro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylI]-amine (P-0213), (3-Bromo-pyridin-4-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0214), (2-Methoxy-pyridin-3-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0215), (2-Chloro-benzyl)-[5-(I H-pyrrolo[2,3 -b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0216), (2-Methyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0217), (1-Methyl-I H-benzoimidazol-2-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-pyridin-2 yl]-amine (P-0218), (6-Methoxy-pyridin-3-ylmethyl)-[5-(IH-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0219), (1H-Benzoimidazol-2-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0220), (2-Chloro-4-fluoro-benzyl)-[5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0221), (5-Methoxy-pyridin-3-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0222), (3-Fluoro-pyridin-4-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0223), (6-Methoxy-pyridin-2-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine 32 WO 2008/064255 PCT/US2007/085289 (P-0224), (4-Fluoro-2-trifluoromethyl-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0225), [5-(I H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl-(2-trifluoromethyl-benzyl)-aminc (P-0226), (3,5-Dichloro-pyridin-4-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0227), (6-Morpholin-4-yl-pyridin-2-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0228), (3-Fluoro-pyridin-2-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-amine (P-0229), (5-Fluoro-pyridin-3-ylmethyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0230), (3-Chloro-pyridin-4-ylmethyl)-[5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0235), 3-{6-[(3-Chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0256), 3-[6-(4-Chloro-benzylamino)-pyridin-3-ylmethyll-I H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0257), Propane-l -sulfonic acid (2,4-difluoro-3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 ylamino]-methyl)-phenyl)-amide (P-0258), Propane-i -sulfonic acid (3-{[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 ylamino]-methyl)-2,4-difluoro-phenyl)-amide (P-0259), 3-[6-(4-Trifluoromethyl-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0269), [5-(5-Chloro-11H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-fluoro-benzyl)-amine (P-0270), 3-[6-(2-Fluoro-benzylamino)-pyridin-3-ylmethyl]-IH-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0271), (2-Fluoro-benzyl)-[5-(5-methyl-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0272), 3-(6-[(6-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1 H-pyrrolo[2,3 blpyridine-5-carbonitrile (P-0273), 3-[6-(2-Trifluoromethyl-benzylamino)-pyridin-3-ylmethyl]-IH-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0274), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-(2-trifluoromethyl-bnzyl) 33 WO 2008/064255 PCT/US2007/085289 amine (P-0275), [5-(5-Methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0276), 3-[6-(2,6-Difluoro-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0277), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-difluoro-benzyl)-amine (P-0278), (2-Chloro-benzyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0279), (2-Chloro-benzyl)-[5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0280), 3-[6-(2-Chloro-benzylamino)-pyridin-3-ylmethyl]- H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0281), (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yi]-amine (P-0282), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3 ylmethyl)-amine (P-0283), 3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0284), (2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine (P-0285), [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-(2-methoxy-pyridin-3 ylmethyl)-amine (P-0286), 3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmthyl}-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0287), (2-Ethoxy-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0288), (2,5-Difluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0296), (2,5-Difluoro-benzyl)-[5-(5-methyl-) H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yi]-amine (P-0297), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-(2,5-difluoro-benzyl)-amine (P-0298), 3-[6-(2,5-Difluoro-benzylamino)-pyridin-3-ylmethyl]-I H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0299), 3-[6-(2-Trifluoromethoxy-benzylamino)-pyridin- 3 -ylmethyl]-I H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0321), [5-( H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethoxy-benzyl)-amine 34 WO 2008/064255 PCT/US2007/085289 (P-0322), 3-[6-(2-Ethoxy-benzylamino)-pyridin-3-ylmethyl]-IH-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0323), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-pyridin-3-ylmethyl) amine (P-0324), [5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0325), [5-(5-Methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0326), (2-Chloro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0327), (2-Chloro-benzyl)-[5-(5-methoxy-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0328), (2,5-Difluoro-benzyl)-[5-(5-fluoro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0329), (2,5-Difluoro-benzyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-amine (P-0330), [5-(5-Fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin- 3 -ylmethyl) amine (P-0331), (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yI]-amine (P-0332), (2,6-Difluoro-benzyl)-[5-(5-fluoro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0333), (2,6-Difluoro-benzyl)-[5-(5-methoxy-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0334), (2-Methoxy-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0336), 3-[6-(2-Methoxy-benzylamino)-pyridin-3-ylmethyl]- I H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0337), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-(2-difluoromethoxy-benzyl) amine (P-0338), 3-[6-(2-Difluoromethoxy-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0339), (2,6-Difluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0340), (2,6-Difluoro-benzyl)-[5-(5-methyl-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0341), (2,4-Dichloro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0342), 35 WO 2008/064255 PCT/US2007/085289 (3-Fluoro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0343), (2-Fluoro-4-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0344), (4-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0345), (3-Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0346), (2-Morpholin-4-yI-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylJ amine (P-0347), (4-Chloro-3-trifluoromethyl-benzyl)-[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0348), (2-Chloro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0349), ' (2-Fluoro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0350), (2,3-Dichloro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0351), (2-Fluoro-3-methoxy-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0352), Dimethyl-(5- ([5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyrimidin-2 yl)-amine (P-0353), (3-Chloro-2-fluoro-benzyl)-[5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0354), (5-Fluoro-pyridin-2-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0355), (3,5-Difluoro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0356), (2-Propoxy-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0357), (2-Morpholin-4-yl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0358), (2-Chloro-3-methoxy-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yli]-amine (P-0359), (2-Fluoro-6-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0360), [2-(2-Morpholin-4-yl-ethoxy)-benzyl-[5-(1 H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0361), (2,3-Difluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0362), (2-Chloro-3-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl] 36 WO 2008/064255 PCT/US2007/085289 amine (P-0363), (2-Chloro-5-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0364), (2-Fluoro-3-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0365), (5-Fluoro-2-methoxy-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0366), (2-Difluoromethoxy-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0367), (2-Fluoro-4-methyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0368), [2-(3-Dimethylamino-propoxy)-benzyl]-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0369), (2,6-Dimethoxy-pyridin-3-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0370), (2-Fluoro-5-methoxy-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-amine (P-0371), (4-Fluoro-2-methyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0372), (3 -Chloro-5-fluoro-benzyl)-[5-(l H-pyrrolo[2,3 -b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0373), (6-Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0374), (5-Fluoro-2-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0375), [5-(IH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[2-(2,2,2-trifluoro-ethoxy)-pyridin-3 ylmethyl]-amine (P-0376), Propane-] -sulfonic acid (2-fluoro-3-{[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 ylamino]-methyl} -phenyl)-amide (P-0377), (2,5-Dichloro-benzyl)-[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yli]-amine (P-0380), Pyrimidin-5-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0381), (5-Chloro-2-fluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0382), (2-Ethyl-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0383), 2,2-Dimethyl-N-(3- {[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl} pyridin-2-yl)-propionamide (P-0384), 37 WO 2008/064255 PCT/US2007/085289 Methyl-(3-{[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyridin-2-yl) amine (P-0385), Methyl-(5-{[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyrimidin-2 yl)-amine (P-0386), (2-Chloro-4-methanesulfonyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0387), Possibly to be added (P-0388), (5-Fluoro-2-methyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0397), Dimethyl-(3-{ [5-(l H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl} -pyridin-2 yl)-amine (P-0399), (5-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0400), (2-Methoxy-pyrimidin-5-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0401), [5-(5-Chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-[6-(2,2,2-trifluoro-ethoxy) pyridin-3-ylmethyl]-amine (P-0409), 1-(3-Fluoro-phenyl)-3-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-urea (P-0412) , and all salts, prodrugs, tautomers, and isomers thereof. 10050] In one embodiment, a compound of the invention is: (4-Chloro-benzyl)-[6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridazin-3-yl]-amine (P-0092), (4-Morpholin-4-ylmethyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylj-amine (P-0093), (2-Methoxy-ethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0098), [4-Chloro-1 -ethyl-5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l H-pyrazol-3-yl]-[1 -(4-fluoro phenyl)-meth-(E)-ylidene]-amine (P-0166), ( (2,2-Difluoro-benzo[ 1,3]dioxol-4-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine (P-0398); or any salts, prodrugs, tautomers, and isomers thereof. 10051] In certain embodiments of the above compounds, compounds are excluded where N (except where N is a heteroaryl ring atom), 0, or S is bound to a carbon that is also bound to N (except where N is a heteroaryl ring atom), 0, or S, except where the carbon forms a double bond with one of the heteroatoms, such as in an amide, carboxylic acid, and the like; or where N (except where N is a heteroaryl ring atom), 0, C(S), C(O), or S(O), (n is 0-2) is bound to an alkene carbon 38 WO 2008/064255 PCT/US2007/085289 of an alkenyl group or bound to an alkyne carbon of an alkynyl group; accordingly, in certain embodiments compounds which include linkages such as the following are excluded from the present invention: -NR-CH 2 -NR-, -O-CH 2 -NR-, -S-CH 2 -NR-, -NR-CH 2 -O-, -O-CH 2 -O-,
-S-CH
2
-O-,-NR-CH
2 -S-, -O-CH 2 -S-, -S-CH 2 -S-, -NR-CH=CH-, -CH=CH-NR-, -NR-C EC-, -C aC-NR-, -O-CH=CH-, -CH=CH-O-, -0-C EC-, -C -0-, -S(O)o.,-CH=CH-, -CH=CH-S(0)o.2-, -S(0) 0
.
2 -C C-, -C C-S(0) 0
.
2 -, -C(O)-CH=CH-, -CH=CH-C(0)-, -C iC-C(0)-, or -C(O)-C EC-, -C(S)-CH=CH-, -CH=CH-C(S)-, -C C-C(S)-, or -C(S)-C a-. 100521 In reference to compounds herein, specification of a compound or group of compounds includes pharmaceutically acceptable salts of such compound(s), prodrug(s), and all stereoisomers, unless clearly indicated to the contrary. In reference to compounds of Formula II, it is understood that such reference includes compounds of Formulae a, Ib, Ie, IIg and Hp, and all sub embodiments thereof. 10053) In another aspect, the invention provides methods for treating a c-kit-mediated disease or condition in an animal subject (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal c-kit activity (e.g. kinase activity). Invention methods involve administering to the subject suffering from or at risk of a c-kit mediated disease or condition an effective amount of a compound of Formula II or Formula III, and all sub-embodiments thereof. In one embodiment, the c-kit mediated disease is selected from the group consisting of malignancies, including, but not limited to, mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors (GISTs), glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, mastocytosis, melanoma, and canine mast cell tumors, and inflammatory diseases, including, but not limited to, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, and hypereosinophilia. [00541 In a related aspect, compounds of Formula II or Formula III, and all sub-embodiments thereof, can be used in the preparation of a medicament for the treatment of a c-kit-mediated disease or condition selected from the group consisting of malignancies, including, but not limited to, mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors (GISTs), glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myelocytic leukemia, acute lymphocytic 39 WO 2008/064255 PCT/US2007/085289 leukemia, chronic myelogenous leukemia, mastocytosis, melanoma, and canine mast cell tumors, and inflammatory diseases, including, but not limited to, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, and hypereosinophilia. 100551 In a further aspect, the invention provides methods for treating a c-fins-mediated disease or condition in an animal subject (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), e.g., a disease or condition characterized by abnormal c-fms activity (e.g. kinase activity). Invention methods involve administering to the subject suffering from or at risk of a c fins-mediated disease or condition an effective amount of compound of Formula II or Formula III, and all sub-embodiments thereof. In one embodiment, the c-fns mediated disease is selected from the group consisting of immune disorders, including, but not limited to, rheumatoid arthritis, systemic lupus erythematosis (SLE), and transplant rejection; inflammatory diseases including, but not limited to, osteoarthritis, inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease (COPD), emphysema, Kawasaki's Disease, hemophagocytic syndrome (macrophage activation syndrome), multicentric reticulohistiocytosis, and atherosclerosis; metabolic disorders, including, but not limited to, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, and lipolysis; disorders of bone structure, mineralization and bone formation and resorption, including, but not limited to, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, infection-mediated osteolysis (e.g. osteomyelitis), peri-prosthetic or wear-debris-mediated osteolysis, and metastasis of cancer to bone; kidney and genitourinary diseases, including, but not limited to, endometriosis, nephritis (e.g. glomerulonephritis, interstitial nephritis, Lupus nephritis), tubular necrosis, diabetes associated renal complications (e.g. diabetic nephropathy), and renal hypertrophy; disorders of the central nervous system, including, but not limited to, multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease; inflammatory and chronic pain, including, but not limited to, bone pain; and cancers, including, but not limited to, multiple myeloma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), prostate cancer, breast cancer, ovarian cancer, melanoma, glioblastoma multiforme, metastasis of tumors to other tissues, and other chronic myeloproliferative diseases such as myelofibrosis. [00561 In a related aspect, compounds of Formula II or Formula III, and all sub-embodiments thereof, can be used in the preparation of a medicament for the treatment of a c-fins-mediated disease or condition selected from the group consisting of immune disorders, including, but not limited to, rheumatoid arthritis, systemic lupus erythematosis (SLE), and transplant rejection; 40 WO 2008/064255 PCT/US2007/085289 inflammatory diseases including, but not limited to, osteoarthritis, inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease (COPD), emphysema, Kawasaki's Disease, hemophagocytic syndrome (macrophage activation syndrome), multicentric reticulohistiocytosis, and atherosclerosis; metabolic disorders, including, but not limited to, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, and lipolysis; disorders of bone structure, mineralization and bone formation and resorption, including, but not limited to, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, infection-mediated osteolysis (e.g. osteomyelitis), peri-prosthetic or wear-debris-mediated osteolysis, and metastasis of cancer to bone; kidney and genitourinary diseases, including, but not limited to, endometriosis, nephritis (e.g. glomerulonephritis, interstitial nephritis, Lupus nephritis), tubular necrosis, diabetes-associated renal complications (e.g. diabetic nephropathy), and renal hypertrophy; disorders of the central nervous system, including, but not limited to, multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease; inflammatory and chronic pain, including, but not limited to, bone pain; and cancers, including, but not limited to, multiple myeloma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), prostate cancer, breast cancer, ovarian cancer, melanoma, glioblastoma multiforme, metastasis of tumors to other tissues, and other chronic myeloproliferative diseases such as myelofibrosis. [0057] In a further aspect, the invention provides methods for treating, in an animal subject (e.g. a mammal such as a human, other primates, sports animals, animals of commercial interest such as cattle, farm animals such as horses, or pets such as dogs and cats), a disease or condition mediated by c-fms and c-kit, e.g., a disease or condition characterized by abnormal c-fms activity and c-kit activity (e.g. kinase activity). Invention methods involve administering to the subject suffering from or at risk of a disease or condition mediated by c-fms and c-kit an effective amount of compound of Formula II or Formula III, and all sub-embodiments thereof. In one embodiment, the condition mediated by c-fms and c-kit is selected from the group consisting of mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovarian cancer, prostate cancer, canine mast cell tumors, metastasis of cancer to bone or other tissues, chronic myeloproliferative diseases such as myelofibrosis, renal hypertrophy, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, osteoarthritis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, Kawasaki's Disease, hemophagocytic syndrome (macrophage 41 WO 2008/064255 PCT/US2007/085289 activation syndrome), multicentric reticulohistiocytosis, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, infection-mediated osteolysis (e.g. osteomyelitis), peri-prosthetic or wear-debris-mediated osteolysis, endometriosis, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory pain, chronic pain, and bone pain. [0058] In a related aspect, compounds of Formula II or Formula III, and all sub-embodiments thereof, can be used in the preparation of a medicament for the treatment of a disease or condition mediated by c-fins and c-kit selected from the group consisting of mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovarian cancer, prostate cancer, canine mast cell tumors, metastasis of cancer to bone or other tissues, chronic myeloproliferative diseases such as myelofibrosis, renal hypertrophy, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, osteoarthritis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, Kawasaki's Disease, hemophagocytic syndrome (macrophage activation syndrome), multicentric reticulohistiocytosis, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, infection-mediated osteolysis (e.g. osteomyelitis), peri-prosthetic or wear-debris-mediated osteolysis, endometriosis, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory pain, chronic pain, and bone pain. 10059] In particular embodiments, the compound has an IC 50 of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, or less than 5 nM as determined in a generally accepted kinase activity assay. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-kit than on Ret, PDGF, or both Ret and PDGF. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-kit than on c-fms. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-fins than on c-kit. In certain embodiments, the 42 WO 2008/064255 PCT/US2007/085289 compound has in combination each pairing of activity (e.g. IC5 0 ) and/or selectivity as specified in this paragraph. [0060] In particular embodiments, the compound has an IC 50 of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, or less than 5 nM as determined in a generally accepted kinase activity assay for c-kit, c-fins, or both c-kit and c-fms kinase activity. In certain embodiments, the selectivity of the compound is such that the compound is at least 2-fold, 5-fold, 10-fold, or 100-fold more active on c-kit, c-fins, or both c-kit and c-fins than on Ret, PDGF, or both Ret and PDGF. [0061] In particular embodiments, the compound has an IC 50 of less than 100 nM, less than 50 nM, less than 20 nM, less than 10 nM, or less than 5 nM as determined in a generally accepted kinase activity assay for c-kit, c-fms, or both c-kit and c-fns kinase activity, and further has an
IC
50 of less than 100 nM, less than 50 iM, less than 20 nM, less than 10 nM, or less than 5 nM as determined in a generally accepted kinase activity assay for at least one of HGK, TrkA, or TrkB kinase activity. 10062] An additional aspect of this invention relates to compositions that include a therapeutically effective amount of a compound of Formula II or Formula III and all sub embodiments thereof and at least one pharmaceutically acceptable carrier, excipient, and/or diluent, including combinations of any two or more compounds of Formula II or Formula III. The composition can further include one or more different pharmacologically active compounds, which can include one or more compounds of Formula II or Formula III. [00631 In one aspect, the invention provides a method of treating a cancer by administering to the subject an effective amount of a composition including a compound of Formula II or Formula III, in combination with one or more other therapies or medical procedures effective in treating the cancer. Other therapies or medical procedures include suitable anticancer therapy (e.g. drug therapy, vaccine therapy, gene therapy, photodynanic therapy) or medical procedure (e.g. surgery, radiation treatment, hyperthermia heating, bone marrow or stem cell transplant). In one aspect, the one or more suitable anticancer therapies or medical procedures is selected from treatment with a chemotherapeutic agent (e.g. chemotherapeutic drug), radiation treatment (e.g. x-ray, y-ray, or electron, proton, neutron, or a particle beam), hyperthermia heating (e.g. microwave, ultrasound, radiofrequency ablation), Vaccine therapy (e.g. AFP gene hepatocellular carcinoma vaccine, AFP adenoviral vector vaccine, AG-858, allogeneic GM-CSF-secretion breast cancer vaccine, dendritic cell peptide vaccines), gene therapy (e.g. Ad5CMV-p53 vector, adenovector encoding MDA7, 43 WO 2008/064255 PCT/US2007/085289 adenovirus 5-tumor necrosis factor alpha), photodynamic therapy (e.g. aminolevulinic acid, motexafin lutetium), surgery, and bone marrow and stem cell transplantation. [0064] In one aspect, the invention provides a method of treating a cancer by administering to the subject an effective amount of a composition including a compound of Formula II or Formula III, in combination with one or more suitable chemotherapeutic agents. In one aspect, the one or more suitable chemotherapeutic agents is selected from an alkylating agent, including, but not limited to, adozelesin, altretamine, bizelesin, busulfan, carboplatin, carboquone, carmustine, chlorambucil, cisplatin, cyclophosphamide, dacarbazine, estramustine, fotemustine, hepsulfam, ifosfamide, improsulfan, irofulven, lomustine, mechlorethamine, melphalan, oxaliplatin, piposulfan, semustine, streptozocin, temozolomide, thiotepa, and treosulfan; an antibiotic, including, but not limited to, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, menogaril, mitomycin, mitoxantrone, neocarzinostatin, pentostatin, and plicamycin; an antimetabolite, including, but not limited to, azacitidine, capecitabine, cladribine, clofarabine, cytarabine, decitabine, floxuridine, fludarabine, 5-fluorouracil, ftorafur, gemcitabine, hydroxyurea, mercaptopurine, methotrexate, nelarabine, pemetrexed, raltitrexed, thioguanine, and trimetrexate; an immunotherapy, including, but not limited to, alemtuzumab, bevacizumab, cetuximab, galiximab, gemtuzumab, panitumumab, pertuzumab, rituximab, tositumomab, trastuzumab, and 90 Y ibritumomab tiuxetan; a hormone or hormone antagonist, including, but not limited to, anastrozole, androgens, buserelin, diethylstilbestrol, exemestane, flutamide, fulvestrant, goserelin, idoxifene, letrozole, leuprolide, magestrol, raloxifene, tamoxifen, and toremifene; a taxane, including, but not limited to, DJ-927, docetaxel, TPI 287, paclitaxel and DHA-paclitaxel; a retinoid, including, but not limited to, alitretinoin, bexarotene, fenretinide, isotretinoin, and tretinoin; an alkaloid, including, but not limited to, etoposide, homoharringtonine, teniposide, vinblastine, vincristine, vindesine, and vinorelbine; an antiangiogenic agent, including, but not limited to, AE-941 (GW786034, Neovastat), ABT-510, 2-methoxyestradiol, lenalidomide, and thalidomide; a topoisomerase inhibitor, including, but not limited to, amsacrine, edotecarin, exatecan, irinotecan (also active metabolite SN-38 (7-ethyl-10-hydroxy-camptothecin)), rubitecan, topotecan, and 9-aminocamptothecin; a kinase inhibitor, including, but not limited to, erlotinib, gefitinib, flavopiridol, imatinib mesylate, lapatinib, sorafenib, sunitinib malate, AEE-788, AG 013736, AMG 706, AMN107, BMS-354825, BMS-599626, UCN-01 (7-hydroxystaurosporine), and vatalanib; a targeted signal transduction inhibitor including, but not limited to bortezomib, geldanamycin, and rapamycin; a biological response modifier, including, but not limited to, imiquimod, interferon-a, and interleukin-2; and other chemotherapeutics, including, but not limited to 3-AP (3-amino-2-carboxyaldehyde thiosemicarbazone), aminoglutethimide, asparaginase, bryostatin-1, cilengitide, E7389, ixabepilone, procarbazine, sulindac, temsirolimus, 44 WO 2008/064255 PCT/US2007/085289 tipifarnib. Preferably, the method of treating a cancer involves administering to the subject an effective amount of a composition of Formula II, Formula III or Formula IV in combination with a chemotherapeutic agent selected from 5-fluorouracil, carboplatin, dacarbazine, gefitinib, oxaliplatin, paclitaxel, SN-38, temozolomide, vinblastine, bevacizumab, cetuximab, or erlotinib. [0065] In another aspect, the invention provides a method of treating or prophylaxis of a disease or condition in a mammal, by administering to the mammal a therapeutically effective amount of a compound of Formula II or Formula III, a prodrug of such compound, or a pharmaceutically acceptable salt of such compound or prodrug. The compound can be alone or can be part of a composition. [00661 In a related aspect, the invention provides kits that include a composition as described herein. In particular embodiments, the composition is packaged, e.g., in a vial, bottle, flask, which may be further packaged, e.g., within a box, envelope, or bag; the composition is approved by the U.S. Food and Drug Administration or similar regulatory agency for administration to a mammal, e.g., a human; the composition is approved for administration to a mammal, e.g., a human, for a c-kit- and/or c-fins-mediated disease or condition; the kit of the invention includes written instructions on use and/or other indication that the composition is suitable or approved for administration to a mammal, e.g., a human, for a c-kit- and/or c-fms-mediated disease or condition; the composition is packaged in unit dose or single dose form, e.g., single dose pills, capsules, or the like. [00671 In another aspect, the present invention also provides a method for modulating c-kit or c-fms activity by contacting c-kit or c-fms with an effective amount of a compound of Formula II or Formula III and all sub-embodiments thereof active on c-kit and/or c-fms (such as compounds developed using methods described herein). The compound is preferably provided at a level sufficient to modulate the activity of the c-kit or c-fms by at least 10%, more preferably at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or greater than 90%. In many embodiments, the compound will be at a concentration of about 1 pM, 100 pM, or 1 mM, or in a range of 1-100 nM, 100-500 nM, 500-1000 nM, 1-100 pM, 100-500 pM, or 500-1000 pM. In particular embodiments, the contacting is carried out in vitro. [00681 Additional aspects and embodiments will be apparent from the following Detailed Description and from the claims. 45 WO 2008/064255 PCT/US2007/085289 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS 100691 As used herein the following definitions apply: [00701 "Halo" and "halogen" refer to all halogens, that is, chloro (Cl), fluoro (F), bromo (Br), or iodo (1). [00711 "Hydroxyl" and "hydroxy" refer to the group -OH. [0072] "Thiol" refers to the group -SH. [0073] "Lower alkyl" alone or in combination means an alkane-derived radical containing from I to 6 carbon atoms (unless specifically defined) that includes a straight chain alkyl or branched alkyl. The straight chain or branched alkyl group is attached at any available point to produce a stable compound. In many embodiments, a lower alkyl is a straight or branched alkyl group containing from 1-6, 1-4, or 1-2, carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, t butyl, and the like. "Optionally substituted lower alkyl" denotes lower alkyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound. For example "fluoro substituted lower alkyl" denotes a lower alkyl group substituted with one or more fluoro atoms, such as perfluoroalkyl, where preferably the lower alkyl is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms. While it is understood that substitutions are attached at any available atom to produce a stable compound, when optionally substituted alkyl is an R group of a moiety such as OR, -NHR, -C(O)NHR, and the like, substitution of the alkyl R group is such that substitution of the alkyl carbon bound to any -0-, -S-, or -N- of the moiety (except where -N- is a heteroaryl ring atom) excludes substituents that would result in any -0-, -S-, or -N- of the substituent (except where -N- is a heteroaryl ring atom) being bound to the alkyl carbon bound to any -0-, -S-, or -N of the moiety. 10074] "Cycloalkyl" refers to saturated or unsaturated, non-aromatic monocyclic, bicyclic or tricyclic carbon ring systems of 3-10, also 3-8, more preferably 3-6, ring members per ring, such as cyclopropyl, cyclopentyl, cyclohexyl, adamantyl, and the like. A "substituted cycloalkyl" is a cycloalkyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound. 100751 "Heterocycloalkyl" refers to a saturated or unsaturated non-aromatic cycloalkyl group having from 5 to 10 atoms in which from 1 to 3 carbon atoms in the ring are replaced by heteroatoms of 0, S or N, and are optionally fused with benzo or heteroaryl of 5-6 ring members. 46 WO 2008/064255 PCT/US2007/085289 Heterocycloalkyl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N oxide of a tertiary ring nitrogen. Heterocycloalkyl is also intended to include compounds in which one of the ring carbons is oxo substituted, i.e. the ring carbon is a carbonyl group, such as lactones and lactams. The point of attachment of the heterocycloalkyl ring is at a carbon or nitrogen atom such that a stable ring is retained. Examples of heterocycloalkyl groups include, but are not limited to, morpholino, tetrahydrofuranyl, dihydropyridinyl, piperidinyl, pyrrolidinyl, pyrrolidonyl, piperazinyl, dihydrobenzofuryl, and dihydroindolyl. A "substituted heterocycloalkyl" is a heterocycloalkyl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound. [00761 "Aryl" alone or in combination refers to a monocyclic or bicyclic ring system containing aromatic hydrocarbons such as phenyl or naphthyl, which may be optionally fused with a cycloalkyl of preferably 5-7, more preferably 5-6, ring members. A "substituted aryl" is an aryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound. [00771 "Heteroaryl" alone or in combination refers to a monocyclic aromatic ring structure containing 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing one or more, preferably 1-4, more preferably 1-3, even more preferably 1-2, heteroatoms independently selected from the group consisting of 0, S, and N. Heteroaryl is also intended to include oxidized S or N, such as sulfinyl, sulfonyl and N-oxide of a tertiary ring nitrogen. A carbon or nitrogen atom is the point of attachment of the heteroaryl ring structure such that a stable compound is produced. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, pyrazinyl, quinaoxalyl, indolizinyl, benzo[b]thienyl, quinazolinyl, purinyl, indolyl, quinolinyl, pyrimidinyl, pyrrolyl, oxazolyl, thiazolyl, thienyl, isoxazolyl, oxathiadiazolyl, isothiazolyl, tetrazolyl, imidazolyl, triazinyl, furanyl, benzofuryl, and indolyl. "Nitrogen containing heteroaryl" refers to heteroaryl wherein any heteroatoms are N. A "substituted heteroaryl" is a heteroaryl that is independently substituted, with one or more, preferably 1, 2, 3, 4 or 5, also 1, 2, or 3 substituents, attached at any available atom to produce a stable compound. [0078] "Lower alkoxy" denotes the group -ORz, where R' is lower alkyl. "Substituted lower alkoxy" denotes lower alkoxy in which R' is lower alkyl substituted with one or more substituents as indicated herein attached at any available atom to produce a stable compound. Preferably, substitution of lower alkoxy is with 1, 2, 3, 4, or 5 substituents, also 1, 2, or 3 substituents. For example "fluoro substituted lower alkoxy" denotes lower alkoxy in which the lower alkyl is substituted with one or more fluoro atoms, where preferably the lower alkoxy is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms. While it is understood that substitutions on 47 WO 2008/064255 PCT/US2007/085289 alkoxy are attached at any available atom to produce a stable compound, substitution of alkoxy is such that -0-, -S-, or -N- (except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkoxy -0-. Further, where alkoxy is described as a substituent of another moiety, the alkoxy oxygen is not bound to a carbon atom that is bound to an -0-, -S-, or -N- of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety. [0079] "Lower alkylthio" denotes the group -SR", where R" is lower alkyl. "Substituted lower alkylthio" denotes lower alkylthio in which R" is lower alkyl substituted with one or more substituents as indicated herein attached at any available atom to produce a stable compound. Preferably, substitution of lower alkylthio is with 1, 2, 3, 4, or 5 substituents, also 1, 2, or 3 substituents. For example "fluoro substituted lower alkylthio" denotes lower alkylthio in which the lower alkyl is substituted with one or more fluoro atoms, where preferably the lower alkylthio is substituted with 1, 2, 3, 4 or 5 fluoro atoms, also 1, 2, or 3 fluoro atoms. While it is understood that substitutions on alkylthio are attached at any available atom to produce a stable compound, substitution of alkylthio is such that -0-, -S-, or -N- (except where N is a heteroaryl ring atom), are not bound to the alkyl carbon bound to the alkylthio -S-. Further, where alkylthio is described as a substituent of another moiety, the alkylthio sulfur is not bound to a carbon atom that is bound to an -0-, -S-, or -N- of the other moiety (except where N is a heteroaryl ring atom), or to an alkene or alkyne carbon of the other moiety. [00801 "Mono-alkylamino" denotes the group -NHRbb where Rbb is lower alkyl. "Di alkylamino" denotes the group -NRCR", where Rbb and R" are independently lower alkyl. "Cycloalkylamino" denotes the group -NR ddR", where Rd' and Re combine with the nitrogen to form a 5-7 membered heterocycloalkyl, where the heterocycloalkyl may contain an additional heteroatom within the ring, such as -0-, -N-, or -S-, and may also be further substituted with lower alkyl. Examples of 5-7 membered heterocycloalkyl include, but are not limited to, piperidine, piperazine, 4-methylpiperazine, morpholine, and thiomorpholine. While it is understood that when mono-alkylamino, di-alkylamino, or cycloalkylamino are substituents on other moieties that are attached at any available atom to produce a stable compound, the nitrogen of mono-alkylamino, di-alkylamino, or cycloalkylamino as substituents is not bound to a carbon atom that is bound to an -0-, -S-, or -N- of the other moiety. [00811 As used herein, the term c-kit-mediated disease or condition refers to a disease or condition in which the biological function of c-kit affects the development and/or course of the disease or condition, and/or in which modulation of c-kit alters the development, course, and/or symptoms. For example, mutations in the c-kit gene such as the W42, Wv, and W41 mutations 48 WO 2008/064255 PCT/US2007/085289 reported by Herbst et al al (J. Biol. Chem., 1992, 267: 13210-13216) confer severe, intermediate, and mild phenotypic characteristics, respectively. These mutations attenuate the intrinsic tyrosine kinase activity of the receptor to different degrees and are models for the effect of modulation of c-kit activity. A c-kit mediated disease or condition includes a disease or condition for which c-kit inhibition provides a therapeutic benefit, e.g. wherein treatment with c-kit inhibitors, including compounds described herein, provides a therapeutic benefit to the subject suffering from or at risk of the disease or condition. [00821 As used herein, the term c-fms-mediated disease or condition refers to a disease or condition in which the biological function of c-fims affects the development and/or course of the disease or condition, and/or in which modulation of c-fms alters the development, course, and/or symptoms. For example, the Csflr-/Csflr- mutant mouse of Dai et al (Blood, 2002, 99: 111-120) which lacks c-fins is an animal model for diseases or conditions wherein c-fins activity has been abolished. A c-fins mediated disease or condition includes a disease or condition for which c-fins inhibition provides a therapeutic benefit, e.g. wherein treatment with c-fims inhibitors, including compounds described herein, provides a therapeutic benefit to the subject suffering from or at risk of the disease or condition. [00831 As used herein, the term "composition" refers to a formulation suitable for administration to an intended animal subject for therapeutic purposes that contains at least one pharmaceutically active compound and at least one pharmaceutically acceptable carrier or excipient. [00841 The term "pharmaceutically acceptable" indicates that the indicated material does not have properties that would cause a reasonably prudent medical practitioner to avoid administration of the material to a patient, taking into consideration the disease or conditions to be treated and the respective route of administration. For example, it is commonly required that such a material be essentially sterile, e.g., for injectibles. [0085] In the present context, the terms therapeuticallyy effective" and "effective amount" indicate that the materials or amount of material is effective to prevent, alleviate, or ameliorate one or more symptoms of a disease or medical condition, and/or to prolong the survival of the subject being treated. [0086] As used herein, the term "modulating" or "modulate" refers to an effect of altering a biological activity, especially a biological activity associated with a particular biomolecule such as c-kit or c-fms. For example, an agonist or antagonist of a particular biomolecule modulates the activity of that biomolecule, e.g., an enzyme. 49 WO 2008/064255 PCT/US2007/085289 [0087] The term "c-kit activity" refers to a biological activity of c-kit, particularly including kinase activity. The term "c-fins activity" refers to a biological activity of c-fns, particularly including kinase activity. I. General [00881 In one aspect, the present invention concerns compounds of Formula II, Ila, IIb, Ile, Ig, Ilp or III and all sub-embodiments thereof, that are inhibitors of c-kit, c-fins, or both c-kit and c-fins, and the use of the compounds in treating diseases that are mediated by c-kit, c-fins, or both c-kit and c-fins. Exemplary Diseases Associated with c-Kit. 10089] The compounds described herein are useful for treating disorders related to c-kit e.g., diseases related to unregulated kinase signal transduction, including cell proliferative disorders, fibrotic disorders and metabolic disorders, among others. As described in more detail below and in Lipson et al., U.S. 20040002534 (U.S. application 10/600, 868, filed June 23, 2003) which is incorporated herein by reference in its entirety, cell proliferative disorders which can be treated by the present invention include cancers, and mast cell proliferative disorders. 10090] The presence of c-kit has also been associated with a number of different types of cancers. In addition, the association between abnormalities in c-kit and disease are not restricted to cancer. As such, c-kit has been associated with malignancies, including mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors (GISTs), glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myelocytic leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, mastocytosis, melanoma, and canine mast cell tumors, and inflammatory diseases, including asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, inflammatory bowel syndrome, transplant rejection, and hypereosinophilia. Exemplary diseases associated with c-fins [0091] The presence of c-fis has been associated with a number of different types of diseases. As such, c-fins has been associated with immune disorders, including, but not limited to, rheumatoid arthritis, systemic lupus erythenatosis (SLE), and transplant rejection; inflammatory diseases including, but not limited to, inflammatory bowel syndrome, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease (COPD), emphysema, Kawasaki's Disease, hemophagocytic syndrome (macrophage activation syndrome), multicentric reticulohistiocytosis, 50 WO 2008/064255 PCT/US2007/085289 and atherosclerosis; metabolic disorders, including, but not limited to, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, and lipolysis; disorders of bone structure, mineralization and bone formation and resorption, including, but not limited to, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, infection-mediated osteolysis (e.g., osteomyelitis), peri-prosthetic or wear-debris-mediated osteolysis, and metastasis of cancer to bone; kidney and genitourinary diseases, including, but not limited to, endometriosis, nephritis (e.g. glomerulonephritis, interstitial nephritis, Lupus nephritis), tubular necrosis, diabetes associated renal complications (e.g. diapetic nephropathy), and renal hypertrophy; disorders of the central nervous system, including, but not limited to, multiple sclerosis, stroke, Alzheimer's disease and Parkinson's disease; inflammatory and chronic pain, including, but not limited to, bone pain; and cancers, including, but not limited to, multiple myeloma, acute myeloid leukemia (AML), chronic myeloid leukemia (CML), prostate cancer, breast cancer, ovarian cancer, melanoma, glioblastoma multiforme, metastasis of tumors to other tissues, and other chronic myeloproliferative diseases such as myelofibrosis. Exemplary diseases associated with TrkA and TrkB 10092] TrkA: Target kinase TrkA (i.e., neurotrophic tyrosine kinase, receptor, type 1) is a 140 kDa tyrosine kinase encoded by chromosome 1 q21 -q22 (symbol: NTRK1). TrkA inhibitors may be useful in treating pain (e.g. chronic pain, neuropathic pain), cancer (e.g. prostate cancer, lung cancer, myeloid leukemia, pancreatic cancer), arthritis, allergic disorders (e.g. asthma), diabetic retinopathy, macular degeneration and psoriasis. 10093] TrkB: Target kinase TrkB (i.e., neurotrophic tyrosine kinase, receptor, type 2) is a 145 kDa tyrosine kinase encoded by chromosome 9q22.1 (symbol: NTRK2). TrkB inhibitors may be useful in treating various cancers and their metastases (e.g. prostate cancer, lung cancer, Wilm's tumors, neuroblastoma, and pancreatic cancer), and various neuropathies (e.g. stroke, multiple sclerosis, transverse myelitis, and encephalitis). Exemplary diseases associated with HGK [0094] H1gK Target kinase HGK (i.e., Hematopoietic progenitor kinase/Gerninal center kinase like Kinase, aka mitogen-activated protein kinase kinase kinase kinase 4) is a 130 kDa serine/threonine kinase encoded by chromosome 2q1 1.2-q 12 (symbol: MAP4K4). HGK inhibitors may be useful in treating metabolic indications, including re-sensitizing fat and muscle cells to insulin, ameliorating the pathology in adipocytes, ameliorating the pathology in muscle cells, and 51 WO 2008/064255 PCT/US2007/085289 type II diabetes; a broad range of oncology indications, including blocking the migration, invasion and metastasis in many different tumor types; and T-cell mediated autoimmune diseases. V. Organic Synthetic Techniques [00951 A wide array of organic synthetic techniques exist in the art to meet the challenge of constructing potential modulators. Many of these organic synthetic methods are described in detail in standard reference sources utilized by those skilled in the art. One example of suh a reference is March, 1994, Advanced Organic Chemistry: Reactions, Mechanisms and Structure, New York, McGraw Hill. Thus, the techniques useful to synthesize a potential modulator of kinase function are readily available to those skilled in the art of organic chemical synthesis. VI. Alternative Compound Forms or Derivatives 100961 Alternative forms or derivatives, such as (a) Isomers, Prodrugs, and Active Metabolites (b) Tautomers, Stereoisomers, Regioisomers, and Solvated Forms (c) Prodrugs and Metabolites (d) Pharmaceutically acceptable salts and (e) Polymorphic forms, are described, for example, in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference in its entirety. VI. Administration [0097] The methods and compounds will typically be used in therapy for human subjects. However, they may also be used to treat similar or identical indications in other animal subjects. In this context, the terms "subject," "animal subject," and the like refer to human and non-human vertebrates, e.g. mammals, such as non-human primates, sports and commercial animals, e.g., equines, bovines, porcines, ovines, rodents, and pets, e.g., canines and felines. A description of possible methods and routes of administration may be found, for example, in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference in its entirety. EXAMPLES 10098] A number of examples illustrative of the present invention are described below. In most cases, alternative techniques could also be used. The examples are intended to be illustrative and are not limiting or restrictive to the scope of the invention. Unless specifically noted to the contrary, in cases where a compound number is not preceeded by a "P-" (e.g., "P-0001") in the Examples section, compound naming and/or enumeration is not related to naming and/or enumeration employed in other sections of this application. Similarly, structure and substituent 52 WO 2008/064255 PCT/US2007/085289 naming and enumeration within the Examples are independent of structure and substituent naming and enumeration in above sections of this application unless clearly indicated otherwise. 10099] In the following Examples, it is understood that the solvents and reagents used or suggested are not limiting, and can be substituted appropriately with solvents and reagents known to those of skill in the art. Reaction products may be isolated by means known in the art, such as extraction with a suitable solvent, precipitation from a suitable solvent, chromatography using a suitable solvent system, including silica gel column chromatography, HPLC, preparative TLC, and the like. Exemplary methods for synthesis of compounds of the present invention may be found in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference. The IH-pyrrolo[2,3-b]pyridine core of compounds described in the examples may also be referred to as 7-azaindole in the examples. Example 1: Synthesis of 15-(5-Bromo-1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-(4 chloro-benzyl)-amine (P-0038) 101001 [5-(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-chloro-benzyl) amine P-0038 was synthesized in 5 steps from commercially available 2-Amino-5-bromopyridine 15 as shown in Scheme 19. Scheme 19 0 0 NH2 Br H H H 0 Hl' N Ste 1 N Step 2 N Step 3 N N +N-Ntp *~*)~1-H H Boc Br 1 5 C 4 0 41 CI 42 CI 43 C Cl Cl Br HO / NBoc / NH + N N Br -N BrStp -N H|5\4P-0038 N N N N H H Step I- Synthesis of (5-Bromo-pyridin-2-yl)-(4-chloro-benzyl)-amine (41) 10101] To 2-Amino-5-bromopyridine (15, 6.10 g, 0.0352 mol) in toluene (90.0 mL) were added 4-chlorobenzaldehyde (40, 5.00 g, 0.0356 mol), trifluoroacetic acid (8.0 ml., 0.10 mol) and triethylsilane (16.5 mL, 0.103 mol). The reaction was heated to reflux for 48 hours. The reaction 53 WO 2008/064255 PCT/US2007/085289 was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated. The crude residue was crystallized with ethyl acetate to give compound (41, 6.8 g, 65.4%). Step 2 - Synthesis of 6-(4-Chloro-benzylamino)-pyridine-3-carbaldehyde (42) 10102] To (5-Bromo-pyridin-2-yl)-(4-chloro-benzyl)-amine (41, 10.00 g, 0.03360 mol) in tetrahydrofuran (400.0 mL) under an atmosphere of nitrogen at -78 "C was added n-butyllithium (17.5 mL, 2.00 M in cyclohexane). After 90 minutes, tert-butyllithium (42.00 mL, 1.70 M in hexane) was added to the reaction. After 80 minutes, N,N-dimethylformamide (6.9 mL, 0.089 mol) was added to the reaction. The reaction mixture was stirred at -78 "C for 2 hours, then allowed to warm to room temperature for 1 hour. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate and concentrated to give the crude compound, which was crystallized from tert-butoxyl methyl ether to provide compound (42, 7.66 g, 92.2%). Step 3 - Synthesis of (4-Chloro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (43) [0103] To 6-(4-Chloro-benzylamino)-pyridine-3-carbaldehyde (42, 2.00 g, 8.11 mmol) in dichloromethane (20.0 mL) were added triethylamine (1.70 mL, 12.2 mmol), di-tert butyldicarbonate (2.00 g, 9.16 mmol) and 4-dimethylaminopyridine (52.3 mg, 0.43 mmol). The reaction was stirred at room temperature for 48 hours. The reaction was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give compound (43, 2.50 g, 89.3%). Step 4 - Synthesis of (5-[(5-Bromo-JH-pyrrolo[2,3-bpyridin-3-yl)-hydroxy-methyl]-pyridin-2-y} (4-chloro-benzyl)-carbanic acid tert-butyl ester (45) [0104] To 5-bromo-7-azaindole (44, 198.0 mg, 1.01 mmol) in methanol (30.0 mL, 0.741 mol) were added (4-Chloro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (43, 355.0 mg, 1.02 mmol) and potassium hydroxide (80.0 mg, 1.42 mmol). The reaction was stirred at room temperature 48 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 8% methanol in dichloromethane to give compound (45, 200.0 mg, 36.8%). 54 WO 2008/064255 PCT/US2007/085289 Step 5 - Synthesis of [5-(5-Bromo-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-chloro benzyl)-amine (P-0038) [01051 To {5-[(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl}-(4 chloro-benzyl)-carbamic acid tert-butyl ester (45, 180.0 mg, 0.33 mmol) in acetonitrile (30.0 mL) were added trifluoroacetic acid (2.0 mL, 0.026 mol) and triethylsilane (4.0 mL, 0.025 mol). The reaction was heated to reflux for 4 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 10% methanol in dichloromethane to give compound (P-0038, 120 mg, 85.2%). MS(ESI)[M+H*]' = 427.2, 429.2. 10106] Additional compounds were prepared following the protocol of Scheme 19, optionally replacing 4-chlorobenzaldehyde 40 with an appropriate aldehyde in Step I and optionally replacing 5-bromo-7-azaindole 44 with an appropriate azaindole in Step 4. The following compounds were made following this procedure: [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0181), [5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl) amine (P-0182), 3-[6-(4-Chloro-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0257), 3-[6-(4-Trifluoromethyl-benzylamino)-pyridin-3-ylmethyl]-lH-pyrrolo[2,3-blpyridine-5 carbonitrile (P-0269), [5-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-fluoro-benzyl)-amine (P-0270), 3-[6-(2-Fluoro-benzylamino)-pyridin-3-ylmethyl]-1 H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0271), (2-Fluoro-benzyl)-[5-(5-methyl-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0272), 3-{6-[(6-Trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl} -1 H-pyrrolo[2,3 b]pyridine-5-carbonitrile (P-0273), 3-[6-(2-Trifluoromethyl-benzylamino)-pyridin-3-ylmethyl]-IH-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0274), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0275), [5-(5-Methyl-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) 55 WO 2008/064255 PCT/US2007/085289 amine (P-0276), 3-[6-(2,6-Difluoro-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0277), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-difluoro-benzyl)-amine (P-0278), (2-Chloro-benzyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0279), (2-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0280), 3-[6-(2-Chloro-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0281), (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine (P-0282), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3 ylmethyl)-amine (P-0283), 3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0284), (2-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine (P-0285), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylI]-(2-methoxy-pyridin-3 ylmethyl)-amine (P-0286), 3-{6-[(2-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl}-1IH-pyrrolo[2,3-blpyridine-5 carbonitrile (P-0287), (2-Ethoxy-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0288), (2,5-Difluoro-bcnzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0296), (2,5-Difluoro-benzyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0297), [5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,5-difluoro-benzyl)-amine (P-0298), 3-[6-(2,5-Difluoro-benzylamino)-pyridin-3-ylmethyl]- 1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0299), 3-[6-(2-Trifluoromethoxy-benzylamino)-pyridin-3-ylmethyl]-1 H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0321), [5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-(2-trifluoromethoxy-benzyl)-amine (P-0322), 3-[6-(2-Ethoxy-benzylamino)-pyridin-3-ylmethyl]-IH-pyrrolo[2,3-bjpyridine-5-carbonitrile 56 WO 2008/064255 PCT/US2007/085289 (P-0323), [5-(5-Fluoro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0325), [5-(5-Methoxy-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0326), (2-Chloro-benzyl)-[5-(5-fluoro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl)-amine (P-0327), (2-Chloro-benzyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0328), (2,5-Difluoro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0329), (2,5-Difluoro-benzyl)-[5-(5-methoxy- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0330), [5-(5-Fluoro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl) amine (P-0331), (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methoxy-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine (P-0332), (2,6-Difluoro-benzyl)-[5-(5-fluoro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0333), (2,6-Difluoro-benzyl)-[5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0334), (2-Methoxy-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0336), 3-[6-(2-Methoxy-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0337), (2,6-Difluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0340), and (2,6-Difluoro-benzyl)-[5-(5-methyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI]-amine (P-0341). The following table indicates the aldehyde used in Step 1 in Column 3 and the azaindole used in Step 4 in Column 2 to provide the compound of Column 4. Column 1 provides the compound number and Column 5 the measured mass spectrometry result. Compound Azaindole Aldehyde Compound structure MS [M+H-]l number in Step 4 in Step 1 CI N o F P-O81N CF3 c N CN P-0 181
C
3 C5 418.2 57 WO 2008/064255 PCT/US2007/085289 CF3 -N 34. P-0 182 KN N / CF -- I 8. H - N N rH P-0257 I C 374.2 N N N H~ HH P-0269 N N~ CF 3 NC . N /a C3408.7 NN. H N N P-0270 -l N' F 367.0 H F N.. 0 / P-0271 ~ I ~ -NC, NH F 358.0 N N N H F N N P02 JLNY - 347.0 HN N H N P -0273 N.. / CF 3 -/ N1N N I> 409.4 ~N N -NNC N H NN H~ H N N P-0274 N - F3C~ ~I 417.0 N O P I H~ N N H P-0277 ""C /N.J F 317.5 N N H CF HTr F F P-0276 /C F 395.0 HH F NH _ _ _ _ _ _ N C_ _ N__ _ HF_ _ 58 WO 2008/064255 PCT/US2007/085289 P-0279 NI 6. 'N~~~- N'N 9 P-0280 NL l N CI 383.3 H TiN N P-0281 NC, Ci 374.0 N NN H Ni H P-0282 0 360.8 H N N s NI P-0283 o /a 0 -j 1 Q 380.0 NN H HN P-0284 0 ~ N N 371.5 N N ~ H N__ _ _ _ _ _ _ _ _ _ _ P-0285 f-.NH N 360.1 H 0 N/NNl H N_ __ P-0286 "N CI N 380.0 H 00N N N K H NN N C P-028 / NJrH 3f. N NQN H 0 N P-0287NIN6( 3571.6 N N HH o N N P-0288 - '() N 3659.5 N N r HH N N _ _ _ _ _F H 59 WO 2008/064255 PCT/US2007/085289 F F P-0298 cl N N I H- 385.9 HH N__ _ F F P-0299 N 91. N 376.4 N N H F P-0321 - C..(.)'4J42. N N 0-N H 0CF 3 N _____ P-0322 KNY -N 399.5 CF 05CN _________ C 3 N H P-0323 -NC I, 384.7 N NN H F 3 N N H F 0 - - NlH P-0325 /C F Nc 367.2 N N H NCN H cH P-0326 'o 0 FI N N /F F36. H F N N FF P-0327 u' /N 31. N N C H ___NN 60F WO 2008/064255 PCT/US2007/085289 0 ,N N P-0331 F& F N 364.5 H N HH P-0332 I O 'o N 36.6 H3 N 3 F 'F P-33 OON 381.6 P-0336 O Nr ) 345.7 P-0337 N 3707 F (NC N C FF P-034 0 NH 351.5 P-034 O N 365.5 N N j0107] Additional compounds were prepared following the protocol of Scheme 19, Steps 4 and 5, replacing (4-Chloro-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester 43 with an appropriate protected aldehyde and 5-bromo-7-azaindole 44 with an appropriate azaindole in Step 4. Aldehydes were prepared as described in Example 60. The following compounds were made following this procedure: 3- {2-Chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino)-pyridin-3-ylmnethyl} -1H pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0232), [6-Chloro-5-(5-methyl- I1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0233), 61 WO 2008/064255 PCT/US2007/085289 [6-Chloro-5-(5-methyl-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0234), (3-Chloro-pyridin-4-ylmethyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0235), 3-{6-[(3-Chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-ylmethyl}-1 H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0256), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-(2-difluoromethoxy-benzyl) amine (P-0338), 3-[6-(2-Difluoromethoxy-benzylamino)-pyridin-3-ylmethyl]- 1H-pyrrolo[2,3-b]pyridine-5 carbonitrile (P-0339), The following table indicates the aldehyde used in Column 2 and the azaindole used in Column 3 to provide the compound of Column 4. Column I provides the compound number and Column 5 the measured mass spectrometry result. Compound Aldehyde Azaindole Compound MS [M+H] number _____________________ NOI~C N'. P-0232 CFNC 443 CI H N H H P-0233 * C4s /O O NI r~i CF 3 [46Hl. H P-0235 ~F N Cc N N 30.1 P-025NHNN N 7. P3c CC, N 41. - N/N -033 FI N N o N P-0348 74~o C N 0 F1 N N F P-33 , Boc N-.. NC f N40. N //' Nr N H CI N H rIXN62 WO 2008/064255 PCT/US2007/085289 Example 2: Synthesis of 1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde 47. 101081 Compound 47 was synthesized in 2 steps from 7-azaindole 1 as described in Scheme 20. Scheme 20 Step 1 H Step 2 H N N N N H H TIPS 1 46 47 Step I - Preparation of 1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (46): [01091 To IH-Pyrrolo[2,3-b]pyridine (1, 16.0 g, 135 mmol) in water (110 mL), were added hexamethylenetetramine (26.0 g, 185 mmol), and acetic acid (55.0 mL, 967 mmol). The reaction was refluxed for 12 hours. Water (329 mL) was added and the reaction was cooled to room temperature. The reaction was filtrated and washed with water to give compound (46, 15.0 g, 76%). MS(ESI)[M+H] = 147. Step 2 - Preparation of 1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (47): 101101 To 1H-Pyrrolo[2,3-b]pyridine-3-carbaldehyde (46, 4.05 g, 27.71 mmol) in tetrahydrofuran (30.0 mL) were added sodium hydride (60% in mineral oil, 1.5 g, 38 mmol) and triisopropylsilyl chloride (8.0 mL, 38 mmol) under an atmosphere of nitrogen. The reaction was stirred for 2 hours at room temperature. The reaction was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 10 % ethyl acetate in hexane to give compound (47, 3.0 g, 36%). MS(ESI)[M+H*]*= 303. 101111 1-(tert-Butyl-dimethyl-silanyl)-3-iodo-H-pyrrolo[2,3-b]pyridine 66 was prepared following the protocol of Scheme 20 Step 2, substituting IH-Pyrrolo[2,3-b]pyridine 3-carbaldehyde 46 with 3-iodo-1H-pyrrolo[2,3-b]pyridine and triisopropylsilyl chloride with tert Butyl-dimethyl-silyl chloride. 63 WO 2008/064255 PCT/US2007/085289 [0112 1 -Benzenesulfonyl-I1H-pyrrolo[2,3-bjpyridine-3-carbaldehyde 55 0 H H N was prepared following the protocol of Scheme 20, substituting triisopropylsilyl chloride with benzenesulfonyl chloride in Step 2. Example 3: Synthesis of 5 substituted 7-azaindole intermediates 101131 5-(2-Morpholin-4-yl-ethoxy)-1H-pyrrolo[2,3-b]pyridine 79 was synthesized in I Step from commercially available 5-bromo-azaindole as shown in Scheme 31. Scheme 31 N N OH Br Step 1 0 N 1 N N N 78 44 79 Step 1 - 5-(2-Morpholin-4-yl-ethoxy)-JH-pyrrolo[2,3-b]pyridine (79): [01141 To 4-morpholineethanol (30 mL, 0.2 mol) in N, N-dimethylformamide (30 mL) was slowly added sodium hydride (7 g, 60% dispersion in mineral oil, 0.2 mol). After the solution turned clear, a solution of 5-bromo-7-azaindole (44, 1.0 g, 0.0051 mol) in N,N-dimethylformamide (5 mL) and copper(I) bromide (1.4 g, 0.0098 mol) were added. The reaction mixture was stirred at 120 *C under nitrogen for 2 hours. The reaction mixture was concentrated and the residue was dissolved in ethyl acetate and water. The organic layer was collected, washed with a solution of ammonium chloride and ammonium hydroxide (4:1), brine, and dried over magnesium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexane to provide the compound as an off-white solid (79, 0.62 g, 50%). MS (ESI) [M+H*]* = 248.25. 101151 Additional 5-substituted 7-azaindoles were prepared following the protocol of Scheme 31, replacing 4-morpholineethanol with either 2-diethylamino-ethanol, 3-diethylamino-propan-l ol, 2-piperidin-1-yl-ethanol, or 2-pyrrolidin-1-yl-ethanol to provide diethyl-[2-(1H-pyrrolo[2,3 64 WO 2008/064255 PCT/US2007/085289 b]pyridin-5-yloxy)-ethyl]-amine, Diethyl-[3-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)-propyl]-amine, 5 (2-piperidin-I -yl-ethoxy)-1H-pyrrolo[2,3-b]pyridine, and 5-(2-pyrrolidin-I -yl-ethoxy)-1H pyrrolo[2,3-b]pyridine, respectively. Example 4: Synthesis of 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole 1-carboxylic acid benzylamide P-0084 [01161 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I-carboxylic acid benzylamide P-0084 was synthesized in 6 steps from dimethyl-(l H-pyrrolo[2,3-b]pyridin-3 ylmethyl)-amine 2 as shown in Scheme 158. Scheme - 158 / / 0 N N C1 Step 1 Step 2 Step 3 N Step 4 N N N N N N N N H Boc Boc Boc 2 511 512 513 H N H Step 5 0 Step 6 0 N N N N N N Boc Boc H P-0084 514 515 Step 1: Preparation of 3-Dinethylaminomethyl-pyrrolo[2,3-blpyridine-I -carboxylic acid tert butyl ester (511) [0117] To dimethyl-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-amine (2, 2.50 g, 14.3 mmol,) in tetrahydrofuran (200.0 mL) was added sodium hydride (0.685 g, 60% in mineral oil, 17.1 mmol). After 10 minutes, di-tert-butyldicarbonate (3.74 g, 17.1 mmol) was added to the reaction. The reaction was stirred at room temperature overnight. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 30% ethyl acetate in hexane to give as a white solid (511, 3.80 g, 96.7%). Step 2: Preparation of 3-Chloromethyl-pyrrolo[2,3-b]pyridine-I-carboxylic acid tert-butyl ester (512) [0118] To 3-dimethylaminomethyl-pyrrolo[2,3-b]pyridine-I-carboxylic acid tert-butyl ester (511, 2.60 g, 9.44 mmol) in toluene (50.00 mL) was added isopropyl chloroformate (11.3 mL, 1.0 M in toluene) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 3 65 WO 2008/064255 PCT/US2007/085289 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give a white solid (512, 2.0 g, 79.4%). Step 3 - Preparation of3-(2-Acetyl-3-oxo-butyl)-pyrrolo(2,3-b]pyridine-1-carboxylic acid tert butyl ester (513): [0119] To acetylacetone (0.563 g, 5.62 mmol) in dimethyl sulfoxide (29.0 mL) was added sodium hydride (0.225 g, 60% in mineral oil, 5.62 mmol). After 20 minutes, 3-chloromethyl pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester (512, 1.00 g, 3.75 mmol) was added to the reaction. The reaction was stirred at room temperature for 2 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 40% ethyl acetate in hexane to give a colorless oil (513, 0.59 g, 48.0%). MS (ESI) [M+H*]'= 331.4. Step 4 - Preparation of 3-(3,5-Dimethyl-JH-pyrazol-4-ylmethyl)-pyrrolo[2,3-blpyridine-] carboxylic acid tert-butyl ester (514) 101201 To 3-(2-acetyl-3-oxo-butyl)-pyrrolo[2,3-b]pyridine-I-carboxylic acid tert-butyl ester (513, 1.20 g, 3.63 mmol) in methanol (15.0 mL), cooled to -20 *C under an atmosphere of nitrogen, was added hydrazine (0.128 g, 4.00 mmol) in dichloromethane (6.0 mL). The reaction was stirred for 2 hours. The reaction was concentrated to remove the solvents, and the residue was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 60% ethyl acetate in hexane to give a white solid (514, 1.0 g, 84.4%). MS (ESI) [M+H*]*= 327.4. Step 5 - Preparation of 3-(1-Benzylcarbamoyl-3,5-dimethyl-JH-pyrazol-4-ylmethyl)-pyrrolo[ 2 ,3 b]pyridine-1-carboxylic acid tert-butyl ester (515) [01211 To 3-(3,5-dimethyl-1H-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester (514, 60.0 mg, 0.18 mmol) in dichloromethane (6.0 mL) were added 1,8 diazabicyclo[5.4.0]undec-7-ene (0.033 mL, 0.220 mmol) and benzyl isocyanate (29.4 mg, 0.220 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 2 hours. The reaction was concentrated and purified by silica gel column chromatography eluting with 30% ethyl acetate in hexane to give crude compound (515, approx. 50 mg) that was used in the next step directly. MS (ESI) [M+H*J = 460.5. 66 WO 2008/064255 PCT/US2007/085289 Step 6 - 3,5-Dimethyl-4-(aH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid benzylamide (P-0084) [0122] To 3-( I-benzylcarbamoyl-3,5-dimethyl-1 H-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine 1-carboxylic acid tert-butyl ester (515, 50.0 mg, 0.11 mmol) in dichloromethane (6.0 mL) was added trifluoroacetic acid (0.20 mL, 2.6 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 20 minutes. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 30% ethyl acetate in hexane to give a white solid (P-0084, 11.0 mg, 28.1%). MS (ESI) [M+H*]* = 360.5. [01231 3-(3,5-Dimethyl- IH-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine P-0124 -N NH N N H was prepared from 3-(3,5-Dimethyl- I H-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine- -carboxylic acid tert-butyl ester (514, 15.0 mg, 0.046 mmol) by dissolving in dichloromethane (10.0 mL) to which trifluoroacetic acid (0.10 mL, 1.3 mmol) was added. The reaction was stirred at room temperature for 1 hour, then poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate in hexane to give an off-white solid (P-0124, 7.5 mg, 72.0%). MS (ESI) [M+H*]* = 227.3. [01241 Additional compounds were prepared following the protocol of Scheme 158, replacing dimethyl-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-amine 2 with (5-chloro- 1 H-pyrrolo[2,3 b]pyridin-3-ylmethyl)-dimethyl-amine (prepared as described in Example 10, Scheme 164, isolated after step 1) in Step 1 and replacing benzyl isocyanate with an appropriate electrophile in Step 5. The following compounds were made following this procedure: 4-(5-Chloro- I -pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole- -carboxylic acid [2-(4-fluoro-phenyl)-ethyl]-amide (P-0157), 4-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-1-carboxylic acid 4-fluoro-benzylamide (P-0158), 4-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-1 -carboxylic acid 4-chloro-benzylamide (P-0159), and 67 WO 2008/064255 PCT/US2007/085289 4-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-1-carboxylic acid [(S)- 1 -(4-fluoro-phenyl)-ethyl]-amide (P-0 160). 101251 The electrophile used in place of benzyl isocyanate in Step 5 is indicated in Column 2 of the following table, with the compound structure given in Column 3. Column I provides the compound number and Column 4 the experimental mass spectrometry result. MS(ESI) Electrophile Compound [M+H'] observed IN H P-0157 N 0 CI N NF 426.2 F NN C _ _ _H N C -N H F P-0158 0C IN IIN 412.2 0 NN N N N H F P-0 160 1 ~ 426.2 F INN Example 5: Synthesis of [4-chloro-5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl] pyridin-4-ylmethyl-amine P-0168 [0126] [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl amine P-0168 was synthesized in 5 steps as shown in Scheme 159. 68 WO 2008/064255 PCT/US2007/085289 Scheme 159 N N 0 H CN I SSte Step32 BocB Step -4 Be H 'N 519N NN N P T9 P NS 0 N TIPS 516 H 1 H C 518 9 51 HCc CI CI CI 1 HO NN N Stp N Step 4 SStep 5 H~ 519 H 2 N N P-0168 TIPS Step I - Preparation of4-chloro-2-[(pyridin-4-ylnethyl)-anino]-thiazole-5-carbaldehyde (517): 101271 To a solution of 4-(aminomethyl)pyridine (516, 1.16 mL, 11.5 mmol) and N,N diisopropylethylamine (3.8 mL, 22 mmol) in tetrahydrofuran (50 mL) was added 2,4-dichloro thiazole-5-carbaldehyde (93, 2.0 g, 11.0 mmol) in tetrahydrofuran (5 mL) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. The crude compound 4-chloro-2-[(pyridin-4-ylmethyl)-amino]-thiazole-5-carbaldehyde (517) was used for the next step without purification. Step 2 - Preparation of (4-chloro-5-formyl-thiazol-2-yl)-pyridin-4-ylmethyl-carbamic acid tert butyl ester (518): [01281 A mixture of 4-chloro-2-[(pyridin-4-ylmethyl)-amino]-thiazole-5-carbaldehyde (517, 3.28 g, 11.0 mmol), di-tert-butyldicarbonate (4.0 g, 18 mol) and triethylamine (10 mL, 74 mmol) in dichloromethane (120 mL) was stirred at room temperature for 6 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexanes to provide the desired compound as a yellow solid (518, 564 mg, 15%). MS (ESI) [M+H*]'= 354.1. Step 3 - Preparation of (4-chloro-S-[hydroxy-(1-triisopropylsilanyl-JH-pyrrolo(2,3-b]pyridin- 3 yl)-methyl]-thiazol-2-yl)-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (519): 10129] To a solution of 3-iodo-I-triisopropylsilanyl-IH-pyrrolo[2,3-b]pyridine (96, 0.44 g, 1.1 mmol) in tetrahydrofuran (20 mL) at -20 *C, isopropylmagnesium chloride (2 M in tetrahydrofuran, 0.6 mL, 1.2 mmol) was added dropwise. The reaction mixture was allowed to warm to 0 *C in 10 minutes. The reaction mixture was then cooled to -40 "C. A solution of (4 69 WO 2008/064255 PCT/US2007/085289 chloro-5-formyl-thiazol-2-yI)-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (518, 0.26 g, 0.73 mmol) in tetrahydrofuran (4 mL) was added to the reaction mixture. The reaction mixture was allowed to warm to -10 "C over 30 minutes. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexanes to provide the desired compound as a yellow solid (519, 397 mg, 86%). MS (ESI) [M+H*]+= 628.3. Step 4 - Preparation of [4-chloro-5-(IH-pyrrolo[2,3-bpyridin-3-ylmethyl)-thiazol-2-yl]-pyridin 4-ylmethyl-carbamic acid tert-butyl ester (520): 10130] A mixture of (4-chloro-5-[hydroxy-(1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3 yl)-methyl]-thiazol-2-yl}-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (519, 0.397 g, 0.57 mmol), triethylsilane (1.0 mL, 6.3 mmol), and trifluoroacetic acid (0.5 mL, 6 mmol) in acetonitrile (10 mL) was stirred at 40 "C for 2 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with sodium bicarbonate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with methanol in dichloromethane to provide the desired compound as a yellow solid (520, 126 mg, 49%). MS (ESI) [M+H*]*= 456.2. Step 5 - Preparation of [4-chloro-5-(H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin 4-ylmethyl-amine (P-0168): 10131] To a solution of [4-chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl] pyridin-4-ylmethyl-carbamic acid tert-butyl ester (520, 126 mg, 0.000276 mol) in dichloromethane (2 mL) was added hydrogen chloride (4 M in 1,4-dioxane, 2 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into cold sodium bicarbonate solution, extracted with ethyl acetate, washed with brine and dried over magnesium sulfate. After removal of solvents, the residue was washed with ethyl acetate to provide the desired compound as a light yellow solid (P-0168, 68.4 mg, 70%). MS (ESI) [M+H*]= 356.2. 101321 Additional compounds were prepared following the protocol of Scheme 159, replacing 4-(aminomethyl)pyridine 516 with an appropriate amine. The following compounds were made following this procedure: [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl-amine (P-0 164), [4-Chloro-5-(H-pyrrolo [2,3 -b]pyridin-3-ylmethyl)-th iazo -2-yl] -pyridin-2- ymethyl-amine (P-0167), 70 WO 2008/064255 PCT/US2007/085289 [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyTidin-2 ylmethyl)-amine (P-0171), [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine (P-0173), [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(1,5-dimethyl-I H-pyrazol-3 ylmethyl)-amine (P-0172), [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,5-dimethyl-2H-pyrazol- 3 ylmethyl)-amine (P-0175), and [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine
(P
0156). The following table indicates the amine (Column 2) used in Scheme 159 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the observed mass. MS(ESI) Compound Amine Compound [M+H*]' number observed s H N
H
2 N N 35 6 P-0164 N N 356.1 QNJN0 H N S N P-0167 H 2 N N 356.1 NP C H P-0171 H 2 N N 370.2 P 5N 6N H H
CF
3 P-0173 H 2 N N 'N N 424.2 P-0172 N' />~ 373.2 QN C1 H H N-N
H
2 N - N S P-0175 1/ /37. N C1 H P-0 156 N 2 N~j 373.1 71 WO 2008/064255 PCT/US2007/085289 Example 6: Synthesis of [4-ethyl-5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yll-( 4 fluoro-benzyl)-amine P-0162 and (4-fluoro-benzyl)-[4-methyl-5-(1H-pyrrolo[2,3-blpyridin-3 ylmethyl)-thiazol-2-yl]-amine P-0162 10133] [4-Ethyl-5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine P-0162 was synthesized in I step from [4-chloro-5-(lH-pyrrolo[2, 3-b] pyridin-3-ylmethyl) thiazol-2-yI]-(4-fluoro-benzyl)-amine P-0156 as shown in Scheme 160. Scheme 160 SF F H F H F SqN ~ yN N ci Step 1 N P0156 N N P-0162 Step I - Preparation of[4-ethyl-5-(H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-(4-floro benzyl)-amine (P-0162): 10134] Into a round bottom flask, under an atmosphere of nitrogen, [1,1'-bis(diphenyl phosphino) ferrocene] dichloro palladium (II), complex with dichloromethane (1:1), was placed with toluene (15 mL, 140 mmol). [4-Chloro-5-(1 H-pyrrolo[2,3-b] pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro benzyl)-amine (P-0156,145 mg, 0.4 mmol) was added in 5 ml of toluene at room temperature. The mixture was stirred for 10 minutes. To the stirring reaction, a solution of 3.13 M ethyl magnesium bromide in ether (1.86 mL) was added dropwise at room temperature. The opaque solution was heated to 60 *C. Tetrahydrofuran (10 mL) was added to the warm solution. The mixture was heated to reflux for an additional two hours. After cooling to 0 "C, the reaction was quenched with a solution of citric acid at pH 4-5 in ice-water and stirred to room temperature. The mixture was diluted with ethyl acetate and washed with saturated sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. Purification with flash chromatography, eluting with a gradient of ethyl acetate:hexanes (20:100), gave a yellow solid that was further washed with ethyl acetate to give P 0162 (15 mg,10%) as an off-white solid. MS (ESI) [M+H*]*= 367.2. 101351 (4-Fluoro-benzyl)-[4-methyl-5-(1H-p yrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl] amine P-0163 72 WO 2008/064255 PCT/US2007/085289 F N N N H was prepared using the protocol of Scheme 160, substituting the 3.13 M ethyl magnesium bromide in ether solution with 1.4 M of methylmagnesium bromide in tetrahydrofuran. MS (ESI) [M+H*]* = 353.2. Example 7: Synthesis of (4-Chloro-benzyl)-[6-(1H-pyrrolol2,3-bjpyridin-3-ylmethyl) pyridazin-3-yl]-amine P-0092 101361 (4-Chloro-benzyl)-[6-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridazin-3-yl]-amine
P
0092 was synthesized in 3 steps as shown in Scheme 161. Scheme 161 Br Br N Step HN +% CI *N40 522 Bc 521 C5 2 512 Cl CI CI /-rC r-G C1 / NH / NH N=N N=N Step 2 Step3 N B 523 N N P-0092 N Boo 2 H Step I - Synthesis of (6-bromo-pyridazin-3-yl)-(4-chloro-benzyl)-amine (522): 10137] To 6-bromo-pyridazin-3-ylamine (521, 0.85 g, 0.0049 mol) in acetonitrile (30.0 mL) were added 4-chlorobenzaldehyde (40, 0.82 g, 0.0058 mol), triethylsilane (4.0 mL, 0.025 mol) and trifluoroacetic acid (2.0 mL, 0.026 mol). The reaction was heated to reflux for 4 hours, then poured into water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and washed with ethyl acetate to give a white solid (522, 1.0 g). MS (ESI) [M+H*]*= 298.3, 300.2. Step 2 - Preparation of3-[6-(4-chloro-benzylamino)-pyridazin-3-ylmethyl]-pyrrolo[2,3 b]pyridine-l-carboxylic acid tert-butyl ester (523): 73 WO 2008/064255 PCT/US2007/085289 [0138] To (6-bromo-pyridazin-3-yl)-(4-chloro-benzyl)-amine (522, 0.560 g, 1.88 mmol) in tetrahydrofuran (45.0 mL), under an atmosphere of nitrogen at -78 'C, was added n-butyllithium (2.50 M in hexane, 0.760 mL) slowly. After 10 minutes, 1,2-bis-(chloro-dimethyl-silanyl)-ethane (0.201 g, 0.94 mmol) in tetrahydrofuran (5.0 mL) was added to the reaction. The reaction mixture was allowed to stir at room temperature for 3 hours. The reaction was cooled to -78 *C, followed by addition of 1.70 M of tert-butyllithium in hexane (1.20 mL) slowly. The reaction was stirred for 20 minutes, followed by addition of a solution of CuCN.2LiCl (0.6 M in tetrahydrofuran, 3.00 mL) and 3-chloromethyl-pyrrolo[2,3-b]pyridine-I-carboxylic acid tert-butyl ester (512, 0.47 g, 1.8 mol) in tetrahydrofuran (10.0 mL). After 30 minutes, the reaction was allowed to warm to room temperature for 10 minutes. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was treated with trifluoroacetic acid (1.0 mL) dissolved in dichloromethane (10.0 mL) for 10 minutes. The reaction was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified with silica gel column chromatography eluting with 60% ethyl acetate in hexane to give the desired compound (523, 0.10 g, 23.8%). MS (ESI) [M+H*]* = 450.1. Step 3 - Preparation of (4-chloro-benzyl)-[6-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridazin-3 yl]-amine (P-0092): 10139] To 3-[6-(4-chloro-benzylamino)-pyridazin-3-ylmethyl]-pyrrolo[2,3-b]pyridine-l carboxylic acid tert-butyl ester (523, 50.0 mg, 0.111 mmol) in dichloromethane (10.0 mL) was added trifluoroacetic acid (0.30 mL, 0.0039 mol). The reaction was stirred at room temperature overnight. The reaction was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate and hexane to give an off-white solid (P 0092, 7.3 mg, 19.0%). MS (ESI) [M+H*]* = 350.1. Example 8: Synthesis of i1-ethyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yI] (4-fluoro-benzyl)-amine P-0165 10140] (1-Ethyl-5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl]-(4-fluoro-benzyl) amine P-0165 was synthesized in 7 steps as shown in Scheme 162. 74 WO 2008/064255 PCT/US2007/085289 Scheme 162
N
2
N
2
NO
2
NH
2 0 H O NN2 Step1 O NN Step2 O N Step 3 N + HO H -O H .- O K. 528 524 525 526 527 F F F HN HN Step 4 Step 5 Step 6 NN ' N : 'N 529 N' 530 ~ N H 0o N-N N-N F Step7 F F~ F N N 531 N N P-0165 H H Step I - Preparation of 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (525): [0141] To 5-nitro-2H-pyrazole-3-carboxylic acid (524, 10.0 g, 0.0637 mol) in methanol (100.0 mL) was added concentrated sulfuric acid (1.00 mL, 0.0180 mol). The reaction was stirred at room temperature overnight. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give a white solid (525, 1.5 g, 13.8%). Step 2 - Preparation of 2-ethyl-5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (526): 10142] To 5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (525, 2.50 g, 0.0146 mol) in N,N dimethylformamide (62.5 mL) were added iodoethane (1.2 mL, 0.0 16 mol) and potassium carbonate (4.17 g, 0.0301 mol) under an atmosphere of nitrogen. The reaction was stirred at room temperature overnight. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (526, 1.3 g, 44.7%). Step 3 - Preparation of 5-amino-2-ethyl-2H-pyrazole-3-carboxylic acid methyl ester (527): 75 WO 2008/064255 PCT/US2007/085289 [01431 To 2-ethyl-5-nitro-2H-pyrazole-3-carboxylic acid methyl ester (526, 1.30 g, 6.53 mmol) in methanol (60.0 mL) was added 20% Pd(OH) 2 /C (0.1 g). The reaction was stirred under an atmosphere of hydrogen overnight. The reaction was filtered and concentrated to give a light yellow solid (527, 1.0 g, 90.6%). Step 4 - Preparation of 2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazole-3-carboxylic acid methyl ester (529): [01441 To 5-amino-2-ethyl-2H-pyrazole-3-carboxylic acid methyl ester (527, 1.00 g, 5.91 mmol) in acetonitrile (27.5 mL) were added 4-fluorobenzaldehyde (528, 0.660 mL, 6.26 mmol), triethylsilane (4.77 mL, 0.0298 mol) and trifluoroacetic acid (2.38 mL, 0.0310 mol). The reaction was stirred at 80 *C for 4 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (529, 1.00 g, 61%). Step 5 - Preparation of2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazole-3-carbaldehyde (530): [01451 To 2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazole-3-carboxylic acid methyl ester (529, 1.00 g, 3.61 mol) in tetrahydrofuran (70.0 mL) under an atmosphere of nitrogen at room temperature, lithium tetrahydroaluminate (1.00 M of in tetrahydrofuran, 10.00 mL) was slowly added. The reaction was stirred at room temperature overnight, followed by slowly adding sodium sulfate decahydrate (15.0 g). After 2 hours, the reaction was filtered, concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a yellow oil (530, 0.16 g, 18%). MS (ESI) [M+H*I*= 248.2. Step 6 - Preparation of I-ethyl-5-[methoxy-(IH-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-IH-pyrazol 3-yl-(4-fluoro-benzyl)-amine (531): [0146] To IH-Pyrrolo[2,3-b]pyridine (1, 54.0 mg, 0.46 mmol) in methanol (15.0 mL) were added 2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazole-3-carbadehyde (530, 110.0 mg, 0.44 mmol) and potassium hydroxide (0.60 g, 0.011 mol) under an atmosphere of nitrogen. The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 40% ethyl acetate in hexane to give a white solid (531, 0.12 g, 71.1%). MS (ESI) [M-H*I = 378.2. Step 7 - Preparation of [1-ethyl-5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-IH-pyrazol-3-yl]-(4 fluoro-benzyl)-amine (P-0165): 76 WO 2008/064255 PCT/US2007/085289 10147] To 1-ethyl-5-[methoxy-(1 H-pyrrolo[2,3-b]pyridin-3-yl)-methyl]-1 H-pyrazol-3-yl-(4 fluoro-benzyl)-amine (531, 0.12 g, 0.32 mmol) in acetonitrile (10.0 mL, 0.191 mol) were added triethylsilane (0.60 mL, 0.0038 mol) and trifluoroacetic acid (0.30 mL, 0.0039 mol). The reaction was stirred at 80 *C for 2 hours. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate and hexane to give crude compound. 'H NMR indicated that the reaction was incomplete. The crude compound was dissolved in dichloromethane (15.0 mL), trifluoroacetic acid (0.30 mL) and triethylsilane (0.60 mL). The reaction was stirred at 43 *C for 72 hours. The reaction was concentrated, poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate and hexane to give an off-white solid (P-0165, 18.7 mg, 17%). MS (ESI) [M+H']= 350.3. 10148] (4-Fluoro-benzyl)-[1-methyl-5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-IH-pyrazol-3-yl] amine P-0169 N-N N H F N N H was prepared using the protocol of Scheme 162, substituting iodoethane with iodomethane in Step 2. MS (ESI) [M+H]* = 336.3. 10149] [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l -methyl-I H-pyrazol-3-yl]-(4-fluoro benzyl)-amine P-0 170 N-N CIF NN N N H was prepared using the protocol of Scheme 162, substituting iodoethane with iodomethane in step 2 and 1H-pyrrolo[2,3-b]pyridine I with 5-chloro-IH-pyrrolo[2,3-b]pyridine in step 6. MS (ESI) [M+H*] = 370.3 10150] (4-Fluoro-benzyl)-{1-methyl-5-[5-(I-methyl-I H-pyrazol-4-yl)- IH-pyrrolo[2,3-b]pyridin 3-ylmethyl]- I H-pyrazol-3-yl}-amine P-0180 77 WO 2008/064255 PCT/US2007/085289 N-N N N HF NN H was prepared using the protocol of Scheme 162, substituting iodoethane with iodomethane in step 2 and 1 H-Pyrrolo[2,3-b]pyridine 1 with 5-(1-Methyl-i H-pyrazol-4-yl)- 1 H-pyrrolo[2,3-b]pyridine (prepared as described in Example 18, Scheme 172) in step 6. MS (ESI) [M+H*]* = 416.2. [01511 3-[5-(4-Fluoro-benzylamino)-2-methyl-2H-pyrazol-3-ylmethyl]-1H-pyrrolo[2,3 b]pyridine-5-carbonitrile P-0191 N N N F H was prepared using the protocol of Scheme 162, substituting 1H-Pyrrolo[2,3-b]pyridine 1 with I H Pyrrolo[2,3-b]pyridine-5-carbonitrile in Step 6. MS (ESI) [M+H*] = 361.5. Example 9: Synthesis of [4-chloro-1-ethyl-5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-1H pyrazol-3-yl]-[1-(4-fluoro-phenyl)-meth-(E)-ylidenle]-amine P-0166 [01521 [4-chloro-1-ethyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-lH-pyrazol-3-yl]-[1-(4 fluoro-phenyl)-meth-(E)-ylidene)-amine P-0166 was synthesized in 1 step as shown in Scheme 163. Scheme 163 N-N N-N H N 5FStep 1 F F -1 F N N P-01 65 N- N H H P-0166 Step I - Preparation of[4-chloro-1-ethyl-5-(JH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-JH-pyrazol-3 yl]-[-(4-fluoro-phentyl)-meth-(E)-ylidene]-amine (P-0166): 101531 To [1-ethyl-5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)- IH-pyrazol-3-yl]-(4-fluoro-benzyl) amine (P-0165, 10.1 mg, 0.0289 mmol, prepared as described in Example 8, Scheme 162) in acetonitrile (8.0 mL) was added N-chloro-succinimide (4.18 mg, 0.0318 mmol). The reaction was stirred at room temperature for 2 hours. The reaction was concentrated and purified by silica gel 78 WO 2008/064255 PCT/US2007/085289 column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0166, 1.1 mg). MS (ESI) [M+H] = 382.1. Example 10: Synthesis of 5-chloro-3-chloromethyl-pyrrolo[2,3-bpyridine--carboxylic acid tert-butyl ester [0154] 5-chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester was synthesized in 3 steps as shown in Scheme 164. Scheme 164 N C1 / N_ N C I Step 1 C1 tep 2 C Step 3 N~~ N N BocB Hr H oc53 532 533 534 Step I - Preparation of (5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylnethyl)-dimethyl-amine (533): [01551 To 5-Chloro-1H-pyrrolo[2,3-b]pyridine (532, 8.00 g, 0.0524 mol) in isopropyl alcohol (250.0 mL) were added dimethylamine hydrochloride (4.79 g, 0.0587 mol) and formaldehyde (1.77 g, 0.0589 mol). The reaction was stirred at room temperature overnight, followed by refluxing for 4 hours. The reaction was concentrated, poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give crude compound (533, 10.0 g, 91%), that was used directly in the next step. Step 2 and 3 - Preparation of 5-chloro-3-chzlorometlyl-pyrrolo[2,3-b]pyridine-l-carboxylic acid tert-butyl ester (535): (01561 5-Chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester 535 was prepared following the protocol of Scheme 158 (Example 4) steps I and 2, substituting dimethyl-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-amine 2 with (5-chloro-1 H-pyrrolo[2,3 b]pyridin-3-ylmethyl)-dimethyl-amine 533 in step 1. Example 11: Synthesis of (4-chloro-benzyl)-15-(5-chloro-1H-pyrrolo[2,3-blpyridin-3 ylmethyl)-6-fluoro-pyridin-2-yi]-amine P-0132 [01571 (4-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2 ylj-amine P-0132 was synthesized in 3 steps as shown in Scheme 165. Scheme 165 79 WO 2008/064255 PCT/US2007/085289
NH
2 / F Br NH N N + Step 1 Step 2 NH F 5861 58 C--- 536 -- 537 CI Cl F '_N H Cl / N CI Step 3 P-0132 Bo NN 535 H Step I - Preparation of (4-chloro-benzyl)-(6-fluoro-pyridin-2-yI)-amine (536): [0158] To 2,6-difluoropyridine (58, 9.85 g, 0.0856 mol) in N-methylpyrrolidinone (50.0 mL) were added p-chlorobenzylamine (61, 10.5 mL, 8.63 mmol) and N,N-diisopropylethylamine (30.0 mL, 0.172 mol). The reaction was stirred at 90 *C overnight. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25% ethyl acetate in hexane, then washed with ethyl acetate/hexane to give a white solid (536, 10 g, 50%). Step 2 - Preparation of(5-bromo-6-fluoro-pyridin-2-yl)-(4-chloro-benzyl)-amine (537): 101591 To (4-chloro-benzyl)-(6-fluoro-pyridin-2-yl)-amine (536, 1.03 g, 4.35 mmol) in acetonitrile (30.0 mL), under an atmosphere of nitrogen, N-bromosuccinimide (0.820 g, 4.61 mol) was added slowly. After 2 hours, the reaction was poured into a solution of sodium thiosulfate and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and crytstallized with ethyl acetate and hexane to give a white solid (537, 1.10 g, 80.1%). Step 3 - Preparation of(4-chloro-benzyl)-[5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylnethyl)-6 fluoro-pyridin-2-yl]-amine (P-0132): 10160] To (5-bromo-6-fluoro-pyridin-2-yl)-(4-chloro-benzyl)-amine (537, 2.76 g, 8.75 mol) in tetrahydrofuran (90.0 mL), under an atmosphere of nitrogen at -78 *C, n-butyllithium (2.50 M in hexane, 3.64 mL) was added slowly. After 60 minutes, 1,2-bis-(chloro-dimethyl-silanyl)-ethane (0.942 g, 4.38 mol) in tetrahydrofuran (8.0 mL) was added to the reaction. The reaction mixture was allowed to stir at room temperature for 2 hours. The reaction was cooled to -78 "C, followed by addition of tert-butyllithium (1.70 M in hexane, 10.50 mL). The reaction was stirred for 30 80 WO 2008/064255 PCT/US2007/085289 minutes, followed by addition of 0.65 M of CuCN.2LiCI in tetrahydrofuran (14.0 mL). The reaction was stirred at -35 *C for 10 minutes, followed by addition of 5-chloro-3-chloromethyl pyrrolo[2,3-b]pyridine-1 -carboxylic acid tert-butyl ester (535, 1.70 g, 5.64 mol, prepared as described in Example 10, Scheme 164) in tetrahydrofuran (10.0 mL). The reaction was allowed to warm to room temperature for 1 hour and 2 N HCl (30 mL) was added to the reaction mixture, then stirred for 30 minutes. The reaction was poured into aqueous ammonia and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified with silica gel column chromatography eluting with 30% ethyl acetate in hexane to give the desired compound (P-0132, 0.75 g, 33.1%). MS (ESI) [M+H]* = 401.1. Example 12: Synthesis of 5-chloro-3-(2,6-difluoro-pyridin-3-ylmethyl)-1 H-pyrrolo[2,3 b~pyridine P-0155 [01611 5-Chloro-3-(2,6-difluoro-pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine P-0155 was synthesized in 1 step as shown in Scheme 166. Scheme 166 F' F Fp CClSe1 CI NNN + Stepi N N N N F 58 535 Boc H P-0155 Step I - Preparation of 5-chloro-3-(2,6-difluoro-pyridin-3-ylmethyl)-JH-pyrrolo[2,3-b]pyridine (P-0155): [01621 To 2,6-Difluoropyridine (58, 3.40 g, 0.0295 mol) in tetrahydrofuran (200.0 mL), under an atmosphere of nitrogen at -78 *C, 2.50 M of n-butyllithium in hexane (12.0 mL) was added slowly. After 60 minutes, CuCN.2LiCl (0.75 M in tetrahydrofuran, 40.0 mL) was added to the reaction mixture. After 5 minutes, 5-chloro-3-chloromethyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert butyl ester (535, 4.20 g, 0.0139 mol, prepared as described in Example 10, Scheme 164) in tetrahydrofuran (20 mL) was added to the reaction. The reaction was stirred at -78 *C overnight, then poured into water and ammonia (10 mL), and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 15% ethyl acetate in hexane to give a white solid (P-0155, 300 mg, 7.7%). MS (ESI) [M-H*]- = 278.1. 81 WO 2008/064255 PCT/US2007/085289 Example 13: Synthesis of 3-(2,6-difluoro-pyridin-3-ylmethyl)-1H-pyrrolo[2,3-bipyridine
P
0154 [01631 3-(2,6-difluoro-pyridin-3-ylmethyl)-1H-pyrrolo[2,3-b]pyridine P-0154 was synthesized in 1 step as shown in Scheme 167. Scheme 167 F ' F N Step I F F N N N N Boc H 536 P-0154 Step 1 - Preparation of 3-(2,6-difluoro-pyridin-3-ylmethyl)-IH-pyrrolo[ 2 ,3-b]pyridine (P-0154): [01641 To 3-(2,6-difluoro-pyridin-3-ylmethyl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert butyl ester (536, 0.35 g, 1.0 mmol, prepared as described in Example 10, Scheme 164, replacing 5 chloro-1H-pyrrolo[2,3-b]pyridine 532 with IH-pyrrolo[2,3-b]pyridine in step 1) in N methylpyrrolidinone (3.00 mL) were added p-chlorobenzylamine (0.20 mL, 1.6 mmol) and N,N diisopropylethylamine (0.30 mL, 0.0017 mol). The reaction was stirred at 50 *C for 72 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and the crude intermediate was dissolve in dichloromethane (15.0 mL) and trifluoroacetic acid (0.5 mL). The reaction was stirred at room temperature for 2 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 35% ethyl acetate in hexane to give a white solid (P-0154, 0.18 g, 72%). MS (ESI) [M+H*] = 246.2. Example 14: Synthesis of 5-((1H-pyrrolo[2,3-blpyridin-3-yl)methyl)-N-(4-chlorobenzyl)- 6 chloropyridin-2-amine P-0161 10165] 5-((IH-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-(4-chlorobenzyl)-6-chloropyridin-2-amine P-0161 was synthesized in 6 steps as shown in Scheme 168. Scheme 168 82 WO 2008/064255 PCT/US2007/085289 Br, H 0 H C1 CCI C SH 2 1 -t Step 2 HN Step 3 HN -N + Se 1 HN /539 540 Cl 537 Cl 40 538 __ C1 CI CI HO O H NBoc NH C N) N + S-N 5 N Ste 6 -N Step 4 Bac J1I CI IC 54 N C 541H H H C1 Step I - Preparation of (4-chloro-benzyl)-(6-chloro-pyridin-2-yl)-amine (538): [0166] To 6-chloro-pyridin-2-ylamine (537, 5.60 g, 0.0436 mol) in acetonitrile (300 mL) were added 4-chlorobenzaldehyde (40, 6.7 g, 0.048 mol), trifluoroacetic acid (13 mL, 0.17 mol) and triethylsilane (21 mL, 0.13 mol). The reaction was heated to reflux for 4 hours, then concentrated, poured into water, extracted with ethyl acetate, and washed with sodium bicarbonate and brine. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated. The filtrate was purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (538, 6.5 g, 59%). MS (ESI) [M+H*]* = 255.1. Step 2 - Preparation of (5-bromo-6-chloro-pyridin-2-yl)-(4-chloro-benzyl)-amine (539): [01671 To (4-chloro-benzyl)-(6-chloro-pyridin-2-yl)-amine (538, 4.00 g, 0.0158 mol) in acetonitrile (66.7 mL, 1.28 mol) under an atmosphere of nitrogen, N-bromosuccinimide (2.81 g, 0.0158 mol) in acetonitrile (20 mL) was added slowly. The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and crystallized with ethyl acetate in hexane to give a white solid (539, 2.60 g, 95.3%). Step 3 - Preparation of 2-chloro-6-(4-chloro-benzylamino)-pyridine-3-carbaldehyde (540): 101681 To (5-bromo-6-chloro-pyridin-2-yl)-(4-chloro-benzyl)-amine (539, 2.60 g, 7.83 mmol) in tetrahydrofuran (60.0 mL) under an atmosphere of nitrogen at -78 "C, isopropylmagnesium chloride (2.00 M in tetrahydrofuran, 4.20 mL) was added over 10 minutes. The reaction was stirred at -78 *C for 20 minutes, then allowed to warm to room temperature for 10 minutes. The reaction was cooled to -78 *C. tert-Butyllithium (1.70 M in hexane, 10.2 mL) was added to the reaction over 10 minutes. After 40 minutes, N,N-dimethylformamide (1.80 mL, 0.0232 mol) was added to the reaction. The reaction was stirred at -78 "C for 40 minutes, then allowed to warm to 83 WO 2008/064255 PCT/US2007/085289 room temperature for another 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 35% to 100% ethyl acetate in hexane to give a light yellow solid (540, 1.0 g, 45.4%). MS (ESI) [M-H* = 279.0. Step 4 - Preparation of (4-chloro-benzyl)-(6-chloro-5-formyl-pyridin-2-yl)-carbamic acid tert butyl ester (541): 101691 To 2-chloro-6-(4-chloro-benzylamino)-pyridine-3-carbaldehyde (540, 0.40 g, 1.42 mmol) in dichloromethane (10.0 mL) were added 4-dimethylaminopyridine (10.0 mg, 0.082 mmol), di tert-butyldicarbonate (0.693 g, 3.17 mmol) and triethylamine (0.50 mL, 0.0036 mol). The reaction was stirred at room temperature overnight, then concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (541, 0.45 g, 83.0%). Step 5 - Preparation of (4-chloro-benzyl)-6-chloro-5-[hydroxy-(JH-pyrrolo[23-b]pyridin-3-yl) methyl]-pyridin-2-yl-carbamic acid tert-butyl ester (542): [01701 To lH-Pyrrolo[2,3-b]pyridine (1, 465 mg, 3.93 mmol) in methanol (50 mL) were added sodium hydroxide (0.630 g, 0.0157 mol) and (4-chloro-benzyl)-(6-chloro-5-formyl-pyridin-2-yl) carbamic acid tert-butyl ester (541, 1.5 g, 0.0039 mol). The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (542, 1.0g, 51%). MS (ESI) [M+H*]*= 499.1. Step 6- Preparation of 5-((IH-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-(4-chlorobenzyl)-6 chloropyridin-2-amine (P-0161): [01711 To (4-chloro-benzyl)-6-chloro-5-[hydroxy-(1H-pyrrolo[2,3-b]pyridin-3-yl)-methyl] pyridin-2-yl-carbamic acid tert-butyl ester (542, 1.00 g, 2.00 mmol) in acetonitrile (130.0 mL) were added triethylsilane (11.5 mL, 0.0720 mol) and trifluoroacetic acid (5.5 mL, 0.071 mol). The reaction was heated to reflux for 2 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate and hexane to give a light yellow solid (P-0161, 480 mg, 62%). MS (ESI) [M+H]* = 383.1, 385.1. 101721 [6-Chloro-5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine P-0174 84 WO 2008/064255 PCT/US2007/085289 H N / N / CF 3 -- N ' Cl N N H was prepared following the protocol of Scheme 168, substituting 4-chloro-benzaldehyde 40 with 6-trifluoromethyl-pyridine-3-carbaldehyde in step 1. MS (ESI) [M+H*] = 418.2. [0173] [6-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6 trifluoromethyl-pyridin-3-ylmethyl)-amine P-0176 H N CN CF 3 I N N N H was prepared following the protocol of Scheme 168, substituting 4-chloro-benzaldehyde 40 with 6-trifluoromethyl-pyridine-3-carbaldehyde in step I and 1H-Pyrrolo[2,3-b]pyridine 1 with 5 chloro-1H-pyrrolo[2,3-b]pyridine in step 5. MS (ESI) [M+H*] = 452.0. [0174] {6-Chloro-5-[5-(1-methyl-iH-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl] pyridin-2-yl}-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0179 H N N 3N / CF 3 NJ -N CI N N H was prepared following the protocol of Scheme 168, substituting 4-chloro-benzaldehyde 40 with 6-trifluoromethyl-pyridine-3-carbaldehyde in step I and I H-Pyrrolo[2,3-b]pyridine 1 with 5-(1 Methyl-IH-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine (prepared as described in Example 18, Scheme 172) in step 5. MS (ESI) [M+H*]* = 498.0. Example 15: Synthesis of (3-chloro-benzyl)-[5-(1H-pyrrolo[2,3-bJpyridin-3-ylmethyl) pyridin-2-yi]-amine P-0129 [0175] (3-Chloro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine P-0129 was synthesized in 1 step as shown in Scheme 169. Scheme 169 85 WO 2008/064255 PCT/US2007/085289 H Br NH 2 / HN N N Step C1 N 4 N N P-0129 sl_ 543 Step 1 - Preparation of(3-chloro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0129): 101761 3-(6-bromo-pyridin-3-ylmethyl)-1-triisopropylsilanyl- 1H-pyrrolo[2,3-b]pyridine (6a, 10 mg, 0.023 mmol) was combined with 3-chlorobenzyl amine (543, 13 mg, 0.093 mmol) in dioxane (0.3 mL). Tris(dibenzylideneacetone)-dipalladium(0) (3 mg), 4,5-bis(diphenylphosphino)-9,9 dimethylxanthene (Xantphos, 3 mg) and sodium tert-butoxide (15 mg) were added. The mixture was heated at 100 *C overnight. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in DMSO and purified by reverse phase HPLC on a YMC-Pack ODS-A C-18 column (50mm x 10mm ID), eluting with water with 0.1 % trifluoroacetic acid and 5-40% acetonitrile with 0.1% trifluoroacetic acid over 13 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0129. MS (ESI) [M+H*]*= 349.1. 10177] Additional compounds were prepared following the protocol of Scheme 169, replacing 3-chlorobenzyl amine 543 with an appropriate amine. The following compounds were made following this procedure: (4-Morpholin-4-ylmethyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y] amine (P-0093), Pyridin-3-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0094), (5-Methyl-isoxazol-3-ylmethyl)-[5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0095), (2-Pyrrolidin-1-yl-ethyl)-[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0096), [1 -(4-Methanesulfonyl-phenyl)-ethyl]-[5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yi] amine (P-0097), (2-Methoxy-ethyl)-[5-(H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0098), (2-Morpholin-4-yl-ethyl)-[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0099), ((R)-I-Phenyl-ethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylI]-amine (P-0125), (3-Morpholin-4-yl-benzyl)-[5-( IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0126), 86 WO 2008/064255 PCT/US2007/085289 [1-(2-Fluoro-phenyl)-ethyl]-[5-(IH-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0127), [2-(3-Fluoro-phenyl)-ethyl]-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0128), (I-Methyl-IH-imidazol-4-ylmethyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0130), and (1,5-Dimethyl-I H-pyrazol-3-ylmethyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2 yl]-aminc (P-0131). 10178] The following table indicates the amine (Column 2) used in Scheme 169 to provide the compounds (Column 3). Column I provides the compound number and column 4 the observed mass. MS(ESI) Compound Amine Compound [M+HT] number observed 2 N P-0093 2 NN414.3 N O NNH P-00 94 NH NHr P-0094 2 N 316.3 t~ 1 N NH
H
2 N N, P-N095 N' 319.9 H -HO P-0097
H
2 N.. d O N,32. H H2N N P-0099 N N N 328.3 N N 87 N P-0099 HN > N I N> 338.3 87 WO 2008/064255 PCT/US2007/085289 ~~ n MS(ESI) Compound Amine Compound [M+H*]* number observed - N N P-012 329.1 P-0126 H 2 N~ CO 400.3 P-012752 P-0128 HNINFr F 347.1 H HN H N P-l1H 2 N 333.1 4 __' H P-012b P -011 347.1 F NN N H2N N S O C1 P-012 N N P3-9.1 F ~N N N N N.3. P-benzamide P-oil 88 P-H11 2 N Ntp 333.1I Ga~~ N N p01 N H SExapl 16 Syrenrteion of3-chloro-N-[-(--pyrrolo[2, 3-b]pyridin-3-ylmethyl)-pyridin-2 ybenzaide P-0111) 1079 -ClooN-5-]-prrl[23-~yrdi--ymchl)pyiin2-i-bnzm88-0l WO 2008/064255 PCT/US2007/085289 101801 3-(6-Bromo-pyridin-3-ylmethyl)-l-triisopropylsilanyl-1 H-pyrrolo[2,3-b]pyridine (6a, 10 mg, 0.023 mmol) was combined with 3-chloro-benzamide (544, 15 mg, 0.096 mmol) in dioxane (0.4 mL). Tris(dibenzylideneacetone)-dipalladium(0) (3 mg), 4,5-bis(diphenylphosphino)-9,9 dimethylxanthene (Xantphos, 3 mg), and sodium tert-butoxide (15 mg) were added. Cesium carbonate (20 mg) was added and the mixture was heated at 100 *C overnight. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in DMSO (0.2 mL) and purified by reverse phase HPLC on a YMC-Pack ODS-A C-18 column (50mm x 10mm ID), eluting with water with 0.1 % trifluoroacetic acid and 5-40% acetonitrile with 0.1% trifluoroacetic acid over 13 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0111. MS (ESI) [M+H*]*= 363.1. [01811 Additional compounds were prepared following the protocol of Scheme 170, replacing 3-chloro-benzamide 544 with an appropriate amide. The following compounds were made following this procedure: 3,4-Dichloro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0100), 2-Chloro-4-fluoro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide
(P
0101), 2,5-Dimethyl-2H-pyrazole-3-carboxylic acid [5-(1 H-pyrrolo[2,3-blpyridin-3-ylmethyl) pyridin-2-yl]-amide (P-0102), Thiophene-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide (P-0103), 2-Methoxy-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonicotinamide
(P
0104), N-[5-(1 H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-isonicotinamide (P-0105), Pyrazine-2-carboxylic acid [5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide (P 0106), Pyridine-2-carboxylic acid [5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amide (P 0107), 6-Methyl-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-nicotinamide (P-0108), 4-Fluoro-3-methyl-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yli]-benzamide
(P
0109), 5-Methyl-pyrazine-2-carboxylic acid [5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amide (P-0110), 4-Fluoro-N-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethyl bcnzamide (P-0 112), 89 WO 2008/064255 PCT/US2007/085289 N-[5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethoxy-benzamide
(P
0113), N-[5-(lH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-3-trifluoromethyl-benzamide
(P
0114), 3-Chloro-4-fluoro-N-[5-(H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide
(P
0115), 3,4-Difluoro-N-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0116), 2-Chloro-N-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0 117), 5-Fluoro-2-methyl-N-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide
(P
0118), 2-Fluoro-N-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-01 19), 3-Methoxy-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0120), 3-Fluoro-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0121), 3-Methyl-N-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-benzamide (P-0122), and 2-Chloro-N-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-isonicotinamide (P-0123). [0182] The following table indicates the amide (Column 2) used in Scheme 170 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the observed mass. MS(ESI) Compound Amide Compound [M+H*] number observed P 97.1CI P-0100 N NH2 397.1 C NN H 0 H HCI FIIhhN NFN P-0101 N NH, N 0 347.1 N- N P-O03 NH 2 0 335.1 0 N N 0 N9S WO 2008/064255 PCT/US2007/085289 CompoundMS(ESI) Cumbun Amide Compound [M+HT] numberobserved P-0104 N NH 2 N 0 0 360.3 N-N N 0 ,_UN P-0 105 OA' NH 2 N'0329.9 H N N. N P-0106 ~ N NH 2 0 331.1 N N N H P-0 107 :P N2 329.9 YIN N N H P-0108~~~ NNN 2 N 4. 0 N0 P-0 108 0;1 fANH 2 0 361.1 N N N P-0i109 N kNH2 0 341.1 N N - N H P-01 10 F l N H N 0 C345.1 N 'N N H 0 H P-0 112 N H N 0 A CF 3 397.1 __ __ __CF 3 H __ __ __0_ _ H__ _ _ _ _ _ __ _ _ _ _ 91N WO 2008/064255 PCT/US2007/085289 CompundMS (ES I) Cumboun Amide Compound MH] numberobserved 0H N N -~NH, ~ N P-01 15 0 Fl 385.1 FN N 0 H~ P-01 17 0 363.1 N( F NNH H P-01 19 < iNH 2 NN 367.1 N) N H P- 11 f) NH 2 N F 347.1 P-012 18 NH0 ~
T
~I 343.1 F~ N N H P-012 19 NH 2 1 N 0 C 3647.3 N0 NNN __________ N'/___________H__Q_____ P-0 10 NH20 a--3592 WO 2008/064255 PCT/US2007/085289 Example 17: Synthesis of 3,5-dimethyl-4-(1H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyrazole-1 carboxylic acid 4-methoxy-benzylamide P-0135 101831 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid 4 methoxy-benzylamide P-0135 was synthesized in 1 step as shown in Scheme 171. Scheme 171 O'_ -N H NCO IN H Step 1 N N N N + N N N N4H P-0135 514 0 545 Step 1 - Preparation of 3,5-dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1 carboxylic acid 4-methoxy-benzylamide (P-0135): 10184] 3-(3,5-dimethyl-1H-pyrazol-4-ylmethyl)-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert butyl ester (514, 10 mg, 0.03 mmol) was dissolved in dichloromethane (0.5 mL). 1,8 Diazabicylo[5.4.0]unde-7-ene (6 mg, 0.04 mmol) was added. 1-Isocyanatomethyl-4-methoxy benzene (545, 6.5 mg, 0.04 mmol) was added. The reaction was allowed to proceed at room temperature for 30 minutes. Acetic acid (0.2 mL) was added to the reaciton. The solvents were removed under reduced pressure. The residue was dissolved in dimethyl sulfoxide (0.2 mL) and purified by reverse phase HPLC on a Phenomenex column (50mm x 10mm ID), eluting with water with 0.1 % trifluoroacetic acid and 20-100% acetonitrile with 0.1% trifluoroacetic acid over 16 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0135. MS (ESI) [M+H*]*= 390.3. 101851 Additional compounds were prepared following the protocol of Scheme 171, replacing 1 -isocyanatomethyl-4-methoxy-benzene 545 with an appropriate isocyanate or bromide. The following compounds were made following this procedure: 3-(I-Benzyl-3,5-dimethyl- IH-pyrazol-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine (P-0133), 2-[3,5-Dimethyl-4-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazol-1-yl)-1-phenyl-ethanone (P-0134), 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 2-chloro benzylamide (P-0136), 93 WO 2008/064255 PCT/US2007/085289 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid 2-fluoro benzylamide (P-0137), 3-[3,5-Dimethyl-l-(5-trifluoromethyl-furan-2-ylmethyl)-1H-pyrazol-4-ylmethyl]-
IH
pyrrolo[2,3-b]pyridine (P-0138), 3-[3,5-Dimethyl-l-(5-methyl-isoxazol-3-ylmethyl)-1H-pyrazol-4-ylmethyl]- 1H-pyrrolo[2,3 b]pyridine (P-0139), 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid 4-chloro benzylamide (P-0140), 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid [2-(4 ethoxy-phenyl)-ethyl]-amide (P-0141), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid 3-methoxy benzylamide (P-0142), 3-{3,5-Dimethyl-1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-1H-pyrazol-4 ylmethyl}-1H-pyrrolo[2,3-b]pyridine (P-0143), 3-[3,5-Dimethyl-1-(4-methyl-2-phenyl-thiazol-5-ylmethyl)- 1H-pyrazol-4-ylmethyl]-1H pyrrolo[2,3-b]pyridine (P-0144), 3,5-Dimethyl-4-(l H-pyrrolo[2,3 -b]pyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 2-methoxy benzylamide (P-0145), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid [2-(2,4 dichloro-phenyl)-ethyl]-amide (P-0146), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l-carboxylic acid [2-(4 fluoro-phenyl)-ethyl]-amide (P-0147), 3,5-Dimethyl-4-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1-carboxylic acid [2-(2 fluoro-phcnyl)-ethyl]-amide (P-0148), 3,5-Dimethyl-4-( H-pyrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-1 -carboxylic acid ((S)-1 phenyl-ethyl)-amide (P-0149), 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- 1 -carboxylic acid 3-fluoro benzylamide (P-0150), 3,5-Dinethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- -carboxylic acid 4-fluoro benzylamide (P-0151), 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I -carboxylic acid 4-methyl benzylamide (P-0152), and 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 2-methyl benzylamide (P-0153). 94 WO 2008/064255 PCT/US2007/085289 [01861 The following table indicates the isocyanate or bromide (Column 2) used in Scheme 171 to provide the compounds (Column 3). Column I provides the compound number and Column 4 the observed mass. CompoundMS(ESI) Com und Isocyanate or bromide Compound [M+H ] observed Br P-0133 N 317.1 PNN H N N H O=C-N P-0136 c N y N CI O=C=N -N P-0137 F . 378.3 N N_, N H F BrN I-> P-0138 B ) ' j 0 _CF, 375.1
CF
3 N N Br N P-0139 N N C 322.3 0 N N O=C=N N P-N N NO P N 404.3 P-0141 BFC2 5 N P-0 142 Ni 0 ,a 390.3 0 N N Br~ -N -aC P-0143 N-, IS48.
CF
3 N1 N 95 WO 2008/064255 PCT/US2007/085289 Compound MS(ESI) number Isocyanate or bromide Compound [M+HT] observed Br -N P-0144 -"' 414iiJ39.3 NN NH P-0146 NT y0 cI 442.3 O~CN N P-0147 .y 392.3 ,-OF N N H F_ _ O=C=N -N P-0148 91 y 0~ F 392.3 O=C=N N~C -N , 7 . P-0149 . 373 N N
H
O=C=N P-0 150 NP N 0N.k~JN 378.3 F NI N ozczN -N P-0151 N~J 0 FN-K 378.3 FN N H N P.0152 N 374.3 H P-0153 N N--- - n 374.3 Iii HN N N _________________ _____________________H________ 96 WO 2008/064255 PCT/US2007/085289 Example 18: Synthesis of 5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-blpyridine 547. [01871 5-(1-Methyl-1H-pyrazol-4-yl)-lH-pyrrolo[2,3-b]pyridine 547 was synthesized in I step from 5-bromo-1H-pyrrolo[2,3-b]pyridine 44 as shown in Scheme 172. Scheme 172 Br B 1 Br"+ - Step 1 N N N-N N N H 44 546 547 Step 1 - Preparation of 5-(1-Methyl-JH-pyrazol-4-yl)-JH-pyrrolo[2,3-b]pyridine (547): 10188] To 5-bromo-7-azaindole (44, 1.04 g, 5.28 mmol) in 1.00 M potassium carbonate in water (15.8 mL) and tetrahydrofuran (50.0 mL) were added I -methyl-4-(4,4,5,5-tetramethyl (1,3,2]dioxaborolan-2-yl)-1H-pyrazole (546, 1.65 g, 7.92 mmol), Tetrakis(triphenylphosphine)palladium(0) (0.305 mg, 0.26 mmol) and tetra-n-butylammonium iodide (0.20 g, 0.53 mmol). The reaction mixture was stirred at 70 *C overnight. The reaction mixture was poured into water and the organic layer was washed with brine, dried over sodium sulfate, and concentrated. The residue was purified with silica gel column chromatography eluting with 25% ethyl acetate in hexane to provide a light yellow solid (547, 670 mg, 64.0%). MS(ESI)[M+H*] = 199.4. Example 19: Synthesis of [2-(4-fluoro-benzylamino)-thiazol-5-yl]-(1H-pyrrolo[2,3-b]pyridin 3-yl )-methanone P-0177. 10189] [2-(4-Fluoro-benzylamino)-thiazol-5 -yl]-(1 H-pyrrolo[2,3-bjpyridin-3-yl )-methanone P 0177 was synthesized in 2 steps as shown in Scheme 173. Scheme 173 Boc, Boc N N N HO S-( 0 , 0~( 0 1 N Stepi 8 Ste 1 Step 2 N548 F N N 59 F N -17 F TIPS H H 97 WO 2008/064255 PCT/US2007/085289 Step 1 - Preparation of(4-fluoro-benzyl)-[5-(IH-pyrrolo[2, 3-b]pyridine-3-carbonyl)-thiazol-2 yl]-carbamic acid tert-butyl ester (549): 10190] A mixture of {4-chloro-5-[hydroxy-(1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3 yl)-methyl]-thiazol-2-yl}-pyridin-4-ylmethyl-carbamic acid tert-butyl ester (548, 0.397 g, 0.57 mmol, prepared according to the protocol of Scheme 159, Example 5, replacing 4 (aminomethyl)pyridine 516 with 4-fluoro-benzylamine in step 1, isolated after step 3), triethylsilane (1.0 mL, 6.3 mmol), and trifluoroacetic acid (0.5 mL, 6 mmol) in acetonitrile (10 mL) was stirred at 40 *C for 2 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with sodium bicarbonate and brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with methanol in dichloromethane to provide the desired compound as a yellow solid (549, 0.11 g, 9%). MS (ESI) [M-H*]*= 451.10. Step 2 - Preparation of[2-(4-fluoro-benzylamino)-thiazol-5-yl]-(IH-pyrrolo[2,3-b]pyridin-3-yl ) methanone (P-0177): 10191] To a solution of (4-fluoro-benzyl)-[5-(1H-pyrrolo[2, 3-b]pyridine-3-carbonyl)-thiazol-2 yl]-carbamic acid tert-butyl ester (549, 0.11 g, 0.2 mmol) in dichloromethane (2 mL) was added hydrogen chloride (4 M in 1,4-dioxane, 2 mL). The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into cold sodium bicarbonate solution, extracted with ethyl acetate, washed with brine and dried over magnesium sulfate. After removal of solvents, the residue was washed with ethyl acetate to provide the desired compound as a yellow solid (P-0177, 9 mg, 10%). MS (ESI) [M+H*]*= 353.12. Example 20: Synthesis of {2-[(4-chloro-benzyl)-methyl-amino]-thiazol-5-yl}-(1H-pyrrolo[2,3 bjpyridin-3-yl)-methanone P-0178. 10192] {2-[(4-Chloro-benzyl)-methyl-amino]-thiazol-5-yl)-(1H-pyrrolo[2,3-b]pyridin-3-yl) methanone P-0178 was synthesized in 3 steps as shown in Scheme 174. 98 WO 2008/064255 PCT/US2007/085289 Scheme 174 0 / N S NH S_. HCI + Step 1O N + N N N N 93 5 50 H CI 551 CI 96 TIPS HO 0 S N N N 0 / Step 2 Step 3 552 CI N N P-0178 C' TIPS Step I - Preparation of 4-chloro-2-[(4-chloro-benzyl)-methy I-amino]-thiazole-5-carbaldehyde (551): 10193] To a solution of (4-chloro-benzyl)-methyl-amine (550, 2 g, 0.01 mol) and N,N-diisopropylethylamine (4 mL, 0.03 mol) in tetrahydrofuran (50 mL) was added 2,4-dichloro thiazole-5-carbaldehyde (93, 3 g, 0.01 mmmol) in tetrahydrofuran (20 mL) at room temperature. The reaction mixture was stirred at room temperature overnight. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was collected by filtration and washed with hexanes to provide the desired compound as a light-yellow solid (551, 3.6 g, 90%). Step 2 - Preparation of (4-chloro-2-[(4-chloro-benzyl)-methyl-amino]-thiazol-5-yl} (1-triisopropylsilanyl-IH-pyrrolo[2,3-b]pyridin-3-yl)-methanol (552): 10194] To a solution of 3-iodo-l-triisopropylsilanyl-IH-pyrrolo[2,3-b]pyridine (96, 0.82 g, 2.0 mmol) in tetrahydrofuran (5 mL) at -20 *C, isopropylmagnesium chloride (2 M in tetrahydrofuran, 1.1 mL, 2.2 mmol) was added dropwise. The reaction mixture was allowed to warm to 0 *C in 10 minutes. The reaction mixture was then cooled to -40 "C. To the reaction mixture was added a solution of 4-chloro-2-[(4-chloro-benzyl)-methyl-amino]-thiazole-5-carbaldehyde (551, 0.41 g, 1.4 mmol) in tetrahydrofuran (10 mL). The reaction mixture was allowed to warm to -10 *C in 30 minutes. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with ethyl acetate in hexanes to provide the desired compound as a yellow solid (552, 0.5 g, 60%). MS (ESI) [M+H*]'= 575.29. Step 3 - Preparation of (2-[(4-chloro-benzyl)-methyl-amino]-thiazol-5-yl)-(JH-pyrrolo[2,3 b]pyridin-3-yl)-methanone (P-0178). 99 WO 2008/064255 PCT/US2007/085289 [0195] A mixture of {4-chloro-2-[(4-chloro-benzyl)-methyl-amino]-thiazol-5-yl} -(1 triisopropylsilanyl-l H-pyrrolo[2,3-b]pyridin-3-yl)-methanol (552, 1 g, 2 mmol), triethylsilane (2 mL, 12 mmol), and trifluoroacetic acid (I mL, 13 mmol) in acetonitrile (10 mL) was stirred at 40 *C for 2 hours. The reaction mixture was poured into ice water, extracted with ethyl acetate, washed with sodium bicarbonate and brine, and dried over sodium sulfate. After removal of solvent, the residue was purified by silica gel column chromatography eluting with methanol in dichloromethane to provide the desired compound as a yellow solid (P-0178, 0.17 g, 30%). MS (ESI) [M+H*]*= 383.09. Example 21: Synthesis of aldehyde intermediates, 101961 (3-Chloro-pyridin-4-ylmethyl)-(5-formyl-pyridin-2-y)-carbamic acid tert-butyl ester 558 was synthesized in 4 steps from 6-amino-nicotinic acid methyl ester 553 as shown in Scheme 175. Scheme 175 0 O NH 0 N Step ON CI Step 2 N NH 2 -NH KN 553 554 555 HO f CN C Step4 O Bo CI .. Step 3 N N' N.N ' 556 H 557N 558 Step I - Synthesis of 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-nicotinic acid methyl ester (555): 101971 To 6-amino-nicotinic acid methyl ester (553, 2.15 g, 0.014 mol) in acetonitrile (60.0 mL) were added 3-chloro-pyridine-4-carbaldehyde (554, 2.00 g, 0.014 mol), triethylsilane (11.00 mL, 0.069 mol) and trifluoroacetic acid (5.00 mL, 0.065 mol). The reaction was stirred at 80 "C overnight. The reaction was concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (555, 1.5 g, 38.2%). MS (ESI) [M+H*]*= 278.9. Step 2 - Synthesis of 6-[(3-Chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-yl-methanol (556): 101981 To 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-nicotinic acid methyl ester (555, 1.00 g, 3.60 mmol) in tetrahydrofuran (120 mL) was added a solution of lithium tetrahydroaluminate (1.00 M in tetrahydrofuran, 5.00 mL) under an atmosphere of nitrogen at room temperature. The reaction 100 WO 2008/064255 PCT/US2007/085289 was stirred at room temperature overnight, followed with addition of sodium sulfate decahydrate. After 1 hour, the reaction mixture was filtered, concentrated, and purified with silica gel column chromatography eluting with 2% to 20% methanol in dichloromethane to give the desired compound as a white solid (556, 0.5 g, 56%). MS (ESI) [M+H] = 250.1. Step 3 - Synthesis of6-[(3-chloro-pyridin-4-ylmethyl)-amino]-pyridine-3-carbaldehyde (557): [0199] To 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-pyridin-3-yl-methanol (556, 0.50 g, 2.00 mmol) in tetrahydrofuran (20.0 mL) was added Dess-Martin periodinane (1.02 g, 2.40 mmol). The reaction was stirred at room temperature for 10 minutes, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give crude compound (557, 0.45 g, 91%) that was used in the next step without further purification. Step 4 - Synthesis of (3-chloro-pyridin-4-ylmethyl)-(5-formyl-pyridin-2-yl)-carbanmic acid tert butyl ester (558): 10200] To 6-[(3-chloro-pyridin-4-ylmethyl)-amino]-pyridine-3-carbaldehyde (557, 0.45 g, 1.80 mmol) in dichloromethane (20.0 mL) were added di-tert-butyldicarbonate (0.65 g, 3.00mmol), 4-dimethylaminopyridine (0.0 12 g, 0.0 10 mmol) and triethylamine (0.28 mL, 2.00 mmol). The reaction was stirred at room temperature overnight, then concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (558, 250 mg, 40.0%). 10201] (2-Difluoromethoxy-benzyl)-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester 559 F W -F N_ N 0 was prepared following the protocol of Scheme 175, substituting 3-chloro-pyridine-4-carbaldehyde 554 with 2-difluoromethoxy-benzaldehyde in Step 1. 102021 [2,6-Difluoro-3-(propane- I -sulfonylamino)-benzyl]-(5-formyl-pyridin-2-y)-carbamic acid tert-butyl ester 560 F O N" 0 O O F HN-S-/ 101 WO 2008/064255 PCT/US2007/085289 was prepared following the protocol of Scheme 175, substituting 3-chloro-pyridine-4-carbaldehyde 554 with propane-i -sulfonic acid (2,4-difluoro-3-formyl-phenyl)-amide in Step 1. MS (ESI) [M+H]* = 470.3. 102031 (6-Fluoro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 565 was synthesized in 4 steps from 2,6-Difluoro-nicotinic acid methyl ester 60 as shown in Scheme 176. Scheme 176 0 00 O F HN CsStep 1 OCStep 2 H-H F N F N6 CF 3 F 60 561 F N 563 N CF 3 564 N CF 3 565 N 3 Step I - Synthesis of2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-nicotinic acid methyl ester (562): [0204] To 2,6-difluoro-nicotinic acid methyl ester (60, 1.82 g, 0.0105 mol) in N,N dimethylformamide (20.0 mL), under an atmosphere of nitrogen at -40 *C, C-(6-trifluoromethyl pyridin-3-yl)-methylamine (561, 1.00 g, 5.68 mmol) was added. The reaction was stirred at -40 *C, then allowed to warm to room temperature for 2 hours. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 35% to 100% ethyl acetate in hexane to give a white solid (562, 1.40 g, 74.9). MS (ESI) [M+HJ*= 330.1. Step 2 - Synthesis of 2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl methanol (563): 10205] To 2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-nicotinic acid methyl ester (562, 1.40 g, 4.25 mmol) in tetrahydrofuran (100.0 mL) under an atmosphere of nitrogen at room temperature, a solution of lithium tetrahydroaluminate (1.00 M in tetrahydrofuran, 10.0 mL) was added slowly. The reaction was stirred at room temperature overnight, followed by addition of an appropriate amount of sodium sulfate decahydrate. After 1 hour, the reaction mixture was filtered and concentrated to give crude compound (563, 1.2 g, 93.7%) that was used in the next step without further purification. 102 WO 2008/064255 PCT/US2007/085289 Step 3 - Synthesis of2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3 carbaldehyde (564): [0206) To 2-fluoro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridin-3-yl-methanol (563, 1.20 g, 3.98 mmol) in dichloromethane (40.0 mL) was added Dess-Martin periodinane (1.86 g, 4.38 mmol). The reaction was stirred at room temperature for 10 minutes, then poured into aqueous sodium thiosulfate and potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (564, 0.28 g, 23.5%). Step 4 - Synthesis of (6-fluoro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl) carbamic acid tert-butyl ester (565): [0207] To 2 -fluoro- 6
-[(
6 -trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3-carbaldehyde (564, 0.28 g, 0.94 mmol) in tetrahydrofuran (10.0 mL) were added di-tert-butyldicarbonate (0.245 g, 1.12 mmol) and 4-dimethylaminopyridine (0.050 g, 0.41 mmol). The reaction was stirred at room temperature overnight, then concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (565, 0.22 g, 59%). [02081 (6-Chloro-5-formyl-pyridin-2-y)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 570 was synthesized in 4 steps from 6-chloro-pyridin-2-ylamine 537 as shown in Scheme 177. Scheme 177 Step CI CFStep 2 CI N" NH 2 + - N- CF 3 567 N C 3 537 566 0 0 Br B Step 3 Step 4 NZ: C N, N CI N N 568 N CF 3 569 N CF 3 570 CF 3 Step 1 - Synthesis of (6-chloro-pyridin-2-yl)-(6-trfluoromethyl-pyridin-3-ylmethyl)-amine (567): 10209] To 6-chloro-pyridin-2-ylamine (537, 0.760 g, 5.91 mmol) in acetonitrile (30.0 mL), 6-trifluoromethyl-pyridine-3-carbaldehyde (566, 1.06 g, 6.05 mmol), trifluoroacetic acid (3.00 mL, 103 WO 2008/064255 PCT/US2007/085289 0.0389 mol) and triethylsilane (6.00 mL, 0.0376 mol) were added. The reaction was heated to reflux for 4 hours. The reaction was concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated and purified with silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (567, 1.60 g, 94.1%). Step 2 - Synthesis of (5-bromo-6-chloro-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl) amine (568): [02101 To (6-chloro-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (567, 4.50 g, 0.0 156 mol) in acetonitrile (120.0 mL) under an atmosphere of nitrogen, N-bromosuccinimide (3.03 g, 0.0 170 mol) in acetonitrile (50 mL) was added slowly. The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over sodium sulfate, concentrated and purified with silica gel column chromatography eluting with 25% to 100% ethyl acetate in hexane to give a white solid (568, 6.20 g, 80.2%). Step 3 - Synthesis of2-chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3 carbaldehyde (569): [0211] To (5-bromo-6-chloro-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (568, 4.60 g, 0.0125 mol) in tetrahydrofuran (60.0 mL) under an atmosphere of nitrogen at -78 *C, isopropylmagnesium chloride (2.00 M in tetrahydrofuran, 6.44 mL) was added over 10 minutes. The reaction was stirred at -78 *C for 20 minutes, and then allowed to warm to room temperature for 10 minutes. The reaction was cooled to -78 *C, followed by adding tert-butyllithium (1.70 M in hexane, 15.3 mL) over 10 minutes. After 40 minutes, N,N-dimethylformamide (1.23 mL, 0.0158 mol) was added and the reaction was stirred at -78 *C for 40 minutes, then allowed to warm to room temperature for 30 minutes. The reaction mixture was poured into water and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 35% to 100% ethyl acetate in hexane to give a light yellow solid (569, 2.84 g, 71.7%). Step 4 - Synthesis of (6-chloro-5-formyl-pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl) carbamic acid tert-butyl ester (570) 10212] To a solution of 2-chloro-6-[(6-trifluoromethyl-pyridin-3-ylmethyl)-amino]-pyridine-3 carbaldehyde (569, 0.545 g, 1.73 mmol) in tetrahydrofuran (10 mL), N,N-diisopropylethylamine (0.60 mL, 3.40 mmol), 4-dimethylaminopyridine (20 mg, 0.10 mmol), and a solution of di-tert butyldicarbonate (0.41 g, 0.0019 mol) were added. The reaction mixture was stirred at room temperature overnight, then concentrated, poured into water, and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica 104 WO 2008/064255 PCT/US2007/085289 gel column chromatography cluting with 20% to 100% ethyl acetate in hexane to give the desired compound (570, 0.60 g, 83.6%). [02131 (5-Bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-amine 571 Br N F CI was prepared following the protocol of Steps 1 and 2 of Scheme 177, substituting 6-chloro pyridin-2-ylamine 537 and 6-trifluoromethyl-pyridine-3-carbaldehyde 566 with 6-fluoro-pyridin 2-ylamine and 2-chloro-benzaldehyde, respectively in Step 1. [0214] (6-Fluoro-5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert butyl ester 572 O Nr O' N IO F was prepared following the protocol of Scheme 177, substituting 6-chloro-pyridin-2-ylamine 537 and 6-trifluoromethyl-pyridine-3-carbaldehyde 566 with 6-fluoro-pyridin-2-ylamine and 6 methoxy-pyridine-3-carbaldehyde, respectively in Step 1. [02151 (5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 631 OO F Br ~N F was prepared following the protocol of Scheme 177, substituting 6-chloro-pyridin-2-ylamine 537 and 6-trifluoromethyl-pyridine-3-carbaldehyde 566 with 6-fluoro-pyridin-2-ylamine and 5-fluoro pyridine-3-carbaldehyde, respectively in Step 1, without Step 3 (i.e. the product of Step 2 is reacted according to Step 4). 10216] (5-Bromo-6-fluoro-pyridin-2-yl)-(4-chloro-benzyl)-carbamic acid tert-butyl ester 637 0)yO Br Cl F 105 WO 2008/064255 PCT/US2007/085289 was prepared following the protocol of Scheme 177, substituting 6 -chloro-pyridin-2-ylamine 537 and 6 -trifluoromethyl-pyridine-3-carbaldehyde 566 with 6 -fluoro-pyridin-2-ylamine and 5-chloro benzaldehyde, respectively in Step 1, without Step 3 (i.e. the product of Step 2 is reacted according to Step 4). Example 22: Synthesis of propane-1-sulfonic acid ( 2
,
4 -difluoro-3-15-(1H-pyrrolo[2,3 blpyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl-phenyl)-amide P-0258 [02171 Propane-i -sulfonic acid (2,4-difluoro-3-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyridin- 2 -ylamino]-methyl-phenyl)-amide P-0258 was synthesized in 2 steps from 3-lodo-I triisopropylsilanyl-1H-pyrrolo(2,3-b]pyridine 96 as shown in Scheme 178. Scheme 178 F F - Bac IHO I, N!) 0~o O N O Step 1 HO Bo N N-OO F HN-5- F H TIPS 560 N 574 96 TIPS F -H Step 2 N N N H P-0258 Step I - Synthesis of [2, 6 -difluoro-3-(propane--sulfonylamino)-benzyl]-5-[hydroxy-( triisopropylsilanyl-lH-pyrrolo[2,3-b]pyr idin- 3 -yl)-methyl]-pyridin-2-yl-carbamic acid tert-butyl ester (574): 102181 To a solution of 3 -Iodo-I-triisopropylsilanyl-IH-pyrrolo[2,3-b]pyridine (96, 0.644 g, 1.61 mmol) in tctrahydrofuran (10.0 mL) at -40 *C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.80 mL) was added slowly. The reaction was allowed to warm to 15 *C over 100 minutes, then cooled to -40 *C, followed by adding [ 2
,
6 -difluoro-3-(propane-I sulfonylamino)-benzyl]-(5-formyl-pyridin-2-yl)-carbamic acid tert-butyl ester (560, 0.100 g, 0.21 mmol, prepared as described in Example 21, Scheme 175) in tetrahydrofuran (2.0 mL). The reaction was allowed to warm to 5 *C over 2 hours, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a yellow solid (574, 75 mg, 47%). MS (ESI) (M+H-]* = 744.7. 106 WO 2008/064255 PCT/US2007/085289 Step 2 - Synthesis of Propane-I-sulfonic acid (2,4-difluoro-3-[5-(H-pyrrolo[2,3-b]pyridin-3 ylmethyl)-pyridin-2-ylamino)-methyl-phenyl)-amide (P-0258): [0219] To [2,6-difluoro-3-(propane-1-sulfonylamino)-benzyl]-5-[hydroxy-( I-triisopropylsilanyl I H-pyrrolo[2,3-b]pyr idin- 3 -yl)-methyl]-pyridin-2-yl-carbamic acid tert-butyl ester (574, 75.0 mg, 0.10 mmol) in acetonitrile (10.0 mL) were added triethylsilane (0.40 mL, 2.5 mmol) and trifluoroacetic acid (0.20 mL, 2.6 mmol). The reaction was stirred at 80 *C for 4 hours. The reaction was poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15% methanol in di 6 hloromethane to give an off-white solid (P-0258, 29.3 mg, 61.6%). MS (ESI) [M+H]* = 472.4. [02201 Propane-i -sulfonic acid ( 3 -{[5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin 2-ylamino]-methyl } -2,4-difluoro-phenyl)-amide (P-0259), [6-Fluoro-5-(l H-pyrrolo[2,3-blpyridin 3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl)-amine (P-0378), and [5-(5-Chloro- H-pyrrolo[2,3-b]pyridin-3-ylmthyl)-6-fluoro-pyridin-2-yl]-(6-methoxy-pyridin-3 ylmethyl)-amine (P-0379), F NNH ci N F N- NO , n H H and respectively, were prepared following the protocol of Scheme 178. P-0259 was prepared by replacing 3-iodo-i-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine 96 with 5-chloro-3-iodo-1 triisopropylsilanyl- I H-pyrrolo[2,3-b]pyridine in Step 1 (MS [M+H*]* = 506.1). P-0378 was prepared by replacing [2,6-difluoro-3-(propane-I-sulfonylamino)-benzyl]-(5-formyl-pyridin-2-yl) carbamic acid tert-butyl ester 560 with (6-Fluoro-5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3 ylmethyl)-carbamic acid tert-butyl ester 572 (prepared as described in Example 21, Scheme 177) in Step I (MS [M+H+* = 364.1). P-0379 was prepared by replacing both azaindole 96 with 5 chloro-3-iodo-1 -triisopropylsilanyl-I H-pyrrolo[2,3-b]pyridine and aldehyde 560 with aldehyde 572 in Step I (MS [M+H*]*= 400.0). Example 23: Synthesis of [6-fluoro-5-(5-methoxy-1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl) pyridin-2-yI]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0187 [02211 [ 6 -Fluoro-5-(5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6 trifluoromethyl-pyridin-3-ylmethyl)-amine P-0187 was synthesized in 3 steps from I-benzenesulfonyl-3-iodo-5-methoxy-1H-pyrrolo[2,3-b]pyridine 575 as shown in Scheme 179. 107 WO 2008/064255 PCT/US2007/085289 Scheme 179 HO - Boc H N: 0 CFStep 1 O0 N' + F NA F Step 2 173BocQn1 N S2Ph F 3
SO
2 Ph 575 565 576 - H - - H N N -CF 3 NN CF, 'O Step 3 -O N F _.. F N N N N P-0187 S0 2 Ph 577 H Step I - Synthesis of 5-[(-benzenesulfonyl-5-methoxy-IH-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy methyl]- 6 -fluoro-pyridin-2-yl-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (576): 10222] To I-benzenesulfonyl-3-iodo-5-methoxy- IH-pyrrolo[2,3-b]pyridine (575, 0.326 g, 0.000788 mol) in tetrahydrofuran (3.00 mL) at -45 *C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.380 mL) was added slowly. The reaction was allowed to warm to -25 *C in 30 minutes, and then cooled to -45 *C followed by adding (6-fluoro-5-formyl pyridin-2-yl)-(6-trifluoromethyl-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (565, 80.0 mg, 0.20 mmol, prepared as described in Example 21, Scheme 176) in tetrahydrofuran (1.0 mL). The reaction was allowed to warm to room temperature over 2 hours. The reaction was poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (576, 0.080 g, 60%). MS (ESI) [M+H*]* = 688.1. Step 2 - Synthesis of [5-(I-Benzenesulfonyl-5-methoxy-H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6 fluoro-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (5 77): 102231 To 5-[(I-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyJ-6 fluoro-pyridin-2-yl-(6-trifluoromethyl-pyridin-3-ylmethy )-carbamic acid tert-butyl ester (576, 0.100 g, 0.15 mmol) in acetonitrile (12.6 mL) were added triethylsilane (0.34 mL, 2.10 mmol) and trifluoroacetic acid (0.17 mL, 2.20 mmol). The reaction was heated to 80 *C for 2 hours. The reaction was poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated to give the crude compound (577, 90 mg, 100%) that was used in the next step without further purification. 108 WO 2008/064255 PCT/US2007/085289 Step 3 - Synthesis of [6-Fluoro-5-(5-methoxy-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] (6-trifluoromethyl-pyridin-3-ylmethyl)-amine (P-0187): 102241 To [5-(1-benzenesulfonyl-5-methoxy-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine (577, 0.08 g, 0.13 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.110 g, 0.35 mmol). The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give an off-white solid (P-0187, 8.1 mg, 10%). MS (ESI) [M+H] = 431.9. 102251 [6-Fluoro-5-(5-chloro-1 H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyridin-2-yl]-(6 trifluoromethyl-pyridin-3-ylmethyl)-amine P-0186 and [6-Fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3 ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3-ylmethyl)-amine P-0188, _ H . . C CF3 , N -CF 3 NN NNN H and H respectively, were prepared following the protocol of Scheme 179, substituting I -benzenesulfonyl-3-iodo-5 methoxy- I H-pyrrolo[2,3-b]pyridine 575 with 1 -benzenesulfonyl-3-iodo-5-chloro- 1 H-pyrrolo[2,3 b]pyridine or 1 -Benzenesulfonyl-3-iodo-l H-pyrrolo[2,3-b]pyridine, respectively, in Step 1. MS (ESI) [M+H*]* = 435.7 and 401.6, respectively. Example 24: Synthesis of [6-(2-fluoro-benzylamino)-pyridin-3-yl]-(1H-pyrrolo[2,3-blpyridin 3-yl)-methanone P-0403 [02261 Synthesis of [6-(2-fluoro-benzylamino)-pyridin-3-yi]-( IH-pyrrolo[2,3-b]pyridin-3-yl) methanone P-0403 was synthesized in 2 steps from 3-lodo- 1 -triisopropylsilanyl- I H-pyrrolo[2,3 b]pyridine 96 as shown in Scheme 180. Scheme 180 Boc. HN , + 0 Bo Step 1 Boc Step 2 TISN N NN TIPS 579 F H 580 H P-0403 Step I -(2-Fluoro-benzyl)-[5-( -pyrrolo[2.3-b]pyridine-3-carbonyl)-pyridin-2-yl]-carbamic 109 WO 2008/064255 PCT/US2007/085289 acid tert-butyl ester (580): [02271 To 3-iodo-1-triisopropylsilanyl-lH-pyrrolo[2,3-b]pyridine (96, 0.550 g, 1.37 mmol) in tetrahydrofuran (15.0 mL) at -40 *C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.65 mL) was added slowly. The reaction was allowed to warm to 5 *C over 70 minutes, then cooled to -40 *C, followed by adding (2-fluoro-benzyl)-(5-formyl-pyridin-2-yl) carbamic acid tert-butyl ester (579, prepared according to the protocol of Example 1, Scheme 19, Steps 1-3, replacing 4-chlorobenzaldehyde 40 with 2-fluoro-benzaldehyde in Step 1) in tetrahydrofuran (4.0 mL). The reaction was allowed to warm to room temperature over 1 hour, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (580, 0.14 g, 26%). MS (ESI) [M+H*]* = 447.0. Step 2 - Synthesis of [6-(2-Fluoro-benzylaniino)-pyridin-3-yl]-(H-pyrrolo[2,3-b]pyridin-3-y) methanone (P-0403): [02281 To (2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-pyridin-2-yl]-carbamic acid tert-butyl ester (580, 0.080 g, 0.18 mmol) in dichloromethane (3.0 mL) was added trifluoroacetic acid (1.0 mL, 0.013 mol). The reaction was stirred at room temperature overnight, then concentrated, poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15 % methanol in dichloromethane to give the desired compound (P-0403, 15.0 mg, 23.0%). MS (ESI) [M+H*]* = 347.5. Example 25: Synthesis of (5-chloro-1H-pyrrolo[2,3-blpyridin-3-y)-[6-(2-fluoro benzylamino)-pyridin-3-yl]-methanone P-0404 [0229] (5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-[6-(2-fluoro-benzylamino)-pyridin-3-yl] methanone P-0404 was synthesized in 4 steps from 1-benzenesulfonyl-5-chloro-3-iodo-1H pyrrolo[2,3-b]pyridine 581 as shown in Scheme 181. 110 WO 2008/064255 PCT/US2007/085289 Scheme 181 Ca + O NNtp1 C B9Se HI _- Boc H Q/ - N N + Stepi I I Ste 2 N N -N )f Sep
SO
2 Ph F N N 581 S0 2 Ph 552 Boc Boc Step 4 I N 0 N i~ N N FF P NN H 58 P-0404 SO2Ph 583 H 584 Step I - Synthesis of 5-[(I-benzenesulfonyl-5-chloro-JH-pyrrolo[2,3-b]pyridin-3-yI)-hydroxy methyl]-pyridin-2-yl-(2-fluoro-benzyl)-carbamic acid tert-butyl ester (582) 102301 To a solution of 1-benzenesulfonyl-5-chloro-3-iodo-1H-pyrrolo[2,3-b]pyridine (581, 0.420 g, 1.00 mmol) in tetrahydrofuran (15.0 mL) at -40 *C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.49 mL) was added slowly. The reaction was allowed to warm to 5 *C over 70 minutes, then cooled to -40 *C, followed by adding (2-fluoro-benzyl)-(5-formyl pyridin-2-yl)-carbamic acid tert-butyl ester 579 in tetrahydrofuran (6.0 mL). The reaction was allowed to warm to room temperature over 1 hour, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (582, 0.25 g, 41%). MS (ESI) [M+H*]* = 623.1. Step 2 - Synthesis of[5-(-Benzenesulfonyl-5-chloro- JH-pyrrolo[2,3-b]pyridine-3-carbonyl) pyridin-2-yl]-(2-fluoro-benzyl)-carbamic acid tert-butyl ester (583): 102311 To 5-[(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl] pyridin-2-yl-(2-fluoro-benzyl)-carbamic acid tert-butyl ester (582, 0.25 g, 0.40 mmol) in dichloromethane (5.0 mL) was added Dess-Martin periodinane (0.20 g, 0.48 mmol). The reaction was stirred at room temperature for 10 minutes, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (583, 0.060 g., 24%). Step 3 - Synthesis of[5-(5-Chloro-JH-pyrrolo[2,3-b]pyridine-3-carbonyl)-pyridin-2-yl]-(2-fluoro benzyl)-carbamic acid tert-butyl ester (584): 102321 To [5-(1-benzenesulfonyl-5-chloro- IH-pyrrolo[2,3-b]pyridine-3-carbonyl)-pyridin-2-y] 111 WO 2008/064255 PCT/US2007/085289 (2-fluoro-benzyl)-carbamic acid tert-butyl ester (583, 60.0 mg, 0.097 mmol) in tetrahydrofuran (1.0 mL) was added aqueous potassium carbonate (1.0 M, 1.0 mL). The reaction was irradiated with microwave on 300 watts, 1 00"C for 10 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give crude compound (584, 0.040 g, 64%) that was used in the next step without further purification. Step 4 - Synthesis of (5-Chloro-IH-pyrrol6[2, 3 -b]pyridin-3-yl)-[6-(2-fluoro-benzylamino) pyridin-3-yl]-methanone (P-0404): [0233] To [5-(5-chloro-1H-pyrrolo[ 2
,
3 -bpyridine-3-carbonyl)-pyridin-2-yl]-(2-fluoro-benzyl) carbamic acid tert-butyl ester (584, 0.030 g, 0.062 mmol) in dichloromethane (1.0 mL) was added trifluoroacetic acid (1.0 mL, 0.013 mol). The reaction was stirred at room temperature overnight, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15% methanol in dichloromethane to give the desired compound (P-0404, 2.8 mg, 12%). MS (ESI) [M+H] *= 381.0. Example 26: Synthesis of (5-chloro-1H-pyrrolo[2,3-bipyridin-3-yl)-6-[(6-methoxy-pyridin-3 ylmethyl)-amino]-pyridin-3-yl-methanone P-0405 [02341 (5-Chloro-lH-pyrrolo[ 2
,
3 -b]pyridin-3-yl)-6-[(6-methoxy-pyridin-3-ylmethyl)-amino] pyridin-3-yl-methanone P-0405 was synthesized in 3 steps from 5-Chloro-1 H-pyrrolo[2,3 b]pyridine 532 as shown in Scheme 182. Scheme 182 OH Bo OCNB O Boc C1 Stp1Ni H N N N H N N 58 585 532 H 586 Step 2 C l Bo StepN3 Cl0 N N 587 N N P-0405 H H Step I - Synthesis of 5-[(5-chloro-JH-pyrrolo[2, 3 -b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl
(
6 -methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (586): 102351 To 5-chloro-1lH-pyrrolo[2,3-b]pyridine (532, 0.092 g, 0.60 mmol) in methanol (15.0 mL) were added (5-formyl-pyridin-2-yl)-(6-methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 112 WO 2008/064255 PCT/US2007/085289 (585, 0.240 g, 0.70 mmol, prepared according to the protocol of Example 1, Scheme 19, Steps 1-3, replacing 4-chlorobenzaldehyde 40 with 6 -methoxy-pyridine-3-carbaldehyde in Step 1) and potassium hydroxide (1.2 g, 0.021 mol). The reaction was stirred at room temperature ovemight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (586, 0.110 g, 37%). Step 2 - Synthesis of [5-(5-chloro-1H-pyrrolo(2,3-bjpyridine-3-carbonyl)-pyridin-2-yl]-(6 methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (587): 102361 To 5-[(5-chloro- H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-pyridin-2-yl-(6 methoxy-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (586, 0.060 g, 0.12 mmol) in dichloromethane (10.0 mL) was added Dess-Martin periodinane (0.062 g, 0.15 mmol). The reaction was stirred at room temperature for 10 minutes. The reaction was concentrated and purified with a silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (587, 0.020 g, 33%). Step 3 - Synthesis of (5-chloro-IH-pyrrolo[2, 3 -b]pyridin-3-yl)-6-[(6-methoxy-pyridin-3-ylmethyl) amino]-pyridin-3-yl-methanone (P-0405): [02371 To [5-(5-chloro-1H-pyrrolo[ 2
,
3 -b]pyridine-3-carbonyl)-pyridin-2-yl-(6-methoxy pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (587, 0.020 g, 0.040 mmol) in dichloromethane (2.0 mL) was added trifluoroacetic acid (0.30 mL, 0.0039 mol). The reaction was stirred at room temperature for 2 hours, then poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0405, 5.5 mg, 34%). MS (ESI) [M+H*]= 394.3. 102381 { 6
-[(
6 -Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-yl}-(1 H-pyrrolo[2,3-b]pyridin-3 yl)-methanone P-0406 H 0 N O '0 0 N N H was prepared following the protocol of Scheme 182, substituting 5-chloro-I H-pyrrolo[2,3 bjpyridine 532 with 5-methoxy-1H-pyrrolo[2,3-bjpyridine in step 1. MS (ESI) [M+H*] = 390.1. 113 WO 2008/064255 PCT/US2007/085289 Example 27: Synthesis of intermediate 5-(l-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3 b]pyridin- 3 -ylmethyl)-4-chloro-thiazol-2-ylamine 592 [02391 5-(I-Benzenesulfonyl-5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol 2-ylamine 592 was synthesized in 4 steps from 2 -amino-4-chloro-thiazole-5-carbaldehyde 588 as shown in Scheme 183. Scheme 183 HO ,~-,,NHBoc S ,-NH 2 Step I S>NHBoc C Step 2 CC N N1 N N C 588 Cl 589 581 SO2Ph 590 SO2Ph NH2 NHBoc SI Step 3 C1 StIep 4 j CN CI N N N N
SO
2 Ph
SO
2 Ph 592 591 Step I - Synthesis of (4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (589): 10240] To 2 -amino- 4 -chloro-thiazole-5-carbaldehyde (588, 5.00 g, 0.0308 mol) in tetrahydrofuran (122 mL) were added di-tert-butyldicarbonate (7.38 g, 0.0338 mol) and 4 -dimethylaminopyridine (0.35 g, 0.0029 mol). The reaction was stirred at 58 *C for 2 hours, then concentrated and purified with silica gel column chromatography eluting with 20% to 80% ethyl acetate in hexane to give a yellow solid (589, 7.0 g, 87%). Step 2 - Synthesis of 5-[(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy methyl]-4-chloro-thiazol-2-yl-carbamic acid tert-butyl ester (590): 10241] To a solution of I -benzenesulfonyl-5-chloro-3-iodo-1 H-pyrrolo[2,3-b]pyridine (581, 4.40 g, 10.5 mmol) in tetrahydrofuran (30.0 mL) at -45 *C under nitrogen, a solution of isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 5.4 mL) was added slowly over 10 minutes. The reaction was allowed to warm to -25 'C over 30 minutes. The reaction was cooled to -65 "C, followed by adding the cold deprotonated ( 4 -chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester 589, which was prepared in situ by adding isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 5.0 niL) to ( 4 -chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (589, 2.51 g, 9.55 mmol) in tetrahydrofuran (23.0 mL) at -78 *C under an atmosphere of nitrogen. The reaction was allowed to warm to room temperature in 2 hours, then poured into aqueous ammonium chloride, and extracted with ethyl acetate. The organic layer was dried over anhydrous 114 WO 2008/064255 PCT/US2007/085289 sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25%to 100% ethyl acetate in hexane to give the desired compound (590, 3.70 g, 60.3%). MS (ESI) [M+H*]* = 554.2. Step 3 - Synthesis of[5-(-benzenesulfonyl-5-chloro-JH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4 chloro-thiazol-2-yl]-carbamic acid tert-butyl ester (591): [02421 To 5-[(I-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-yl)-hydroxy-methyl]-4 chloro-thiazol-2-yl-carbamic acid tert-butyl ester (590, 0.200 g, 0.32 mmol) in dichloromethane (15.0 mL) were added triethylsilane (0.600 mL, 376 mmol) and trifluoroacetic acid (0.300 mL, 3.89 mmol). The reaction was stirred at room temperature for 3 hours, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25%to 100% ethyl acetate in hexane to give the desired compound (591, 0.155 g, 88.7%). MS (ESI) [M+H*= 538.9. Step 4 - Synthesis of 5-(-Benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmneihyl)-4 chloro-thiazol-2-ylamine (592): 10243] To [5-(] -benzenesulfonyl-5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro thiazol-2-yl]-carbamic acid tert-butyl ester (591, 4.30 g, 7.97 mmol) in dichloromethane (70.0 mL) was added a solution of hydrogen chloride (4.00 M in 1,4-dioxane, 42.0 mL). The reaction was stirred at room temperature for 2 days, then concentrated, and titrated with ethyl ether and ethyl acetate to give the desired compound (592, 2.60 g, 74.2%). MS (ESI) [M+H*]' = 439.0. 102441 5-(1 -Benzenesulfonyl-1 H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine 593 S NH2 N CN- CI S02Ph was prepared following the protocol of Scheme 183, substituting l-benzenesulfonyl-5-chloro-3 iodo- I H-pyrrolo[2,3-blpyridine 581 with 1 -benzenesulfonyl-3-iodo- 1 H-pyrrolo[2,3-bjpyridine in Step 2. MS (ESI) [M+H*]= 404.4. 115 WO 2008/064255 PCT/US2007/085289 Example 28: Synthesis of [ 4 -Chloro-5-(5-chloro-1H-pyrrolo[2,3-blpyridin-3-ylmethyl) thiazol- 2 -yl]-(5-fluoro-pyridin-3-ylmethyl)-amine P-0231 [0245] [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro pyridin-3-ylmethyl)-amine P-0231 was synthesized in 2 steps from 5-(1-benzenesulfonyl-5-chloro lH-pyrrolo[ 2 ,3-bJpyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine 592 as shown in Scheme 184. Scheme 184 N N H N' HF H F NN N R1 -N CI C C N O Step I Step 2 1 N N 2 Ph N 5 H P-0231 592 594 595 Step 1 - Synthesis of [5-(1-benzenesulfonyl-5-chloro-H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4 chloro-thiazol-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (595): [0246] To 5-(1-benzenesulfonyl-5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro thiazol-2-ylamine (592, 50.0 mg, 0.11 mmol, prepared as described in Example 27, Scheme 183) in ethanol (1.60 mL) and acetic acid (0.08 mL) were added 5-fluoro-pyridine-3-carbaldehyde (594, 43 mg, 0.34 mmol) and silica supported cyanoborohydride (1.21 mmol/g, 0.180 g). The reaction was irradiated with microwave on 300 watts, 100*C for 7 minutes. The reaction was poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% ethyl acetate in hexane to give the desired compound (595, 0.030 g, 48%). Step 2 - Synthesis of[4-chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5 fluoro-pyridin-3-ylmethyl)-amine (P-0231): [0247] To [5-(l -benzenesulfonyl-5-chloro-1 H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-4-chloro thiazol-2-yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (595, 0.030 g, 0.055 mmol) in tetrahydrofuran (6.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.034 g, 0.11 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 3 hours, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0231, 1.5 mg, 116 WO 2008/064255 PCT/US2007/085289 6.7%). MS (ESI) [M+H*]*= 408.1. Example 29: Synthesis of 5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-blpyridin-3 ylmethyl)-pyridin-2-ylaniinc 599 10248] 5-(1-Benzenesulfonyl-5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine 599 was synthesized in 4 steps from 5-chloro-1H-pyrrolo(2,3-b]pyridine 532 as shown in Scheme 185. Scheme 185 CStep1 C Step2- C1 O BrNH2 N N NN N N N N 2 NH H SO 2 Ph 532 596 597 15 HO 1- 1 NH 2
-,NH
2 Cl Step4 CI N NN NN S0 2 Ph 50 2 Ph 598 599 Step I - Synthesis of 5-chloro-IH-pyrrolo[2,3-b]pyridine-3-carbaldehyde (596): [0249] To 5-chloro-I H-pyrrolo[2,3-b]pyridine (532, 10.0 g, 65.5 mmol) in acetic acid (28.3 mL) were added hexamethylenetetramine (11.9 g, 85.2 mmol) and water (56.7 mL). The reaction was refluxed overnight, followed by addition of 200 mL of water. After 30 minutes, the reaction was filtered to recover the solid, then dried under air to give the desired compound (596, 7.0 g. 59%). Step 2 - Synthesis of 1-benzenesulfonyl-5-chloro-JH-pyrrolo[2,3-b]pyridine-3-carbaldehyde (597): 102501 To 5-chloro-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (596, 3.60 g, 0.0199 mol) in dichloromethane (100 mL) were added a solution of potassium hydroxide (9 M in water, 50 mL), tetrabutylammonium hydrogen sulfate (400 mg, 0.001 mol) and benzenesulfonyl chloride (2.9 mL, 0.023 mol). The reaction was stirred at room temperature for 3 hours, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate to give a white solid (597, 2.3 g, 36.0%). Step 3 - Synthesis of (6-amino-pyridin-3-yl)-(l-benzenesulfonyl-5-chloro-IH-pyrrolo[2.3 b]pyridin-3-yl)-methanol (598): [0251] To 2-amino-5-bromopyridine (15, 3.10 g, 17.9 mmol) in tetrahydrofuran (80.0 mL) under 117 WO 2008/064255 PCT/US2007/085289 an atmosphere of nitrogen at -78 *C, a solution n-butyllithium (2.50 M in hexane, 7.10 mL) was added slowly. After 30 minutes, 1,2-bis-(chloro-dimethyl-silanyl)-ethane (3.90 g dissolved in tetrahydrofuran 20.0 mL, 18.1 mmol) was added to the reaction mixture slowly, and then allowed to warm to room temperature for 1 hour. The reaction was cooled to -78 *C followed by adding a solution of n-butyllithium (2.50 M in Hexane, 7.10 mL). The reaction mixture was stirred at -78 *C for 30 minutes, then allowed to warm to room temperature for 60 minutes. The reaction mixture was cooled to -78 *C, followed by adding a solution of n-butyllithium (2.50 M in Hexane, 7.50 mL) slowly. After 60 minutes, I -benzenesulfonyl-5-chloro- 1 H-pyrrolo[2,3-b]pyridine-3 carbaldehyde (597, 1.90 g in 30 mL tetrahydrofuran, 5.92 mmol) was added to the reaction mixture. The reaction mixture was stirred at -78 *C for 2 hours, then allowed to warm to room temperature for 1 hour. The reaction was poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 20% methanol in dichloromethane to give the desired compound (598, 1.25 g, 50.9%). MS (ESI) [M+H]* = 415.2. Step 4 - Synthesis of 5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridin 2-ylamine (599): [0252] To (6-amino-pyridin-3-yl)-(1-benzenesulfonyl-5-chloro-1H-pyrrolo(2,3-b]pyridin-3-y) methanol (598, 1.00 g, 0.00241 mol) in dichloromethane (25.0 mL) were added triethylsilane (3.00 mL, 0.0188 mol) and trifluoroacetic acid (1.50 mL, 0.0195 mol). The reaction was stirred at room temperature overnight, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (599, 0.70 g, 73%). [0253] 5-(1-Benzenesulfonyl-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine 600 / NH 2 CN N' N
SO
2 Ph was prepared following the protocol of Scheme 185, substituting 5-chloro-IH-pyrrolo[2,3 b]pyridine 532 with 1H-pyrrolo[2,3-b]pyridine in Step 1. MS (ESI) [M+H*] = 365.2. Example 30: Synthesis of [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5 fluoro-pyridin-3-ylmethyl)-amine P-0324 118 WO 2008/064255 PCT/US2007/085289 [0254] [5-(5-Chloro-IH-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-pyridin-3 ylmethyl)-amine P-0324 was synthesized in 2 steps from 5-(l-benzenesulfonyl-5-chloro-l
H
pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-ylamine 599 as shown in Scheme 186. Scheme 186 r--NH 2 - H ,N - H .N H FStep 1 C F Step 2 C1 N S0 2 Ph F N NNN 599 594 SO 2 Ph 601 H P-0324 Step I - Synthesis of[5-(l-benzenesulfonyl-5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyridin- 2 -yl]-(5-fluoro-pyridin-3-ylmethyl)-amine (601): 10255] To 5-(1-benzenesulfonyl-5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 ylamine (599, 80.0 mg, 0.20 mmol, prepared as described in Example 29, Scheme 185) in ethanol (2.0 mL) and acetic acid (0.10 mL, 0.0018 mol) were added 5-fluoro-pyridine-3-carbaldehyde (594, 62.7 mg, 0.50 mmol) and sodium cyanoborohydride on silica gel (1.200 mmol/g loading; 0.251 g, 0.30 mmol). The reaction was irradiated with microwave on 300 watts, 100 *C for 10 minutes. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (601, 0.060 g, 59%). Step 2 - Synthesis of[5-(5-chloro-JH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(5-fltoro pyridin-3-ylmethyl)-amine (P-0324).: 102561 To [5-(1-benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] (5-fluoro-pyridin-3-ylmethyl)-amine (601, 0.060 g, 0.12 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.11 g, 0.35 mmol). The reaction was stirred at room temperature overnight, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0324, 13.5mg, 31%). MS (ESI) [M+H']* = 368.0. Example 31: Synthesis of (3-Chloro-pyridin-4-ylmethyl)-[5-(1H-pyrrolo[2,3-blpyridin-3 ylmethyl)-pyridin-2-yl]-amine P-0183 119 WO 2008/064255 PCT/US2007/085289 [02571 (3-Chloro-pyridin-4-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y] amine P-0183 was synthesized in 2 steps from 5-(1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-3 ylmethyl)-pyridin-2-ylamine 600 as shown in Scheme 187. Scheme 187 H .. N - H N Ni N N NH O Step 1 Step 2 C CNN N N NN
SO
2 Ph 554 SO 2 Ph 602 H P-0183 600 Step I - Synthesis of [5-(-benzenesulfonyl-JH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] (4-chloro-pyridin-3-ylmethyl)-anine (602): [02581 To 5-(1 -benzenesulfonyl- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine (600, 120.0 mg, 0.33 mmol, prepared as described in Example 29, Scheme 185) in acetonitrile (10.0 mL) were added 3-chloro-pyridine-4-carbaldehyde (554, 51.3 mg, 0.36 mmol), trifluoroacetic acid (0.30 mL, 0.0039 mol) and triethylsilane (0.60 mL, 0.0038 mol). The reaction was heated to reflux overnight, then poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 30% to 100% ethyl acetate in hexane to give the desired compound (602, 80 mg, 49.6%). MS [M+H*]*= 490.2. Step 2 - Synthesis of (3-chloro-pyridin-4-ylmethyl)-[5-(JH-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyridin-2-yl]-amine (P-0183). [0259] To [5-(1-benzenesulfonyl- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(4-chloro pyridin-3-ylmethyl)-amine (602, 0.08 g, 0.16 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.240 g, 0.76 mmol). The reaction was stirred at room temperature overnight. The reaction was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a yellow solid (P-0183, 4.0 mg, 7%). MS (ESI) [M+H*]* = 350.2. Example 32: Synthesis of [5-(5-Chloro-1H-pyrrolo[2,3-bjpyridin-3-ylmcthyl)-pyridin-2-yl] 16-(2,2,2-trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine P-0409 [0260] [5-(5-Chloro-IH-pyrrolo[2,3-bpyridin-3-ylmethyl)-pyridin-2-yl]-(5-fluoro-pyridin-3 ylmethyl)-amine P-0409 was synthesized in 2 steps from 5-(l-benzenesulfonyl-5-chloro-I H pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamine 599 as shown in Scheme 188. 120 WO 2008/064255 PCT/US2007/085289 Scheme 188
NH
2 H N C k N O N N O CF3 + C Step 1 N N /0 - I
SO
2 Ph N p-0409 599 603 Step 1 - Synthesis of [5-(5-chloro-JH-pyrrolo[2, 3 -b]pyridin-3-ylmehyl)-pyridin-2-y][6(22 2 trifluoro-ethoxy)-pyridin-3-ylmethyl]-amine (P-0409). [0261] To 5-(1-benzenesulfonyl-5-chloro-1 IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 ylamine (599, 124.1 mg, 0.31 mmol, prepared as described in Example 29, Scheme 185) in ethanol (3.00 mL) and acetic acid (0.2 mL) were added 6
-(
2
,
2 ,2-trifluoro-ethoxy)-pyridine-3 carbaldehyde (603, 164.0 mg, 0.80 mmol) and silica supported cyanoborohydride (1.21 mmol/g, 0.700 g). The reaction was irradiated with microwave on 300 watts, 100*C for 150 minutes. To the reaction was added a solution of potassium hydroxide (9.0 M in water, 1.0 mL). The reaction was irradiated with microwave on 300 watts, 100 *C for 10 minutes. The reaction was poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (P-0409, 10.6 mg, 7.6%). MS ESI) [M+H 4 ]' = 448.4. Example 33: Synthesis of 1-(3-fluoro-phenyl)-3-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmthyl) pyridin-2-yi]-urea P-0412 [0262] 1-(3-Fluoro-phenyl)-3-[5-(l H-pyrrolo( 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl-urea P-0412 was synthesized in 2 steps from 5-(1-benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-3 ylmethyl)-pyridin-2-ylamine 600 as shown in Scheme 189. Scheme 189 NHH HH
NH
2 NHC=O 1 N N Ste 1 0 N 0 - QF Step 2 0 CX-F
SO
2 h FN N N N 600S2Ph 604
SO
2 Ph 605 H P-0412 Step 1 - Synthesis of J-[5-(l-benzenesulfonyl-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] 3
-(
3 -fluoro-phenyl)-urea (605): 121 WO 2008/064255 PCT/US2007/085289 102631 To 5-(l -benzenesulfonyl- IH-pyrrolo[2,3-bpyridin-3-ylmethyl)-pyridin-2-ylamine (600, 150.0 mg, 0.41 mmol, prepared as described in Example 29, Scheme 185) in acetonitrile (12.5 mL) were added 3 -fluoro-isocyanato-benzene (604, 61.6 mg, 0.45 mmol), 4 -dimethylaminopyridine (10.0 mg, 0.082 mmol) and triethylamine (0.25 mL, 0.0018 mol). The reaction mixture was heated at 70 *C overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (605, 0.100 g, 48.4%). Step 2 - Synthesis of I-(3-Fluoro-phenyl)-3-[5-(H..-pyrrolo[2, 3 -b]pyridin-3-ylmethyl)-pyridin-2 yl]-urea (P-0412): [02641 To 1-[5-(1-benzenesulfonyl-lH-pyrrolo[2,3-bJpyridin-3-ylmethyl)-pyridin-2-ylj-3-(3 fluoro-phenyl)-urea (605, 0.100 g, 0.20 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.240 g, 0.76 mmol). The reaction was stirred at room temperature for 5 hours, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0412, 17.9 mg, 24.8%). MS (ESI) [M+H*] = 362.2. Example 34: Synthesis of (2-chloro-benzyl)-6-fluoro-5-(I H-pyrrolo[2,3-bipyridin-3 ylmethyl)-pyridin-2-yll-amine P-0335 [02651 ( 2 -Chloro-benzyl)-[6-fluoro-5-(lH-pyrrolo[2,3-bpyridin-3-ylmethyl)-pyridin-2-yl] amine P-0335 was synthesized in 2 steps from (5-bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl) amine 571 as shown in Scheme 190. Scheme 190 Q.H O I-- N Hr N Step 1 S 2 Br N N I bi (7I step 2 FN F 1N NN N N N 571 47 TIPS TIPS 606 H P-0335 Step 1 - Synthesis of[6-(2-chloro-benzylamino)-2-fluoro-pyridin-3-yl]-(I-triisopropylsilanyl-1H pyrrolo[2, 3 -blpyridin-3-yl)-methanol (606): [0266] To (5-bromo-6-fluoro-pyridin-2-yl)-(2-chloro-benzyl)-amine (571, 0.635 g, 2.01 mmol, prepared as described in Example 21, Scheme 177) in tetrahydrofuran (25.0 mL) under an 122 WO 2008/064255 PCT/US2007/085289 atmosphere of nitrogen at -78 "C, a solution of n-butyllithium (2.50 M in hexane, 0.80 mL) was added slowly. Afler 20 minutes, tert-butyllithium (1.7 M in hexane, 2.40 mL) was added to the reaction and after 30 minutes, I-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine-3-carbaldehyde (47, 0.575 g, 1.90 mmol) in tetrahydrofuran (8.0 mL) was added to the reaction. The reaction mixture was stirred at -78 "C for 60 minutes, then allowed to warm to room temperature for another 10 minutes. The reaction mixture was poured into aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was washed with brine, dried over sodium sulfate, concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (606, 0.180 g, 17.6%). MS (ESI) [M+H*]*= 539.2. Step 2 - Synthesis of ( 2 -chloro-benzyl)-[6-fluoro-5-(1H-pyrrolo[2, 3 -b]pyridin-3-ylmethyl)-pyridin 2-yl]-amine (P-0335): 10267] To [ 6
-(
2 -chloro-benzylamino)-2-fluoro-pyridin-3-yl]-(1-triisopropylsilanyl- 1 H pyrrolo[2,3-b]pyridin-3-yl)-methanol (606, 180.0 mg, 0.33 mmol) in acetonitrile (15.0 mL) were added triethylsilane (1.00 mL, 6.26 mmol) and trifluoroacetic acid (0.50 mL, 6.50 mmol). The reaction was heated to reflux for 2 hours, then poured into aqueous potassium carbonate and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0335, 24.9 mg, 19.4%). MS (ESI) [M+H*]* = 367.0. Example 35: Synthesis of 1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5 ylmethyl)-1H-pyrrolo[2,3-bjpyridine 610 10268 1 -Benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H pyrrolo[2,3-b]pyridine 610 was synthesized in 3 steps from 1-benzenesulfonyl-5-chloro-3-iodo IH-pyrrolo[2,3-b]pyridine 581 as shown in Scheme 191. Scheme 191 C HO N St + 06 N N N NO
SO
2 Ph SOPPh 56 1 907 608 S .N N *0 0 0 CI-S ItN i ' e S' es, N Ne3NN N N
SO
2 Ph S0 2 Ph N OP2 609 610 611 0P 123 WO 2008/064255 PCT/US2007/085289 Step I - Synthesis of (1-benzenesulfonyl-5-chloro- H-pyrrolo[2,3-b]pyridin-3-y)-(2 methylsulfanyl-pyrinidin-5-y)-methanol (608): [02691 To a solution of 1-Benzenesulfonyl-5-chloro-3-iodo- H-pyrrolo[2,3-b]pyridine (581, 4.36 g, 10.4 mmol) in tetrahydrofuran (100.0 mL) at -40 *C under nitrogen, isopropylmagnesium chloride (2.0 M in tetrahydrofuran. 5.06 mL) was added slowly. The reaction was allowed to warm to 5 *C over 60 minutes, then cooled to -40 *C, followed by adding 2 -methylsulfanyl-pyrimidine 5-carbaldehyde (607, 1.30 g, 8.43 mmol, dissolved in tetrahydrofuran 15.0 mL). The reaction was allowed to warm to 10 *C over 2 hours. The reaction was poured into aqueous ammonium chloride and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 15% methanol in dichloromethane to give the desired compound (608, 3.00 g, 79.6%). MS (ESI) [M+H*]* = 447.2. Step 2 - Synthesis of 1-benzenesulfonyl-5-chloro-3-(2-methylsulfanyl-pyrimidin-5-ylmethyl)-1H pyrrolo[2,3-b]pyridine (609): [0270] To (1-benzenesulfonyl-5-chloro- IH-pyrrolo[2,3-b]pyridin-3-yl)-(2-methylsulfanyl pyrimidin-5-yl)-methanol (608, 0.35 g, 0.78 mmol) in dichloromethane (15.0 mL) were added triethylsilane (2.00 mL, 12.52 mmol) and trifluoroacetic acid (1.00 mL, 13.0 mmol). The reaction was stirred at 35 *C overnight, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (609, 0.25 g, 74%). MS (ESI) [M+H*J = 430.9. Step 3 - Synthesis of 1-benzenesulfony-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-JH pyrrolo[2,3-b]pyridine (610) and 1-benzenesulfonyl-5-chloro-3-(2-methanesulfinyl-pyrimidin-5 ylmethyl)-IH-pyrrolo[2,3-b]pyridine (611): J02711 To 1-benzenesulfonyl-5-chloro-3-(2-methylsulfanyl-pyrimidin-5-ylmethyl)-1
H
pyrrolo[2,3-b]pyridine (609, 0.500 g, 1.16 mmol) in dichloromethane (15.0 mL) was added meta chloroperoxybenzoic acid (max. 77%, 0.572 g, 2.55 mmol) at 0 *C. The reaction was stirred at 0 *C for 70 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compounds (610, 0.3 10 g, 57.7%), MS (ESI) [M+H'J' = 463.1; and (611, 0.200 g, 38.6%), MS (ESI) [M+H*]* = 447.2. 124 WO 2008/064255 PCT/US2007/085289 [0272 1 -Benzenesulfonyl-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H-pyrrolo[2,3 b]pyridine 612 0 N O N N
SO
2 Ph was prepared following the protocol of Scheme 191, substituting 1-benzenesulfonyl-5-chloro-3 iodo-1H-pyrrolo[2,3-b]pyridine 581 with 1-benzenesulfonyl-3-iodo- IH-pyrrolo[2,3-b]pyridine in Step 1. Example 36: Synthesis of (4-chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3 ylmethyl)-pyrimidin-2-yli]-amine P-0260 102731 (4-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine P-0260 was synthesized in 2 steps from 1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl pyrimidin-5-ylmethyl)-1H-pyrrolo[2,3-b]pyridine 610 as shown in Scheme 192. Scheme 192 N 0 NH NH Cl N NH 2 SN 6NP ON2 C l +Ci Step 2 C +Stepi I I N N N N N P06
SO
2 Ph SO 2 Ph 613 NH P06 610 61 Step I - Synthesis of[5-(-benzenesulfonyl-5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyrimidin-2-ylJ-(4-chloro-benzyl)-amine (613): [0274] To 1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)- H pyrrolo[2,3-b]pyridine (610, 0.060 g, 0.13 mmol, prepared as described in Example 35, Scheme 191) in N-methylpyrrolidinone (1.80 mL) was added p-chlorobenzylamine (61, 0.20 g, 1.4 mmol). The reaction was irradiated with microwave on 300 watts, 150 *C for 15 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (613, 0.05 g, 74%). MS (ESI) [M+H*] = 524.3. Step 2 - Synthesis of (4-chloro-benzyl)-[5-(5-chloro-JH-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyrimidin-2-yl]-amine (P-0260): 10275] To [5-(1-benzenesulfonyl-5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2 125 WO 2008/064255 PCT/US2007/085289 yl)-(4-chloro-benzyl)-amine (613, 0.050 g, 0.095 mmol) in tetrahydrofuran (10.0 mL) was added tetrabutylammonium fluoride, trihydrate (0.20 g, 0.63 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature overnight, then poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and washed with ethyl acetate in hexane to give an off-white solid (P-0260, 16.9 mg, 46%). MS (ESI) [M+H] = 385.9. [02761 Additional compounds were prepared following the protocol of Scheme 192, substituting p-chlorobenzylamine 61 with a suitable amine in Step 1. The following compounds were prepared following this protocol: [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,6-difluoro-benzyl)-amine (P-0261), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl) amine (P-0262), (2-Chloro-benzyl)-[5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0263), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-benzyl)-amine (P-0264), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,4-difluoro-benzyl)-amine (P-0265), [5-(5-Chloro-IH-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl) amine (P-0266), [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,5-difluoro-benzyl)-amine (P-0267), and [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trifluoromethyl-benzyl) amine (P-0268). The following table indicates the amine (Column 2) used in Scheme 192 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result. MS (ESI) Compound Amine in Step I Compound [M+H]+ number observed F P-0261 H 2 N c N N 384.1 F ( N2 126 WO 2008/064255 PCT/US2007/085289 NH-C P-0262 H 2 N c § N 3 C 418.9 N N P-0263 H2N CF 3 H
H
2 N C P-0263 H2N CF3 C 384.2 C F N
H
2 N -N P-0264 C N F 368.2 F N N
H
2 N FN F P-0265 -er.F386.2 P-0266 H 2 N CF3 cC N CF3 419 NN YCH F F P-0267 H 2 N cI s [M-fbo N F 384.0 F N N H
H
2 N /--N/ P-0268 C CF 3 419.2 N N Example 37: Synthesis of (2-fluoro-5-trifluoromethyl-benzyl)-15-(1H-pyrrolo 12,3-bipyridin 3-ylmethyl)-pyrimidin-2-ylJ-amine P-0291 [0277] (2-Fluoro-5-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-bjpyridin-3-ylmcthyl) pyrimidin-2-yl]-amine P-0291 was synthesized in I step from 1-benzenesulfonyl-3-(2 methanesulfonyl-pyrimidin-5-ylmethyl)-1H-pyrrolo[2,3-bjpyridine 612 as shown in Scheme 193. Scheme 193
CF
3 -N H -N
CF
3 -N N H 2 N C3 Step N N F 1 N+ F/- N N F 614 N N P-0291
SO
2 Ph H 612 127 WO 2008/064255 PCT/US2007/085289 Step I - Synthesis of (2-fluoro-5-trifluoromethyl-benzyl)-[5-(JH-pyrrolo[2,3-b]pyridin-3 ylmethyl)-pyrimidin-2-yl]-amine (P-0291): 102781 To 1-benzenesulfonyl-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-l H-pyrrolo[2,3 b]pyridine (612, 0.080 g, 0.19 mmol, prepared as described in Example 35, Scheme 191) in N methylpyrrolidinone (1.00 mL) was added 2-fluoro-5-trifluoromethyl-benzylamine (614, 0.20 g, 1.0 mmol). The reaction was irradated with microwave on 300 watts, 150*C for 15 minutes. Potassium hydroxide in water (1.00 M, 2.00 mL) was added to the reaction. The reaction was irradiated with microwave on 300 watts, 90*C for 10 minutes, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0291, 37.4 mg, 50%). MS (ESI) [M+H']* = 402.6. [02791 Additional compounds were prepared following the protocol of Scheme 193, substituting 2-fluoro-5-trifluoromethyl-benzylamine 614 with a suitable amine. The following compounds were prepared following this protocol: (2,5-Difluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0292), (2-Chloro-5-trifluoromethyl-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0293), (3-Fluoro-5-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0294), (3,5-Difluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0295), (2-Fluoro-benzyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0300), (2-Chloro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0301), [5-( 1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl)-amine (P-0302), [5-( IH-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethoxy-benzyl)-amine (P-0303), (5-Chloro-2-fluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]-amine (P-0304), (2,4-Dichloro-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl-amine (P-0305), (2,4-Difluoro-benzyl)-(5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0306), (4-Chloro-benzyl)-[5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0307), [5-(1H-Pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl)-amine (P-0308), (2-Fluoro-3-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] 128 WO 2008/064255 PCT/US2007/085289 amine (P-0309), (2,5-Dichloro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-aminc (P-0310), (3-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0311), (2-Difluoromethoxy-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0312), (2,3-Dichloro-benzyl)-[5-(] H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0313), (4-Chloro-2-fluoro-benzyl)-[5-(l H-pyrrolo(2,3-bJpyridin-3-ylmethyl)-pyrimidin-2-ylJ-amine (P-0314), (5-Fluoro-2-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0315), (2-Chloro-4-fluoro-benzyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0316), (5-Chloro-2-methyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0317), (5-Fluoro-2-methyl-benzyl)-[5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0318), (2-Fluoro-4-trifluoromethyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0319), (4-Fluoro-2-trifluoromethyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0320), and (2-Chloro-5-fluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine (P-0407). The following table indicates the amine (Column 2) used in Scheme 193 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result. Compound MS (ESI) number Amine Compound served F F P-0292 H 2 N N N 352.3
CF
3
CF
3 P-0293 H 2 N F/N F 418.2 1 N N H 129 WO 2008/064255 PCT/US2007/085289
CF
3
CF
3 P-0294 H 2 N, - N 402.5 F NH F F P-0295 H 2 N NH- 352.3 FI FN H P-31H 2 N N c 39. P-0300 2 N N N F 334.0 F H P-33H 2 N '. N40. P-0301 N 2 /l 367.9 P-0302 HN _- i-"- F 383.9 C F I HN F H 2NI P-0303 HN /- 3 H45 P-30 H , / C 3 34. ______________ H
H
2 N / P-0304 It -S -NFC 302.5 _____N FFF _____F H_ _ _ P-0305cl N c 3130 WO 2008/064255 PCT/US2007/085289 -O N389.0 H CCI H H -N P-0311 2 N, /N CH C 3 5. CIPC NN H
H
2 N
-
N P-0312 0 N/ 387.9 F -F
H
2 N~ N. ( F> _ CF H
H
2 NF P-0313 / 368. CI H P-0314 H 2 N - 34. F F P-0315 -NH-/34. H F2 NH P-0317 H 2 N NN H 3 0. F H7 P-0318 2N 131 WO 2008/064255 PCT/US2007/085289 F F P-0407 H 2 N N 368.3 CIi Example 38: Synthesis of [5-(5-Chloro-1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2 yl]-(2-difluoromethoxy-benzyl)-amine P-0390 [02801 [5-(5-Chloro-1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-y]-(2-difluoromethoxy benzyl)-amine P-0390 was synthesized in I step from 1-benzenesulfonyl-5-chloro-3-(2 methanesulfonyl-pyrimidin-5-ylmethyl)- I H-pyrrolo[2,3-b]pyridine 610 as shown in Scheme 194. Scheme 194 0 -N H
CN'H
2 N C l- N + O F Step C1F N N N1 H 610 SO2Ph F P-0390 Step 1 - Synthesis of {5-(5-Chloro-1H-pyrrolo[2,3-bipyridin-3-ylmethyl)-pyrimidin-2-y]-(2 difluoromethoxy-benzyl)-amine (P-0390) 102811 To 1-benzenesulfonyl-5-chloro-3-(2-methanesulfonyl-pyrimidin-5-ylmethyl)-1H pyrrolo[2,3-b]pyridine (610, 0.060 g, 0.13 mmol, prepared as described in Example 35, Scheme 191) in N-methylpyrrolidinone (1.40 mL) was added 2-difluoromethoxy-benzylamine (615, 0.200 g, 1.16 mmol). The reaction was irradiated with microwave on 300 watts, 150 "C for 15 minutes. Potassium hydroxide in water (1.00 M, 2.00 mL) was added to the reaction. The reaction was irradiated with microwave on 300 watts, 90 *C for 10 minutes, then poured into ethyl acetate and water. The organic layer was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (P-0390, 10.9 mg, 20%). MS (ESI) [M+H*]*= 418.0. [0282] Additional compounds were prepared following the protocol of Scheme 194, substituting 2-difluoromethoxy-benzylamine 615 with a suitable amine. The following compounds were prepared following this protocol: [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-5-trifluoromethyl benzyl)-amine (P-0289), [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(5-fluoro-2-trifluoromethyl benzyl)-amine (P-0391), 132 WO 2008/064255 PCT/US2007/085289 (3-Chloro-2-fluoro-benzyl)-[S-(5-chloro. 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y] amine (P-0392), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin3-ylmethyl)pyrimidin2yl]-(2fluoro.3triluoromethyl. benzyl)-amine (P-0393), [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethy).pyrimidin-2.y!j.(2-fluoro-4trifluoromethylI benzyl)-amine (P-03 94), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y1-(2,3 -difluoro-benzyl)-amine (P-0395), (2-Chloro-4-fluoro-benzvl)-[5-(5-chloro-l1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-yij. amine (P-0396), [5-(5-Chloro- 1H-pyrrolo[2,3-blpyridin-3.ylmethyl).pyrimidin-2-y1](2trifluoromethoxybenzyl). amine (P-0402), (2-Chloro-S-fluoro-benzyl)-[5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3.ylmethyI).pyrimidin-2.yl]. amine (P-0408), [5-(5-Chloro- 1 H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)pyrimidin-2-ylJ-pyridin-4.ylmethyl-amine (P-0416), [5-(5-Chloro- I H-pyrrolo[ 2 ,3-blpyridin-3-ylmethyl)-pyrimid in-2-yIJ.(2..pyrrolidin-I -yi-ethyl) amine (P-0417), Benzyl-[5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl).pyrimidin-2-ylj-amine (P-041 8), Benzyl-[5-(5-chloro-l1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin.2-yli]methyl-amine (P-041 9), [5-(5-Chloro-1 H-pyr-rolo[2,3-b]pyridin-3-ylmethyl).pyrimidin-2-yI]-(4-trifluoromethoxy-benzyl) amine (P-0420), (3-Chloro-benzyl)-[5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y] -amine (P-042 1), [5-(S-Chloro- IH-pyrrolo[2,3-blpyridin-3.ylmethyl).pyrimidin-2.yl].pyridin-3..ylmethyl-amine (P-0422), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI]-(4-fluoro-benzyl).amine (P-0423), (3-Chloro-benzyl)-[5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin.2.yI].methyl. amnine (P-0424), [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2.yI].(3,5-difluoro-benzyl)-amine (P.0425), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3.ylmethy)-pyrimidin-2y1].[ 1-(2-fluoro-phenyl)-cthylj amine (P-0426), [1 -(4-Chloro-phcnyl)-ethyl]-[5-(5-chloro- 1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-yl] 133 WO 2008/064255 PCT/US2007/085289 amine (P-0427), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yJ-[(S)- 1 -(4-fluoro-phenyl) ethyl]-amine (P-0428), [5-(5-Chloro- 1H-pyrrolo[2,3-blpyridin-3-ylmetbyl)-pyrimidin-2-ylJ-(6-trifluoromethyl-pyridin-3 ylmethyl)-aniine (P-0429), (2-Chloro-benzyl)-[5-(5-chloro- 1H-pyrrolo[2,3-b]pvridin-3-ylmethyl)-pyrimidin-2-yl]-methyl amine (P-0430), [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI]-(2-methyl-benzyl)-amine (P-0431), [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]-(2-methoxy-benzyl)-amine (P-0433), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]-(2-morpholin-4-yl-ethyl) amine (P-0434), [5-(5-Chloro- 1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-yl]-cyclohexylmethyl-amine (P-0435), [5-(5-Chloro- I H-pyrrolo[2,3-bjpyi-idin-3-ylmethyl)-pyrimidin-2-yI]-pyridin-2-ylmethyl-amine (P-0436), [2-(4-Chloro-phenyl)-etbyl]-[5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI] amine (P-0437), [5-(5-Chloro- 1 H-pyrrolo[2,3-hjpyridin-3-ylmetbyl)-pyrimidin-2-y]-(4-difluoromethoxy-benzyl) amine (P-0438), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylI-(4-methoxy-benzyl)-amine (P-0439), [5-(5-Chloro-lIH-pyrriolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yi]-(4-methyl-benzyl)-amine (P-044 0), [5-(5-Chloro- 1 H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-methoxy-ethyl)-amine (P-0441I), [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-fluoro-benzyl)-amin (P-0442), (3-Chloro-4-fluoro-benzyl)-[5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0443), [5-(5-Chloro- 1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-y]-(2-ethoxy-benzyl)-amine (P-0444), [5-(5-Chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmetbyl)-pyrimidin-2-yJ-(4-morpholin-4-yI-benzyl) amine (P-0445), [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-difluoroniethoxy-benzyl) 134 WO 2008/064255 PCT/US2007/085289 amine (P-0446), (4-Chloro-3-fluoro-benzyl)-[5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine (P-0447), [5-(5-Chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-[1-(3-fluoro-phenyl)-ethyl] amine (P-0448), and [5-(5-Chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-dimethylamino-benzyl) amine (P-0449). The following table indicates the amine (Column 2) used in Scheme 194 to provide the compounds (Column 3). Column I provides the compound number and Column 4 the experimental mass spectrometry result. Compound MS (ESI) number Amine Compound [M+H] observed CF~ F P-0289 H 2 N F, C0 )-N Cp 436.0 P-0391______H2N_ P-0392 H2N C.C I 436.0 P-33H CCA CN CF343
CF
3 N N H P-03942 2 F CI 1 ' C~ 0 42. 2F C F F1 N Nr P-0396 H 2 N F . N F F C 3 N F 434. C_ _N H P 1H 2 N CF5 PH039 - N" F 386I40.0 F FN N H
H
2 N H, CI CF N N ______________N H _ _ _ _ H2N C3 -, N,_4;135F WO 2008/064255 PCT/US2007/085289 P-0402 N 2 .C ~44 0
CF
3 C~ I'N CF F F P-0408 H 2 N Nl- 402.0 II N N H P0H1 H%,N 351.1 Nl N H f P-0417 H- 2 N, ~N H 357.1 I N P-0418 H 2 N 1 ~ N H N jNN HH P-0419 H N I 8. CI NN NN N N O-368. ' N N H P-042 H2N N H38. OntN I N Fl N N FN H 136N,.D F 6.
WO 2008/064255 PCT/US2007/085289 P-0426 N H NNN - IF N'H FP-04d27 HNc H-N / C 398.3 CIN' N H P-0428 ~i>F 382.3 N ;;:]-"
H
2 N - , -NH ,F CIN N N H P-0429 NNH N41.
H
2 N / CF 3
.N,.
4
CF
3 41. NW N P-04f30 HN / 9. I CI ci N N P-0431 H _ .4 .9 6. ' H P-0433 H 2 > f 8. ci T ~0 0 N P-0434 H 2 NH eN 373.1 N-)c N N N P-04356C N .LC 351.3
H
2 N %NC NN PH43 -NNH 357.9 No' CICi N N P-0437 H2N~f~~.) N H1. H P-0438 H 2 N~-O 380.3 XH 137; WO 2008/064255 PCT/US2007/085289 P-0440 H2N~C ~ 364. P-41 H 2 N~ 317.9 P-044 H 2 N ~ Q CIN
.
368.3 Fl F N N H2H P-0441 H 2
N~
4 - H 40H1.9 CI CIN P0442HN
HN,
3 ~.Q N 435. N FF HH P-0443 2 ~..I-).K*~C 0. f2NF NI H NN N N P-0444 H 2 N H N 393. N N H P-044 -138 WO 2008/064255 PCT/US2007/085289 Example 39: Synthesis of (2-chloro-6-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3 ylmetbyl)-pyridin-2-yl]-amine P-0210 102831 (2-Chloro-6-fluoro-benzyl)-[5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine P-0210 was synthesized in 2 steps from 5-(1-Benzenesulfonyl-1H-pyrrolo[2,3-bjpyridin-3 ylmethyl)-pyridin-2-ylamine 600 as shown in Scheme 195. Scheme 195 NH C H N N N' Stp1Step 2~ 1 F N N N I~617N N 600 SO 2 Ph F 516 SO 2 Ph H P-0210 Step I -Preparation of[5-(I-benzenesulfony-l-H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-( 2 -chloro-6-fluoro-benzyl)-amine (617): 102841 5-(1-Benzenesulfonyl- IH-pyrrolo[ 2 ,3-bjpyridin-3-ymethyl)-pyridin-2-ylamine (600, 30 mg, 0.083 mmol, prepared as described in Example 29, Scheme 185) was combined with 2-chloro 6-fluoro-benzaldehyde (616, 26.2 mg, 0.165 mmol) in a 2 mL microwave reaction vial. The mixture was dissolved in ethanol:acetic acid (95:5, 0.6 mL). Silica supported cyanoborohydride (1.0 mmol/g, 83 mg, 0.083 mmol) was added and the mixture was irradiated with microwave on 300 watts for 5 minutes at 100 *C. The silica was separated by centrifuging and the supernatant solution was decanted. The silica residue was rinsed with ethanol (0.500 mL) and centrifuged. The solvents were combined and removed under reduced pressure to give compound 617, which was used in the next step without further purification. Step 2 - Preparation of ( 2 -chloro-6-fluoro-benzyl)-[5-(H-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyridin-2-yl]-amine (P-0210): [0285J [5-(1-Benzenesulfonyl-1H-pyrrolo[ 2 ,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-(2-chloro-6 fluoro-benzyl)-amine 617 was combined with methanol:potassium hydroxide (I M) (1:1, 0.5 mL). The mixture was heated at 80 "C for 2 hours. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in dimethylsulfoxide (0.4 mL) and purified by reverse phase HPLC on a Phenomenex column (50mm x 10mm ID) eluting with 0.1 % trifluoroacetic acid in water and 20-100 % acetonitrile with 0.1% trifluoroacetic acid over 16 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0210. MS (ESI) [M+H-J'= 367.1. 139 WO 2008/064255 PCT/US2007/085289 [02861 Additional compounds were prepared following the protocol of Scheme 195, replacing 2 -chloro-6-fluoro-benzaldehyde 616 with an appropriate aldehyde in Step 1. T'he following compounds were made following this procedure: Phencthyl-[5-(I lfIpyrrolo[2,3-b]pyridin.-3ylmethyl)-pyridin.2.yly-amine (P-02 1), (2,4-Difluoro-benzyl)-[5s( H-pyrrolo[2,3.bjpyridin3ylmethyl)pyidin-2-y1J.aine (P-0212), (2-Fluoro-benzyl).[5-( IH-pyrrolo[ 2 ,3-bjpyridin-3ylmethyl).pyridin.2 yIj amine (P-0213),
(
3 -Bromo-pyridin-4.ylmethyl).[5-(IH-pyrrolo[2,3 -bjpyridin-3-ylmethyl)pyridin2-ylyamine
(P
0214), (2-Methoxy-pyridin-3.ylmethyl)[5.( 1H-pyrrolo[2,3 .b]pyridin-3.ylmethyl).pyridin2ylj-amine (P-0215), (2-Chloro-benzyl).[5-(lH-pyrrolo[ 2
,
3 .bjpyridin3ylmethyl)-pyridin-2-yi]aine (P.0216), (2-Methyl-benzyl).[5-(I H-pyrrolo[2,3.bjpyridin-3.ylmethyl)-pyridin-2y3 amine (P-0217), (1-Methyl-I H-benzoimidazol.2.ylmethyI)-[5.(l1H-pyrrolo[2,3-b~pyridin-3.ylmethyl)-py-jdin-2 yI]-aminc (P-0218), (6-Methoxy-pyridin-3.ylmethyl).{s.( 1H-pyrrolo[2,3.bjpyridin-3 -ylmethyl)-pyridin-2.ylJ-amine (P-0219), (I H-Benzoimidazol.2.ylmethyl).[5.( lH-pyrrolo[2,3-b]pyridin3ylmethy)-pyridin.2y].anne (P-0220), (2-Chloro-4.fluoro-benzyl).{5.(I H-pyrrolo[ 2
,
3 .bjpyridin-3..ylmethyl)-pyridin-2.yl]-amine (P. 0221), (5-Methoxy-pyridin-3 -ylmethyl)-[5-( 1H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyridin-2.ylI-amine (P-0222),
(
3 .Fluoro-pyridin-4.ylmethyl)-[5.( lH-pyrrolo[ 2
,
3 -b]pyridin-3.ylmethyl)pyr.idin.2.yl].amine
(P
0223), (6-Methoxy-pyridin-2.ylmethyl).[5.(l H-pyrrolo[ 2
,
3 -b]pyridin-3.ylmethyl)-pyridin-2.yly-amine (P-0224),
(
4 .Fluoro.2-tr-ifluoromethyl-benzyl).[5.( lH-pyrrolo[ 2 ,3.bjpyridin-3ymethyl)-pyridin-2-y3. amine (P-0225), [5-( HProo23bprdn3ylehl-yii--l-2trfurmty-ezl-mn (P-0226),
(
3 ,S-Dichloro-pyridin-4.ylmethyl).[5.(I IHpyrrolo[ 2
,
3 .bjpyridin-3.ylmethy1)-pyridin-2-y]-anine (P-0227),
(
6 -Morpholin-4.yl-pyridin-2ylmethy1).[5.( lH-pyrrolo[2,3.bjpyridin-3ylmethyl)pTidin-2-y 1 . amine (P-0228), (3-Fluoro-pyridin-2.ylmethyi)-[5.( I H-pyrrolo[2,3 .bjpyridin-3.ylmethyl)-pyridin-2ylami 1 e (P. 0229), 140 WO 2008/064255 PCT/US2007/085289 (5-Fluoro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[ 2 ,3-blpyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0230), (2,4-Dichloro-benzyl)-[5-(1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0342), (3-Fluoro-benzyl)-[5-(I H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0343),
(
2 -Fluoro-4-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-bjpyridin-3-ylmcthyl)-pyridin-2-yl] amine (P-0344), (4-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0345), (3-Fluoro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0346),
(
2 -Morpholin-4-yl-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0347), (4-Chloro-3-trifluoromethyl-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yi] amine (P-0348),
(
2 -Chloro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0349),
(
2 -Fluoro-5-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0350), (2,3-Dichloro-benzyl)-[5-(] H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-035 1), (2-Fluoro-3-methoxy-benzyl)-[5-(1 H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0352), Dimethyl-(5-{ [5-(lH-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyrimidin-2 yl)-amine (P-0353), (3-Chloro-2-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0354), (5-Fluoro-pyridin-2-ylmethyl)-[5-(1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0355), (3,5-Difluoro-benzyl)-[5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]-amine (P-0356), (2-Propoxy-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyridin-2-yi]-amine (P-0357), (2-Morpholin-4-yI-benzyl)-[5-(lH-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0358), (2-Chloro-3-methoxy-benzyl)-[5-(1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0359),
(
2 -Fluoro-6-trifluoromethyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmthyl)-pyridin-2-yl] amine (P-0360),
[
2 -(2-Morpholin-4-yl-ethoxy)-benzylj-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-y]] 141 WO 2008/064255 PCT/US2007/085289 amine (P-0361), (2,3-Difluoro-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0362), (2-Chloro-3-trifluoromethyl-benzyl)-[5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yy] amine (P-0363), (2-Chloro-5-fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0364), (2-Fluoro-3-trifluoromethyl-benzyl)-[5-(1 H-pyrrolo[2,3-bpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0365), (5-Fluoro-2-methoxy-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ymethyl)-pyridin-2-yl]-amine
(P
0366), (2-Difluoromethoxy-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0367), (2-Fluoro-4-methyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0368), [2-(3-Dimethylamino-propoxy)-benzyl]-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0369), (2,6-Dimethoxy-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0370), (2-Fluoro-5-methoxy-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0371), (4-Fluoro-2-methyl-benzyl)-[5-(1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-ylj-amine
(P
0372), (3-Chloro-5-fluoro-benzyl)-[5-(IH-pyrrolo[ 2
,
3 -bjpyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0373),
(
6 -Cyclopentyloxy-pyridin-3-ylmethyl)-[5-(I H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0374), (5-Fluoro-2-trifluoromethyl-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine (P-0375), [5-(1H-Pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-[2-(2,2,2-trifluoro-ethoxy)-pyridin-3 ylmethyl]-amine (P-0376), Propane-I -sulfonic acid (2-fluoro-3-{[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 ylamino]-methyl}-phcnyl)-amide (P-0377), (2,5-Dichloro-benzyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0380), Pyrimidin-5-ylmethyl-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yi]-amine (P-0381), (5-Chloro-2-fluoro-benzyl)-[5-(1 H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0382), 142 WO 2008/064255 PCT/US2007/085289 (2-Ethyl-benzyl)-[5-(1H-pyrrolo[ 2 ,3-bjpyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0383), 2,2-Dimethyl-N-(3-{[5-(1 H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl} pyridin-2-yl)-propionamide (P-0384), Methyl-(3-{[5-(1H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl)-pyridin-2-yl) amine (P-0385), Methyl-(5-{[5-(l H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyrimidin-2 yl)-amine (P-0386),
(
2 -Chloro-4-methanesulfonyl-benzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yI] amine (P-0387), (5-Fluoro-2-methyl-benzyl)-[5-(I H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0397), (2,2-Difluoro-benzo[1,3]dioxol-4-ylmethyl)-[5-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine (P-0398), Dimethyl-(3-{[5-(1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyridin-2-ylamino]-methyl}-pyridin-2 yl)-amine (P-0399), (5-Chloro-pyridin-3-ylmethyl)-[5-(1H-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine
(P
0400), and (2-Methoxy-pyrimidin-5-ylmethyl)-[5-(1H-pyrrolo[ 2
,
3 -blpyridin-3-ylmethyl)-pyridin-2-yl]-amine (P-0401). The following table indicates the aldehyde (Column 2) used in Step I of Scheme 195 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result. Compound MS(ESI) number Aldehyde Compound
[M+H*]
4 observed P-0211 O 32. H P-0'2O N F 351.1 P-0213 O 338.1 N N H 143 WO 2008/064255 PCT/US2007/085289 Compound MLS(ESI) number Aldehyde Compound [M+H4]* _________________observed H 0 N N P-0214 349.1 Br NN H N_ N NQ P-0215 N~-36. O N N P-T1 N'/ 45.9 0 NN NN N P-0216 / 349.1 H 35. HH P-0217 0 I 367.1 CI 1 N 0/ N P-0219 / N 0 N /o345.9 N N H 144 WO 2008/064255 PCT/US2007/085289 Compound AleyeMS(ESI) nudebed Compound MH] I -- _ -- I I observed H
:PICF
3 33. NN H NH PN026N 383.9 NN ftH o N P-0227I- NN 8. P-0228 o N N~ N I N 401. o-22 N, N FH N P-030 -' N F333 NN N cl H P-03442/ F 401.1 0 F N H P-03F H P/34 N F 33.1 P-0344 0C.r- F FF 401.1 F N N Fp H P-0345 c 145 WO 2008/064255 PCT/US2007/085289 Compound MS(ESI) number Aldehyde Compound [M+H-] observed P-0347 N N 401.1 H 0 R F NH Cla NN ( _ C H FFH CF3 P-0349 H417.1 O NN OI H FF C F F P-0356F 3 1.1 H P-035 S 373.1 146N H6 360. o H P-035 2 FN 0/ F' N HF H 35. P-0353 N {aCN" N -- C, />-33 0/1 / N 14 WO 2008/064255 PCT/US2007/085289 Compound MS(ESI) number Aldehyde Compound [M+HT+ observed CID P-0358 ____ __ oN N __ _ _ H0 P-0359 b 444. F F F, 0 N P0361 - 417.1 /N N C-o 0/p H F F P-0362 P03F 367.1 0 CNI F FH F N. I F-33clN c CF 3 4017.1 /cZ N N p l H P-0364 ®r- 363.1 o F H FF N NF _ _ _ _ _0 HH P-03668 4 6. F H 4. __ __ _ 0 N NF -0368 N F 3147 WO 2008/064255 PCT/US2007/085289 Compound MS(ESI) number Aldehyde Compound [M±-f observed -N N ~ P-0369 I ro 416.3 N~r N, , NC/r'.'., P-0370 I N -N 376.3 0 H F P-0371 _ N-0363.1 o N N H P..0372 0/ r- /N 367.1 0 I N N 0 H FF F P-0373 N ~N__- 401.1 H P-0377 N N F 400. / N N HH CI3 Fo F I H H_ __ _ P-0376/ / ' 1. o N N3 0 H 148 WO 2008/064255 PCT/US2007/085289 Compound AleyeMS(ESI) number AleyeCompound [M+i-f Ft CH cl observed / F o C N N H P-0383 N,33. 0, N N 34. HH -:38:]NN N N/ 0 NH415.2 NHH P-0385 -NN 0', -NH 345.4 N N H P-0386NH ' N I " 345.2 NN H o F NN P-0387 N -- r 036. 0. 0 N H pF o H CI'C 0 ~C N N H 0149 WO 2008/064255 PCT/US2007/085289 Compound MS(ESI) number Aldehyde Compound [M+H*]* observed NN P 0 NH .N1 N H Example 40: Synthesis of [ 4 -Chloro-5-(5-chloro-1H-pyrrolof2,3-bjpyridin-3-ylmethyl) thiazol- 2 -yl]-(6-methoxy-pyridin-3-ylmethyl)-amine P-0190 [02871 [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methoxy pyridin-3-ylmethyl)-amine P-0190 was synthesized in 2 steps from 5-(l-benzenesulfonyl-5-chloro IH-pyrrolo[ 2
,
3 -b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-ylamine 592 as shown in Scheme 196. Scheme 196 H H N Cl NH 2 S e-C N St 2N N N N /% N CI Sep1 C NStep 2 C, C SNN 61 N -1 P.19 592 SO 2 Ph 618
SO
2 Ph Step I - Preparation of [5-(J-benzenesulfonyl-5-chloro-JH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4 chloro-thiazol-2-yl]-(6-methoxy.-pyridin-3-ylmethyl)-amine (619): [0288J 5-(1 -Benzenesulfonyl-5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol 2-ylamine (592, 30 mg, 0.083 mmol, prepared as described in Example 27, Scheme 183) was combined with 6 -methoxy-pyridine-3-carbaldehyde (618, 26.2 mg, 0.165 mmol) in a 2 mL microwave reaction vial. The mixture was dissolved in ethanol: acetic acid (95:5, 0.6 mL). Silica supported cyanoborohydride (1.0 mmol/g, 83 mg, 0.083 mmol) was added and the mixture was irradiated with microwave on 300 watts for 5 minutes at 100 "C. The silica was separated by centrifuging and the supernatant solution was decanted. The silica residue was rinsed with ethanol (0.500 mL) and centrifuged. The solvents were combined and removed under reduced pressure to give the desired compound 619, which was used without further purification. Step II - Preparation of [4-chloro-5-(5-chloro-JH-pyrrolo[2,3-blpyridin-3-ylmethyl)-thiazol-2 yl]-( 6 -methoxy-pyridin-3-ylmethyl)-amine (P-0190): 150 WO 2008/064255 PCT/US2007/085289 102891 [5-(1-Benzenesulfonyl-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-4-chloro-thiazol-2-yl]-(6 methoxy-pyridin-3-ylmethyl)-amine 619 was combined with methanol: potassium hydroxide (IM) (1:1, 0.5 mL). The mixture was heated at 80 *C for 2 hours. Acetic acid (0.1 mL) was added and the solvents removed under reduced pressure. The remaining residue was dissolved in dimethylsulfoxide (0.4 mL) and purified by reverse phase HPLC on a Phenomenex column (50mm x 10mm ID) eluting with 0.1 % trifluoroacetic acid in water and 20-100 % acetonitrile with 0.1% trifluoroacetic acid over 16 minutes at a flow rate of 6 mL/minute to provide the desired compound P-0190. MS (ESI) [M+H*]*= 419.9. 102901 Additional compounds were prepared following the protocol of Scheme 196, replacing 6-methoxy-pyridine-3-carbaldehyde 618 with a suitable aldehyde in Step 1. The following compounds were made following this procedure: [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-thiazol-2-ylmethyl amine (P-0189), Benzyl-[4-chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine (P-0192), [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-methoxy-benzyl) amine (P-0193), (4-Chloro-benzyl)-[4-chloro-5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl] amine (P-0194), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl) amine (P-0195), (4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,4-dimethyl-thiazol-5 ylmethyl)-amine (P-0196), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-5-methyl-3H imidazol-4-ylmethyl)-amine (P-0197), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-2H-pyrazol-3 ylmethyl)-amine (P-0198), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylj-(6-methoxy-pyridin-2 ylmethyl)-amine (P-0 199), [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-fluoro-pyridin-4 ylmethyl)-amine (P-0200), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methyl-thiazol-4 ylmethyl)-amine (P-0201), [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-methyl-thiazol-5 ylmethyl)-amine (P-0202), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-chloro-pyridin-2 151 WO 2008/064255 PCT/US2007/085289 ylmethyl)-amine (P-0203), [4-Chloro-5-(5-chloro-1IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl amine (P-0236), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl amine (P-0237), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-chloro-pyridin-4 ylmethyl)-amine (P-0238), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylj-(1-ethyl-IH-pyrazol-4 ylmethyl)-amine (P-0239), [4-Chloro-5-(5-chloro-l H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2 ylmethyl)-amine (P-0240), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yi]-(5-methoxy-pyridin-3 ylmethyl)-amine (P-0241), [4-Chloro-5-(5-chloro-I H-pyrrolo[2,3-bpyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine (P-0242), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-chloro-6-fluoro benzyl)-amine (P-0243), [4-Chloro-5-(5-chloro-I H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-phenethyl-amine (P-0244), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-bpyridin-3-ylmethyl)-thiazol-2-yl]-(2,4-difluoro-benzyl) amine (P-0245), [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-fluoro-benzyl) amine (P-0246), (4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methoxy-pyridin-3 ylmethyl)-amine (P-0247), (2-Chloro-benzyl)-[4-chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl) amine (P-0248), [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methyl-benzyl) amine (P-0249), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-chloro-4-fluoro benzyl)-amine (P-0250), [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylj-(3-fluoro-pyridin-2 ylmethyl)-amine (P-0251), [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-bpyridin-3-ylmethyl)-thiazol-2-yl]-(6-morpholin-4-yl pyridin-2-ylmethyl)-amine (P-0252), [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3,5-dichloro-pyridin-4 152 WO 2008/064255 PCT/US2007/085289 ylmethyl)-amine (P-0253), [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-(2-trifluoromethyl benzyl)-amine (P-0254), and [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2 ylmethyl)-amine (P-0255). The following table indicates the aldehyde (Column 2) used in Step 1 of Scheme 196 to provide the compounds (Column 3). Column I provides the compound number and Column 4 the experimental mass spectrometry result. MS(ESI) Compound Aldehyde Compound [M+H] observed CI P-0189 O c 395.9 N N Cil P-0192 C1 s -0 389.1 0CI P-Ol193 OCI s 419.1 P-l9/ C ci s 42. oN N H CI P-0197 Oi N CH - 4219.1 / 153 c' N N CI P-0 194 CI Gil S Hci- 407.1 0 N N H P//-9 CI . H H - F 421.1 N N ___________________ H________ 153 WO 2008/064255 PCT/US2007/085289 noube Aldehyde Compound [M±W'] number_______________ observed KNN CN P-0 98 NN S>N-/ IT H N-N 407.1 0", N N P-019 0 CIHN( 419.9 N N P-0200 CI / F Dt407.9 F N N N N P-0201 Ss cl H s409.9 N N H CI 0 N N ~~ N -4 P-0202 /0 cl SH S( 39.3 N N P-023 Nl 390.3-f o// NC 0N H _ _ _ _ _ _ 4 3 . Ci N N P-0236 NH "39. 0 I N C 0 N54 WO 2008/064255 PCT/US2007/085289 CompoundMS(ESI) Comoun Aldehyde Compound [M+HT] numberobservedi cI N P-0240 F l H F -0' F 407.9 0 NN N 0- ci 0 P-0241 clH N419.9 o N N N H cI N P-0242 / /CF 3 ci S'N'CF3 458.3 0 N N N H P-0243 H c 443.1 F N N H P-0244 c - 0. a-1 / H40. N N H F cI P-0245 r-O F CIN H F 424.7 /7: o N N F NI H F/O,-/ 407.1 P-0246 /r l o N N H CI P-0247 0 N ci H 0 N41. 0 N N H CI SN'~ P-0248 l N HC 1-, 424.7 0 PCI C, N N H________ e55 WO 2008/064255 PCT/US2007/085289 ~- MS(ESI) Compound SS) Comber Aldehyde Compound [M+H+]* number observed CI P-0250 O F 1 S H F 441.1 CI N CI P-0251 ci H F 407.9 c c - 0 N N H 4Q N - NJ P-0254 O ci H 475.1 C N N PC25 CI H I P-0255 O cis40. C 0 NN H [ 029 Adiinlopud weepeaedfloigth7rtc.1fShm 96 elcn CN N P-0253 /' / NCI CI ~40. N N H 5-( 1-benzenesulfonyl-5-chloro- 1H-yrl[,- yii--lehy)4clr-hao--lmn 592 with 5-(1 -benzenesulfonyl- 1H-pyrrolo[2,3-b]pyridin-3ylmethyl)4chloro-thiazol- 2 -ylamine 593 (prepared as described in Example 27, Scheme 183) in addition to replacing 6-methoxy pyridine-3-carbaldehyde 618 with a suitable aldehyde in Step 1. The following compounds were made following this procedure: [4-Chloro-5-(1 H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-thiazol-2-yl]-.(2,4-dimethyl-thiazol-5 ylmethyl)-amine (P-0204), [4-Chloro-5-(1 H-yrl[,-Iyidn3ymty)tizo--l-2ehl5-ehl3-mdz 4-ylmethyl)-amine (P-0205), [4-Chloro-5-(1Hproo23b yii--lehy)tizl2yl-5fur-yidn2ymty) amine (P-0206), [4-Chloro-5-(l H -proo23bprdn3ymty)tizo---5mtoyprdn3ymty) 156 WO 2008/064255 PCT/US2007/085289 amine (P-0207), [4-Chloro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4,5-dimethyl-thiophen-2 ylmethyl)-amine (P-0208), [4-Chloro-5-(l H-pyIrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y)-(2,5-dimethyl-thiophen-3 ylmethyl)-amine (P-0209), The following table indicates the aldehyde (Column 2) used in Step 1 of Scheme 196 to provide the compounds (Column 3). Column 1 provides the compound number and Column 4 the experimental mass spectrometry result. MS(ESI) Compound Aldehyde Compound [M+H*]* number observed CI P-0204 N S H 390.3 N CI P-0205 O N... S H HN 387.1 0N N H CI P-0206 / F S 373.9 o N 5 Q N NH CI 0- 'N _f P-0207 .~~ H ~-386.3 o NN N H CI N P-0208 1/ N 389.1 N N H 157 WO 2008/064255 PCT/US2007/085289 Example 41: Synthesis of 5-11-(1IH-pyrrolo[2,3-blpyridin-3-yl)-ethylI-pyridin- 2 -yl-( 4 trifluoromethyl-benzyl)-amine P-0388 [0292] 5-[1-(IH-Pyrrolo[2,3-b]pyridin-3-yl)-ethyl]-pyridin-2-yl-(4-trifluoromethyl-benzyl) amine P-0388 was synthesized from (5-bromo-pyridin-2-yl)-(4-trifluoromethyl-benzyl)-amine 17 as shown in Scheme 197. Scheme 197 0 0 Step NH Step 2 N 1StO + 3 N NH -tP1 N HNO N N Cj.. 620 CF31. 621 CF3.. 96 TIPS TTIPS 117 a CF 3 62 ~ CF 3 62
CF
3 9 H / H H/ CF N CF3 HO -, N~Q 3 ___N Step 5 _' N Step4 N N N38 N N 622 H 623 P08 TIPS Step 1 - Preparation of 1-[6-(4-trifluoromethyl-benzylamino)-pyridin-3-ylj-ethanonle (620): [0293] (5-Bromo-pyridin-2-yl)-(4-trifluoromethyl-benzyl)-amine (17, 3.00 g, 9.06 mmol) was dissolved in tetrahydrofuran (80 mL). The reaction was cooled at -78 *C under an atmosphere of argon. 2.5 M n-butyllithium in hexane (10.9 mL) was added. The reaction was stirred at -78 *C for 60 minutes. N-Methoxy-N-methylacetamide (1.93 mL, 18.1 mmol) was added to the reaction, which was allowed to warm to room temperature. The reaction was poured into I M ammonium chloride and brine and extracted with ethyl acetate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography (ethyl acetate:hexanes) to provide the desired compound as an oil that crystallized to a white solid (620, 1.328 g, 50%), consistent with the compound structure by 'H-NMR and MS(ESI): [M+H*}*=295.3. Step 2 - Preparation of (5-acetyl-pyridin-2-yl)-(4-trifuoromethyl-benzyl)-carbamic acid tert-butyl ester (621).: 102941 To 1-[6-(4-trifluoromethyl-benzylamino)-pyridin-3-yl)-ethanone (620, 1.30 g, 4.42 mmol) in tetrahydrofuran (15.0 mL) were added di-tert-butyldicarbonate (1.10 g, 5.04 mmol), 4 dimethylaminopyridine (0.0259 g, 0.21 mmol) and N,N-diisopropylethylamine (0.888 mL, 5.10 mmol) under an atmosphere of nitrogen. The reaction was stirred at room temperature for 3 days. 158 WO 2008/064255 PCT/US2007/085289 The mixture was extracted with ethyl acetate and saturated sodium bicabonate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography (0-15% ethyl acetate:hexanes) to provide the desired compound as an oil that solidified to a white solid (621, 1.29g, 74%), consistent with the compound structure by 'H-NMR. Step 3 - Preparation of 1-[6-(4-trifluoromethyl-benzylamino)-pyridin- 3 -yl]-l-(J triisopropylsilanyl-IH-pyrrolo[ 2 ,3-b]pyridin-3-yl)-ethanol (622): 102951 3-Iodo-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridine (96, 485.9 mg, 1.21 mmol) was dissolved in tetrahydrofuran (8 mL) at -20 *C under an atmosphere of nitrogen. 2.0 M isopropylmagnesium chloride in tetrahydrofuran (0.655 mL) was added. The reaction was stirred at -20 0 C for 1 hour. Into the reaction was added (5-acetyl-pyridin-2-yl)-(4-trifluoromethyl benzyl)-carbamic acid tert-butyl ester (621, 300.0 mg, 0.76 mmol) in tetrahydrofuran (6 mL) The reaction was allowed to warm to room temperature overnight. The mixture was extracted with ethyl acetate and saturated sodium bicabonate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography on the (ethyl acetate:hexanes), to provide the desired compound as an oil (622, 125 mg, 29%), consistent with the compound structure by 'H-NMR. Step 4 - Preparation of 5-[I-(H-pyrrolo[2,3-b]pyridin-3-yl)-vinyl]-pyridin-2-yl-(4 trifluoromethyl-benzyl)-amine (623): 10296] 1-[6-(4-Trifluoromethyl-benzylamino)-pyridin- 3 -yl]-1-(1 -triisopropylsilanyl-1H pyrrolo[2,3-b]pyridin-3-yl)-ethanol (622, 125.0 mg, 0.22 mmol) was dissolved in acetonitrile (11.7 mL) and trifluoroacetic acid (0.175 mL, 2.3 mmol) and triethylsilane (0.292 mL, 1.8 mmol) were added. The reaction was heated to reflux overnight. The reaction was concentrated, then washed with ethyl acetate and saturated sodium bicarbonate. The organic portions were dried with anhydrous sodium sulfate, filtered and the filtrate was adsorbed onto silica. The mixture was purified by silica gel chromatography (0-60% ethyl acetate:hexanes) to provide the desired compound (623, 43 mg, 50%), consistent with the compound structure by 'H-NMR. Step 5 - Preparation of 5-[J-(JH-pyrrolo[2,3-b]pyridin-3-yl)-ethlyl]-pyridin-2-yl-( 4 trifluoromethyl-benzyl)-amine (P-0388): 10297] 5-[1 -(1 H-Pyrrolo[2,3-bjpyridin-3-yl)-vinyl]-pyridin-2-yl-(4-trifluoromethyl-benzyl) amine (623, 0.043 g, 0.00011 mol) was dissolved in tetrahydrofuran (10 mL) and methanol (10 mL). The reaction was shaken under an atmosphere of hydrogen (30 psi) overnight. The reaction was filtered through Celite and the filtrate adsorbed onto silica and purified by silica gel column chromatography (ethyl acetate:hexanes) to provide the desired compound as a white solid (P-0388, 159 WO 2008/064255 PCT/US2007/085289 2.1 mg, 5%), consistent with compound structure by 'H-NMR and MS(ESI): [M+H]*=397.6. Example 42: Synthesis of [5-(5-Chloro-1H-pyrrolo[2,3-bipyridin-3-ylmethyl)-thiazol-2-yl] (4-fluoro-benzyl)-amine P-0290 10298] [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine P-0290 was synthesized in four steps from (4-fluoro-benzyl)-(4-chloro-5-formyl-thiazol-2-yl) carbamic acid tert-butyl ester 624 as shown in Scheme 198. Scheme 198 Boc HO OHC S Boc OHC S Boc CI PS S C1+ >-K -41. Step 2 CN TNP Nte 1N F TIPSTIPS 624 625 626 627 tips F F H Boc N NS1 Step 3 / Step 4 C N C N N F N N F H P-0290 H 628 Step I - Preparation of (4-fluoro-benzyl)-(4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (625): 10299] To a solution of (4-fluoro-benzyl)-(4-chloro-5-for-myl-thiazol-2-yl)-carbamic acid tert butyl ester (624, 1 g, 2.70 mmol, prepared as described in Example 5, Scheme 159, Step 2, where 4-(aminomethyl)pyridine 516 is replaced with p-fluorobenzylamine, i.e. intermediate in preparing compound P-0156) in methanol (100 mL) was added Pd/C (100 mg, 50% water wet) and sodium acetate (660 mg, 8.09 mmol) and the mixture was shaken under an atmosphere of hydrogen (50 psi) overnight observing -50% conversion by LC/MS. The mixture was filtered over a bed of Celite and the solvent was removed in vacuo and purified by silica gel chromatography (ethyl acetate/heptane) to provide the desired compound as an off-white solid (450 mg, 50 %), consistent with compound structure by 'H-NMR. Step 2 - Preparation of (5-[(5-chloro-l-triisopropylsilanyl-IH-pyrrolo[ 2 ,3-b]pyridin-3-yl) kvdroxy-methyl]-thiazol-2-yl}-(4-fluoro-benzyl)-carbamic acid tert-butyl ester (627): [0300] To a solution of 5-chloro-3-iodo-1-(triisopropylsilyl)- IH-pyrrolo[2,3-bjpyridine (626, 300 mg, 0.69 mmol) in tetrahydrofuran (10 mL) at -20 *C was added dropwise iso-propyl 160 WO 2008/064255 PCT/US2007/085289 magnesium chloride (2M in tetrahydrofuran, 0.44 mL, 0.88 mmol). The reaction mixture was allowed to warm to 0 "C over 10 minutes and then cooled to -40 "C. To this reaction mixture was added a solution of (4-fluoro-benzyl)-(4-chloro-5-formyl-thiazol-2-yl)-carbamic acid tert-butyl ester (625, 211 mg, 0.63 mmol) in tetrahydrofuran (5 mL). The reaction mixture was allowed to warm to 0 "C over 30 minutes and then quenched with brine (50 mL). The mixture was transferred to a separatory funnel and the layers were separated. The organic layer was dried over sodium sulfate and evaporated in vacuo to give the crude material which was purified by silica gel column chromatography (0-30% ethyl acetate/heptane) to provide the desired compound as a foam (120 mg, 30%), consistent with structure by 'H-NMR. Step 3 - Preparation of[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol- 2 -yl]-( 4 fluoro-benzyl)-carbamic acid tert-butyl ester (628): [0301] To a solution of {5-[(5-chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl) hydroxy-methyl]-thiazol-2-yl}-(4-fluoro-benzyl)-carbamic acid tert-butyl ester (627, 120 mg, 0.186 mmol) in acetonitrile (3 mL) was added trifluoroacetic acid (0.14 mL, 1.86 mmol) and triethylsilane (0.30 mL, 1.86 mmol). The resulting mixture was stirred for 2 hours at 40 "C. The solvent was then removed in vacuo and the residue was used directly in the next step. Step 4: Preparation of[5-(5-chloro-H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro benzyl)-amine (P-0290): 10302] To the solution of crude [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol- 2 -yl] (4-fluoro-benzyl)-carbamic acid tert-butyl ester (628, 0.186 mmol theory) in dichloromethane (5 mL) at room temperature was added trifluoroacetic acid (1 mL) and the reaction was allowed to stir overnight. The solvent was removed in vacuo and the residue taken up in ethyl acetate and then washed with saturated aqueous potassium carbonate making sure basicity was reached. The layers were separated and the aqueous layer was back-extracted with ethyl acetate. The combined organic layers were dried over sodium sulfate and evaporated in vacuo to give the crude compound which was purified by silica gel chromatography (0-10% methanol/ethyl acetate). The solvent was removed in vacuo and the material was triturated with dichloromethane to give the desired compound as an off-white solid (20 mg, 29 % over 2 steps) consistent with compound structure by 'H-NMR and MS(ESI): [M+H*]*=372.9. 161 WO 2008/064255 PCT/US2007/085289 [0303] (4-Fluoro-benzyl)-[5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine P-0389 H N Cl N NF H was synthesized following the protocol of Scheme 198, replacing 5-chloro-3-iodo-1 (triisopropylsilyl)-1H-pyrrolo[2,3-bipyridine 626 with 3-iodo-1-triisopropylsilanyl-1H pyrrolo[2,3-b]pyridine 96, to provide the desired compound, consistent with structure by 1H-NMR and MS(ESI): [M+H*]*=339.0. Example 43: Synthesis of (5-chloro-1H-pyrrolo[2,3-blpyridin-3-yi)-[2-ethyl-5-( 4 -fluoro benzylamino)-2H-pyrazol-3-y]-methanone P-0184 10304] (5-Chloro- IH-pyrrolo[2,3-bjpyridin- 3-yl)-[2-ethyl-5-(4-fluoro-benzylamino)-2H pyrazol-3-yl]-methanone P-0184 was synthesized from 5-chloro-1H-pyrrolo[2,3-b]pyridine 532 in 1 step as shown in Scheme 199. Scheme 199 F FH H C1 Step 1 0 P 1 -NN N N ( P0B K 530 H N N 532 H Step 1 - Synthesis of (5-chloro-JH-pyrrolo[ 2 ,3-b]pyridin- 3-yl)-[2-ethyl-5-(4-fluoro-benzylamino) 2H-pyrazol-3-yl]-methanone (P-0184): [0305] 5-Chloro-1H-pyrrolo[2,3-b]pyridine (532, 0.068 g, 0.44 mmol) was combined with methanol (10 mL) and potassium hydroxide (0.16 g, 2.8 mmol). The mixture was stirred for 50 minutes, then 2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazole-3-carbaldehyde (530, 0.100 g, 0.40 mmol, prepared as described in Example 8, Scheme 162, Step 5) was added and the reaction was stirred overnight at room temperature and then concentrated. Ethyl acetate was added and the mixture was washed with sodium bicarbonate saturated solution and brine. After drying over anhydrous sodium sulfate the solvent was removed under reduced pressure. Purification with silica gel column chromatography eluting with a gradient of ethyl acetate (10-100%) in hexanes provided the desired compound (0.0033 g, 2%). MS (ESI) [M+H]* = 398.1. 162 WO 2008/064255 PCT/US2007/085289 Example 44: Synthesis of [5-(5-chloro-1H-pyrrolo[2,3-bIpyridin-3-ylmethyl)-1-ethyl-1H pyrazol-3-ylj-(4-fluoro-benzyl)-amine P-0185 [0306] [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1 -ethyl- I H-pyrazol-3-yl]-(4-fluoro benzyl)-amine P-0185 was synthesized from 5-chloro-3-iodo-l-triisopropylsilanyl-IH-pyrrolo[2,3 b]pyridine 629 in 2 steps as shown in Scheme 200. Scheme 200 F F IH HOH N NP H CH N N N H | Step 1 Step 2 P-118 O N- N N N N 630 N N 530 629 TIPS H H Step 1 - Synthesis of (5-chloro-JH-pyrrolo[2,3-b]pyridin-3-yl)-[2-ethyl-5-(4-fluoro-benzylamino) 2H-pyrazol-3-yl]-methanol (630): 10307] 5-Chloro-3-iodo-1-triisopropylsilanyl-IH-pyrrolo[2,3-b]pyridine (629, 0.15 g, 0.34 mmol) was dissolved in tetrahydrofuran (3 mL, 40 mmol) and the solution was cooled to -20 *C. 2 M isopropylmagnesium chloride in tetrahydrofuran (200 pL) was added dropwise and the reaction was stirred and allowed to warm to -5 *C. After the reaction was cooled to -20 *C, 2-ethyl-5-(4 fluoro-benzylamino)-2H-pyrazole-3-carbaldehyde (530, 0.043g, 0.17 mmol, prepared as described in Example 8, Schemel62, Step 5) in tetrahydrofuran (4 mL) was added to the mixture. The reaction was stirred and allowed to warm to -5 *C, then concentrated, ethyl acetate was added and the mixture was washed with sodium bicarbonate saturated solution and brine. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure. Purification with silica gel column chromatography eluting with a gradient of ethyl acetate (5-80%) in hexanes gave the desired compound (630, 0.038 g, 40%). Step 2 - Synthesis of 5-(5-chloro-JH-pyrrolo[2,3-bjpyrid in-3-ylmethyl)-1 -ethyl-JH-pyrazol-3 -yl] (4-fluoro-benzyl)-amine (P-0185): 10308] (5-Chloro-1-triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-[2-ethy l-5-(4-fluoro benzylamino)-2H-pyrazol-3-yl]-methanol (630, 0.045 g, 0.081 mmol) was dissolved in acetonitrile (5 mL) and triethylsilane (0.4 mL, 2.0 mmol) was added, followed by trifluoroacctic acid (0.2 mL, 2.0 mmol). The reaction was stirred at room temperature for 45 minutes, then stirred at 60 *C for 45 minutes. The solvent was removed under reduced pressure, ethyl acetate was added and the organic was washed with sodium bicarbonate saturated solution and brine. After drying over anhydrous sodium sulfate, the solvent was evaporated to dryness. Purification with silica gel 163 WO 2008/064255 PCT/US2007/085289 column chromatography eluting with a gradient of ethyl acetate (40-100%) in hexanes gave the desired compound (P-0185, 0.0068 g, 22%). MS (ESI) [M+H']*= 384.1. Example 45: Synthesis of 3-2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3 ylmethyl-1H-pyrroIo[2,3-blpyridine-5-carbonitrile P-0415 10309] 3-2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl-1H-pyrrolo[2,3 b]pyridine-5-carbonitrile P-0415 was synthesized in 5 steps from 1H-Pyrrolo[2,3-b]pyridine-5 carbonitrile 632 as shown in Scheme 201. Scheme 201 N N S N C + BrC >~I Stepi 1 Step 2 N~ ~tpN ~~ B N N- N N N' N Ste NN +B-J 632 H 633H 634 Boc 635 Boc F 631 SBo 4 N Bo Step 5 N F -, N, F N N H -4 H 636 NH -U1 Step I - Synthesis of 3-dimethylaminomethyl-JH-pyrrolo[2,3-b]pyridine-5-carbonitrile (633): [0310] To 1H-Pyrrolo[2,3-b]pyridine-5-carbonitrile (632, 3.00 g, 0.0210 mol) in isopropyl alcohol (120 mL) were added dimethylamine hydrochloride (1.91 g, 0.0235 mol) and formaldehyde (0.708 g, 0.0236 mol). The reaction was heated to reflux overnight, then concentrated, poured into water, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 5% to 30% methanol in dichloromethane containing 0.3% triethyl amine to give the desired compound (633, 2.0 g, 48%). Step 2 - Synthesis of 5-cyano-3-dimethylaminomethyl-pyrrolo[ 2 ,3-b]pyridine-1-carboxylic acid tert-butyl ester (634).: 10311] To 3-dimethylaminomethyl-IH-pyrrolo[2,3-b]pyridine-5-carbonitrile (633, 2.0 g, 0.010 mol) in tetrahydrofuran (60.0 mL) were added di-tert-butyldicarbonate (2.62 g, 0.0120 mol), 4-dimethylaminopyridine (0.12 g, 0.0010 mol) and triethylamine (4.0 mL, 0.029 mol). The reaction was stirred at 45 *C over a weekend, then concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 2% to 30% methanol in dichloromethane in hexane to give the 164 WO 2008/064255 PCT/US2007/085289 desired compound (634, 2.50 g, 83%). Step 3 - Synthesis of 3-chloromethyl-5-cyano-pyrrolo[ 2 ,3-b]pyridine-1-carboxylic acid tert-butyl ester (635): [0312] To 5-cyano-3-dimethylaminomethyl-pyrrolo[2,3-b]pyridine-1-carboxylic acid tert-butyl ester (634, 2.60 g, 8.66 mmol) in toluene (60.0 mL) under an atmosphere of nitrogen was added ethyl chloroformate (0.828 mL, 8.66 mmol). The reaction was stirred at room temperature for 3 hours, then poured into water and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give a white solid (635, 400 mg, 16%). Step 4 - Synthesis of [5-(5-cyano-JH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yl]-(5 fluoro-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (636): 10313] To (5-bromo-6-fluoro-pyridin-2-yl)-(5-fluoro-pyridin-3-ylmethyl)-carbamic acid tert butyl ester (631, 0.600 g, 1.50 mmol, prepared as described in Example 21) in tetrahydrofuran (10.0 mL) at -25 *C under an atmosphere of nitrogen, was added a solution of isopropylmagnesium chloride (2.0 M in tetrahydrofuran, 0.730 mL). The reaction was allowed to warm to 5 *C over 1 hour. The reaction was cooled to -35 "C, followed by addition of a solution of CuCN.2LiCI (0.65 M in tetrahydrofuran, 2.4 mL). After 5 minutes, 3-chloromethyl-5-cyano pyrrolo[2,3-b]pyridine-1 -carboxylic acid tert-butyl ester (635, 0.086 g, 0.29 mmol) in tetrahydrofuran (4.0 mL) was added to the reaction. The reaction was allowed to warm to room temperature over 1 hour, then poured into a diluted ammonia solution, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 20% to 100% ethyl acetate in hexane to give the desired compound (636, 0.13 g, 92%). MS (ESI) [M+H*] = 477.4. Step 5 - Synthesis of 3-2-fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl-1H pyrrolo[2,3-b]pyridine-5-carbonitrile (P-0415): 10314] To [5-(5-cyano-1 H-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-6-fluoro-pyridin-2-yl]-(5-fluoro pyridin-3-ylmethyl)-carbamic acid tert-butyl ester (636, 0.130 g, 0.27 mmol) in dichloromethane (10.0 mL) was added trifluoroacetic acid (1.00 mL, 0.0130 mol). The reaction was stirred at room temperature overnight. The reaction was concentrated, poured into aqueous potassium carbonate, and extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and purified by silica gel column chromatography eluting with 25% to 100% ethyl acetate in hexane to give a white solid (P-0415, 85.6 mg, 83.4%). MS (ESI) [M+H]* = 377.0. 165 WO 2008/064255 PCT/US2007/085289 10315] (5-Fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl) pyridin-2-yl]-amine P-0414 F N N H was prepared following the protocol of Scheme 201, substituting 1H-Pyrrolo[2,3-b]pyridine-5 carbonitrile 632 with 1 H-Pyrrolo[2,3-b]pyridine in Step 1. MS (ESI) [M+H*] = 352.5. [0316] 3-[6-(4-Chloro-benzylamino)-2-fluoro-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5 carbonitrile P-0432 NC C N N H was prepared following the protocol of Scheme 201, replacing 5-bromo-6-fluoro-pyridin-2-yl)-(5 fluoro-pyridin-3-ylmethyl)-carbamic acid tert-butyl ester 631 with (5-Bromo-6-fluoro-pyridin-2 yl)-(4-chloro-benzyl)-carbamic acid tert-butyl ester 637 (prepared as described in Example 21) in Step 4. MS (ESI) [M+H*]* = 391.9. Example 46: Synthesis of (3-chloro-benzyl)-[5-(5-chloro-1H-pyrrolo [2,3-b] pyridin-3 ylmethyl)-1-methyl-11-pyrazol-3-yl]-amine P-0410 [0317] (3-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo [2,3-b]pyridin-3-ylmethyl)-1- methyl-iH pyrazol-3-yl]-amine P-0410 was synthesized in I I steps from 1H-pyrazole-3,5-dicarboxylic acid monohydrate 638 as shown in Scheme 202. 166 WO 2008/064255 PCT/US2007/085289 Scheme 202 HO 0- HO 0 0 0 O N 3 O St 1 0 Step2 0 V Step 3 O / Step 4 N N' SteO N N1,% N HO H N' N.N 68 0 H 639 40 % 641 O 1 642 63H8 3 k H
NH
2 O / Cc Step 5 O 4 Step 6 N H | Step 7 NH Step 8 NH O N643 O CI O N N647 0844 645 0 I 646 HO C0 C I N C I CIHO NH Stp9 NNH StplC + CL T Step 10 CI NH e 11 C4 N NIP NIN P-0410 N' N N 0 629 TP H 648 Step I - Preparation ofIH-pyrazole-3,5-dicarboxylic acid dimethyl ester (639): [03181 I H-Pyrazole-3,5-dicarboxylic acid monohydrate (638, 21.1 g, 121.0 mmol) was combined with methanol (350 mL) and hydrogen chloride (10 mL). The reaction was stirred at reflux overnight and then concentrated. The resulting solid was washed with ethyl acetate and hexanes and dried under reduced pressure. The obtained compound 639 was used without further purification. MS (ESI) [M+H]*= 185.0. Step 2 - Preparation of I-methyl-JH-pyrazole-3,5-dicarboxylic acid dimethyl ester (640): [0319] IH-Pyrazole-3,5-dicarboxylic acid dimethyl ester (639, 9.1 g, 49.0 mmol) was combined with acetone (400 mL) and potassium carbonate (10.2 g, 74.1 mmol). The mixture was stirred for 40 minutes under an atmosphere of nitrogen. To the stirring suspension, methyl iodide (3.4 mL, 54.0 mmol) was added dropwise. The reaction was stirred at room temperature overnight and then the solvent was evaporated under reduced pressure. The resulting solid was washed with water and filtered. After toluene was added, the solvent was removed under reduced pressure. The resulting compound 640 was used without further purification. Step 3 - Preparation of I-methyl-1H-pyrazole-3.5-dicarboxylic acid 5-methyl ester (641): 10320] 1-Methyl-1H-pyrazole-3,5-dicarboxylic acid dimethyl ester (640, 3.7 g, 19.0 mmol) was combined with 1,4-dioxane (20 mL) and water (60 mL). Concentrated sulfuric acid (1.0 mL) in 2 mL of water was added to the solution. After the reaction was stirred at reflux overnight, it was cooled to room temperature and concentrated until precipitation began. The obtained mixture was left standing overnight. The resulting solid was filtered and dried under reduced pressure. The 167 WO 2008/064255 PCT/US2007/085289 collected aqueous fractions were extracted with ethyl acetate. The organic portion was dried over anhydrous sodium sulfate and concentrated. Additional solid was crystallized from ethyl acetate to give the desired compound (641, 2.33 g, 68%). MS (ESI) [M+H*]*= 185.0, melting point 175 *C. Step 4 - Preparation of 5-azidocarbonyl-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (642): [03211 1-Methyl-lH-pyrazole-3,5-dicarboxylic acid 5-methyl ester (641, 3.2 g, 17.0 mmol) was combined with thionyl chloride (5 mL). The reaction was heated to reflux for 40 minutes and then concentrated twice from toluene. The resulting solid was dried under reduced pressure overnight. The product was dissolved into acetone (20 mL) and sodium azide (3.5 g, 54.0 mmol) was added in water (10 mL) rapidly at once. The obtained solution was stirred for one minute and then poured into ice-water (5OmL). The precipitate was filtered and dried under reduced pressure. The final compound was used without further purification (642, 2.8 g, 77%). Step 5 - Preparation of 5-benzyloxycarbonylamino-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (643): [0322] 5-Azidocarbonyl-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (642, 2.8 g, 13.0 mmol) was combined with toluene (35 mL) and benzyl alcohol (2.1 mL, 20.0 mmol). The reaction was heated to reflux for 45 minutes and then the solvent was removed under reduced pressure. The compound (643, 2.4 g, 62%) was washed with methanol and dried under vacuum. MS (ESI) [M+H*]* = 290.3. Step 6 - Preparation of 5-aniino-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (644): [0323] 5-Benzyloxycarbonylamino-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (643, 2.2 g, 7.6 mmol) was combined with methanol (50 mL) and 10% palladium on carbon (500 mg). The mixture was stirred under an atmosphere of hydrogen for three hours. The mixture was filtered through Celite and the solvent was removed under reduced pressure to give the desired compound (644, 1.2 g, 98%). (ESI) [M+H*]*= 156.1. Step 7 - Preparation of 5-(3-chloro-benzylamino)-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (646): 10324] 5-Amino-2-methyl-2H-pyrazole-3-carboxylic acid methyl ester (644, 1.3 g, 8.0 mmol) was combined with 3-chlorobenzaldehyde (645, 0.95 mL, 8.4 mmol) and acetonitrile (40 mL). Trifluoroacetic acid (3.2 mL, 42.0 mmol) was added followed by triethylsilane (6.7 mL, 42.0 mmol). The reaction was heated to reflux overnight and then concentrated. Ethyl acetate was added and the solution was washed with IN potassium carbonate. The organic portion was dried over anhydrous sodium sulfate, filtered and concentrated. The compound (646, 0.944 g, 42%) was 168 WO 2008/064255 PCT/US2007/085289 crystallized from a mixture of ethyl acetate: hexane. Step 8- Preparation of[5-(3-chloro-benzylamino)-2-nmethyl-2H-pyrazol-3-yl]-methanot (647): [03251 5-(3-Chloro-benzylamino)-2-methyl-2 H-pyrazole-3-carboxylic acid methyl ester (646, 0.944 g, 3.37 mmol) was combined with tetrahydrofuran (20 mL) and the solution was cooled to -40 *C. 1.0 M lithium tetrahydroaluminate in tetrahydrofuran (3.7 mL) was added and the reaction was stirred for 45 min at -20 *C. 1.0 M lithium tetrahydroaluminate in tetrahydrofuran (3.7 mL) was added at -40 *C and the reaction was stirred to 10*C. Sodium sulfate decahydrate was added in small portions and the mixture was stirred for two hours at room temperature, then filtered through Celite and concentrated. The resulting compound (647, 0.821 g, 97%) was washed with a mixture of ethyl acetate: hexanes and dried under reduced pressure. Step 9- Preparation of 5-(3-chloro-benzylamino)-2-metliyl-2H-pyrazole-3-carbaldehyde (648): 103261 [5-(3-Chloro-benzylamino)-2-methyl-2H-pyrazol-3-yl]-methanol (647, 0.821 g, 3.26 mmol) was combined with dichloromethane (70 mL) and manganese(IV) oxide (4 g). The reaction was stirred at room temperature overnight under an atmosphere of nitrogen. The mixture was filtered through Celite and concentrated. Purification by silica gel column chromatography eluting with a gradient of ethyl acetate (10-100%) in hexane gave the desired aldehyde (648, 0.482 g, 60%). Step 10- Preparation of[5-(3-chloro-benzylamino)-2-methyl-2H-pyrazol-3-yl]-(5-chloro-l triisopropylsilanyl-1H-pyrrolo[2,3-b]pyridin-3-yl)-methanol (649): [03271 5-Chloro-3-iodo-l-triisopropylsilanyl- IH-pyrrolo[2,3-b]pyridine (629, 0.19 g, 0.44 mmol) was dissolved in tetrahydrofuran (0.9 mL). The solution was cooled to -20 *C. 2M isopropylmagnesium chloride in tetrahydrofuran (200 pL) was added dropwise to the mixture, then stirred to -5 *C. After the reaction was cooled to -20 "C, 5-(3-chloro-benzylamino)-2-methyl-2 H pyrazole-3-carbaldehyde (648, 0.050 g, 0.20 mmol) in 2 mL of tetrahydrofuran was added at once to the mixture. The reaction was stirred to 0 "C and then concentrated. Ethyl acetate was added and the mixture was washed with sodium bicarbonate saturated solution and brine. The organic portion was dried over anhydrous sodium sulfate and concentrated. Purification with silica gel column chromatography eluting with a gradient of ethyl acetate (5-80%) in hexane gave the desired compound (649, 0.033 g, 30%). (ESI) [M+H*]*= 558.3, 560.9. Step 11 - Preparation of (3-chloro-benzyl)-[5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-I methyl-I H-pyrazol-3-yl]-amine (P-0410): 103281 [5-(3-Chloro-benzylamino)-2-methyl-2HI-pyrazol-3-yl]-(5-chloro--triisopropylsilanyl IH-pyrrolo[2,3-b]pyridin-3-yl)-methanol (649, 0.033 g, 0.059 mmol) was combined with 169 WO 2008/064255 PCT/US2007/085289 dichloromethane (5 mL, 0.08 mol) and triethylsilane (200 pL, 1.0 mmol) was added, followed by trifluoroacetic acid (100 1 ±L, 1.0 mmol). The reaction was stirred at room temperature overnight and then concentrated. Ethyl acetate was added and the organic portion was washed with 1 M potassium carbonate, dried over anhydrous sodium sulfate and concentrated. Purification with silica gel flash chromatography eluting with a gradient of methanol (2-20%) and dichloromethane followed by washes with a mixture of ethyl acetate:hexane gave the desired compound (P-0410, 0.0039 g, 17%). (ESI) [M+H*]*= 387.30. 103291 [5-(5-Chloro-1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-1-methyl-IH-pyrazol-3-yl]-(2,5 difluoro-benzyl)-amine P-0411 and [5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l-methyl 1 H-pyrazol-3-yl]-(2-fluoro-benzyl)-amine P-0413, N-N N-N ". NN N ci H F clH F N N NC and H respectively, were prepared following the protocol of Scheme 202, replacing 3-chlorobenzaldehyde 645 with 2,5-difluorobenzaldehyde and 2-fluorobenzaldehyde, respectively, in Step 7. (ESI) [M+H]*= 389.95 (P-0411) and 370.20 (P-0413). Example 47: Enzyme activity assays [03301 Assays for the activity of c-Kit or c-Fms are known in the art, for example as described in US Patent Application Publication number US 2007/0032519, the disclosure of which is hereby incorporated by reference in its entirety. Similar assays may be used to assess the activity of TrkA, TrkB, and HGK. [0331] Additional cell based assays can be correlated to the Fms activity of compounds of the invention. For example, the ability of osteoclast precursor cells (commercially available from Lonza) to differentiate into mature osteoclasts, due to stimulation by M-CSF and RANKL, in the presence of compounds, can be measured using a method analogous to that previously reported (Hudson et al., Journal of Urology, 1947, 58:89-92), where the amount of acid phosphatase in the supernatant (i.e. TRAP5b excreted by mature osteoclasts) is proportional to the number of mature osteoclasts present. In another example, the ability of M-CSF-dependent murine macrophage cells (BACl.2F5) to proliferate in the presence of compounds can be measured by culturing cells as previously described (Morgan et al., Journal of Cellular Physiology, 1987, 130:420-427) and 170 WO 2008/064255 PCT/US2007/085289 determining cell viability by analysis of ATP levels in the cell culture (Crouch et al., Journal of Immunological Methods, 1993, 160:81-8). 10332] Compounds P-0092, P-0093, P-0094, P-0095, P-0096, P-0097, P-0098, P-0099, P-0100, P-0101, P-0102, P-0103, P-0104, P-0105, P-0107, P-0108, P-0109, P-0111, P-01 12, P-0113, P-01 14, P-0115, P-01 16, P-0118, P-0120, P-0121, P-0122, P-0123, P-0125, P-0126, P-0127, P-0128, P-0129, P-0131, P-0132, P-0138, P-0143, P-0144, P-0145, P-0148, P-0154, P-0156, P-0157, P-0159, P-0161, P-0163, P-0170, P-0171, P-0173, P-0174, P-0176, P-0177, P-0179, P-0180, P-0181, P-0182, P-0186, P-0187, P-0188, P-0190, P-0192, P-0193, P-0194, P-0195, P-0197, P-0199, P-0201, P-0203, P-0205, P-0206, P-0208, P-021 1, P-0212, P-0213, P-0214, P-0215, P-0216, P-0217, P-0218, P-0219, P-0221, P-0222, P-0224, P-0225, P-0226, P-0228, P-0234, P-0237, P-0239, P-0240, P-0242, P-0243, P-0244, P-0245, P-0246, P-0252, P-0253, P-0255, P-0257, P-0258, P-0259, P-0260, P-0262, P-0263, P-0264, P-0265, P-0266, P-0267, P-0268, P-0269, P-0270, P-0271, P-0272, P-0273, P-0274, P-0275, P-0276, P-0277, P-0278, P-0279, P-0280, P-0281, P-0282, P-0283, P-0284, P-0285, P-0286, P-0287, P-0288, P-0289, P-0290, P-0291, P-0294, P-0297, P-0298, P-0301, P-0302, P-0303, P-0305, P-0306, P-0307, P-0308, P-0309, P-0311, P-0312, P-0313, P-0314, P-0316, P-0319, P-0320, P-0321, P-0322, P-0323, P-0324, P-0325, P-0326, P-0327, P-0328, P-0329, P-0330, P-033 1, P-0332, P-0334, P-0336, P-0337, P-0338, P-0339, P-0340, P-0341, P-0342, P-0343, P-0344, P-0345, P-0346, P-0347, P-0348, P-0350, P-0351, P-0352, P-0354, P-0355, P-0356, P-0357, P-0358, P-0359, P-0361, P-0362, P-0363, P-0365, P-0366, P-0367, P-0368, P-0369, P-0370, P-0371, P-0372, P-0373, P-0375, P-0376, P-0377, P-0378, P-0379, P-0382, P-0383, P-0385, P-0387, P-0390, P-0392, P-0393, P-0394, P-0395, P-0396, P-0402, P-0404, P-0406, P-0407, P-0408, P-0409, and P-0412 demonstrated an IC 5 0 of less than 1 pM in at least one of the c-kit assays described in US Patent Application Publication number US 2007/0032519. [0333] Compounds P-0092, P-0093, P-0094, P-0095, P-0096, P-0097, P-0098, P-0099, P-0100, P-0101, P-0102, P-0103, P-0104, P-0105, P-0106, P-0107, P-0108, P-0109, P-0110, P-Ol il, P-01 12, P-0113, P-01 14, P-0115, P-01 16, P-01 17, P-011 8, P-0 119, P-0 120, P-0121, P-0122, P-0123, P-0125, P-0126, P-01 27, P-0128, P-0129, P-0130, P-0131, P-0132, P-0134, P-0135, P-0136, P-0137, P-0140, P-0141, P-0142, P-0143, P-0144, P-0145, P-0146, P-0147, P-0148, P-0149, P-0150, P-0151, P-0152, P-0153, P-0154, P-0156, P-0157, P-0158, P-0159, P-0160, P-01 61, P-0163, P-0164, P-0165, P-0167, P-0168, P-0169, P-0170, P-0171, P-0172, P-0173, P-0174, P-0175, P-0176, P-0179, P-0180, P-0181, P-0182, P-0183, P-0185, P-0186, P-0187, P-0188, P-0189, P-0190, P-0191, P-0192, P-0193, P-0194, P-0195, P-0196, P-0197, P-0198, P-0199, P-0200, P-0201, P-0202, P-0203, P-0204, P-0205, P-0206, P-0207, 171 WO 2008/064255 PCT/US2007/085289 P-0208, P-0209, P-0210, P-0211, P-0212, P-0213, P-0214, P-0215, P-0216, P-0217, P-0218, P-0219, P-0220, P-0221, P-0222, P-0223, P-0224, P-0225, P-0226, P-0227, P-0228, P-0229, P-0230, P-0231, P-0232, P-0233, P-0234, P-0235, P-0236, P-0237, P-0238, P-0239, P-0240, P-0241, P-0242, P-0243, P-0244, P-0245, P-0246, P-0247, P-0248, P-0249, P-0250, P-0251, P-0252, P-0253, P-0254, P-0255, P-0256, P-0257, P-0258, P-0259, P-0260, P-0261, P-0262, P-0263, P-0264, P-0265, P-0266, P-0267, P-0268, P-0269, P-0270, P-0271, P-0272, P-0273, P-0274, P-0275, P-0276, P-0277, P-0278, P-0279, P-0280, P-028 1, P-0282, P-0283, P-0284, P-0285, P-0286, P-0287, P-0288, P-0289, P-0290, P-0291, P-0292, P-0293, P-0294, P-0295, P-0296, P-0297, P-0298, P-0299, P-0300, P-0301, P-0302, P-0303, P-0304, P-0305, P-0306, P-0307, P-0308, P-0309, P-0310, P-0311, P-0312, P-0313, P-0314, P-0315, P-0316, P-0317, P-0318, P-0319, P-0320, P-0321, P-0322, P-0323, P-0324, P-0325, P-0326, P-0327, P-0328, P-0329, P-0330, P-0331, P-0332, P-0333, P-0334, P-0335, P-0336, P-0337, P-0338, P-0339, P-0340, P-0341, P-0342, P-0343, P-0344, P-0345, P-0346, P-0347, P-0348, P-0349, P-0350, P-0351, P-0352, P-0353, P-0354, P-0355, P-0356, P-0357, P-0358, P-0359, P-0360, P-036 1, P-0362, P-0363, P-0364, P-0365, P-0366, P-0367, P-0368, P-0369, P-0370, P-0371, P-0372, P-0373, P-0374, P-0375, P-0376, P-0377, P-0378, P-0379, P-0380, P-0381, P-0382, P-0383, P-0384, P-0385, P-0386, P-0387, P-0390, P-0391, P-0392, P-0393, P-0394, P-0395, P-0396, P-0402, P-0403, P-0404, P-0405, P-0406, P-0407, P-0408, P-0409, and P-0412 had IC 50 of less than I pM in at least one of the Fms assays described in US Patent Application Publication number US 2007/0032519. [03341 Compounds were similarly assayed to determine IC 5 0 values with respect to inhibition of TrkA kinase activity, for which compounds P-0157, P-0171, P-0179, P-0180, P-0303 and P-0412 had IC 50 of less than I 1 M. in this TrkA assay. Compounds were similarly assayed to determine
IC
5 0 values with respect to inhibition of HGK kinase activity, for which compounds P-0156, P-0177, P-0179, P-0195, P-0201, P-0203, P-0206, P-0207, P-0231, P-0240, P-0241, P-0255, P-0324, P-0341, and P-0403 had IC 50 of less than 1 pM. 10335] All patents and other references cited in the specification are indicative of the level of skill of those skilled in the art to which the invention pertains, and are incorporated by reference in their entireties, including any tables and figures, to the same extent as if each reference had been incorporated by reference in its entirety individually. [0336] One skilled in the art would readily appreciate that the present invention is well adapted to obtain the ends and advantages mentioned, as well as those inherent therein. The methods, variances, and compositions described herein as presently representative of preferred embodiments are exemplary and are not intended as limitations on the scope of the invention. Changes therein 172 WO 2008/064255 PCT/US2007/085289 and other uses will occur to those skilled in the art, which are encompassed within the spirit of the invention, are defined by the scope of the claims. [03371 It will be readily apparent to one skilled in the art that varying substitutions and modifications may be made to the invention disclosed herein without departing from the scope and spirit of the invention. For example, variations can be made to provide additional compounds of Formulae II or III and/or various methods of administration can be used. Thus, such additional embodiments are within the scope of the present invention and the following claims. [03381 The invention illustratively described herein suitably may be practiced in the absence of any element or elements, limitation or limitations which is not specifically disclosed herein. The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention that in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions thereof, but it is recognized that various modifications are possible within the scope of the invention claimed. Thus, it should be understood that although the present invention has been specifically disclosed by preferred embodiments and optional features, modification and variation of the concepts herein disclosed may be resorted to by those skilled in the art, and that such modifications and variations are considered to be within the scope of this invention as defined by the appended claims. [0339] In addition, where features or aspects of the invention are described in terms of Markush groups or other grouping of alternatives, those skilled in the art will recognize that the invention is also thereby described in terms of any individual member or subgroup of members of the Markush group or other group. [03401 Also, unless indicated to the contrary, where various numerical values are provided for embodiments, additional embodiments are described by taking any 2 different values as the endpoints of a range. Such ranges are also within the scope of the described invention. [0341] Thus, additional embodiments are within the scope of the invention and within the following claims. 173

权利要求:
Claims (22)
[1] 1. A compound having the chemical structure of Formula II, A2....-- D B N N H all salts, prodrugs, tautomers, and isomers thereof, wherein: D has a structure selected from the group consisting of Q12 Q22 Q52 .N _Qi N Q.... 4 5 Ma~N 14 024 Q 54 Q72 N-N Q 1 52 ~' M 0 -Q 6 1 P M 1 8 Q141 , and in which indicates the attachment point of D to A 2 of Formula II; A 2 is -CH 2 - or -C(O)-; B is selected from the group consisting of hydrogen, -CN, -OR 41 , -SR 4 ', -NHR 41 , -NR 4 IR 4 1 , -NR 3 9 C(O)R 41 , -NR"S(O) 2 R 4 ', halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as B, or as substituents of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH 2 , -CN, -NO 2 , -S(O) 2 NH 2 , -C(O)NH 2 , -OR 42 , -SR4 2 , -NHR 42 , -NR 4 2 R 42 , -NR" 9 C(O)R 42 , -NR"S(O) 2 R 42 , -S(O) 2 R 4 2 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; M 4 is -NR 39 CH 2 -, -NR 39 CH(R 4 0 )-, -NR"CH 2 CH 2 -, or -NR 39 C(O)-; 174 WO 2008/064255 PCT/US2007/085289 M 5 M 10 , and M 18 are selected from the group consisting of a bond, -NR 39 -, -S-, -0-, -NRCH-, -NR"CH 2 CH 2 -, -NR"CH(R 4 0 )-, -SCH 2 -, -OCH 2 -, -C(O)NR 9 -, -S(O) 2 NR 3 9 -, -CH 2 NR"-, -CH(R 40 )NR 3 9 -, -NR"C(O)-, and -NR"S(O) 2 -; Ms is selected from the group consisting of a bond, -CH 2 -, -CH 2 C(O)-, -S(O) 2 -, -S(0) 2 CH 2 -, -S(0) 2 CH(CH 3 )-, -S(O) 2 CH 2 CH 2 -, -S(O) 2 NR 39 -, -S(O) 2 NR"CH 2 -, -S(O) 2 NR" 3 CH(CH 3 )-, -S(O) 2 NR"CH 2 CH 2 -, -C(O)-, -C(O)CH 2 -, -C(O)CH(CH 3 )-, -C(O)CH 2 CH 2 -, -C(O)NR"-, -C(O)NR"CH 2 -, -C(O)NR 9 CH(CH 3 )-, and -C(O)NR 9 CH2CH 2 -; Q' is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of -OR 4 1 , -SR 41 , -S(O)R 41 , -S(0) 2 R 41 , -NH R 41 , -NR 4 R 41 , -NR 9 C(O)R 4 1 , -NR 3 9 S(O) 2 R 4 1 , halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as Q'or as a substituent of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH 2 , -CN, -NO 2 , -S(O) 2 NH 2 , -C(O)NH 2 , -OR 4 2 , -SR 42 , -NHR 42 , -NR QR 4 , -NR 3 ' 9 C(O)R 4 , -NR 3 ' 9 S(0) 2 R 4 , -S(0) 2 R 42 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; Q 1 1 , Q 4 1 , Q 6 ', and Q"' 4 are lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein lower alkyl is optionally substituted with one or more fluoro, lower alkoxy, or fluoro substituted lower alkoxy, and wherein cyclaolkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of -OR 4 , -SR", -S(O)R 4 ', -S(O) 2 R'", -NH1R 4 , -NR 4 'R 4 ', -NR 9 C(O)R 4 ', -NR 3 ' 9 S(O) 2 R 41 , halogen, lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as a substituent of Q", Q 41 , Q1', or Q' 41 , or as a substituent of lower alkyl are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH 2 , -CN, -NO 2 , -S(O) 2 NH 2 , -C(O)NH 2 , -OR 42 , -SR 4 , -NHR , -NRR 4 , -NR" 9 C(O)R 42 , -NR 3 ' 9 S(O) 2 R 4 1, -S(0) 2 R 42 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; Q1 2 is fluoro, chloro or -CF 3 ; 175 WO 2008/064255 PCT/US2007/085289 Q 3 and Q" are independently hydrogen, fluoro, chloro, lower alkyl, or fluoro substituted lower alkyl; Q 2 2 , Q 24 , Q 52 , and Q 5 4 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl, -NR 44 R 4 1, -OR 4 4 , and -SR4, provided, however, that at least one of Q 2 2 and Q 24 and at least one of Q1 2 and Q1 4 is hydrogen, fluoro, chloro, lower alkyl or fluoro substituted lower alkyl; Q1 4 and Q1 2 are hydrogen, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, -NR1R4 4 , -OR4, or -SR"; Q 7 1 is hydrogen, lower alkyl or fluoro substituted lower alkyl; R" at each occurrence is independently hydrogen or lower alkyl; R 4 0 is lower alkyl or fluoro substituted lower alkyl; R4 at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R or as substituents of lower alkyl are are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH 2 , -CN, -NO 2 , -S(0) 2 NH 2 , -C(O)NH 2 , -OR 42 , -SR 42 , -NHR 42 , -NR 42 R 4 2 , -NR 39 C(O)R 42 , -NR"S(O) 2 R 42 , -S(0) 2 R 42 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; R 42 at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono alkylamino, di-alkylamino, and cycloalkylamino, and wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy and fluoro substituted lower alkoxy; and each R4 is independently hydrogen, lower alkyl or fluoro substituted lower alkyl; provided, however, that the compound is not H 0 H 0N CNC N NC N N N C CF 3 N N N N H H 176 WO 2008/064255 PCT/US2007/085289 H N~-I/~ ~ N ' Cl SN N N H N N -N I N-N N HN N N N N -N N I-N H 0 0 H H H CI C CN N N N H ,or H
[2] 2. The compound of Claim 1 having the structure of Formula Ha, Q1 2 A 2 M 4 I5 Q14 Q 1 3 H all salts, prodrugs, tautomers, and isomers thereof, wherein: Q"a is aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 41 R 41 , and -OR 4 1; Q 5 is hydrogen, -CN, -OR41, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, aryl or heteroaryl, wherein aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4 'R 4 ', and -OR 4 '; and A 2 , M 4 , Q", Q11, Q' 4 and R 4 ' are as defined for Claim 1. 177 WO 2008/064255 PCT/US2007/085289
[3] 3. The compound of Claim 2 selected from the group consisting of: (4-Chloro-benzyl)-[5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ytmethyl)-6-fluoro-pyridin-2-yl amine, (4-Chloro-benzyl)-[6-chloro-5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine, [6-Chloro-5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine, [6-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine, {6-Chloro-5-[5-( 1-methyl- I H-pyrazol-4-yl)- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl]-pyridin-2-y} (6-trifluoromethyl-pyridin-3-ylmethyl)-amine, [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-yJ-(6-trifluoromethyl pyridin-3-ylmethyl)-amine, [6-Fluoro-5-(5-methoxy- I H-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine, [6-Fluoro.5-( 1 H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyridin-2-ylJ-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine, 3- (2-Chloro-6-[(6-trifluoromethyl-pyridin-3 -ylmethyl)-amino]-pyridin-3-ylmethy} -1I11 pyrrolo[2,3-b]pyridine-5-carbonitrile, [6-Chloro-5-(5-methyl- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine, [6-Chloro-5-(5-methyl- I H-pyrrolo[2,3-bjpyridin-3-ylmethyI)-pyridin-2-y] -(6-trifluoromethyl pyridin-3-ylmethyl)-amine, [6-Fluoro-5-( I H-pyrrolojj2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3-ylmethyl) amine, [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-6-fluoro-pyridin-2-y]-(6-methoxy-pyridin-3 ylmethyl)-amine, (5-Fluoro-pyridin-3-ylmethyl)-[6-fluoro-5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl] amine, 3- {2-Fluoro-6-[(5-fluoro-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl) -1 H-pyrrolo[2,3 b]pyridine-5-carbonitrile, 3-[6-(4-Chloro-benzylamino)-2-fluoro-pyridin-3-ylmethyl-1 H-pyrrolo[2,3 -b]pyridine-5 carbonitrile; and all salts, prodrugs, tautomers, and isomers thereof. 1 78 WO 2008/064255 PCT/US2007/085289
[4] 4. A compound of Claim 1 having the structure of Formula fib Q 22 N~ N o15 A3 X N N H all salts, prodrugs, tautomers, and isomers thereof, wherein: A 3 is -CH 2 - or -C(O)-; Q'" is hydrogen, -CN, -OR 4 ', fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4 'R 41 , and -OR 4 '; and M 5 , Q 1 1 , Q 2 2 , Q 24 , and R 41 , are as defined for Formula 11.
[5] 5. The compound of Claim 4 selected from the group consisting of: ( 4 -Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]-amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,6-difluoro-benzyl)-amine, [5-(5-Chloro-lH-pyrrolo[ 2 , 3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-trifluoromethyl-benzyl) amine, ( 2 -Chloro-benzyl)-[5-(5-chloro- H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine, [5-(5-Chloro- H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-benzyl)-amine, [5-(5-Chloro-1H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y]-(2,4-difluoro-benzyl)-amine, [5-(5-Chloro- H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl) amine, [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,5-difluoro-benzyl)-amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trifluoromethyl-benzyl) amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-5-trifluoromethyl benzyl)-amine, ( 2 -Fluoro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[ 2 , 3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine, (2,5-Difluoro-benzyl)-[5-(lH-pyrrolo[ 2 , 3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine, ( 2 -Chloro-5-trifluoromethyl-benzyl)-[5-(lH-pyrrolo[ 2 , 3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl 179 WO 2008/064255 PCT/US2007/085289 amine, (3-Fluoro-5-trifluoromethyl-benzyl)-15-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidil-2-yl] amine, (3 ,5-Difluoro-benzyl)H5-(1 H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyrimidil-2-yi] -amine, (2-Fluoro-benzyl)-[S-( 1 H-pyrrolaII2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yI]-amile, (2-Chloro-benzyl)-[5-( 1 H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyrimidin-2-yI]-amine, [5-(lI H-PyrroloII2,3-b]pyridin-3-ylmethyl)-pyrimfidifl-2-yl -(2-trifluoromethyl-benzyl)-amiine, [5-(l H-PyrroloI2,3-bprdn3ymty)pyiii--i-2tilormtoybny)aie (5-Chloro-2-fluoro-benzyl)-[5 -(1 H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyrimidil-2-y1]-amile, (2,4-Dichloro-benzyl)-15-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidil-2-yI] -amine, (2,4-Difluoro-benzyl)-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidil-2-yi] -amine, (4-Chloro-benzyl)-[5 -(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyrimidil-2-yI]-amile, [5-(l H-yrl[,-~ yii--lehl-yi ii--l-4tiloo ch lbny)a ie (2-Fluoro-3-trifluoromethyl-benzyl)-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethy1)-pyrimidifl- 2 -yl] amine, (2,5 -Dichloro-benzyl)-[5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidil-2-yI]-amifle, (3 Chloro-2-fluoro-benzyl)-15-( IH-pyrroloII2,3-b]pyridin-3-ylmetbyl)-pyrimidifl-2-yi]-amifle, (2-Difluoromcthoxy-benzyl)-[5-( IH yrl[,-~yii--lety)prmdn2y]aie (2,3-Dichloro-benzyl)-[5-( I H-pyrrolo[2,3-b]pyridin-3-ylmetbyl)-pyrimidif-l21amilc, (4-Chloro-2-fluoro-benzyl)-[5-(1 I1-pyrrolo[2,3-b]pyridin-3-ylmetbyl)-pyrimidifl 2 -yiI-amine, (5-Fluoro-2-trifluoromethyl-benzyl)-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyt)-pyrimlidin-2-yIF amine, (2-Chloro-4-fluoro-benzyl)-15-( I H-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyrimidin- 2 -yl]-amine, (5-Chloro-2-methyl-benzyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethy)-pyrimidin- 2 -yl]-amile, (5-Fluoro-2-methyl-benzyl)-[5-( IH-pyrroloII2,3-b]pyidin-3-ylmethy1)-pyrimidin-2-yI]-amine, (2-Fluoro-4-trifluoromethyl-benzy)-LI$( I H-pyrrolo[2,3-b]pyridin-3-ylmethy)-pyrimidil-2-yI] amnine, (4-Fluoro-2-trifluoromethyl-belzyl)-[5-( I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidifl 2 -yi] amine, [5-(5-Chloro- 1 H-yrl[,-~yii--lehl-yiii--l-2dfurmtoybny) amine, [5-(5-Chloro- 1 H-yrl[,-jyii--lehl-yimdn2yj(-loo2tilooehl benzyl)-amine, (3-Chloro-2-fluoro-benzyl)-[5-(5-choro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethy)-pyrimidin-2-yI] amine, r5-(5-Chloro- 1 H-yrl[,-lyii--lehl-yiii--l-2fur--rfumehl 180 WO 2008/064255 PCT/US2007/085289 benzyl)-amine, [5-(5-Chloro-1 H-pyrrolo[2,3 .b]pyridin- 3 -yImethyl)-pyrimidin2.yj(2fluoro-4-trifuoromethy.. benzyl)-amine, [5-(5-Chloro- Hproo23bprdn3vmty)pfrndn2y,(,-iloobny)aie ( 2 -Chloro-4-fluoro-benzyl)-[5.(5-chloro IH-pyrrolo[2,3-blpyridin.3-ylmethyl)..pyrimidin-2yI] amine, [5-(5-Chloro- Hproo23bprdn3ylehl-yiii--l-2-rfurmtoybny) amine, (2-Chloro-5-fluoro-benzyl)-[5.(l lHpyrrolo[ 2 ,3-b]pyridin-3ylmethyl)-pyimidin-2yl]amile, ( 2 -Chloro-5-fluoro-benzyl)[5-(5chloro-I H-pyrrolo[2,3 -b]pyridin-3 -ylmethyl)-pyrimidin-2-ylJ amine, [5-(5-Chloro- Hproo23bprdn3ymty)priii--i-yii--iehlaie [5-(5-Chloro- lH-pyrrolo[2,3-b]pyridin3ylmethyI)-pyimidin-2.yij.{2pyrrolidin-I -yi-ethyl) amine, Benzyl-[5-(5-chloro. -yrl[,-bprdn3ymehl-yiiin2yjaie Benzyl-[5 -(5-chioro-I H-yrl[,-jyii--lehl-yiii--i-ehlaie [5-(5-Chloro-I H-yrl[,-~yii--lehl-yimdn2y](-rfurmtoybny amine, (3-Chloro-benzyl)4[5-(5-chloro-. IH-pyrrolo[ 2 , 3 -b~pyridin-3..ylmethyI)..pyrimidin.2-yl]-amine, [5-(5-Chloro-I H-yrl[,-~ yii--l eh l-yi ii--i-yii--l ehla ie [5-(5-Chloro- Hproo23bprdn3-lehl-yiii--lj(-loobny)aie (3-Chloro-benzyl)-[5-(5-chloro- I H-pyrrolo[ 2 , 3 .blpyridin-3-ylmethyl)pyrimidin2yj.methyl amine, [5-(5-Chloro- I -yrl[,-jyii--lehl-yimdn2yl(,-iloobny)aie [5-(5-Chloro- lH-pyrrolo[2,3-bjpyridin-3-ylmethyl)ypyrimidin.2..yI]-[I -(2-fluoro-phenyl)-ethyl] amine, fIl -(4-Chloro-phenyl)-ethyl]-[5-(5-chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)..pyrimidin-2.yll amine, [5-(5-Chloro-I H-pyrolo[ 2 ,3-b]pyridin-3-ylmethyl).pyrimidin.2-yi][(S)- 1 -(4-fluoro-phenyl) ethyl]-amine, [5-(5-Chloro- I -yrl[,-jyii--lehl-yiii--l-6tilooehlprdn3 ylmethyl)-amine, (2-Chloro-benzyl)-[5-(5-chloro. 1 H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyrimidin-2-ylj-methyl amine, [5 -(5-Chloro- IlH-pyrrolo[ 2 , 3 -bjpyridin3-ymethy)pyrimidin2yi]-(2.methyI..benyl) amine, (5-(5-Chloro- I -yrl[,-~yii--lehl-yiii--l-2mtoybny)aie 181 WO 2008/064255 PCT/US2007/085289 [5-(5-Chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-morphoin4-yl-ethyl) amine, [5-(5-Chloro- IH-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyrimidin-2-yl]-cyclohexylmethyl-amine, [S-(5-Chloro- I H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyrimidin-2-yl]-pyridin-2-ylmethy-amilC, [2-(4-Chloro-phenyl)-ethyl]-[5-(5-chloro- 1I--pyrrolo(2,3-b]pyridin-3-ylmcthyl)-pyrimidin-2-yl amine, [5-(5-Chloro- 1H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-difluoromethoxy-belzyl) amnine, (5-(S-Chloro- 1 1-1pyrroo[2,3-b~pyridin-3-ylmethy1)-pyrimidin-2-y]-(4-methoxy-bel)-amin, [5-(5-Chloro- 11 yrl[,-~yii--lehl-yrmdn2y](-ehlbny)aie [5-(5-Chloro- I H-pyrrolo[2,3-bjpyridin-3.ylmethyl)-pyrimidin-2-y]-(2-methoxy-ethyl)-amine, [5-(5-Chloro- 1 H-pyrrolo[2,3-bjpyridin-3-ytmethyl)-pyrimidin-2-yI-(3-fluoro-benzyl)-amile, (3-Chloro-4-fluoro-benzyl)-[5-(5-chloro- 1 l-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl] amine, [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-y](2-ethoxy-benzyl)-amin, [5-(5-Chloro- I H-pyrrolo[2,3-bjpyridin-3ylmethyl)-pyrimidin-2-yI-(4-morphoin-4-yl-benzyI) amine, [5 -(5-Chioro- I H-yrl[,-~yii--lehl-yiii--l-3dfurmtoybny) amine, (4-Chloro-3-fluoro-benzyl)-[5-(5-chloro- 1 H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyrimidil-2-yl] amine, [5-(5-Chloro- 1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrimidin-2-yl]-[ 1 -(3-fluoro-phenyl) -ethyl)] amnine, [5-(5-Chloro-I H-pyrrolo[2,3-blpyridin-3-ylmethy)-pyrimidin-2-y]-(2-dimthylamio-bel) amine; and all salts, prodrugs, tautomers, and isomers thereof.
[6] 6. The compound of Claim 4 selected from the group consisting of: (4-Chloro-benzyl)-[5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amine, [5-(5-Cbloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethy)-pyrimidin-2-yi]-(2-trifluoromethyl-benzyl) amnine, (2-Chloro-benzyl)-[5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-amfine, [5-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrimidin-2-ylI-(2-fluoro-benzyl)-amine, [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3.ylmethyl)-pyrimidin-2-yl-(2,4-difluoro-benzyl)-amine, [5.(5-Chloro-1 H-yrl[,-~yii--hehl-yiii--l-4tilooehlbny) amine, 1 82 WO 2008/064255 PCT/US2007/085289 [5-(5-Chloro-I H-pyrrolo[ 2 , 3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2,5-difluoro-benzyl)-amine, [5-(5-Chloro-1 H-pyrrolo[ 2 ,3-b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(3-trifluoromethyl-benzyl) amine, [5-(5-Chloro-I H-pyrrolo[ 2 , 3 -b]pyridin-3-ylmethyl)-pyrimidin-2-yl]-(2-fluoro-5-trifluoromethyl benzyl)-amine, [5-(lH-Pyrrolo[2,3-b pyridin-3-ylmethyl)-pyrimidin-2-yl]-(4-trifluoromethyl-benzyl)-amine; and all salts, prodrugs, tautomers, and isomers thereof.
[7] 7. The compound of Claim 1 having the chemical structure of Formula le, Q 52 -N Q 45 A 6 NM8aQ41 Q54 N N H all salts, prodrugs, tautomers, and isomers thereof, wherein: A 6 is -CH 2 - or -C(O)-; Ms. is selected from the group consisting of -CHr 2 -, -CH 2 C(O)-, -C(O)NR"CH 2 -, -C(O)NR 9 CH(R 4 0 )-, and -C(O)NR 39 CH 2 CH 2 -; Q45 is hydrogen, -CN, -OR 41 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4 'R 4 ', and -OR 4 1 ; and Q 4 1 , Q 5 2 , Q 5 4 , R 39 , R 40 , and R 4 ' are as defined for Claim 1.
[8] 8. The compound of Claim 7 selected from the group consisting of: 3-(1 -Benzyl-3,5-dimethyl- I H-pyrazol-4-ylmethyl)-1H-pyrrolo[2,3-b]pyridine, 2-[3,5-Dimethyl-4-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazol-I -yl]-1 -phenyl-ethanone, 3,5-Dimethyl-4-(lH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 4-methoxy benzylamide, 3,5-Dimethyl-4-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I -carboxylic acid 2-chloro benzylamide, 3,5-Dimethyl-4-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 2-fluoro benzylamide, 3-[3,5-Dimethyl-I -(5-trifluoromethyl-furan-2-ylmethyl)-I H-pyrazol-4-ylmethyl]-l H-pyrrolo[2,3 183 WO 2008/064255 PCT/US2007/085289 b]pyridine, 3-[3 ,5-Dimethyl-l1-(5 -rnethyl-isoxazol-3-yhnethyl)- 1H-pyrazol-4-ylmethyl]- 1H-pyrrolo[2,3 bjpyridine, 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-bjpyridin-3 -ylmethyl)-pyrazole-l1-carboxylic acid 4-chioro benzylamide, 3,5-Dimethyl-4-( I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- 1 -carboxylic acid [2-(4-methoxy phenyl)-ethyl]-amide, 3,5-Dirnethyl-4-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- 1 -carboxylic acid 3-methoxy benzylamide, 3-{3 ,5-Dimethyl-l1-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazot-5-ylmethyl]- I 11-pyrazol-4 ylmethyl)- 1H-pyrrolo[2,3-blpyridine, 3-[3,5-Dimethyl-l1-(4-methyl-2-phenyl-thiazol-5 -ylmethyl).1 H-pyrazol-4-ylmethyl]- IH pyrrolo[2,3-b]pyridine, 3 ,5-Dimethyl-4-(l H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrazole- I -carboxylic acid 2-methoxy beuzylamide, 3,5-Dimethyl-4-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethy!)-pyrazole-lI-carboxylic acid [2-(2,4 dichloro-phenyl)-ethyl]-amide, 3,5-Dimethyl-4-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l1-carboxylic acid [2-(4-fluoro phenyl)-ethyl]-amide, 3,5-Dimethyl-4-( I H-pyrrolo[2,3-b~pyridin-3-ylmethyl)-pyrazole- 1 -carboxylic acid [2-(2-fluoro phenyl)-ethyl]-amide, 3,5-Dimethyl-4-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-l1-carboxylic acid ((S)-l1-phenyl ethyl)-amide, 3,5-Dimethyl-4-(1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyrazole- 1-carboxylic acid 3-fluoro benzylamide, 3,5-Dimethyl-4-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole- I-carboxylic acid 4-fluoro benzylamide, 3 ,5-Dimethyl-4-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-I -carboxylic acid 4-methyl benzylamide, 3,5-Dimethyl-4-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyrazole-lI-carboxylic acid 2-methyl benzylamide, 4-(5-Chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3 ,5-dimethyl-pyrazole-lI-carboxylic acid [2-(4 fluoro-phenyl)-ethyl]-amide, 4-(5-Chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3 ,5-dimethyl-pyrazole- 1 -carboxylic acid 4 fluoro-benzylamide, 4-(5-Chloro- IH-pyrrolo[2,3-bjpyridin-3-ylmethyl)-3,5-dimethyl-pyrazole- I-carboxylic acid 4 184 WO 2008/064255 PCT/US2007/085289 chloro-benzylamide, 4-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-3,5-dimethyl-pyrazole-1-carboxylic acid [(S) 1-(4-fluoro-phenyl)-ethyl]-amide; and all salts, prodrugs, tautomers, or isomers thereof.
[9] 9. A compound of Claim I having the chemical structure of Formula IIg, Q 72 N-N Q65 A8_1 _ 1_6 N N H all salts, prodrugs, tautomers, and isomers thereof, wherein: A 8 is -CH 2 -, or -C(O)-; Q 6 1 is hydrogen, -CN, -OR 41 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 ', -NR 4 'R 4 1 , and -OR 4 1 ; and M 10 , Q 6 1 , Q 7 2 , Q 7 4 , and R 4 ' are as defined for Claim 1.
[10] 10. The compound of Claim 9 selected from the group consisting of: [I -Ethyl-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1 H-pyrazol-3-yl]-(4-fluoro-bcnzyl)-amine, (4-Fluoro-benzyl)-[l -methyl-5-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1H-pyrazol-3-yl)-amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-l -methyl-1 H-pyrazol-3-yl]-(4-fluoro-benzyl) amine, (4-Fluoro-benzyl)-{ I -methyl-5-[5-(1-methyl-I H-pyrazol-4-yl)-1 H-pyrrolo[2,3-b]pyridin-3 ylmethyl]-l H-pyrazol-3-yl}-amine, (5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-yl)-[2-ethyl-5-(4-fluoro-benzylamino)-2H-pyrazol-3-yl] methanone, [5-(5-Chloro-l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-I -ethyl-i H-pyrazol-3-yl]-(4-fluoro-benzyl) amine, 3-[5-(4-Fluoro-benzylamino)-2-methyl-2H-pyrazol-3-ylmethyl]-1 H-pyrrolo[2,3-b]pyridine-5 carbonitrile, (3-Chloro-benzyl)-[5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-I -methyl-1 H-pyrazol-3-yl] 185 WO 2008/064255 PCT/US2007/085289 amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-1-methyl-lH-pyrazol-3-yl]-(2,5-difluoro benzyl)-amine, [5-(5-Chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-1-methyl-IH-pyrazol-3-ylj-(2-fluoro-benzyl) amine; and all salts, prodrugs, tautomers, or isomers thereof.
[11] 11. The compound of Claim 9 is [5-(5-Chloro-lH-pyrrolo[2,3-b]pyridin-3-ylmethyl) 1-methyl-I H-pyrazol-3-yl]-(4-fluoro-benzyl)-amine, 3-[5-(4-Fluoro-benzylamino)-2-methyl-2H pyrazol-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile, or any salts, prodrugs, tautomers, or isomers thereof.
[12] 12. A compound of Claim 1 having the chemical structure of Formula Ilp, Q 7 2 N-N Q65 A4, M 10 -Q61 Q74 N N H all salts, prodrugs, tautomers, and isomers thereof, wherein: A 8 is -CH 2 -, or -C(O)-; Q 65 is hydrogen, -CN, -OR 41 , fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 4 1 , -NRR 4 ', and -OR 4 1 ; and Mio, Q 1 1, Q11, Q 7 4 , and R 4 ' are as defined for Claim 1.
[13] 13. The compound of Claim 12 selected from the group consisting of: [4-Chloro-5-(IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzy)-amine, [4-Ethyl-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl)-amine, (4-Fluoro-benzyl)-[4-methyl-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine, [4-Chloro-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yi]-pyridin-3-ylmethyl-amine, [4-Chloro-5-(1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-2-ylmethyl-amine, [4-Chloro-5-(l H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl-amine, [4-Chloro-5-(I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2-ylmethyl) 186 WO 2008/064255 PCT/US2007/085289 amine, [4-Chloro-5-( 1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol.2-yJ-( 1,5-dimethyl- 1H-pyrazol-3 ylmethyl)-amine, [4-Chloro-5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylI-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine, [4-Chloro-5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y1]-(2,5-dimethyl-2H-pyrazo-3 ylmethyl)-amine, [2-(4-Fluoro-benzylamino)-thiazol-5-yl]-(1 H-pyrrolo[2,3-b]pyridin-3-yl)-methanone, {2-[(4-Chloro-benzyl)-methyl-amino]-thiazol-5-yl} -(1 H-pyrrolo[2,3-bjpyridin-3-yI)-methanone, [4-Chloro.5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-thiazol-2-ylmethyl amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3.blpyridin-3-ylmethyl)-thiazol-2-ylj-(6-methoxy-pyridin-3 ylniethyl)-amine, Benzyl-[4.chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-amine, [4-Chloro-5-(5 -chloro- 1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-ylJ-(3-methoxy-benzyl) amine, (4-Chloro-benzyl)-[4-chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-thiazol-2-yI] amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4-fluoro-benzyl) amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2,4-dimethyl-thiazal-5 ylmethyl)-amine, [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-blpyridin-3-ylmethyl)-thiazol-2-yl]-(2-ethyl-5-methyl-3H imidazol-4-ylmethyl)-amine, [4.Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(2-ethyl-2H-pyrazol-3 ylmethyl)-amine, [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(6-methoxy-pyridin-2 ylmethyl)-amine, [4-Chloro-5-(5-chloro- 1 11-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-fluoro-pyridin-4 ylmcthyl)-amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmcthyl)-thiazol-2-yl]-(2-methyl-thiazol-4 ylmethyl)-amine, [4-Chloro-5-(5-chloro- IH-pyrrolo [2,3-b]pyridin-3-ylmethyl)-thiazol-2-y!j-(4-methy!-thiazol-5 ylmethyl)-amine, [4-Chloro-5-(5-chloro-l1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yi]-(5-chloro-pyridin-2 ylmethyl)-amine, 187 WO 2008/064255 PCT/US2007/085289 [4-Chloro-5-( I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(2,4-dimethyl-thiazol-5 ylmethyl)-amine, [4-Chloro-5-( 1 H-pyrrolo[2,3 -b]pyridin-3-ylmethyl)-thiazol-2-ylJ-(2-ethyl-5-methyl-3 1--imidazol 4-ylmethyl)-amine, [4-Chloro-5-( 1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2-ylmethyl) amine, [4-Chloro-5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yJ-(5-methoxy-pyridin-3-ylmethyl) amine, [4-Chloro-5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(4,5-dimethyl-thiophen-2 ylmethyl)-amine, [4-Chloro-S-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylIJ-(2,5-dimethyl-thiophen-3 ylmethyl)-amine, [4-Chloro-5-(S-chloro- I H-py,-rolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-3 ylmethyl)-amine, [4-Chlaro-5-(S-chloro- 1 H-pyxrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-3-ylmethyl amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-pyridin-4-ylmethyl amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-chloro-pyridin-4 ylmethyl)-amine, [4-Chloro-5-(5-chloro- 1 H-pyi-rolo[2,3-blpyridin-3 -ylmethyl)-thiazol-2-y]-(1 -ethyl- I H-pyrazol-4 ylmethyl)-amine, [4-Chloro-5-(S-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2 ylmethyl)-axnine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-methoxy-pyridin-3 ylmethyl)-amine, [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine, [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yl]-(2-chloro-6-fluoro benzyl)-amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yJ-phenethyl-amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-bjpyridin-3 -ylmethyl)-thiazol-2-yl]-(2,4-difluoro-benzyl) amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(2-fluoro-benzyl) amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methoxy-pyridin-3 188 WO 2008/064255 PCT/US2007/085289 ylrnethyl)-amine, (2-Chloro-benzyl)-[4-chloro-5-(5-chloro- IH-pyrrolo [2,3-b]pyridin-3-ylmethyl)-thiazol-2-y] amine, [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-blpyridin-3-ylmethyl)-thiazol-2-yl]-(2-methyl-benzyl) amine, [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol.2-ylj-(2-chloro-4-fluoro benzyl)-amine, [4-Chloro-5-(5-chloro- IH-pyrrolo(2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3-fluoro-pyridin-2 ylmethyl)-amine, [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-thiazol-2-yl]-(6-morpholin-4-yl pyridin-2-ylmethyl)-amine, [4-Chloro-5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(3,5.dichloro-pyridin-4 ylmethyl)-amine, [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2.yl]-(2-trifluoromethyl benzyl)-amine, [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b]pyridin-3-yhnethyl)-thiazol-2-yl]-(6-methyl-pyridin-2 ylmethyl)-amine, [5-(5-Chloro- IH-pyrrolo [2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(4-fluoro-benzyl)-amine; and all salts, prodrugs, tautomers, or isomers thereof.
[14] 14. The compound of Claim 12 selected from the group consisting of: [4-Chloro-5.(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(4-fluoro-benzyl)-amine, [4-Chloro-5.{1 H-pyi-rolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-trifluoromethyl-pyridin-3 ylmethyl)-amine, [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methoxy-pyridin-3 ylmethyl)-amine, [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-ylJ-(3-methoxy-benzyl) amine, (4-Chloro-benzyl)-[4-chloro-5-(5-chloro-l1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl] amine, [4-Chloro-5-(5-chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl).thiazol-2-yl]-(4-fluoro-benzyl) amine, [4-Chloro-5-(5-chloro-1 H-pyrrolo[2,3-b~pyridin-3-ylmethyl).thiazol-2-yl]-(6-methoxy-pyridin-2 ylmethyl)-amine, [4-Chloro-5-(5-chloro- IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y] -(3-fluoro-pyridin-4 ylmethyl)-amine, 189 WO 2008/064255 PCT/US2007/085289 [4-Chloro-5-(5-chloro-l H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yI] -(2-methyl-thiazol-4 ylmethyl)-amine, [4-Chloro-5-(5-chloro- I H--pyrrolo[2,3-b~pyridin-3-ylmethyl)-thiazol-2-ylJ-(5-chloro-pyridil-2 ylmethyl)-amine, [4-Chloro-5-( I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl-(5-fluoro-pyridin-2-ylmethyl) amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-3 ylmethyl)-amine, [4-Chloro-5-(5-chloro- I H-pyrrolojl2,3-bjpyridin-3-ylmethyl)-thiazol-2-ylI-pyridin-3-ylmethyl amine, [4-Chloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]j-pyridin-4-ylmethyl amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(3-chloro-pyridin-4 ylmethyl)-amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl] -(1 -ethyl-i H-pyrazol-4 ylmethyl)-amine, [4-Chloro-5-(5 -chloro- 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(5-fluoro-pyridin-2 ylmethyl)-amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yI]-(5-methoxy-pyridin-3 ylmethyl)-amine, (4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-bjpyridin-3 -ylmethyl)-thiazoI-2-yli]-(6-trifluoromethyl pyridin-3-ylmethyl)-amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-phenethyl-amile, [4-Chloro-5-(5 -chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(2,4-difluoro-benl~y) amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-thiazol-2-yI]-(2-fluoro-bcnzyl) amine, [4-Chiloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(2-methoxy-pyridin-3 ylmethyl)-amine, (2-Chloro-benzyl)-[4-chloro-5-(5 -chloro- 1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-thiazol-2-yIJ amine, [4-Chloro-5-(5-chloro- I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(2-methyl-benzyl) amine, [4-Ghloro-5-(5-chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-y]-(2-chloro-4-fluoro benzyl)-amine, [4-Chloro-5-(5-chloro-I I--pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl-(6-morpholil 4 -yI 190 WO 2008/064255 PCT/US2007/085289 pyridin-2-ylmethyl)-amine, [4-Chloro-5-(5-chloro-IH-pyrrolo[2,3-b]pyridin-3-ylmethyl)-thiazol-2-yl]-(6-methyl-pyridin-2 ylmethyl)-amine; and all salts, prodrugs, tautomers, or isomers thereof.
[15] 15. A compound having the chemical structure of Formula III, .. ~ H /N S L 4 -R 8 3 R 1 R 82 N N H all salts, prodrugs, tautomers, and isomers thereof, wherein: L 4 is -CH 2 -, -CH 2 CH 2 -, -CH(R 40 )-, -C(O)- or -C(O)NH-; R 8 ' is selected from the group consisting of hydrogen, -OR 4 ', -CN, fluoro, chloro, lower alkyl, fluoro substituted lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein cycloalkyl, heterocycloalkyl, aryl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, -NHR 41 , -NR 4 1 R 41 , -OR 4 ' and -S(0) 2 R 41 ; R 8 ' is selected from the group consisting of hydrogen, C,. 3 alkyl, fluoro substituted C 2 . 3 alkyl, OH, C,. 3 alkoxy, and fluoro substituted C1 3 alkoxy; Rg6 R 95 R 9 4 R 83 is heterocycloalkyl, heteroaryl, or R 92 R 93 , in which indicates the attachment point of R 8 3 to L 4 of Formula III, wherein heterocycloalkyl or heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHR 4 ', -NR 41 R 41 , -OR'" and -S(O) 2 R 4 1 ; R , R 93 , R 94 , R 95 , and R 96 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, fluoro substituted lower alkyl, cycloalkylamino, -NHS(0) 2 R', -NHC(O)R 4 ', -NHR 4 1 , -NR 4 'R 4 1, -OR 4 ' and -S(O) 2 R41; R 40 is selected from the group consisting of lower alkyl, and fluoro substituted lower alkyl; R4' at each occurrence is independently selected from the group consisting of lower alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, 191 WO 2008/064255 PCT/US2007/085289 lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono-alkylamino, di-alkylamino, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl, and wherein cycloalkyl, heterocycloalkyl, aryl, and heteroaryl as R4' or as substituents of lower alkyl are are optionally substituted with one or more substituents selected from the group consisting of -OH, -NH 2 , -CN, -NO 2 , -S(0) 2 NH 2 , -C(O)NH 2 , -OR 4 2 , -SR", -NHR 4 2 , -NR 2 R 4 , -NR" 9 C(O)R 42 , -NR"S(O) 2 R 4 2 , -S(O) 2 R 42 , halogen, lower alkyl, fluoro substituted lower alkyl, and cycloalkylamino; and R 42 at each occurrence is independently selected from the group consisting of lower alkyl, heterocycloalkyl and heteroaryl, wherein lower alkyl is optionally substituted with one or more substituents selected from the group consisting of fluoro, lower alkoxy, fluoro substituted lower alkoxy, lower alkylthio, fluoro substituted lower alkylthio, mono alkylamino, di-alkylamino, and cycloalkylamino, and wherein heterocycloalkyl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, -CN, lower alkyl, fluoro substituted lower alkyl, lower alkoxy and fluoro substituted lower alkoxy; K'H S N N provided, however, that the compound is not H NN NN NN NNN H NH NH N N NN N N HCF CF I- - _' y N NN N HN H H 1 H C H N N 1N9N 2 HH H N NNj~ C1, NN N N N N H H H 192 WO 2008/064255 PCT/US2007/085289 (0) r C -, Hr~ Ni-JIC - -, N N.. N N NN NN H NH H NH H IikF F N 4n HCF3 N . N rN, N HOr~CF 0 N N NN N N HH H CFY&CF3 F3 I NN N 0 CF3 NN NN H N N HH
[16] 16. The copon ofCam5slece fro hegop Conitn f Pyii-3ymtN![- 1N N-y ~[,-jyiin3ymty)prdN 2yl-mie (2MrhlN-4y-ty)[ 1 N-yrl[,-~yii--lmty)prdn2y]aie N-hoo4fur--5( N-yrl[,- Nrdn3ymthl-yii--y]bnaie 2,-iety-H-yaol--0royi acd0 ( -yrl[,-~yii- ymty)prdn2 Hl]NaHiNeN 5-ehy-yrzne2cabxyi ai H- o-yrl[ 1 -~yidn3ymty)pridn2y 3-hr--flmoro-N-[5-( 1H-pyrolo[2,3-bjpyridin3-ylmthyl)-pyridin-2-yl]-bamie, 3,4-Diloroi-N4--el5-( H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl-ami 3-Mehoxy4-l-N-[5-( H-pyrrolo[2,3-b]pyridin-3-ylmthyl)-pyridin-2-y -benzamide, ((R)-Dim-Phyl-eth-y- e3-abxli cd[5-( H-pyrrolo[2,3-bpyridin-3-ylmethyl)-pyridin-2-yJmie (3-Mhorol--ylbzl5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl ]-en ami ne, [1 -2-fluoro-phNy)hl-[5-( 1 -pyrrolo[2,3-b]pyridin-3-ylmehyl)-pyridin-2-yl - amie, [2-(3-Fluoro-phenyl)-ethyl]-[5-( 1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine, 193 WO 2008/064255 PCT/US2007/085289 (3-Chloro-benzyl)-[5-( 1 H-pyi-rolo[2,3-b]pyridiin-3-ylmethy)-pyridil-2-y1I-amifle, [5-(5-Chloro-I 1 yrl[,-~yii--ymty)prdn2yl(-tilooehlprdn3 ylmethyl)-amine, [5-(l H-yrl[,-lyii--lehl- rdn2-l-6tilooehlprdn3ymty) amine, (3-Chloro-pyridin-4-ylmethyl)-[5-(I H-pyrrolo[2,3-b]pyridin-3-ylmthy)-pyridil-2-y1]-amifle, Phenethyl-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethy)-pyridil-2-yl]-ainifle, (2,4-Difluoro-bcnzyl)-[5-( 1 H-pyrrolo[2,3-b]pyridin-3-ylmethy)-pyridil-2-y1]-amifle, (2-Fluoro-benzyl)-15 -(1 H-pyrrolo[2,3-blpyridin-3-ylmethy)-pyidil- 2 -yI] -amine, (2-Mcthoxy-pyridin-3-ylmethyl)-[5-( 1 H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridin-2-yl] -amine, (2-Methyl-benzyl)-15-( 1 H-pyrrolo[2,3-b]pyridin-3 -ylmethyl)-pyridin-2-yI]-amine, (6-Methoxy-pyridin-3-ylmethyl)-[5-( I H-pyrrolo[2,3-blpyridin-3-ylmethy1)-pyridil-2-yiI-amile, (2-Chloro-4-fluoro-benzyl)-(5-( 1 H-pyrrolo[2,3.blpyridin-3-ylmethyl)-pyridil-2-y1]-amile, (5-Methoxy-pyridin-3-ylmethyD-[5-(I H-pyrrololj2,3-b]pyridin-3 -ylmcthyl)-pyridin-2-yIJ-amine, (3-Fluoro-pyridin-4-ylmethyl)-[5-( I H-pyrrolo[2,3-blpyridin-3-ylmethyl)-pyridil-2-ylI-amilc, (6-Methoxy-pyridin-2-ylmethyl)-[5-(l H-pyrrolo[2,3-b]pyridin-3-ylmthy1)-pyridil-2-y1]-amilC, (4-Fluoro-2-trifluoromethyl-bflzyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridil-2-y1F amine, 15-( 1 roo23bprdi--lehl-yiin2y](-rfurmehlbny)aie (3,5-Dichloro-pyridin-4-ylmethyl-5-( 1H-pyrrolo[2,3-bjpyridin-3-ylmethy)-pyridin-2-yl]-amifle, (6-Morpholin-4.yl-pyridin-2-ylmethy)-I5-(l H-pyrrolo[2,3-bjpyridin-3-ylmethyI)-pyridifl-2-yl] amine, (5-Fluoro-pyridin-3-ylmethyl)-[5-(1 H-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyridifl-2-yl]-amifle, (3-Cbloro-pyridin-4-ylmethyl)-5-(5-chloro-I H-pyrrolo[2,3-bjpyridin-3-ylmethyl)-pyridil-2-yI] amine, 3- {6-[(3-Chloro-pyridin-4-ylmethy1)-amifl-pyridil-3-ylmethyl } -1 H-pyrrolo[2,3-bjpyridine-5 carbonitrile, 3-[6-(4-Chloro-benzylamino)-pyridin-3-ylmethyI]-I H-pyrrolo[2,3-blpyridine-5-carboflitrile, 3-[6-(4-Trifluoromethy1-benzylamino)-pyridifl-3-ylmethyIF 1 H-pyrrolo[2,3-bllpyridine-5 carbonitrile, [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridifl 2 -yl] -(2-fluoro-benzyl)-amine, 3-[6-(2-Fluoro-benzylamino)-pyridin-3-ylmethyl]- 1H-pyrrolo[2,3-b]pyridine-5-carbonitrile, (2-Fluoro-benzyl)-[5-(5-methyl-I1f1-pyrrolo[2,3-b]pyridin-3-ylmethyI)-pyridin-2-yi]amne, 3- (6[6Tilooehlpyii- }ehl-mno-yii--lehl -1 H-pyrrolo[2,3 b]pyridine-5 -carbonitrile, 3-[6-(2-Trifluoromethyl-benzylamino)-pyidil-3-ylmethyl]- 1H-pyrrolo[2,3 -b]pyridine-5 194 WO 2008/064255 PCT/US2007/085289 carbonitrile, [5-(5-Chloro- 1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine, [5-(5-Methyl-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-trifluoromethyl-benzyl) amine, 3-[6-(2,6-Difluoro-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile, [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2,6-difluoro-benzyl)-amine, (2-Chloro-benzyl)-[5-(5-methyl- H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine, (2-Chloro-benzyl)-[5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-amine, 3-[6-(2-Chloro-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile, (6-Methoxy-pyridin-3-ylmethyl)-[5-(5-methyl-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2 yl]-amine, [5-(5-Chloro-1 H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-methoxy-pyridin-3 ylmethyl)-amine, 3-{6-[(6-Methoxy-pyridin-3-ylmethyl)-amino]-pyridin-3-ylmethyl) -1 H-pyrrolo[2,3-b]pyridine-5 carbonitrile, [5-(5-Chloro-I H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(2-methoxy-pyridin-3 ylmethyl)-amine, 3-[6-(2-Trifluoromethoxy-benzylamino)-pyridin-3-ylmethyl]-1 H-pyrrolo[2,3-b]pyridine-5 carbonitrile, 3-[6-(2-Ethoxy-benzylamino)-pyridin-3-ylmethyl]-1H-pyrrolo[2,3-b]pyridine-5-carbonitrile; and all salts, prodrugs, tautomers, or isomers thereof.
[17] 17. A composition comprising a pharmaceutically acceptable carrier and a compound according to any of Claims 1-16.
[18] 18. A method for treating a subject suffering from or at risk of a c-kit and/or c-fins mediated disease or condition, comprising administering to the subject an effective amount of a compound of any of Claims 1-16.
[19] 19. The method of Claim 18, wherein the disease or condition is selected from the group consisting of mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovarian cancer, prostate cancer, canine mast cell tumors, metastasis of cancer to bone or 195 WO 2008/064255 PCT/US2007/085289 other tissues, chronic myeloproliferative diseases such as myelofibrosis, renal hypertrophy, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, osteoarthritis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, Kawasaki's Disease, hemophagocytic syndrome, multicentric reticulohistiocytosis, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, osteomyelitis, peri-prosthetic or wear-debris mediated osteolysis, endometriosis, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory pain, chronic pain, and bone pain.
[20] 20. The method of Claims 19, wherein the compound is approved for administration to a human.
[21] 21. A kit comprising a composition according to Claim 17.
[22] 22. The kit of Claim 21, wherein the composition is approved for a medical indication selected from the group consisting of mast cell tumors, small cell lung cancer, testicular cancer, gastrointestinal stromal tumors, glioblastoma, astrocytoma, neuroblastoma, carcinomas of the female genital tract, sarcomas of neuroectodermal origin, colorectal carcinoma, carcinoma in situ, Schwann cell neoplasia associated with neurofibromatosis, acute myeloid leukemia, acute lymphocytic leukemia, chronic myelogenous leukemia, multiple myeloma, mastocytosis, melanoma, breast cancer, ovarian cancer, prostate cancer, canine mast cell tumors, metastasis of cancer to bone or other tissues, chronic myeloproliferative diseases such as myelofibrosis, renal hypertrophy, asthma, rheumatoid arthritis, allergic rhinitis, multiple sclerosis, osteoarthritis, inflammatory bowel syndrome, transplant rejection, systemic lupus erythematosis, ulcerative colitis, Crohn's disease, chronic obstructive pulmonary disease, emphysema, Kawasaki's Disease, hemophagocytic syndrome, multicentric reticulohistiocytosis, atherosclerosis, Type I diabetes, Type II diabetes, insulin resistance, hyperglycemia, obesity, lipolysis, hypereosinophilia, osteoporosis, increased risk of fracture, Paget's disease, hypercalcemia, osteomyelitis, peri prosthetic or wear-debris-mediated osteolysis, endometriosis, glomerulonephritis, interstitial nephritis, Lupus nephritis, tubular necrosis, diabetic nephropathy, stroke, Alzheimer's disease, Parkinson's disease, inflammatory pain, chronic pain, and bone pain. 196

类似技术:

---

公开号 | 公开日 | 专利标题

---

AU2007323644B2|2013-10-03|Compounds modulating c-fms and/or c-kit activity and uses therefor

---

AU2010315126B2|2015-06-25|Compounds and methods for kinase modulation, and indications therefor

---

US9682981B2|2017-06-20|Compounds and methods for kinase modulation, and indications therefor

---

EP2501236B1|2017-03-29|N-[2-fluoro-3-|-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer

---

US20200172546A1|2020-06-04|Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors

---

AU2009259867A1|2009-12-23|Triazolopyridine JAK inhibitor compounds and methods

同族专利:

---

公开号 | 公开日

---

JP2010510321A|2010-04-02|

---

JP5919253B2|2016-05-18|

---

US9169250B2|2015-10-27|

---

PL2086972T3|2014-05-30|

---

US20150265586A1|2015-09-24|

---

JP6461263B2|2019-01-30|

---

CN103497188A|2014-01-08|

---

US20140243365A1|2014-08-28|

---

TWI432431B|2014-04-01|

---

WO2008064255A3|2008-08-14|

---

MY158447A|2016-10-14|

---

RU2452738C2|2012-06-10|

---

CN101605787B|2013-11-13|

---

US7893075B2|2011-02-22|

---

ZA200903458B|2018-11-28|

---

JP2018021055A|2018-02-08|

---

HK1133649A1|2010-04-01|

---

EP2086972B1|2013-11-20|

---

US8404700B2|2013-03-26|

---

ECSP099357A|2009-06-30|

---

JP2014088407A|2014-05-15|

---

NO342175B1|2018-04-09|

---

US8461169B2|2013-06-11|

---

US9487515B2|2016-11-08|

---

SI2086972T1|2014-04-30|

---

BRPI0721137A2|2014-04-01|

---

NO20091989L|2009-06-19|

---

SV2007002813A|2010-08-17|

---

KR20090083469A|2009-08-03|

---

UA97816C2|2012-03-26|

---

CN101605787A|2009-12-16|

---

AU2007323644B2|2013-10-03|

---

NZ577011A|2012-07-27|

---

UY30732A1|2008-07-03|

---

WO2008064265A2|2008-05-29|

---

JP6203781B2|2017-09-27|

---

US8722702B2|2014-05-13|

---

KR101506044B1|2015-03-25|

---

BRPI0721137B8|2021-05-25|

---

CA2670362A1|2008-05-29|

---

TW200827358A|2008-07-01|

---

SG176511A1|2011-12-29|

---

BRPI0721137B1|2020-08-11|

---

CR10817A|2009-06-12|

---

WO2008063888A2|2008-05-29|

---

CN103497188B|2017-06-23|

---

US20190263800A1|2019-08-29|

---

IL198624A|2014-12-31|

---

PE20081226A1|2008-10-01|

---

RU2009117475A|2010-12-27|

---

AR063878A1|2009-02-25|

---

US20090076046A1|2009-03-19|

---

JP2015205880A|2015-11-19|

---

WO2008063888A3|2008-07-31|

---

US20120309756A1|2012-12-06|

---

ES2447779T3|2014-03-12|

---

PT2086972E|2014-02-25|

---

NI200900093A|2010-01-26|

---

US20110230482A1|2011-09-22|

---

GT200700101A|2008-07-08|

---

CL2007003326A1|2008-05-16|

---

MX2009005428A|2009-06-03|

---

CA2670362C|2018-07-17|

---

DK2086972T3|2014-02-24|

---

US20130178473A1|2013-07-11|

---

WO2008064255A2|2008-05-29|

---

EP2086972A2|2009-08-12|

---

WO2008064265A3|2008-11-13|

---

IL198624D0|2010-02-17|

---

US20170247370A1|2017-08-31|

---

CO6180438A2|2010-07-19|

引用文献:

---

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

---

GB145299A|1919-08-14|1920-07-02|Carl Theodor Thorssell|Improvements in or relating to apparatus for the production of nitrogen products|

---

US2234705A|1940-04-12|1941-03-11|Eastman Kodak Co|Cellulose organic derivative composition containing esters of monoalkoxy benzoic acids|

---

US2413258A|1942-07-07|1946-12-24|United Gas Improvement Co|Polystyrene-type resins plasticized with high boiling fatty acid alkyl esters|

---

BR6794063D0|1966-10-21|1973-09-18|Minnesota Mining & Mfg|PROCESS TO PREPARE N-SUBSTITUTED PERFLUORAL-KILSULPHONAMIDES AND HERBICIDES AND PHYTOREGULATING COMPOSITIONS BASED ON THEM|

---

IL46853D0|1974-03-20|1975-05-22|Bayer Ag|Novel alkoxycarbonylphenylureas,their preparation and their use as herbicides|

---

DE2413258A1|1974-03-20|1975-10-02|Bayer Ag|Herbicidal N--N'-methyl-urea derivs - prepd by reacting alkoxycarbonyl-phenyl isocyanates with methylamines|

---

GB1573212A|1976-04-15|1980-08-20|Technicon Instr|Immunoassay for gentamicin|

---

US4301159A|1980-06-20|1981-11-17|Shionogi & Co., Ltd.|N--2-alkoxy-benzamide derivatives|

---

AU547405B2|1981-07-08|1985-10-17|Sanofi|Amidobenzamides|

---

US4664504A|1983-01-20|1987-05-12|Tokyo Shibaura Denki Kabushiki Kaisha|Image forming apparatus|

---

US4568649A|1983-02-22|1986-02-04|Immunex Corporation|Immediate ligand detection assay|

---

US4626513A|1983-11-10|1986-12-02|Massachusetts General Hospital|Method and apparatus for ligand detection|

---

AU567140B2|1984-01-06|1987-11-12|Shionogi & Co., Ltd.|Sulphonamido-benzamide derivatives|

---

AT56096T|1984-03-15|1990-09-15|Immunex Corp|TEST FOR IMMEDIATELY DETECTING LIGANDS, TEST SET AND ITS PRODUCTION.|

---

IT1196133B|1984-06-06|1988-11-10|Ausonia Farma Srl|FURANIC DERIVATIVES WITH ANTI-ULCER ACTIVITY|

---

US4714693A|1986-04-03|1987-12-22|Uop Inc.|Method of making a catalyst composition comprising uniform size metal components on carrier|

---

DE3642315A1|1986-12-11|1988-06-23|Boehringer Mannheim Gmbh|NEW PYRROLOBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS|

---

US5688655A|1988-02-10|1997-11-18|Ict Pharmaceuticals, Inc.|Method of screening for protein inhibitors and activators|

---

US6054270A|1988-05-03|2000-04-25|Oxford Gene Technology Limited|Analying polynucleotide sequences|

---

US5700637A|1988-05-03|1997-12-23|Isis Innovation Limited|Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays|

---

US5658775A|1988-05-17|1997-08-19|Sloan-Kettering Institute For Cancer Research|Double copy retroviral vector|

---

JP2528706B2|1988-05-30|1996-08-28|ゼリア新薬工業株式会社|Pharmaceutical composition of dihydropyridine compound|

---

WO1990002806A1|1988-09-01|1990-03-22|Whitehead Institute For Biomedical Research|Recombinant retroviruses with amphotropic and ecotropic host ranges|

---

US5703055A|1989-03-21|1997-12-30|Wisconsin Alumni Research Foundation|Generation of antibodies through lipid mediated DNA delivery|

---

US5744101A|1989-06-07|1998-04-28|Affymax Technologies N.V.|Photolabile nucleoside protecting groups|

---

US5527681A|1989-06-07|1996-06-18|Affymax Technologies N.V.|Immobilized molecular synthesis of systematically substituted compounds|

---

US5800992A|1989-06-07|1998-09-01|Fodor; Stephen P.A.|Method of detecting nucleic acids|

---

US5143854A|1989-06-07|1992-09-01|Affymax Technologies N.V.|Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof|

---

WO1991018088A1|1990-05-23|1991-11-28|The United States Of America, Represented By The Secretary, United States Department Of Commerce|Adeno-associated virus -based eucaryotic vectors|

---

DE4022414A1|1990-07-13|1992-01-16|Bayer Ag|SUBSTITUTED PYRROLO-PYRIDINE|

---

US5958930A|1991-04-08|1999-09-28|Duquesne University Of The Holy Ghost|Pyrrolo pyrimidine and furo pyrimidine derivatives|

---

DK0580860T4|1991-04-16|2005-03-21|Nippon Shinyaku Co Ltd|Process for preparing a solid dispersion|

---

CA2113990A1|1991-07-26|1993-02-18|Frederick L. Moolten|Cancer therapy utilizing malignant cells|

---

GB9127531D0|1991-12-31|1992-02-19|Fujisawa Pharmaceutical Co|Heterocyclic compound|

---

FR2687402B1|1992-02-14|1995-06-30|Lipha|NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.|

---

JPH05236997A|1992-02-28|1993-09-17|Hitachi Ltd|Chip for catching polynucleotide|

---

JPH06135946A|1992-10-30|1994-05-17|Otsuka Pharmaceut Co Ltd|Pyrazine derivative|

---

AU686115B2|1992-11-02|1998-02-05|Fujisawa Pharmaceutical Co., Ltd.|Imidazo pyridine derivatives as bradykinin antagonists, pharmaceuticals and processes for their preparation|

---

GB9226855D0|1992-12-23|1993-02-17|Erba Carlo Spa|Vinylene-azaindole derivatives and process for their preparation|

---

CA2156410A1|1993-03-01|1994-09-15|Raymond Baker|Pyrrolo-pyridine derivatives|

---

DE69420394T2|1993-03-01|2000-04-13|Merck Sharp & Dohme|PYRROLOPYRIDINE DERIVATIVES AS DOPAMINE RECEPTOR LIGANDS|

---

NZ261593A|1993-03-01|1996-09-25|Merck Sharp & Dohme|3-piperazinylmethly-1h-indolopyridine derivatives and pharmaceutical compositions|

---

US5576319A|1993-03-01|1996-11-19|Merck, Sharp & Dohme Ltd.|Pyrrolo-pyridine derivatives|

---

US5840485A|1993-05-27|1998-11-24|Selectide Corporation|Topologically segregated, encoded solid phase libraries|

---

JP3394777B2|1993-05-27|2003-04-07|セレクタイドコーポレーション|Topologically separated, encoded solid-phase library|

---

IT1265057B1|1993-08-05|1996-10-28|Dompe Spa|TROPIL 7-AZAINDOLIL-3-CARBOXYAMIDE|

---

US5631236A|1993-08-26|1997-05-20|Baylor College Of Medicine|Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk|

---

US5426039A|1993-09-08|1995-06-20|Bio-Rad Laboratories, Inc.|Direct molecular cloning of primer extended DNA containing an alkane diol|

---

GB9319297D0|1993-09-17|1993-11-03|Wellcome Found|Indole derivatives|

---

US6045996A|1993-10-26|2000-04-04|Affymetrix, Inc.|Hybridization assays on oligonucleotide arrays|

---

US6468742B2|1993-11-01|2002-10-22|Nanogen, Inc.|Methods for determination of single nucleic acid polymorphisms using bioelectronic microchip|

---

US5632957A|1993-11-01|1997-05-27|Nanogen|Molecular biological diagnostic systems including electrodes|

---

US5486525A|1993-12-16|1996-01-23|Abbott Laboratories|Platelet activating factor antagonists: imidazopyridine indoles|

---

US5360882A|1994-02-04|1994-11-01|Isp Investments Inc.|Eutectic compositions of divinyl imidazolidone and vinyl caprolactam|

---

EP1195372A1|1994-04-18|2002-04-10|Mitsubishi Pharma Corporation|N-heterocyclic substituted benzamide derivatives with antihypertensive activity|

---

GB9408577D0|1994-04-29|1994-06-22|Fujisawa Pharmaceutical Co|New compound|

---

US5807522A|1994-06-17|1998-09-15|The Board Of Trustees Of The Leland Stanford Junior University|Methods for fabricating microarrays of biological samples|

---

GB9412719D0|1994-06-24|1994-08-17|Erba Carlo Spa|Substituted azaindolylidene compounds and process for their preparation|

---

US5763198A|1994-07-22|1998-06-09|Sugen, Inc.|Screening assays for compounds|

---

GB9416162D0|1994-08-10|1994-09-28|Merck Sharp & Dohme|Therapeutic agents|

---

EP0775138B1|1994-08-10|2000-02-23|MERCK SHARP &amp; DOHME LTD.|TETRAHYDROPYRIDINYLMETHYL DERIVATIVES OF PYRROLO 2,3-b]PYRIDINE|

---

GB9416189D0|1994-08-10|1994-09-28|Merck Sharp & Dohme|Therapeutic agents|

---

GB9420521D0|1994-10-12|1994-11-30|Smithkline Beecham Plc|Novel compounds|

---

US5556752A|1994-10-24|1996-09-17|Affymetrix, Inc.|Surface-bound, unimolecular, double-stranded DNA|

---

US5830645A|1994-12-09|1998-11-03|The Regents Of The University Of California|Comparative fluorescence hybridization to nucleic acid arrays|

---

US5837815A|1994-12-15|1998-11-17|Sugen, Inc.|PYK2 related polypeptide products|

---

GB9503400D0|1995-02-21|1995-04-12|Merck Sharp & Dohme|Therpeutic agents|

---

GB2298199A|1995-02-21|1996-08-28|Merck Sharp & Dohme|Synthesis of azaindoles|

---

US6117681A|1995-03-29|2000-09-12|Bavarian Nordic Research Inst. A/S|Pseudotyped retroviral particles|

---

GB2299581A|1995-04-07|1996-10-09|Merck Sharp & Dohme|3-pyrrolo[2,3-b]pyridine derivatives as ligands for dopamine receptor subtypes|

---

GB9507291D0|1995-04-07|1995-05-31|Merck Sharp & Dohme|Therapeutic agents|

---

GB9511220D0|1995-06-02|1995-07-26|Glaxo Group Ltd|Solid dispersions|

---

US6110456A|1995-06-07|2000-08-29|Yale University|Oral delivery or adeno-associated viral vectors|

---

US5856174A|1995-06-29|1999-01-05|Affymetrix, Inc.|Integrated nucleic acid diagnostic device|

---

WO1997003967A1|1995-07-22|1997-02-06|Rhone-Poulenc Rorer Limited|Substituted aromatic compounds and their pharmaceutical use|

---

US5866411A|1995-09-08|1999-02-02|Pedersen; Finn Skou|Retroviral vector, a replication system for said vector and avian or mammalian cells transfected with said vector|

---

US5747276A|1995-09-15|1998-05-05|The Scripps Research Institute|Screening methods for the identification of novel antibiotics|

---

US5721118A|1995-10-31|1998-02-24|The Regents Of The University Of California, San Diego|Mammalian artificial chromosomes and methods of using same|

---

US6022963A|1995-12-15|2000-02-08|Affymetrix, Inc.|Synthesis of oligonucleotide arrays using photocleavable protecting groups|

---

US6013440A|1996-03-11|2000-01-11|Affymetrix, Inc.|Nucleic acid affinity columns|

---

US6025155A|1996-04-10|2000-02-15|Chromos Molecular Systems, Inc.|Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes|

---

US5804585A|1996-04-15|1998-09-08|Texas Biotechnology Corporation|Thieno-pyridine sulfonamides derivatives thereof and related compounds that modulate the activity of endothelin|

---

US5959098A|1996-04-17|1999-09-28|Affymetrix, Inc.|Substrate preparation process|

---

US5908401A|1996-05-08|1999-06-01|The Aps Organization, Llp|Method for iontophoretic delivery of antiviral agents|

---

US5725838A|1996-05-31|1998-03-10|Resolution Pharmaceuticals, Inc.|Radiolabeled D4 receptor ligands|

---

AU3568897A|1996-06-07|1998-01-05|Eos Biotechnology, Inc.|Immobilised linear oligonucleotide arrays|

---

CA2248784A1|1996-06-25|1997-12-31|Takeda Chemical Industries, Ltd.|Oxazolone derivatives and their use|

---

US5965452A|1996-07-09|1999-10-12|Nanogen, Inc.|Multiplexed active biologic array|

---

HU229864B1|1996-08-12|2014-10-28|Mitsubishi Tanabe Pharma Corp|Use of amide compounds for the preparation of medicaments|

---

JPH10130269A|1996-09-04|1998-05-19|Nippon Chemiphar Co Ltd|Carboline derivative|

---

JPH1087629A|1996-09-18|1998-04-07|Fujisawa Pharmaceut Co Ltd|New isoquinoline derivative, and its medicinal use|

---

DK0948495T3|1996-11-19|2004-06-01|Amgen Inc|Aryl- and heteroaryl-substituted condensed pyrrole as anti-inflammatory agents|

---

CA2300940A1|1997-08-15|1999-02-25|Radoje Drmanac|Methods and compositions for detection or quantification of nucleic acid species|

---

US6294330B1|1997-01-31|2001-09-25|Odyssey Pharmaceuticals Inc.|Protein fragment complementation assays for the detection of biological or drug interactions|

---

CA2283434A1|1997-03-07|1998-09-11|Tropix, Inc.|Protease inhibitor assay|

---

US5977131A|1997-04-09|1999-11-02|Pfizer Inc.|Azaindole-ethylamine derivatives as nicotinic acetylcholine receptor binding agents|

---

AU7132998A|1997-04-24|1998-11-13|Ortho-Mcneil Corporation, Inc.|Substituted pyrrolopyridines useful in the treatment of inflammatory diseases|

---

US6096718A|1997-06-05|2000-08-01|Gene Targeting Corp.|Tissue specific adenovirus vectors for breast cancer treatment|

---

SG72827A1|1997-06-23|2000-05-23|Hoffmann La Roche|Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives|

---

WO1999000386A1|1997-06-27|1999-01-07|Resolution Pharmaceuticals Inc.|Dopamine d4 receptor ligands|

---

US6235769B1|1997-07-03|2001-05-22|Sugen, Inc.|Methods of preventing and treating neurological disorders with compounds that modulate the function of the C-RET receptor protein tyrosine kinase|

---

US6826296B2|1997-07-25|2004-11-30|Affymetrix, Inc.|Method and system for providing a probe array chip design database|

---

ES2287971T3|1997-08-11|2007-12-16|Pfizer Products Inc.|SOLID PHARMACEUTICAL DISPERSIONS WITH INCREASED BIODISPONIBILITY.|

---

US6161776A|1997-08-12|2000-12-19|Nibco Inc.|Multi-layered, porous mat turf irrigation apparatus and method|

---

EP1012564B1|1997-09-11|2003-03-26|BioVentures, Inc.,|Method of making high density arrays|

---

US6178384B1|1997-09-29|2001-01-23|The Trustees Of Columbia University In The City Of New York|Method and apparatus for selecting a molecule based on conformational free energy|

---

US6465178B2|1997-09-30|2002-10-15|Surmodics, Inc.|Target molecule attachment to surfaces|

---

DE69831013T2|1997-12-22|2006-04-20|Bayer Pharmaceuticals Corp., West Haven|INHIBITION OF RAF KINASE BY SUBSTITUTED HETEROCYCLIC UREA COMPOUNDS|

---

EP1042276B1|1997-12-23|2004-11-17|Warner-Lambert Company Llc|Thioureacompounds, compositions and methods of treating or preventing inflammatory diseases and atherosclerosis|

---

GB9800569D0|1998-01-12|1998-03-11|Glaxo Group Ltd|Heterocyclic compounds|

---

CA2326184A1|1998-04-02|1999-10-14|Feroze Ujjainwalla|Antagonists of gonadotropin releasing hormone|

---

AU3118399A|1998-04-02|1999-10-25|Merck & Co., Inc.|Antagonists of gonadotropin releasing hormone|

---

JP2002510628A|1998-04-02|2002-04-09|メルクエンドカムパニーインコーポレーテッド|Gonadotropin-releasing hormone antagonist|

---

AU3210799A|1998-04-02|1999-10-25|Merck & Co., Inc.|Antagonists of gonadotropin releasing hormone|

---

WO1999051596A1|1998-04-02|1999-10-14|Merck & Co., Inc.|Antagonists of gonadotropin releasing hormone|

---

WO1999051234A1|1998-04-02|1999-10-14|Merck & Co., Inc.|Antagonists of gonadotropin releasing hormone|

---

IL138668D0|1998-04-03|2001-10-31|Phylos Inc|Addressable protein arrays|

---

US6653309B1|1999-04-26|2003-11-25|Vertex Pharmaceuticals Incorporated|Inhibitors of IMPDH enzyme technical field of the invention|

---

US6048695A|1998-05-04|2000-04-11|Baylor College Of Medicine|Chemically modified nucleic acids and methods for coupling nucleic acids to solid support|

---

CA2319495A1|1998-06-08|1999-12-16|Advanced Medicine, Inc.|Multibinding inhibitors of microsomal triglyceride transferase protein|

---

US6113913A|1998-06-26|2000-09-05|Genvec, Inc.|Recombinant adenovirus|

---

WO2000012074A2|1998-08-28|2000-03-09|Scios Inc.|Use of piperidines and/or piperazines as inhibitors of p38-alpha kinase|

---

WO2000012514A1|1998-08-28|2000-03-09|Astrazeneca Ab|Novel compounds|

---

US6594527B2|1998-09-18|2003-07-15|Nexmed Holdings, Inc.|Electrical stimulation apparatus and method|

---

IL141867D0|1998-09-18|2002-03-10|Basf Ag|4-aminopyrrolopyrimidines as kinase inhibitors|

---

US6350786B1|1998-09-22|2002-02-26|Hoffmann-La Roche Inc.|Stable complexes of poorly soluble compounds in ionic polymers|

---

US6277628B1|1998-10-02|2001-08-21|Incyte Genomics, Inc.|Linear microarrays|

---

IT1303759B1|1998-11-17|2001-02-23|Dompe Spa|IMPROVED PROCEDURE FOR THE PREPARATION OF 7-AZAINDOLYL-3-CARBOXYLIC ACID.|

---

US6277489B1|1998-12-04|2001-08-21|The Regents Of The University Of California|Support for high performance affinity chromatography and other uses|

---

US20010001449A1|1998-12-30|2001-05-24|Thomas R. Kiliany|Low-pressure hydrocracking process|

---

CN1198803C|1999-03-05|2005-04-27|第一三得利制药株式会社|Heterocyclic compounds having effect of activating nicoting acetylchloine alpha 4 beta 2 receptor|

---

US6792306B2|2000-03-10|2004-09-14|Biophoretic Therapeutic Systems, Llc|Finger-mounted electrokinetic delivery system for self-administration of medicaments and methods therefor|

---

BR0009083B1|1999-03-17|2011-11-01||an amide derivative comprising a quinazolinone nucleus, process for the preparation of an amide derivative, pharmaceutical composition, and use of an amide derivative.|

---

AR028475A1|1999-04-22|2003-05-14|Wyeth Corp|DERIVATIVES OF AZAINDOL AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION.|

---

US6221653B1|1999-04-27|2001-04-24|Agilent Technologies, Inc.|Method of performing array-based hybridization assays using thermal inkjet deposition of sample fluids|

---

FR2793793B1|1999-05-19|2004-02-27|Adir|NOVEL SUBSTITUTED DIMERIC DERIVATIVES, PROCESS FOR PREPARING THEM AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME|

---

US6492406B1|1999-05-21|2002-12-10|Astrazeneca Ab|Pharmaceutically active compounds|

---

TWI234557B|1999-05-26|2005-06-21|Telik Inc|Novel naphthalene ureas as glucose uptake enhancers|

---

CZ20014244A3|1999-06-03|2002-07-17|Knoll Gmbh|Benzotiazinone and benzoxazinone compounds|

---

KR20020091829A|1999-07-30|2002-12-06|애보트 게엠베하 운트 콤파니 카게|2-Pyrazolin-5-ones|

---

US6653151B2|1999-07-30|2003-11-25|Large Scale Proteomics Corporation|Dry deposition of materials for microarrays using matrix displacement|

---

WO2001024236A1|1999-09-27|2001-04-05|Infineon Technologies North America Corp.|Semiconductor structures having a capacitor and manufacturing methods|

---

GB9924962D0|1999-10-21|1999-12-22|Mrc Collaborative Centre|Allosteric sites on muscarinic receptors|

---

US6316474B1|1999-10-29|2001-11-13|Merck & Co., Inc.|2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists|

---

US20010008765A1|1999-12-06|2001-07-19|Fuji Photo Film Co., Ltd.|DNA chip and reactive solid carrier|

---

US6610688B2|1999-12-21|2003-08-26|Sugen, Inc.|4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors|

---

ES2267605T3|1999-12-22|2007-03-16|Sugen, Inc.|USE OF INDOLINONE COMPOUNDS FOR THE MANUFACTURE OF PHARMACEUTICAL PRODUCTS INTENDED TO MODULATE THE FUNCTION OF C-KIT-TYROSIN-PROTEIN-KINASE.|

---

FR2805259B1|2000-02-17|2002-03-29|Inst Nat Sante Rech Med|NOVEL N-MERCAPTOACYL AMINOACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM|

---

US20020061892A1|2000-02-22|2002-05-23|Tao Wang|Antiviral azaindole derivatives|

---

JP2001278886A|2000-03-28|2001-10-10|Dai Ichi Seiyaku Co Ltd|Benzoxazine derivative and medicament containing the same|

---

GB0007934D0|2000-03-31|2000-05-17|Darwin Discovery Ltd|Chemical compounds|

---

US6335342B1|2000-06-19|2002-01-01|Pharmacia & Upjohn S.P.A.|Azaindole derivatives, process for their preparation, and their use as antitumor agents|

---

SI1294724T1|2000-06-26|2006-08-31|Pfizer Prod Inc|Pyrrolo pyrimidine compounds as immunosuppressive agents|

---

AT300543T|2000-06-26|2005-08-15|Lilly Icos Llc|CONDENSED PYRAZINDION DERIVATIVES AS PDE5 INHIBITORS|

---

BR0113574A|2000-08-31|2003-07-22|Pfizer Prod Inc|Pyrazole derivatives and their use as protein kinase inhibitors|

---

US6618625B2|2000-11-29|2003-09-09|Leon M. Silverstone|Method and apparatus for treatment of viral diseases|

---

CZ20032225A3|2001-02-27|2003-11-12|Astrazeneca Ab|Pharmaceutical formulation|

---

GB0107368D0|2001-03-23|2001-05-16|Novartis Ag|Organic compounds|

---

KR100865262B1|2001-04-11|2008-10-24|센주 세이야꾸 가부시키가이샤|Visual function disorder improving agents|

---

WO2002085896A1|2001-04-24|2002-10-31|Wyeth|Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan|

---

MXPA03010269A|2001-05-11|2004-05-05|Vertex Pharma|2,5-disubstituted pyridine, pyrimidine, pyridazine and 1, 2, 4-triazine derivatives for use as p38 inhibitors.|

---

GB0114417D0|2001-06-13|2001-08-08|Boc Group Plc|Lubricating systems for regenerative vacuum pumps|

---

EP1267111A1|2001-06-15|2002-12-18|Dsm N.V.|Pressurized fluid conduit|

---

US20040171630A1|2001-06-19|2004-09-02|Yuntae Kim|Tyrosine kinase inhibitors|

---

US7291639B2|2001-06-20|2007-11-06|Wyeth|Aryloxy-acetic acid compounds useful as inhibitors of plasminogen activator inhibitor-1 |

---

GB0115109D0|2001-06-21|2001-08-15|Aventis Pharma Ltd|Chemical compounds|

---

SE0102300D0|2001-06-26|2001-06-26|Astrazeneca Ab|Compounds|

---

US20030091974A1|2001-06-29|2003-05-15|Alain Moussy|Method for screening compounds capable of depleting mast cells|

---

SE0102439D0|2001-07-05|2001-07-05|Astrazeneca Ab|New compounds|

---

RU2273639C2|2001-07-09|2006-04-10|Солвей Фармасьютикалс Б.В.|Derivatives of piperazine oxime possessing antagonistic activity with respect to neurokinine-1 receptor|

---

GB0117583D0|2001-07-19|2001-09-12|Astrazeneca Ab|Novel compounds|

---

US6858860B2|2001-07-24|2005-02-22|Seiko Epson Corporation|Apparatus and method for measuring natural period of liquid|

---

GB0118479D0|2001-07-28|2001-09-19|Astrazeneca Ab|Novel compounds|

---

WO2003020698A2|2001-09-06|2003-03-13|Prochon Biotech Ltd.|Protein tyrosine kinase inhibitors|

---

WO2003028724A1|2001-10-04|2003-04-10|Smithkline Beecham Corporation|Chk1 kinase inhibitors|

---

WO2003037862A1|2001-10-30|2003-05-08|Nippon Shinyaku Co., Ltd.|Amide derivatives and drugs|

---

US20030119839A1|2001-12-13|2003-06-26|Nan-Horng Lin|Protein kinase inhibitors|

---

DE60303009T2|2002-01-22|2006-07-13|Warner-Lambert Co. Llc|2- -pyrido [2,3-d] pyrimidine-7-ONE|

---

NZ534171A|2002-02-01|2007-06-29|Astrazeneca Ab|Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability|

---

US20030236277A1|2002-02-14|2003-12-25|Kadow John F.|Indole, azaindole and related heterocyclic pyrrolidine derivatives|

---

US20040171062A1|2002-02-28|2004-09-02|Plexxikon, Inc.|Methods for the design of molecular scaffolds and ligands|

---

FR2836914B1|2002-03-11|2008-03-14|Aventis Pharma Sa|SUBSTITUTED INDAZOLES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE|

---

US6884889B2|2002-03-25|2005-04-26|Bristol-Myers Squibb Co.|Processes for the preparation of antiviral 7-azaindole derivatives|

---

IL164187D0|2002-03-28|2005-12-18|Eisai Co Ltd|7-Azaindole derivatives and pharmaceutical compositions containing the same|

---

AT457312T|2002-03-28|2010-02-15|Eisai R&D Man Co Ltd|AZAINDOLE AS INHIBITORS FROM C-JUN N-TERMINAL KINASEN|

---

WO2003087087A2|2002-04-09|2003-10-23|Astex Technology Limited|Heterocyclic compounds and their use as modulators of p38 map kinase|

---

TW200408638A|2002-06-04|2004-06-01|Wyeth Corp|1--3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands|

---

WO2004005283A1|2002-07-09|2004-01-15|Vertex Pharmaceuticals Incorporated|Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities|

---

TW200403243A|2002-07-18|2004-03-01|Wyeth Corp|1-Heterocyclylalkyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands|

---

TWI329112B|2002-07-19|2010-08-21|Squibb Bristol Myers Co|Novel inhibitors of kinases|

---

US6878887B2|2002-08-07|2005-04-12|Matsushita Electric Industrial Co., Ltd.|Anti-malfunction mechanism for variable output device|

---

EP1388341A1|2002-08-07|2004-02-11|Aventis Pharma Deutschland GmbH|Acylamino-substituted heteroaromatic compounds and their use as pharmaceuticals|

---

EP1388541A1|2002-08-09|2004-02-11|Centre National De La Recherche Scientifique |Pyrrolopyrazines as kinase inhibitors|

---

SE0202463D0|2002-08-14|2002-08-14|Astrazeneca Ab|Novel compounds|

---

JP2006502301A|2002-09-06|2006-01-19|インサートセラピューティクスインコーポレイテッド|Cyclodextrin-based polymer for therapeutic agent delivery|

---

WO2004024895A2|2002-09-16|2004-03-25|Plexxikon, Inc.|Crystal structure of pim-1 kinase|

---

US6766199B2|2002-10-10|2004-07-20|Proventure , Limited|Skin/hair treatment method and system|

---

US7183241B2|2002-10-15|2007-02-27|Exxonmobil Research And Engineering Company|Long life lubricating oil composition with very low phosphorus content|

---

GB0226370D0|2002-11-12|2002-12-18|Novartis Ag|Organic compounds|

---

SE0203654D0|2002-12-09|2002-12-09|Astrazeneca Ab|New compounds|

---

JP2006511554A|2002-12-13|2006-04-06|スミスクラインビーチャムコーポレーション|Piperidine derivatives as CCR5 antagonists|

---

ES2311755T3|2002-12-13|2009-02-16|Smithkline Beecham Corporation|CYCLHEXYL COMPOUNDS AS CCRS ANTAGONISTS.|

---

BR0317524A|2002-12-19|2005-11-16|Pfizer Prod Inc|Pyrrolopyrimidine derivatives, pharmaceutical composition, process for their preparation and their use|

---

US7696225B2|2003-01-06|2010-04-13|Osi Pharmaceuticals, Inc.| thiophene compounds|

---

SE0300119D0|2003-01-17|2003-01-17|Astrazeneca Ab|Novel compounds|

---

SE0300120D0|2003-01-17|2003-01-17|Astrazeneca Ab|Novel compounds|

---

AU2004312215B2|2003-12-24|2009-03-05|Dupont Nutrition Biosciences Aps|Proteins|

---

US20050085463A1|2003-01-23|2005-04-21|Weiner David M.|Use of N-desmethylclozapine to treat human neuropsychiatric disease|

---

US8486447B2|2003-02-03|2013-07-16|Novartis Ag|Pharmaceutical formulation|

---

US20050048573A1|2003-02-03|2005-03-03|Plexxikon, Inc.|PDE5A crystal structure and uses|

---

CA2515571A1|2003-02-14|2004-09-02|Wyeth|Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands|

---

SE0300456D0|2003-02-19|2003-02-19|Astrazeneca Ab|Novel compounds|

---

JP2007524374A|2003-02-28|2007-08-30|プレキシコン，インコーポレーテッド|PYK2 crystal structure and use|

---

US7432375B2|2003-03-06|2008-10-07|Eisai R & D Management Co., Ltd.|JNK inhibitors|

---

US7612086B2|2003-05-16|2009-11-03|Eisai R & D Management Co. Ltd.|JNK inhibitors|

---

US20050079548A1|2003-07-07|2005-04-14|Plexxikon, Inc.|Ligand development using PDE4B crystal structures|

---

AT412650T|2003-07-11|2008-11-15|Warner Lambert Co|ISETHIONATE SALT OF A SELECTIVE CDK4 INHIBITOR|

---

US7348338B2|2003-07-17|2008-03-25|Plexxikon, Inc.|PPAR active compounds|

---

UA88767C2|2003-07-17|2009-11-25|Плексікон, Інк.|Ppar active compounds|

---

CL2004001884A1|2003-08-04|2005-06-03|Pfizer Prod Inc|DRYING PROCEDURE FOR SPRAYING FOR THE FORMATION OF SOLID DISPERSIONS AMORPHES OF A PHARMACO AND POLYMERS.|

---

AR045595A1|2003-09-04|2005-11-02|Vertex Pharma|USEFUL COMPOSITIONS AS INHIBITORS OF KINASE PROTEINS|

---

WO2005044181A2|2003-09-09|2005-05-19|Temple University-Of The Commonwealth System Of Higher Education|Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors|

---

US20050164300A1|2003-09-15|2005-07-28|Plexxikon, Inc.|Molecular scaffolds for kinase ligand development|

---

EP1667983A4|2003-09-23|2010-07-21|Merck Sharp & Dohme|Pyrazole modulators of metabotropic glutamate receptors|

---

KR100793095B1|2003-10-01|2008-01-10|주식회사 프로메디텍|Novel Sulfone Amide Derivatives Capable Of Inhibiting BACE|

---

MXPA06003996A|2003-10-08|2006-07-05|Irm Llc|Compounds and compositions as protein kinase inhibitors.|

---

DE10357510A1|2003-12-09|2005-07-07|Bayer Healthcare Ag|Heteroaryl-substituted benzenes|

---

SI1696920T1|2003-12-19|2015-02-27|Plexxikon Inc.|Compounds and methods for development of ret modulators|

---

US7517970B2|2003-12-19|2009-04-14|Plexxikon, Inc.|Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same|

---

US20070066641A1|2003-12-19|2007-03-22|Prabha Ibrahim|Compounds and methods for development of RET modulators|

---

GB0330042D0|2003-12-24|2004-01-28|Pharmacia Italia Spa|Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them|

---

GB0330043D0|2003-12-24|2004-01-28|Pharmacia Italia Spa|Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them|

---

CN1918158B|2004-02-14|2011-03-02|Irm责任有限公司|Compounds and compositions as protein kinase inhibitors|

---

GB0403635D0|2004-02-18|2004-03-24|Devgen Nv|Pyridinocarboxamides with improved activity as kinase inhibitors|

---

EP1724271A4|2004-02-26|2013-01-23|Kyowa Hakko Kirin Co Ltd|Preventive and/or therapeutic agent for neutrophilic inflammation disease|

---

GB0405055D0|2004-03-05|2004-04-07|Eisai London Res Lab Ltd|JNK inhibitors|

---

EP1722789A2|2004-03-08|2006-11-22|Amgen Inc.|Therapeutic modulation of ppar activity|

---

KR20050091462A|2004-03-12|2005-09-15|한국과학기술연구원|Furopyrimidine compound and ddr2 tyrosine kinase activity inhibitor comprising the same|

---

US7507826B2|2004-03-30|2009-03-24|Vertex Pharmaceuticals Incorporated|Azaindoles useful as inhibitors of JAK and other protein kinases|

---

MXPA06011328A|2004-04-02|2006-12-15|Vertex Pharma|Azaindoles useful as inhibitors of rock and other protein kinases.|

---

EP1765819B1|2004-06-30|2014-03-12|Vertex Pharmaceuticals Inc.|Azaindoles useful as inhibitors of protein kinases|

---

EP1742627A4|2004-05-06|2009-08-26|Plexxikon Inc|Pde4b inhibitors and uses therefor|

---

WO2005115363A2|2004-05-25|2005-12-08|Yale University|Method for treating skeletal disorders resulting from fgfr malfunction|

---

EP1773836B1|2004-05-27|2012-09-05|Pfizer Products Inc.|Pyrrolopyrimidine derivatives useful in cancer treatment|

---

US20090105218A1|2004-05-29|2009-04-23|7Tm Pharma A/S|CRTH2 Receptor Ligands For Therapeutic Use|

---

WO2006009797A1|2004-06-17|2006-01-26|Plexxikon, Inc.|Azaindoles modulating c-kit activity and uses therefor|

---

US7498342B2|2004-06-17|2009-03-03|Plexxikon, Inc.|Compounds modulating c-kit activity|

---

US7140816B2|2004-07-20|2006-11-28|H&S Tool, Inc.|Multi-functional tube milling head|

---

BRPI0513916A|2004-07-27|2008-05-20|Sgx Pharmaceuticals Inc|pyrrol pyridine kinase modulators|

---

US7709645B2|2004-07-27|2010-05-04|Sgx Pharmaceuticals, Inc.|Pyrrolo-pyridine kinase modulators|

---

US7361764B2|2004-07-27|2008-04-22|Sgx Pharmaceuticals, Inc.|Pyrrolo-pyridine kinase modulators|

---

US7626021B2|2004-07-27|2009-12-01|Sgx Pharmaceuticals, Inc.|Fused ring heterocycle kinase modulators|

---

AU2005269387A1|2004-07-27|2006-02-09|Sgx Pharmaceuticals, Inc.|Fused ring heterocycle kinase modulators|

---

US20060024361A1|2004-07-28|2006-02-02|Isa Odidi|Disintegrant assisted controlled release technology|

---

WO2006010637A2|2004-07-30|2006-02-02|Gpc Biotech Ag|Pyridinylamines|

---

US7605168B2|2004-09-03|2009-10-20|Plexxikon, Inc.|PDE4B inhibitors|

---

CA2589896A1|2004-11-30|2006-06-08|Plexxikon, Inc.|Indole derivatives for use as ppar active compounds|

---

CA2588953A1|2004-11-30|2006-06-08|Plexxikon, Inc.|Ppar active compounds|

---

US20060160135A1|2004-12-08|2006-07-20|Weiru Wang|SF-1 and LRH-1 modulator development|

---

JP4954086B2|2004-12-08|2012-06-13|グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー|1H-pyrrolo [2,3-B] pyridine|

---

WO2006114180A1|2005-04-25|2006-11-02|Merck Patent Gmbh|Novel aza- heterocycles serving as kinase inhibitors|

---

FR2884821B1|2005-04-26|2007-07-06|Aventis Pharma Sa|SUBSTITUTED PYRROLOPYRIDINES, COMPOSITIONS CONTAINING SAME, METHOD OF MANUFACTURE AND USE|

---

US7846941B2|2005-05-17|2010-12-07|Plexxikon, Inc.|Compounds modulating c-kit and c-fms activity and uses therefor|

---

EP2354140A1|2005-05-20|2011-08-10|Vertex Pharmaceuticals Incorporated|Pyrrolopyridines useful as inhibitors of protein kinase|

---

US7368606B2|2005-05-23|2008-05-06|Teva Pharmaceutical Industries Ltd.|Amorphous cinacalcet hydrochloride and preparation thereof|

---

CA2612976C|2005-06-21|2012-04-10|Mitsui Chemicals, Inc.|Amide derivative and insecticide containing the same|

---

TWI432193B|2005-06-22|2014-04-01|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

DE102005034406A1|2005-07-22|2007-02-01|Ratiopharm Gmbh|New salts of rosiglitazone|

---

GB0516156D0|2005-08-05|2005-09-14|Eisai London Res Lab Ltd|JNK inhibitors|

---

US7754717B2|2005-08-15|2010-07-13|Amgen Inc.|Bis-aryl amide compounds and methods of use|

---

CA2621406A1|2005-09-07|2007-03-15|Plexxikon, Inc.|Pparactive compounds|

---

RU2419618C2|2005-09-07|2011-05-27|Плекссикон, Инк.|Compounds, active towards ppar |

---

AU2006287528A1|2005-09-07|2007-03-15|Plexxikon, Inc.|1 , 4 and 1 , 5-disubstituted indole derivatives for use as PPAR active compounds|

---

TW200812611A|2006-03-20|2008-03-16|Vertex Pharma|Pharmaceutical compositions|

---

US7963673B2|2006-05-30|2011-06-21|Finn Bruce L|Versatile illumination system|

---

CA2701959C|2006-11-15|2016-01-05|Ym Biosciences Australia Pty Ltd|Inhibitors of kinase activity|

---

WO2008063888A2|2006-11-22|2008-05-29|Plexxikon, Inc.|Compounds modulating c-fms and/or c-kit activity and uses therefor|

---

GB0624084D0|2006-12-01|2007-01-10|Selamine Ltd|Ramipril amino acid salts|

---

US8093246B2|2006-12-14|2012-01-10|Lexicon Pharmaceuticals, Inc.|O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer|

---

PE20081581A1|2006-12-21|2008-11-12|Plexxikon Inc|PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS|

---

WO2008079909A1|2006-12-21|2008-07-03|Plexxikon, Inc.|Pyrrolo [2,3-b] pyridines as kinase modulators|

---

CN101641351A|2006-12-21|2010-02-03|普莱希科公司|Be used for Compounds and methods for and indication thereof that kinases is regulated|

---

JP2010520303A|2007-03-08|2010-06-10|プレキシコン，インコーポレーテッド|PPAR active compounds|

---

PE20090159A1|2007-03-08|2009-02-21|Plexxikon Inc|INDOL-PROPIONIC ACID DERIVED COMPOUNDS AS PPARs MODULATORS|

---

EP2155166A2|2007-05-11|2010-02-24|F. Hoffmann-Roche AG|Pharmaceutical compositions for poorly soluble drugs|

---

TW200908968A|2007-05-29|2009-03-01|Sgx Pharmaceuticals Inc|Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators|

---

US20100190777A1|2007-07-17|2010-07-29|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

MX2010000856A|2007-07-23|2010-04-30|Pharmathen Sa|Pharmaceutical composition containing dihydropyridine calcium channel antagonist and method for the preparation thereof.|

---

JP2009077712A|2007-09-11|2009-04-16|F Hoffmann La Roche Ag|DIAGNOSTIC TEST FOR SUSCEPTIBILITY TO B-Raf KINASE INHIBITOR|

---

CN102015707A|2008-02-29|2011-04-13|阵列生物制药公司|RAF inhibitor compounds and methods of use thereof|

---

CA2716947A1|2008-02-29|2009-09-11|Array Biopharma Inc.|Imidazo [4,5-b] pyridine derivatives used as raf inhibitors|

---

KR20100117686A|2008-02-29|2010-11-03|어레이 바이오파마 인크.|Pyrazole [3,4-b] pyridine raf inhibitors|

---

JP2011513332A|2008-02-29|2011-04-28|アレイバイオファーマ、インコーポレイテッド|N- -3- benzamide derivatives as RAF inhibitors for the treatment of cancer|

---

WO2009115084A2|2008-03-20|2009-09-24|Schebo Biotech Ag|Novel pyrrolopyrimidine derivatives and the use thereof|

---

EP3106462A1|2008-05-06|2016-12-21|Novartis AG|Benzene sulfonamide thiazole and oxazole compounds|

---

PE20091846A1|2008-05-19|2009-12-16|Plexxikon Inc|PIRROLO [2,3-d] -PYRIMIDINE DERIVATIVES AS KINE MODULATORS|

---

US8158636B2|2008-05-19|2012-04-17|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

US8110576B2|2008-06-10|2012-02-07|Plexxikon Inc.|Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications|

---

WO2009152083A1|2008-06-10|2009-12-17|Plexxikon, Inc.|5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor|

---

EP2384326B1|2008-08-20|2014-04-23|Zoetis LLC|Pyrrolo[2,3-d]pyrimidine compounds|

---

UY32251A|2008-11-20|2010-05-31|Glaxosmithkline Llc|CHEMICAL COMPOUNDS|

---

CA2755045A1|2009-03-11|2010-09-16|Plexxikon, Inc.|Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases|

---

KR20110130463A|2009-03-11|2011-12-05|플렉시콘, 인코퍼레이티드|Pyrrolo[2,3-b]pyridine derivatives for the inhibition of raf kinases|

---

WO2010111527A1|2009-03-26|2010-09-30|Plexxikon, Inc.|Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use|

---

CN110269838A|2009-04-03|2019-09-24|豪夫迈罗氏公司|Propane -1- sulfonic acid { 3- [5- -1H- pyrrolo- [2,3-b] pyridine -3- carbonyl] -2,4- difluorophenyl }-amide compositions and application thereof|

---

SG175877A1|2009-05-04|2011-12-29|Plexxikon Inc|Compounds and methods for inhibition of renin, and indications therefor|

---

TW201041888A|2009-05-06|2010-12-01|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

US8329724B2|2009-08-03|2012-12-11|Hoffmann-La Roche Inc.|Process for the manufacture of pharmaceutically active compounds|

---

SG10201407129SA|2009-11-06|2014-12-30|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

WO2011060216A1|2009-11-12|2011-05-19|Concert Pharmaceuticals Inc.|Substituted azaindoles|

---

KR20120097512A|2009-11-18|2012-09-04|플렉시콘, 인코퍼레이티드|Compounds and methods for kinase modulation, and indications therefor|

---

WO2011079133A2|2009-12-23|2011-06-30|Plexxikon, Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

TWI510487B|2010-04-21|2015-12-01|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

FR2964757B1|2010-09-09|2013-04-05|Giroptic|OPTICAL DEVICE FOR CAPTURING IMAGES ACCORDING TO A 360 ° FIELD|

---

WO2012037060A1|2010-09-13|2012-03-22|Concert Pharmaceuticals Inc.|Substituted azaindoles|

---

US8642606B2|2010-09-29|2014-02-04|Plexxikon Inc.|ZAP-70 active compounds|

---

EP2672967B1|2011-02-07|2018-10-17|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

TWI558702B|2011-02-21|2016-11-21|普雷辛肯公司|Solid forms of a pharmaceutically active substance|

---

WO2012138809A1|2011-04-05|2012-10-11|Dawei Zhang|Heterocyclic compounds as kinase inhibitors|

---

KR20140032430A|2011-05-17|2014-03-14|플렉시콘, 인코퍼레이티드|Kinase modulation and indications therefor|

---

US20130172375A1|2011-12-13|2013-07-04|Hoffmann-La Roche Inc.|Pharmaceutical composition|

---

US9134807B2|2012-03-02|2015-09-15|Microsoft Technology Licensing, Llc|Pressure sensitive key normalization|

---

US9358235B2|2012-03-19|2016-06-07|Plexxikon Inc.|Kinase modulation, and indications therefor|

---

US9150570B2|2012-05-31|2015-10-06|Plexxikon Inc.|Synthesis of heterocyclic compounds|

---

DE102012213092B3|2012-07-25|2013-08-22|Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.|Transmission device and sensor system|

---

WO2014039714A2|2012-09-06|2014-03-13|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

WO2014100620A2|2012-12-21|2014-06-26|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

HUE039380T2|2013-03-15|2018-12-28|Plexxikon Inc|Heterocyclic compounds and uses thereof|

---

US20140303121A1|2013-03-15|2014-10-09|Plexxikon Inc.|Heterocyclic compounds and uses thereof|

---

EP3004060B1|2013-05-30|2019-11-27|Plexxikon Inc.|Compounds for kinase modulation, and indications therefor|

---

WO2015134536A1|2014-03-04|2015-09-11|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

WO2016044067A1|2014-09-15|2016-03-24|Plexxikon Inc.|Heterocyclic compounds and uses thereof|SI1696920T1|2003-12-19|2015-02-27|Plexxikon Inc.|Compounds and methods for development of ret modulators|

---

US7498342B2|2004-06-17|2009-03-03|Plexxikon, Inc.|Compounds modulating c-kit activity|

---

TWI432193B|2005-06-22|2014-04-01|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

CN101310336B|2006-01-13|2010-10-13|三菱化学媒体股份有限公司|Optical recording medium|

---

WO2008063888A2|2006-11-22|2008-05-29|Plexxikon, Inc.|Compounds modulating c-fms and/or c-kit activity and uses therefor|

---

PE20081581A1|2006-12-21|2008-11-12|Plexxikon Inc|PIRROLO [2,3-b] PYRIDINES COMPOUNDS AS KINASE MODULATORS|

---

WO2008079909A1|2006-12-21|2008-07-03|Plexxikon, Inc.|Pyrrolo [2,3-b] pyridines as kinase modulators|

---

US20100190777A1|2007-07-17|2010-07-29|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

CN101945877B|2008-02-25|2013-07-03|霍夫曼-拉罗奇有限公司|Pyrrolopyrazine kinase inhibitors|

---

AU2009218607B2|2008-02-25|2014-02-13|F. Hoffmann-La Roche Ag|Pyrrolopyrazine kinase inhibitors|

---

AT519763T|2008-02-25|2011-08-15|Hoffmann La Roche|PYRROLOPYRAZIN KINASE INHIBITORS|

---

CN101952294B|2008-02-25|2014-11-26|霍夫曼-拉罗奇有限公司|Pyrrolopyrazine kinase inhibitors|

---

CN101952295B|2008-02-25|2013-11-20|霍夫曼-拉罗奇有限公司|Pyrrolopyrazine kinase inhibitors|

---

US8158636B2|2008-05-19|2012-04-17|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

WO2009152083A1|2008-06-10|2009-12-17|Plexxikon, Inc.|5h-pyrr0l0 [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor|

---

EP2356116A1|2008-11-20|2011-08-17|OSI Pharmaceuticals, Inc.|Substituted pyrroloý2,3-b¨-pyridines and-pyrazines|

---

AR075111A1|2008-12-24|2011-03-09|Bial Portela & Ca Sa|HETEROCICLIC DERIVATIVES OF DIAZOLS AND TRIAZOLS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND USE OF THE SAME FOR THE TREATMENT OF METABOLISM AND NERVOUS SYSTEM DISORDERS, BETWEEN OTHERS.|

---

CN110269838A|2009-04-03|2019-09-24|豪夫迈罗氏公司|Propane -1- sulfonic acid { 3- [5--1H- pyrrolo- [2,3-b] pyridine -3- carbonyl] -2,4- difluorophenyl }-amide compositions and application thereof|

---

TW201041888A|2009-05-06|2010-12-01|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

US8329724B2|2009-08-03|2012-12-11|Hoffmann-La Roche Inc.|Process for the manufacture of pharmaceutically active compounds|

---

IN2012DN01983A|2009-08-24|2015-07-24|Ascepion Pharmaceuticals Inc||

---

SG10201407129SA|2009-11-06|2014-12-30|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

KR20120097512A|2009-11-18|2012-09-04|플렉시콘, 인코퍼레이티드|Compounds and methods for kinase modulation, and indications therefor|

---

WO2011079133A2|2009-12-23|2011-06-30|Plexxikon, Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

CA2784807C|2009-12-29|2021-12-14|Dana-Farber Cancer Institute, Inc.|Type ii raf kinase inhibitors|

---

US8481541B2|2010-03-22|2013-07-09|Hoffmann-La Roche Inc.|Pyrrolopyrazine kinase inhibitors|

---

US8518945B2|2010-03-22|2013-08-27|Hoffmann-La Roche Inc.|Pyrrolopyrazine kinase inhibitors|

---

WO2011126903A2|2010-03-30|2011-10-13|Verseon, Inc.|Multisubstituted aromatic compounds as inhibitors of thrombin|

---

TWI510487B|2010-04-21|2015-12-01|Plexxikon Inc|Compounds and methods for kinase modulation, and indications therefor|

---

AR081626A1|2010-04-23|2012-10-10|Cytokinetics Inc|AMINO-PYRIDAZINIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME TO TREAT CARDIAC AND SKELETIC MUSCULAR DISORDERS|

---

US9133123B2|2010-04-23|2015-09-15|Cytokinetics, Inc.|Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use|

---

AR081331A1|2010-04-23|2012-08-08|Cytokinetics Inc|AMINO- PYRIMIDINES COMPOSITIONS OF THE SAME AND METHODS FOR THE USE OF THE SAME|

---

AR081039A1|2010-05-14|2012-05-30|Osi Pharmaceuticals Llc|QUINASA FUSIONED BICYCLE INHIBITORS|

---

EP2569315A1|2010-05-14|2013-03-20|OSI Pharmaceuticals, LLC|Fused bicyclic kinase inhibitors|

---

JP2013526558A|2010-05-20|2013-06-24|エフ．ホフマン−ラロシュアーゲー|Pyrrolopyrazine derivatives as SYK and JAK inhibitors|

---

EP2672967B1|2011-02-07|2018-10-17|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

TWI558702B|2011-02-21|2016-11-21|普雷辛肯公司|Solid forms of a pharmaceutically active substance|

---

WO2012135631A1|2011-03-30|2012-10-04|Arrien Pharmaeuticals Llc|Substituted 5--1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors|

---

KR20140032430A|2011-05-17|2014-03-14|플렉시콘, 인코퍼레이티드|Kinase modulation and indications therefor|

---

ES2573831T3|2011-07-27|2016-06-10|Ab Science|Oxazole and thiazole derivatives as selective protein kinase inhibitors |

---

WO2013048949A2|2011-09-26|2013-04-04|Bristol-Myers Squibb Company|Selective nr2b antagonists|

---

EP3569598A1|2011-11-17|2019-11-20|Dana Farber Cancer Institute, Inc.|Inhibitors of c-jun-n-terminal kinase |

---

CN103242225B|2012-02-13|2016-01-06|湖南化工研究院|Picolinate amino pyridine compound and preparation method thereof|

---

US9358235B2|2012-03-19|2016-06-07|Plexxikon Inc.|Kinase modulation, and indications therefor|

---

US9150570B2|2012-05-31|2015-10-06|Plexxikon Inc.|Synthesis of heterocyclic compounds|

---

WO2014039714A2|2012-09-06|2014-03-13|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

CA2885259A1|2012-10-04|2014-04-10|Pfizer Limited|Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors|

---

EP2909194A1|2012-10-18|2015-08-26|Dana-Farber Cancer Institute, Inc.|Inhibitors of cyclin-dependent kinase 7 |

---

WO2014063054A1|2012-10-19|2014-04-24|Dana-Farber Cancer Institute, Inc.|Bone marrow on x chromosome kinaseinhibitors and uses thereof|

---

USRE48175E1|2012-10-19|2020-08-25|Dana-Farber Cancer Institute, Inc.|Hydrophobically tagged small molecules as inducers of protein degradation|

---

WO2014100620A2|2012-12-21|2014-06-26|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

US9783805B2|2013-02-28|2017-10-10|City Of Hope|Replication capable rAAV vectors encoding inhibitory siRNA and methods of their use|

---

US20140303121A1|2013-03-15|2014-10-09|Plexxikon Inc.|Heterocyclic compounds and uses thereof|

---

HUE039380T2|2013-03-15|2018-12-28|Plexxikon Inc|Heterocyclic compounds and uses thereof|

---

EP2968289A1|2013-03-15|2016-01-20|Janssen Pharmaceutica, N.V.|4-cyano-n--6-pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma|

---

EP2970141B1|2013-03-15|2020-02-26|Verseon Corporation|Halogenopyrazoles as inhibitors of thrombin|

---

CA2901637C|2013-03-15|2019-09-24|Kevin Michael Short|Multisubstituted aromatic compounds as serine protease inhibitors|

---

WO2014172616A2|2013-04-18|2014-10-23|President And Fellows Of Harvard College|Methods, compositions and kits for promoting motor neuron survival and treating and diagnosing neurodegenerative disorders|

---

EP3004060B1|2013-05-30|2019-11-27|Plexxikon Inc.|Compounds for kinase modulation, and indications therefor|

---

EP3057956B1|2013-10-18|2021-05-05|Dana-Farber Cancer Institute, Inc.|Polycyclic inhibitors of cyclin-dependent kinase 7 |

---

EP3057955B1|2013-10-18|2018-04-11|Syros Pharmaceuticals, Inc.|Heteroaromatic compounds useful for the treatment of prolferative diseases|

---

CN104710417B|2013-12-11|2020-09-08|上海科州药物研发有限公司|Azaindole derivatives and synthesis method thereof|

---

WO2015134536A1|2014-03-04|2015-09-11|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

US10017477B2|2014-04-23|2018-07-10|Dana-Farber Cancer Institute, Inc.|Janus kinase inhibitors and uses thereof|

---

WO2015164604A1|2014-04-23|2015-10-29|Dana-Farber Cancer Institute, Inc.|Hydrophobically tagged janus kinase inhibitors and uses thereof|

---

WO2016004305A2|2014-07-02|2016-01-07|Pharmacyclics Llc|Inhibitors of bruton's tyrosine kinase|

---

WO2016044067A1|2014-09-15|2016-03-24|Plexxikon Inc.|Heterocyclic compounds and uses thereof|

---

BR112017004704A2|2014-09-17|2018-01-23|Verseon Corp|compound, pharmaceutical composition, and method for treating a disease or disorder in an individual|

---

EP3009435B1|2014-10-15|2016-08-17|F.I.S.- Fabbrica Italiana Sintetici S.p.A.|Apixaban glycol esters as key intermediates and impurities of the synthesis of Apixaban|

---

US10870651B2|2014-12-23|2020-12-22|Dana-Farber Cancer Institute, Inc.|Inhibitors of cyclin-dependent kinase 7 |

---

AU2016224974B2|2015-02-27|2019-09-26|Verseon Corporation|Substituted pyrazole compounds as serine protease inhibitors|

---

US10550121B2|2015-03-27|2020-02-04|Dana-Farber Cancer Institute, Inc.|Inhibitors of cyclin-dependent kinases|

---

WO2016164641A1|2015-04-08|2016-10-13|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

SI3292123T1|2015-05-06|2020-10-30|Plexxikon Inc.|Solid forms of a compound modulating kinases|

---

BR112017023540A2|2015-05-06|2018-07-24|Plexxikon, Inc.|synthesis of 1 h-pyrrolo [2,3-b] pyridin derivatives that modulate kinases|

---

BR112017024917A2|2015-05-22|2018-07-31|Plexxikon Inc|synthesis of heterocyclic compounds|

---

CA2986739A1|2015-05-22|2016-12-01|Plexxikon Inc.|Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases|

---

WO2016188816A1|2015-05-22|2016-12-01|Ucb Biopharma Sprl|Treatment of epilepsy|

---

WO2016193844A1|2015-05-29|2016-12-08|Pfizer Inc.|Novel heterocyclic compounds as inhibitors of vanin-1 enzyme|

---

US10702527B2|2015-06-12|2020-07-07|Dana-Farber Cancer Institute, Inc.|Combination therapy of transcription inhibitors and kinase inhibitors|

---

CR20180109A|2015-07-20|2018-05-03|Genzyme Corp|COLONIA STIMULATOR FACTOR RECEIVER INHIBITORS 1 |

---

US10829484B2|2015-07-28|2020-11-10|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

CA2996978A1|2015-09-09|2017-03-16|Dana-Farber Cancer Institute, Inc.|Inhibitors of cyclin-dependent kinases|

---

CN108137585B|2015-09-21|2021-10-22|普莱希科公司|Heterocyclic compounds and their use|

---

EP3386980B1|2015-12-07|2021-10-13|Plexxikon Inc.|Compounds and methods for kinase modulation, and indications therefor|

---

AU2017232610B2|2016-03-16|2021-07-22|Plexxikon Inc.|Compounds and methods for kinase modulation and indications therefore|

---

US10604521B2|2016-06-17|2020-03-31|Crystal PharmaceuticalsCo., Ltd.|Crystalline forms of PLX3397 hydrochloride, processes for preparation and use thereof|

---

TW201815766A|2016-09-22|2018-05-01|美商普雷辛肯公司|Compounds and methods for IDO and TDO modulation, and indications therefor|

---

CA3039919A1|2016-10-10|2018-04-19|Development Center For Biotechnology|Quinoxaline compounds as type iii receptor tyrosine kinase inhibitors|

---

CA3040914A1|2016-11-03|2018-05-24|Juno Therapeutics, Inc.|Combination therapy of a cell based therapy and a microglia inhibitor|

---

CA3047580A1|2016-12-23|2018-07-26|Plexxikon Inc.|Compounds and methods for cdk8 modulation and indications therefor|

---

AU2018237047A1|2017-03-20|2019-10-17|Plexxikon Inc.|Crystalline forms of 4-ethyl)-6--1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain|

---

KR101798840B1|2017-05-17|2017-11-17|주식회사 레고켐 바이오사이언스|Novel Compounds as Autotaxin Inhibitors and Pharmaceutical Compositions Comprising the Same|

---

US10961242B2|2017-05-17|2021-03-30|Legochem Biosciences, Inc.|Compounds as autotaxin inhibitors and pharmaceutical compositions comprising the same|

---

AU2018275891A1|2017-06-02|2019-12-12|Juno Therapeutics, Inc.|Articles of manufacture and methods related to toxicity associated with cell therapy|

---

RU2019144333A|2017-06-02|2021-07-09|Джуно Терапьютикс, Инк.|PRODUCTS AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY|

---

US10428067B2|2017-06-07|2019-10-01|Plexxikon Inc.|Compounds and methods for kinase modulation|

---

CN110461841B|2017-06-19|2020-09-15|上海和誉生物医药科技有限公司|Nitrogen heteroaryl derivative with CSF1R inhibitory activity, and preparation method and application thereof|

---

AU2018291032A1|2017-06-29|2020-01-16|Juno Therapeutics, Inc.|Mouse model for assessing toxicities associated with immunotherapies|

---

WO2019023198A1|2017-07-25|2019-01-31|Plexxikon Inc.|Formulations of a compound modulating kinases|

---

MA50057A|2017-09-01|2020-07-08|Juno Therapeutics Inc|GENE EXPRESSION AND ASSESSMENT OF A RISK OF DEVELOPING TOXICITY FOLLOWING CELL THERAPY|

---

US10717735B2|2017-10-13|2020-07-21|Plexxikon Inc.|Solid forms of a compound for modulating kinases|

---

WO2019084462A1|2017-10-27|2019-05-02|Plexxikon Inc.|Formulations of a compound modulating kinases|

---

US20200352998A1|2017-11-01|2020-11-12|June Therapeutics, Inc.|Methods associated with tumor burden for assessing response to a cell therapy|

---

WO2019183145A1|2018-03-20|2019-09-26|Plexxikon Inc.|Compounds and methods for ido and tdo modulation, and indications therefor|

---

US11142525B2|2018-11-15|2021-10-12|Pfizer Inc.|Azalactam compounds as HPK1 inhibitors|

---

US20220031746A1|2018-11-30|2022-02-03|Juno Therapeutics, Inc.|Methods for dosing and treatment of b cell malignancies in adoptive cell therapy|

---

JP2022513685A|2018-11-30|2022-02-09|ジュノー セラピューティクス インコーポレイテッド|Methods for Treatment with Adoptive Cell Therapy|

---

WO2021113770A1|2019-12-06|2021-06-10|Juno Therapeutics, Inc.|Methods related to toxicity and response associated with cell therapy for treating b cell malignancies|

---

CN111233857B|2020-01-16|2021-01-08|河南应用技术职业学院|Synthetic method for continuously producing pexidininib|

---

WO2021144360A1|2020-01-17|2021-07-22|F. Hoffmann-La Roche Ag|Small molecule csf-1r inhibitors in therapeutic and cosmetic uses|

法律状态:
2014-01-30| FGA| Letters patent sealed or granted (standard patent)|

优先权:

---

申请号 | 申请日 | 专利标题

---

US86074906P| true| 2006-11-22|2006-11-22||

---

US60/860,749||2006-11-22||

---

PCT/US2007/085289|WO2008064255A2|2006-11-22|2007-11-20|Compounds modulating c-fms and/or c-kit activity and uses therefor|

---